0001558370-24-01543610-Q COGNITION THERAPEUTICS INC 20241113202411130745330745330745330

markets for our product candidates and our ability to serve those markets;â—regulatory developments and approval pathways in the United States and foreign countries for our product candidates; â—the potential scope and value of our intellectual property and proprietary rights;â—our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties; â—economic uncertainty resulting from actual or perceived inflation or banking stability;â—developments relating to our competitors and our industry; â—the extent to which health epidemics and other outbreaks of communicable diseases, including the COVID-19 pandemic or other pandemics, global and regional political turmoil conflicts or increased trade restrictions between the United States, Russia, China, and other relevant markets, political instability, terrorism, or other acts of war could ultimately impact our business, including our current and furture research and our ongoing and future clinical trials; and â—other risk and uncertainties, including those described in Part I, Item 1A â€œRisk Factorsâ€ in our Annual Report on Form 10-K (â€œAnnual Reportâ€) filed with the SEC on March 26, 2024.You should refer to the â€œRisk Factorsâ€ section of our Annual Report for the year ended December 31, 2023 and in this Quarterly Report on Form 10-Q for a discussion of material factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on FormÂ 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.You should read this Quarterly Report on FormÂ 10-Q and the documents that we reference in this Quarterly Report on FormÂ 10-Q and have filed as exhibits to this Quarterly Report on FormÂ 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. We intend the forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Exchange Act, as amended (the â€œSecurities Actâ€) and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€).â€‹4 Table of ContentsPART I â€” FINANCIAL INFORMATIONItem 1.Financial StatementsCOGNITION THERAPEUTICS, INC. AND SUBSIDIARYCONSOLIDATED BALANCE SHEETS(unaudited)(in thousands, except share and per share amounts)â€‹â€‹â€‹

ended SeptemberÂ 30,Â 2024 and 2023, and cash flows for the nine months ended SeptemberÂ 30,Â 2024 and 2023. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of the results for the year ending DecemberÂ 31,Â 2024, or for any future period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended DecemberÂ 31,Â 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 26, 2024.Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.Cash and Cash EquivalentsCash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.11 Table of ContentsReceivablesGrant ReceivablesGrant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (â€œNIHâ€) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.Grant IncomeThe Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company generated grant income of $4,293 and $16,516, respectively, as compared to $7,684 and $18,035 for the three and nine months ended SeptemberÂ 30,Â 2023, respectively, primarily from reimbursements from the National Institute of Aging (the â€œNIAâ€), a division of the NIH for aging research. The current and non-current portion of deferred grant income as of SeptemberÂ 30,Â 2024 was $1,117 and $0, respectively, as compared to the current and non-current portion of deferred grant income as of DecemberÂ 31,Â 2023 of $1,701 and $0, respectively.The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (â€œCROsâ€), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIHâ€™s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Companyâ€™s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of SeptemberÂ 30,Â 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.Research and Development CostsThe Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimerâ€™s disease, dementia with Lewy bodies, and geographic atrophy (â€œGAâ€) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to its research and development activities, including allocated facility-related expenses and external costs of outside vendors, including CROs, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.12 Table of ContentsEquity-based CompensationFollowing the provisions of ASC 718, Compensationâ€‰â€”â€‰Stock Compensation, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company recognizes compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. The grant date fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to a lack of sufficient public market data for the Companyâ€™s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.Prior to the IPO, due to the absence of an active market for the Companyâ€™s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, armâ€™s-length sales of the Companyâ€™s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Companyâ€™s financial position and historical financial performance, the status of technological developments within the Companyâ€™s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Companyâ€™s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors determines the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.Concentration of Credit RiskThe Companyâ€™s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.13 Table of ContentsFair Value of Financial InstrumentsThe Company applies ASC 820, Fair Value Measurement (â€œASC 820â€), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Companyâ€™s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entityâ€™s own assumptions based on market data and the entityâ€™s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.The carrying value of the Companyâ€™s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:â—Level Â 1â€‰â€”â€‰ Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.â—Level Â 2â€‰â€”â€‰ Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.â—Level Â 3â€‰â€”â€‰ Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.Net Loss Per ShareBasic net loss per share is computed by dividing the net loss per share by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. SegmentsThe Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Companyâ€™s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.14 Table of ContentsEmerging Growth Company StatusThe Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.Recent Accounting PronouncementsNot Yet AdoptedIn October 2023, the FASB issued ASU 2023-06, Disclosure Improvements (â€œASU 2023-06â€), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (â€œASU 2023-09â€). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entityâ€™s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entityâ€™s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures. Income TaxesIn accordance with ASC 270,Â Interim Reporting,Â and ASC 740,Â Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate, apply that rate in providing for income taxes on a current year-to-date (interim period) basis, and include the tax impact for discrete items within the interim period. The Company maintains a full valuation allowance against all deferred tax assets as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As ofÂ SeptemberÂ 30,Â 2024Â andÂ DecemberÂ 31,Â 2023, the Company hadÂ no uncertain tax positions.â€‹3. Financial Instruments and Fair Value MeasurementsFinancial assets and liabilities measured at fair value are summarized below:â€‹

As of SeptemberÂ 30,Â 2024	Significant Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
money market funds	$ 21,766	â€”	â€”
Total assets	$ 21,766	â€”	â€”

As of DecemberÂ 31,Â 2023	Significant Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
money market funds	$ 29,391	â€”	â€”
Total assets	$ 29,391	â€”	â€”

4. Accrued ExpensesAccrued expense consists of the following:â€‹

As ofÂ	SeptemberÂ 30,Â 2024	DecemberÂ 31,Â 2023
Employee compensation, benefits, and related accruals	$ 1,480	$ 1,165
Research and development costs	Â 7,795	Â 2,520
Professional fees and other accruals	Â 230	Â 370
Total	$ 9,505	$ 4,055

5. Other Current LiabilitiesIn October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through September 2024. As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the outstanding principal of the loan was $0 and $544, respectively, and is included in other current liabilities on the consolidated balance sheet.6. Commitments and ContingenciesOperating LeasesAmounts reported in the consolidated balance sheets for leases where the Company is the lessee as of SeptemberÂ 30,Â 2024 were as follows:â€‹

As ofâ€‹	SeptemberÂ 30,Â 2024	DecemberÂ 31,Â 2023
Assets		
Operating lease assets	$ 542	$ 657
Total operating lease assets	$ 542	$ 657
Liabilities		
Current		
Operating lease liabilities	$ 188	$ 174
Non-current		
Operating lease liabilities, non-current	392	520
Total operating lease liabilities	$ 580	$ 694

Operating lease costs for the three and nine months ended SeptemberÂ 30,Â 2024 was $55 and $164, respectively, as compared to operating lease costs for the three and nine months ended SeptemberÂ 30,Â 2023 of $53 and $161, respectively.â€‹16 Table of ContentsThe maturities of the operating lease liabilities and minimum lease payments as of SeptemberÂ 30,Â 2024 were as follows:â€‹

For the Years Ended December 31,Â Â Â Â	Operating Leases
2024 (remaining)	$ 562025
2026	1582027
912028	92
Thereafter	39
Total undiscounted lease payments	$ 662
Less: Imputed interest	(82)
Present value of operating lease liabilities	$ 580

The following table summarizes the lease term and discount rate as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, respectively:â€‹

As ofâ€‹	SeptemberÂ 30,Â 2024	DecemberÂ 31,Â 2023
Weighted-average remaining lease term (years)	3.5	4.1
Weighted-average discount rate	8.1%	8.1%

Operating cash flows used for operating leases for the nine months ended SeptemberÂ 30,Â 2024 and 2023 was $168 and $154, respectively.Litigation and ContingenciesFrom time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability but instead discloses the nature and the amount of the claim and an estimate of the loss or range of loss, if such an estimate can reasonably be made.As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, there was no litigation or contingency with at least a reasonable possibility of a material loss.7. Stockholdersâ€™ EquityCommon and Preferred StockThe Company is authorized to issue up toÂ 250,000,000Â shares of common stock with a par value of $0.001Â per share, andÂ 10,000,000Â shares of preferred stock with a par value of $0.001Â per share. Common stockholders are entitled to dividends if and when declared by the Companyâ€™s board of directors subject to the rights of the preferred stockholders. As of SeptemberÂ 30,Â 2024,Â no dividends on common stock had been declared by the Company.17 Table of ContentsATMOn December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate (the â€œShelfâ€). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in ATM offerings under the Shelf. The Company sold 864,404 shares of common stock pursuant to the ATM during the nine months ended SeptemberÂ 30,Â 2024 for gross proceeds of approximately $905. As of SeptemberÂ 30,Â 2024, there was $33,809 remaining of common stock available for sale under the ATM. Lincoln Park Purchase AgreementOn March 10, 2023, the Company entered into a

purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Companyâ€™s sole discretion, over a 36-month period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Parkâ€™s commitment to purchase shares of common stock under the Purchase Agreement (the â€œCommitment Sharesâ€). The Company recorded $318 to other expense, net in connection with the issuance of the Commitment Shares. During the nine months ended SeptemberÂ 30,Â 2024, the Company did not sell any shares of common stock to Lincoln Park. As of SeptemberÂ 30,Â 2024, $34,795 was available to draw pursuant to the Purchase Agreement.March 2024 OfferingIn March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of 7,557,142 shares of its common stock, which included the exercise of the underwritersâ€™ option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwritersâ€™ option to purchase 985,714 additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $11,896, after deducting $1,329 of underwriting discounts and commissions and other offering related expenses payable by the Company.8. Equity-based Compensation2021 Equity Incentive PlanOn October 7, 2021, the date upon which the Companyâ€™s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Companyâ€™s 2021 Equity Incentive Plan (the â€œ2021 Planâ€) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the â€œ2017 Planâ€). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units (â€œRSUsâ€), and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers. As of SeptemberÂ 30,Â 2024, the aggregate number of shares of common stock of the Company that may be issued under the 2021 Plan is 2,547,943. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2024 pursuant to an evergreen provision therein by 643,309 shares, representing 2% of total common shares outstanding at DecemberÂ 31,Â 2023. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Companyâ€™s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Companyâ€™s board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the â€œ2007 Planâ€ and collectively with the 2017 Plan, the â€œPrior Plansâ€) that expire, terminate 18 Table of Contentsor are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.2017 Equity Incentive PlanOn September 15, 2017, the Companyâ€™s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The board of directors, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Companyâ€™s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan provides for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised shall subsequently be available for reissuance under the 2021 Plan.Employee Stock Purchase PlanThe Companyâ€™s board of directors approved the Employee Stock Purchase Plan (the â€œESPPâ€) prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Companyâ€™s common stock at a discounted purchase price. As of SeptemberÂ 30,Â 2024, subject to adjustment as provided in the ESPP, a total of 209,532 shares of common stock are authorized and reserved for issuance under the ESPP. Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i)Â 1,000,000Â shares of common stock, (ii)Â 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above.Stock OptionsThe fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Expected volatilityÂ 91.78%â€“92.29%Â 91.53%â€“92.68%Risk-free interest rateÂ 4.23%â€“4.45%Â 3.46%â€“4.26%Dividend yieldÂ 0%Â 0%Expected term (years)Â 6.10â€“6.20Â 6.18â€“6.36â€‹â€‹19 Table of ContentsExpected Termâ€“The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.Risk-Free Interest Rateâ€“The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awardsâ€™ expected term.Expected Volatilityâ€“Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.Dividend Yieldâ€“The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.Fair Value of Common Stockâ€“Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors determined the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.Activity for options was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

pg/mL experienced a 95% slowing in rate of cognitive decline on the ADAS-Cog 11 scale and 108% decline on the MMSE. The placebo-treated participants with below-median p-tau217 declined almost 3 points on the ADAS-Cog 11 scale by the end of the study. Placebo patients in both analyses experienced cognitive decline.We have enrolled 130 patients in the Phase 2 COG1201 (SHIMMER) study of CT1812 in mild-to-moderate dementia with Lewy bodies, or DLB. The design of this trial is a double-blind, randomized, six-month trial involving three dose groups, two active treatment cohorts and a placebo group. Clinical endpoints of the trial include safety and physical activity measurements, cognitive assessments, and PK and pharmacodynamic biomarker analyses compared to baseline measurements recorded at the beginning of the trial. In addition, as an exploratory analysis, cerebrospinal fluid will be collected and analyzed for Î±-synuclein content and established patterns of differential protein expression. This study is not powered to show significance in the efficacy endpoints. We expect to report topline results from our SHIMMER trial by year-end 2024.Since our inception in 2007, we have incurred significant operating losses and devoted substantially all of our time and resources to developing our lead product candidate, CT1812, building our intellectual property portfolio, raising capital and recruiting management and technical staff to support these operations. As of SeptemberÂ 30,Â 2024, we had an accumulated deficit of $167.3 million. We incurred a net loss of $9.9 million and $26.1 million for the three and nine months ended SeptemberÂ 30,Â 2024, respectively, and net loss of $6.7 million and $17.6 million for the three and nine months ended SeptemberÂ 30,Â 2023, respectively.To date, we have funded our operations primarily with proceeds from grants awarded by the National Institute of Aging (the â€œNIAâ€), a division of the National Institutes of Health (the â€œNIHâ€), and proceeds from our initial public offering (the â€œIPOâ€), completed in October 2021, proceeds from our follow-on public offerings, sales of our common stock through our ATM (as defined below), sales of our convertible promissory notes, convertible preferred stock, simple agreements for future equity (â€œSAFEâ€) and stock option exercises. Since our inception, we have received approximately $171.0 million in cumulative grant awards to fund our clinical trials, primarily from the NIA, and we have raised approximately $126.4 million in net proceeds from sales of our equity securities, convertible notes, SAFE, stock option exercises, IPO and follow-on public offerings, ATM, and equity line financing with Lincoln Park. As of SeptemberÂ 30,Â 2024, we had cash and cash equivalents of $22.0 million. To date, $53.6 million of the cumulative grant funds remain available.On December 23, 2022, we entered into a sales agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (the â€œSales Agentsâ€), providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in â€œat-the-marketâ€ offerings (the â€œATMâ€). We sold 864,404 shares of common stock under the ATM during the nine months ended SeptemberÂ 30,Â 2024 for gross proceeds of approximately $0.9 million. As of SeptemberÂ 30,Â 2024, there was approximately $33.8 million of common stock remaining available for sale under the ATM.On March 10, 2023, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (â€œLincoln Parkâ€) for an equity line financing (the â€œLincoln Park Purchase Agreementâ€). The Lincoln Park Purchase Agreement provides that, subject to the terms and conditions set forth therein, we have the right, but not the obligation, to direct Lincoln Park 23 Table of Contentsto purchase up to $35.0 million of shares of common stock at our sole discretion, over a 36-month period commencing on March 10, 2023. We filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Lincoln Park Purchase Agreement. During the nine months ended SeptemberÂ 30,Â 2024, we did not sell any shares of common stock to Lincoln Park. As of SeptemberÂ 30,Â 2024, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement.On March 14, 2024, we completed our follow-on public offering, pursuant to which we issued and sold 6,571,428 shares of our common stock at a public offering price of $1.75 per share. On March 28, 2024, the underwriters exercised their option to purchase 985,714 shares of our common stock at a public offering price of $1.75 per share. In connection with the follow-on public offering, we received net proceeds of approximately $11.9 million, after deducting underwriting discounts and commissions and other offering related expenses.We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities.As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.We do not own or operate manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of CT1812 for preclinical studies and clinical trials, as well as for commercial manufacture if CT1812 obtains marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute CT1812, if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of CT1812.Impact of COVID-19 on Our BusinessOur business has been and could be adversely affected by the effects of the COVID-19 pandemic or other national health issues. For example, our ongoing and/or planned clinical trials may be impacted by interruptions or delays at clinical trial sites or operations of the FDA and comparable foreign regulatory authorities. Additionally, we have made certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of participants and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA and may need to make further adjustments in the future.24 Table of ContentsWhile the potential further economic impact brought by the COVID-19 pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. As a result, we may face difficulties raising capital through future sales of our common stock or such sales may be on unfavorable terms.Components of Our Results of OperationsOperating ExpensesResearch and Development ExpensesResearch and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of our drug discovery efforts and the development of our product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities, and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables.We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.We cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, as we expand our product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts.General and Administrative ExpensesGeneral and administrative expenses consist primarily of personnel-related costs, including employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, finance and accounting, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred.Other Income (Expense)Grant IncomeGrant income relates to the grants awarded from governmental bodies that are conditional cost reimbursement grants and are recognized as grant income as allowable costs are incurred and the right to payment is realized. The grants awarded relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (â€œCROsâ€), research institutions and /or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we 25 Table of Contentsare reimbursed for eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIHâ€™s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. As of SeptemberÂ 30,Â 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. Our clinical trials have been funded by approximately $171.0 million in cumulative grants awarded primarily by the NIA, which includes an approximately $81.0 million grant from the NIA to fund our Phase 2 (COG0203-START) study of CT1812 in participants with early-stage AD, an approximately $30.5 million grant from the NIA to fund our Phase 2 (COG0201-SHINE) study of CT1812 in participants with mild-to-moderate AD, and an approximately $29.5 million grant from the NIA to fund our Phase 2 (COG1201-SHIMMER) study of CT1812 in participants with dementia with Lewy bodies. Other Income (Expense), NetOther income (expense), net consists primarily of interest income from money market funds, other fees such as offering costs incurred to establish our equity line financing, as well as foreign currency transaction gains or losses.Interest ExpenseInterest expense consisted of interest expense related to the insurance premium financing arrangement with a lender.Results of OperationsComparison of the Three Months Ended SeptemberÂ 30,Â 2024 and 2023The following table summarizes our results of operations (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended SeptemberÂ 30,Â â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeOperating Expenses:Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Research and developmentâ€‹$ 11,392â€‹$ 11,669â€‹$ (277)General and administrativeâ€‹Â 3,071â€‹Â 3,076â€‹Â (5)Total operating expensesâ€‹Â 14,463â€‹Â 14,745â€‹Â (282)Loss from operationsâ€‹Â (14,463)â€‹Â (14,745)â€‹Â 282Other income (expense):â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â â€‹Grant incomeâ€‹Â 4,293â€‹Â 7,684â€‹Â (3,391)Other income, netâ€‹Â 236â€‹Â 314â€‹Â (78)Interest expenseâ€‹Â (3)â€‹Â (2)â€‹Â (1)Total other income, netâ€‹Â 4,526â€‹Â 7,996â€‹Â (3,470)Net lossâ€‹$ (9,937)â€‹$ (6,749)â€‹$ (3,188)â€‹Research and Development ExpensesThe following table summarizes our research and development expenses (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended SeptemberÂ 30,Â â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeClinical programsâ€‹$ 7,977â€‹$ 5,367â€‹$ 2,610PersonnelÂ â€‹ 2,591Â â€‹ 2,213Â â€‹ 378ManufacturingÂ â€‹ 515Â â€‹ 2,699Â â€‹ (2,184)Preclinical programsÂ â€‹ 259Â â€‹ 1,292Â â€‹ (1,033)Other expenseÂ â€‹ 50Â â€‹ 98Â â€‹ (48)â€‹â€‹â€‹$ 11,392â€‹$ 11,669â€‹$ (277)â€‹26 Table of ContentsResearch and development expenses were $11.4 million for the three months ended SeptemberÂ 30,Â 2024, compared to $11.7 million for the three months ended SeptemberÂ 30,Â 2023. The decrease of $0.3 million was primarily due to the following:â—an increase of $2.6 million in clinical programs primarily related to increased Phase 2 trial activities with contract research organizations; â—an increase of $0.4 million in personnel costs associated with expanded research and development activities, and equity-based compensation expense;â—a decrease of $2.2 million in manufacturing related to lower costs with contract manufacturing organizations for the production of pre-clinical and future clinical trial supply; andâ—a decrease of $1.1 million in preclinical programs and other expense primarily due to decreased research activities.General and Administrative ExpensesGeneral and administrative expenses were $3.1 million for the three months ended SeptemberÂ 30,Â 2024, compared to $3.1 million for the three months ended SeptemberÂ 30,Â 2023. The change in general and administrative expenses was not significant period over period.Other Income (Expense)Grant IncomeGrant income was $4.3 million for the three months ended SeptemberÂ 30,Â 2024, compared to $7.7 million for the three months ended SeptemberÂ 30,Â 2023. The change in grant income is correlated with the decrease in eligible reimbursable costs related to clinical trials incurred during 2024 as compared to 2023.Other Income, NetOther income, net was $0.2 million for the three months ended SeptemberÂ 30,Â 2024, compared to other income, net of $0.3 million for the three months ended SeptemberÂ 30,Â 2023. The decrease in other income, net was driven primarily by lower interest earned on money market funds.Interest ExpenseInterest expense was less than $0.1 million for the three months ended SeptemberÂ 30,Â 2024, compared to interest expense of less than $0.1 million for the three months ended SeptemberÂ 30,Â 2023. Interest expense was not significant in either period. 27 Table of ContentsComparison of the Nine Months Ended SeptemberÂ 30,Â 2024 and 2023The following table summarizes our results of operations (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeOperating Expenses:Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Research and developmentâ€‹$ 33,522â€‹$ 25,596â€‹$ 7,926General and administrativeâ€‹Â 9,721â€‹Â 9,939â€‹Â (218)Total operating expensesâ€‹Â 43,243â€‹Â 35,535â€‹Â 7,708Loss from operationsâ€‹Â (43,243)â€‹Â (35,535)â€‹Â (7,708)Other income (expense):â€‹Â Â Â Â â€‹Â Â Â Â â€‹Grant incomeâ€‹Â 16,516â€‹Â 18,035â€‹Â (1,519)Other income (expense), netâ€‹Â 813â€‹Â (129)â€‹Â 942Interest expenseâ€‹Â (20)â€‹Â (18)â€‹Â (2)Loss on currency translation from liquidation of subsidiaryâ€‹â€‹ (195)â€‹â€‹ â€”â€‹â€‹ (195)Total other income, netâ€‹Â 17,114â€‹Â 17,888â€‹Â (774)Net lossâ€‹$ (26,129)â€‹$ (17,647)â€‹$ (8,482)â€‹Research and Development ExpensesThe following table summarizes our research and development expenses (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeClinical programsâ€‹$ 22,312Â $ 11,961â€‹$ 10,351PersonnelÂ â€‹ 8,324â€‹â€‹ 6,875Â â€‹ 1,449ManufacturingÂ â€‹ 1,926â€‹â€‹ 3,527Â â€‹ (1,601)Preclinical programsÂ â€‹ 784â€‹â€‹ 2,910Â â€‹ (2,126)Other expenseÂ â€‹ 176â€‹â€‹ 323Â â€‹ (147)Total research & development expensesâ€‹$ 33,522â€‹$ 25,596â€‹$ 7,926â€‹Research and development expenses were $33.5 million for the nine months ended SeptemberÂ 30,Â 2024, compared to $25.6 million for the nine months ended SeptemberÂ 30,Â 2023. The increase of $7.9 million was primarily due to the following:â—an increase of $10.4 million in clinical programs primarily related to increased Phase 2 trial activities with contract research organizations;â—an increase of $1.4 million in personnel costs associated with expanded research and development activities, and equity-based compensation expense;â—a decrease of $1.6 million in manufacturing related to lower costs with contract manufacturing organizations for the production of pre-clinical and future clinical trial supply; andâ—a decrease of $2.3 million in preclinical programs and other expense, primarily due to decreased research activities.28 Table of ContentsGeneral and Administrative ExpensesGeneral and administrative expenses were $9.7 million for the nine months ended SeptemberÂ 30,Â 2024, compared to $9.9 million for the nine months ended SeptemberÂ 30,Â 2023. The decrease of $0.2 million in general and administrative expenses was driven by lower professional services.Other Income (Expense)Grant IncomeGrant income was $16.5 million for the nine months ended SeptemberÂ 30,Â 2024, compared to $18.0 million for the nine months ended SeptemberÂ 30,Â 2023. The change in grant income is correlated with the decrease in eligible reimbursable costs incurred during 2024 as compared to 2023.Other Income (Expense), NetOther income, net was $0.8 million for the nine months ended SeptemberÂ 30,Â 2024, compared to other expense, net of $0.1 million for the nine months ended SeptemberÂ 30,Â 2023. The increase in other income (expense), net was driven primarily by interest earned on money market funds, as well as prior year expenses related to the Lincoln Park Purchase Agreement not repeated in 2024.Interest ExpenseInterest expense was less than $0.1 million for the nine months ended SeptemberÂ 30,Â 2024, compared to interest expense of less than $0.1 million for the nine months ended SeptemberÂ 30,Â 2023. Interest expense was not significant in either period.Liquidity and Capital ResourcesSources of LiquidityTo date, we have funded our operations primarily with proceeds from grants awarded by the NIA, and proceeds from the sales of our convertible promissory notes, convertible preferred stock, SAFE, stock option exercises, follow-on equity offerings, sales under our ATM and equity line

financing, and our IPO. Since our inception, we have received grant awards primarily from the NIA in the aggregate amount of approximately $171.0 million and have raised approximately $126.4 million in net proceeds from sales of our equity securities, convertible notes and SAFE, stock option exercises, our ATM, our equity line financing with Lincoln Park, our IPO and our follow-on public offering. The net proceeds from our IPO, which closed on October 13, 2021, were approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On November 15, 2022, we closed our follow-on public offering, selling 5,000,000 shares of our common stock at a public offering price of $1.20 per share. The net proceeds were approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On December 23, 2022, we entered into a sales agreement with the Sales Agents, providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in ATM offerings. As of SeptemberÂ 30,Â 2024, we sold 3,723,478 shares of common stock under the ATM for gross proceeds of approximately $6.2 million. As of SeptemberÂ 30,Â 2024, there was $33.8 million of common stock remaining available for sale under the ATM. In addition, in March 2023, we entered into the Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, giving the Company the right, but not the obligation to sell to Lincoln Park up to $35.0 million worth of shares of our common stock. As of SeptemberÂ 30,Â 2024, we have sold 125,000 shares of common stock to Lincoln Park for proceeds of $0.2 million, as part of the equity line financing arrangement. As of SeptemberÂ 30,Â 2024, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement. On March 14, 2024, we closed a follow-on public offering of 6,571,428 shares of our common stock at a public offering price of $1.75 per share. As part of the follow-on offering, the underwriters exercised their option to purchase 985,714 shares of our common stock on March 28, 2024, at a public offering price of $1.75 per share. The net proceeds were approximately $11.9 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us.29 Table of ContentsAs of SeptemberÂ 30,Â 2024, we had $22.0 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, and income from non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures into the second quarter of 2025, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect.As of November 13, 2024, the date of issuance of this Quarterly Report, we believe that our cash and cash equivalents as of SeptemberÂ 30,Â 2024 is not sufficient to fund operations for the period through one year after the date of this filing and therefore we have concluded that substantial doubt exists about our ability to continue as a going concern. To execute our business plans, we will need substantial funding to support our continuing operations and pursue our growth strategy. Until such time that we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. There can be no assurance that additional financing will be available to us or that such financing, if available, will be available on terms acceptable to us. The terms of any financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding, we could be forced to delay, reduce or abandon our product development programs, which could have a material adverse effect on our business prospects.Future Funding RequirementsWe expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company. We anticipate that we will need to raise additional funding in the future to fund our operations, including continuing and completing our clinical trials. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. Our future funding requirements will depend on many factors, including, but not limited to:â—the scope, progress, costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to a pandemic, such as the COVID-19 pandemic or other diseases, macroeconomic conditions, global or political instability, such as the ongoing global and regional conflicts, inflation, or other delays;â—the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;â—the extent to which we develop, in-license or acquire other product candidates and technologies;â—the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;â—the availability, timing, and receipt of any future NIA grants;â—the number and development requirements of other product candidates that we may pursue;â—the costs, timing and outcome of regulatory review of our product candidates;30 Table of Contentsâ—the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;â—the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;â—our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States;â—the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; â—our ability to maintain the listing of our common stock on the Nasdaq Global Market; andâ—the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.Until such time as we can generate significant revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic or other diseases, the ongoing global and regional conflicts, inflation, liquidity constraints, failures and instability in U.S. and international financial banking systems, and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities.31 Table of ContentsCash FlowsThe following table summarizes our cash flows for the periods indicated (in thousands):â€‹â€‹â€‹

results.There is substantial doubt about our ability to continue as a going concern.Â Our management has concluded that, based on our current operating plan, there is substantial doubt as to whether we can continue as a going concern for the twelve months following the issuance of this Quarterly Report. To date, we have not generated any revenues from product sales and have incurred significant operating losses in each year since our inception and we anticipate that losses may continue for the next several years or until such time as we can generate substantial revenues and achieve profitability. As of SeptemberÂ 30,Â 2024, we had $22.0 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, and income from non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures into the second quarter of 2025, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement. Our ability to continue as a going concern is dependent upon raising capital to maintain current operations and continue research and development efforts. We plan to raise additional capital to fund our operations through public or private equity offerings, debt financings, and/or potential collaborations and license arrangement or other sources. There is no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on terms acceptable to us or at all. If such additional capital is not available on satisfactory terms, or is not available in sufficient amounts, or if we are unable to enter into a collaboration, we may be required to delay, limit or eliminate the development of CT1812 and our ability to achieve our business objectives, our competitiveness, and our business, financial condition and results of operations will be materially adversely affected.â€‹If we fail to comply or regain compliance with the continued listing standards of the Nasdaq Global Market, or Nasdaq, we may be delisted and the price of our common stock, or ability to access the capital markets and our financial condition could be negatively impacted. â€‹Our common stock is currently listed on the Nasdaq Stock Market LLC, which has minimum requirements that a company must meet in order to remain listed. These requirements include maintaining a minimum closing bid price of $1.00 per share, which closing bid cannot fall below $1.00 per share for a period of more than 30 consecutive trading days. On September 12, 2024, we received a deficiency letter from the Staff of the Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Rule 5450(a)(1). The Nasdaq deficiency letter has no immediate effect on the listing of our common stock, and our common stock will continue to trade on the Nasdaq under the symbol â€œCGTXâ€ at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been given 180 calendar days, or until March 11, 2025, to regain compliance with Rule 5450(a)(1). If at any time before March 11, 2025, 35 Table of Contentsthe bid price of our common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance.â€‹If we do not regain compliance with Rule 5450(a)(1) by March 11, 2025, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, we must submit an application to transfer the listing of our common stock to The Nasdaq Capital Market, which requires us to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. We intend to actively monitor the closing bid price for our common stock and will consider available options to resolve the deficiency and regain compliance with Rule 5450(a)(1), including transferring the listing of our common stock to The Nasdaq Capital Market and effecting a reverse stock split. However, there can be no assurance that the Company will regain compliance with the minimum bid price requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable. If Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face negative consequences including the reduction of liquidity and market price of our common stock, our ability to obtain sufficient additional capital to fund our operations, and our ability to continue to operate as a going concern would be substantially impaired.â€‹Item 2. Unregistered Sales of Equity Securities and Use of ProceedsRecent Sales of Unregistered SecuritiesThere were no unregistered sales of our equity securities during the fiscal quarter ended SeptemberÂ 30,Â 2024.Use of Proceeds from our Initial Public Offering of Common StockOur registration statement on Form S-1 (File Nos. 333-257999 and 333-260128) relating to the IPO was declared effective by the SEC on October 7, 2021. There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus, dated October 7, 2021, filed with the SEC pursuant to Rule 424(b) under the Securities Act.Repurchase of Shares of Company Equity SecuritiesNone.Item 3. Defaults Upon Senior SecuritiesNone.Item 4. Mine Safety DisclosuresNot applicable.Item 5. Other InformationNone.â€‹36 Table of ContentsItem 6. ExhibitsExhibitÂ Â Â Incorporated by ReferenceÂ FiledNumberÂ Exhibit DescriptionÂ FormÂ File No.Â ExhibitÂ FilingÂ DateÂ Herewith31.1Â Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Â Â Â Â Â Â Â Â Â X31.2Â Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Â Â Â Â Â Â Â Â Â X32.1*Â Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Â Â Â Â Â Â Â Â Â X32.2*Â Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Â Â Â Â Â Â Â Â Â X101.INSÂ Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.Â Â Â Â Â Â Â Â Â X101.SCHÂ Inline XBRL Taxonomy Extension Schema DocumentÂ Â Â Â Â Â Â Â Â Â X101.CALÂ Inline XBRL Taxonomy Extension Calculation Linkbase DocumentÂ Â Â Â Â Â Â Â Â Â X101.DEFÂ Inline XBRL Taxonomy Extension Definition Linkbase DocumentÂ Â Â Â Â Â Â Â Â Â X101.LABÂ Inline XBRL Taxonomy Extension Label Linkbase DocumentÂ Â Â Â Â Â Â Â Â Â X101.PREÂ Inline XBRL Taxonomy Extension Presentation Linkbase DocumentÂ Â Â Â Â Â Â Â Â Â X104â€‹Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Xâ€‹* This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.â€‹37 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Cognition Therapeutics, Inc.Â Â Â Date: November 13, 2024By:/s/ Lisa RicciardiÂ Â Lisa RicciardiÂ Â Chief Executive Officer, President and Director(Principal Executive Officer)Â Â Â Â Â Â Date: November 13, 2024By:/s/ John DoyleÂ Â John DoyleÂ Â Chief Financial Officer(PrincipalÂ Financial and Accounting Officer)â€‹â€‹â€‹38 EX-31.1 2 cgtx-20240930xex31d1.htm EX-31.1 Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO SECTION 302OF THE SARBANES-OXLEY ACT OF 2002I, Lisa Ricciardi, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Cognition Therapeutics, Inc. (the â€œregistrantâ€); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. â€‹â€‹â€‹â€‹â€‹â€‹Date: November 13, 2024By: /s/ Lisa Ricciardiâ€‹â€‹Lisa Ricciardi â€‹â€‹Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹ EX-31.2 3 cgtx-20240930xex31d2.htm EX-31.2 Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICERPURSUANT TO SECTION 302OF THE SARBANES-OXLEY ACT OF 2002I, John Doyle, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Cognition Therapeutics, Inc. (the â€œregistrantâ€); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. â€‹â€‹â€‹â€‹â€‹â€‹Date: November 13, 2024By:/s/ John Doyleâ€‹â€‹John Doyleâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹ EX-32.1 4 cgtx-20240930xex32d1.htm EX-32.1 Â Exhibit 32.1 CERTIFICATION PURSUANT TO18Â U.S.C. SECTIONÂ 1350AS ADOPTED PURSUANT TO SECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of Cognition Therapeutics, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended SeptemberÂ 30,Â 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Lisa Ricciardi, do hereby certify, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that: (1)The Report fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Securities Exchange Act of 1934, as amended; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Date: November 13, 2024By:/s/ Lisa Ricciardiâ€‹â€‹Lisa Ricciardiâ€‹â€‹Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹ EX-32.2 5 cgtx-20240930xex32d2.htm EX-32.2 Â Exhibit 32.2 CERTIFICATION PURSUANT TO18Â U.S.C. SECTIONÂ 1350AS ADOPTED PURSUANT TO SECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of Cognition Therapeutics, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended SeptemberÂ 30,Â 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, John Doyle, do hereby certify, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that: (1)The Report fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Securities Exchange Act of 1934, as amended; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. â€‹â€‹J. â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Date: November 13, 2024By:/s/ John Doyleâ€‹â€‹John Doyleâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹ EX-101.SCH 6 cgtx-20240930.xsd EX-101.SCH 995200100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Description of Business and Financial Condition (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Stockholders' Equity - (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Equity-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Equity-based Compensation - Fair value of options (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Equity-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940806 - Disclosure - Equity-based Compensation - Compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Net Loss per Share - Antidilutive effect (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of Business and Financial Condition link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Equity-based Compensation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Accrued Expenses (Tables) link:presentationLink

link:calculationLink link:definitionLink 99930603 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Equity-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Equity-based Compensation - Activity for options (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cgtx-20240930_cal.xml EX-101.CAL EX-101.DEF 8 cgtx-20240930_def.xml EX-101.DEF EX-101.LAB 9 cgtx-20240930_lab.xml EX-101.LAB Document and Entity Information [Abstract] Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Grants Receivable, Current Grant receivables Prepaid Expense, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Right-of-use assets, operating leases Total operating lease assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total The amount of current portion of deferred grant income as at the end of the reporting period. Deferred Grant Income, Current Deferred grant income, current Operating Lease, Liability, Current Operating lease liabilities, current Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Operating lease liabilities, net of current portion Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 6) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock, $0.001 par value, 250,000,000 shares authorized; 40,806,092 and 32,165,478 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Equity, Attributable to Parent Ending Balances Beginning Balances Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Income (Loss) [Abstract] Operating Expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other income (expense): Amount of income related to grants. Grant Income Grant income Grant income Other Noncash Income (Expense) Other expense, net Other income (expense), net Interest Income (Expense), Nonoperating Interest expense Foreign Currency Transaction Loss, before Tax Loss on currency translation from liquidation of subsidiary Loss on currency translation from liquidation of subsidiary Other Nonoperating Income (Expense) Total other income, net Net loss Net loss Net loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment, including reclassifications Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding, diluted (in shares) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sale of Stock [Axis] Sale of Stock [Domain] Represents information relating to follow on pubic offering. Follow-On Public Offering [Member] Follow-on Public Offering Represents information pertaining to at the market offering. At Market Offering [Member] At The Market Offering Represents information relating to equity line financing. Equity Line Financing [Member] Equity Line Financing Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Gain Increase (Decrease) in Stockholders' Equity [Roll Forward] Shareholders' Equity Shares, Outstanding Ending Balances (in shares) Beginning Balances (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock Stock Issued During Period, Shares, New Issues Shares issued (in shares) Issuance of common stock (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of common stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Options exercised (in shares) Options exercised (in shares) Exercise of common stock options (in shares) Aggregate value of stock related to vesting of Restricted Stock Units during the period. Stock Issued During Period, Value, Vesting of Restricted Stock Units Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes Total number of shares issued during the period, including shares forfeited, as a result of vesting of Restricted Stock Units. Stock Issued During Period, Shares, Vesting of Restricted Stock Units Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Equity-based compensation The amount of reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary. Reclassifications Adjustment of Foreign Currency Translation Included in Net Loss For Liquidation of Subsidiary Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary Other Comprehensive Income (Loss), Net of Tax Other comprehensive gain Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance of common stock, discounts and offering costs CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Share-Based Payment Arrangement, Noncash Expense Equity-based compensation Operating Lease, Right-of-Use Asset, Periodic Reduction Amortization of right-of-use assets The amount of adjustments relating to commitment shares issued for equity line financing. Issuance of Common Stock as Commitment Shares For Equity Line Financing Issuance of common stock as commitment shares for equity line financing Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Amount of increase and decrease in grant receivables. Increase (Decrease) In Grant Receivables Grant receivables Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Amount of increase (decrease) in current deferred grant income. Increase (Decrease) In Deferred Grant Income, Current Deferred grant income and other liabilities Increase (Decrease) in Operating Lease Liability Operating lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Payments for property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from Issuance Initial Public Offering Net proceeds Proceeds from issuance of common stock Proceeds from Stock Options Exercised Proceeds from the exercise of common stock options Payment, Tax Withholding, Share-Based Payment Arrangement Payment of employee withholding taxes on vested restricted stock units Repayments of Short-Term Debt Payments on loan payable Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash and Cash Equivalents [Abstract] Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Description of Business and Financial Condition Business Description and Basis of Presentation [Text Block] Description of Business and Financial Condition Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Financial Instruments and Fair Value Measurements Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Other Current Liabilities. Entire disclosure of other current liabilities. Other Current Liabilities [Text Block] Other Current Liabilities Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity. Equity [Text Block] Stockholders' Equity Equity-based Compensation Share-Based Payment Arrangement [Text Block] Equity-based Compensation Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Receivable [Policy Text Block] Receivables Disclosure of accounting policy for grant income. Grant Income, Policy [Policy Text Block] Grant income Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Share-Based Payment Arrangement [Policy Text Block] Equity-based Compensation Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Segment Reporting, Policy [Policy Text Block] Segments Disclosure of accounting policy for emerging growth company status. Emerging Growth Company [Policy Text Block] Emerging Growth Company Status New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Income Tax, Policy [Policy Text Block] Income Taxes Fair Value, by Balance Sheet Grouping [Table Text Block] Summary of financial assets and liabilities measured at fair value Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Lease, Cost [Table Text Block] Schedule of lease cost Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of minimum lease commitments Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of fair value of options granted using the Black-Scholes option pricing model Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of activity for options Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of restricted stock units award activity Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of total equity-based compensation expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding potentially dilutive common stock Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc. Cantor Fitzgerald And Co And B Riley Securities Inc [Member] Cantor Fitzgerald & Co. and B. Riley Securities, Inc. Represents information pertaining to Lincoln Park Capital Fund, LLC. Lincoln Park Capital Fund LLC [Member] Lincoln Park Over-Allotment Option [Member] Over-Allotment Option Subsidiary, Sale of Stock [Line Items] Description of Business and Financial Condition The maximum amount of aggregate offering price. Maximum Aggregate Offering Price Aggregate offering price Maximum equity impact of the value of new stock to be issued under an agreement. Maximum Value Of Stock To Be Issued Under Agreement Maximum value of stock to be issued under agreement The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Purchase Agreement, Term Term of agreement Remaining value of new stock to be issued under an agreement. Remaining Value Of Stock To Be Issued Under Agreement Amount available to draw under purchase agreement Shares Issued, Price Per Share Offering price per share (in dollars per share) Underwriters option to purchase additional shares. Underwriters, Option To Purchase Additional Shares Underwriters option to purchase additional shares (in shares) The gross cash inflow associated with the amount received from entity's first offering of stock to the public. Proceeds from Issuance Initial Public Offering, Gross Gross proceeds Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Summary of Significant Accounting Policies Amount of allowance for credit loss on grants receivable, classified as current. Allowance for Credit Loss, Grants Receivable, Current Allowance for doubtful accounts on grants receivable Other Liabilities, Noncurrent Deferred grant income, noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Expected dividend yield Number of Operating Segments Number of operating segments Unrecognized Tax Benefits Unrecognized income tax Fair Value, by Balance Sheet Grouping [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money market funds Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Quoted Priced in Active Markets (Level 1) Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Instruments and Fair Value Measurements Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Money market funds Assets, Fair Value Disclosure Total assets Employee-related Liabilities, Current Employee compensation, benefits, and related accruals Represents accrued research and development expenses. Accrued Research And Development Expenses Research and development costs Accrued Professional Fees, Current Professional fees and other accruals Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information relating to insurance premium financing agreement. Insurance Premium Financing Agreement [Member] Insurance Premium Financing Agreement Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Other Current Liabilities [Member] Other Current Liabilities Debt Instrument [Line Items] Other Current Liabilities Debt Instrument, Face Amount Face amount Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Debt Instrument, Periodic Payment Periodic payment Short-Term Debt Short-term loan Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] The amount of operating lease assets as at the end of the reporting period. Operating Lease Assets Operating lease assets Liabilities [Abstract] Liabilities Liabilities, Noncurrent [Abstract] Noncurrent Operating Lease, Liability Total operating lease liabilities Operating Lease, Expense Operating lease costs Loss Contingencies [Table] Loss Contingencies [Line Items] Commitments and Contingencies Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Minimum lease commitments Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 (remaining) Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, To Be Paid, After Year Four Thereafter Lessee, Operating Lease, Liability, to be Paid Total undiscounted lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (years) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Operating Lease, Payments Operating cash flows used for operating leases Stock, Class of Stock [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to underwriting agreement with Titan Partners Group LLC. Underwriting Agreement With Titan Partners Group LLC [Member] Underwriting Agreement With Titan Partners Group LLC Class of Stock [Line Items] Stockholders' Equity Dividends, Common Stock Dividend declared The remaining value of stock to be issued under shares offering agreement. Shares Offering Agreement, Remaining Value of Stock to be Issued Remaining of common stock available for sale Sale of Stock, Price Per Share Public offering price (in dollars per share) The amount of underwriting discounts, commissions and offering expenses. Underwriting Discounts, Commissions And Offering Expenses Offering expenses Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan. Amended And Restated Equity Incentive Plan 2017 [Member] Amended and Restated 2017 Equity Incentive Plan .Represents information relating to 2021 Equity Incentive Plan. Equity Incentive Plan 2021 [Member] 2021 Equity Incentive Plan Represents information relating to Employee Stock Purchase Plan. Employee Stock Purchase Plan [Member]

ESPP Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Equity-based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized Number of additional common shares reserved for future issuance. Common Stock, Additional Capital Shares Reserved for Future Issuance Additional common stock shares reserved for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Maximum percentage of common shares issued and outstanding Common Stock, Capital Shares Reserved for Future Issuance Common stock shares reserved for issuance Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number Number of shares that may be recycled Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Number of additional shares authorized Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Ending Balance (in shares) Beginning Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Options forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Options expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Ending Balance (in dollars per share) Beginning Balance (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Options expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life -Exercisable Restricted Stock Units (RSUs) [Member] Restricted Stock Units Represents the information pertaining to performance based vesting of Restricted Stock Units. Restricted Stock Units, Performance Based Vesting [Member] Restricted Stock Units Performance Based Vesting Represents the information pertaining to time based vesting of Restricted Stock Units. Restricted Stock Units, Time Based Vesting [Member] Restricted Stock Units Time Based Vesting Grantee Status [Axis] Grantee Status [Domain] Director [Member] Person serving on board of non employee directors. Non Employee Director [Member] Non Employee Director Share-Based Payment Arrangement, Employee [Member] Employees Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value (in dollars per share) Represents the total fair value of options granted during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value Fair value of options granted Represents the total fair value of options exercised during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value Fair value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of stock options exercised Number of shares issuable for each award under share-based payment arrangement. ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable for Each Award Number of shares issuable for each award Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Number of target tranches achieved during the period. Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Target Tranches Achieved Number of target tranches achieved Number of target tranches. Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Target Tranches Number of target tranches Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] RSU activity Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending balance Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Equity based compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Beginning balance Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and development General and Administrative Expense [Member] General and administrative Represents information pertaining to performance based stock options. Performance Based Stock Options [Member] Performance-based awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Equity-based Compensation Share-Based Payment Arrangement, Expense Total equity-based compensation Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized compensation cost related to options Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average period over which the unrecognized compensation cost is expected to be recognized Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Equity Option [Member] Options issued and outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Loss per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive common stock equivalents outstanding EX-101.PRE 10 cgtx-20240930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Document and Entity Information [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Securities Act File Number 001-40886 Â Entity Registrant Name Cognition Therapeutics,Â Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 13-4365359 Â Entity Address, Address Line One 2500 Westchester Ave. Â Entity Address, City or Town Purchase Â Entity Address, State or Province NY Â Entity Address, Postal Zip Code 10577 Â City Area Code 412 Â Local Phone Number 481-2210 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol CGTX Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 41,547,995 Entity Central Index Key 0001455365 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name:

dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 22,011 $ 29,922 Grant receivables 3,369 1,281 Prepaid expenses and other current assets 1,450 3,019 Total current assets 26,830 34,222 Property and equipment, net 207 284 Right-of-use assets, operating leases 542 657 Total assets 27,579 35,163 Current liabilities: Â Â Accounts payable 1,895 3,695 Accrued expenses 9,505 4,055 Deferred grant income, current 1,117 1,701 Operating lease liabilities, current 188 174 Other current liabilities Â 544 Total current liabilities 12,705 10,169 Operating lease liabilities, non-current 392 520 Total liabilities 13,097 10,689 Commitments and contingencies (Note 6) Stockholders' equity: Â Â Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common stock, $0.001 par value, 250,000,000 shares authorized; 40,806,092 and 32,165,478 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 41 32 Additional paid-in capital 181,759 165,826 Accumulated deficit (167,318) (141,189) Accumulated other comprehensive loss Â (195) Total stockholders' equity 14,482 24,474 Total liabilities and stockholders' equity $ 27,579 $ 35,163 X - DefinitionThe amount of current portion of deferred grant income as at the end of the reporting period. + ReferencesNo definition available. + Details Name: cgtx_DeferredGrantIncomeCurrent Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and

discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_GrantsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -

Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 CONSOLIDATED BALANCE SHEETS Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 250,000,000 250,000,000 Common stock, shares issued 40,806,092 32,165,478 Common stock, shares outstanding 40,806,092 32,165,478 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating Expenses: Â Â Â Â Research and development $ 11,392 $ 11,669 $ 33,522 $ 25,596 General and administrative 3,071 3,076 9,721 9,939 Total operating expenses 14,463 14,745 43,243 35,535 Loss from operations (14,463) (14,745) (43,243) (35,535) Other income (expense): Â Â Â Â Grant income 4,293 7,684 16,516 18,035 Other income (expense), net 236 314 813 (129) Interest expense (3) (2) (20) (18) Loss on currency translation from liquidation of subsidiary Â Â (195) Â Total other income, net 4,526 7,996 17,114 17,888 Net loss (9,937) (6,749) (26,129) (17,647) Foreign currency translation adjustment, including reclassifications Â Â 195 3 Total comprehensive loss $ (9,937) $ (6,749) $ (25,934) $ (17,644) Net loss per share, basic (in dollars per share) $ (0.25) $ (0.22) $ (0.69) $ (0.59) Net loss per

share, diluted (in dollars per share) $ (0.25) $ (0.22) $ (0.69) $ (0.59) Weighted-average common shares outstanding, basic (in shares) 40,418,065 30,365,506 38,080,658 29,696,296 Weighted-average common shares outstanding, diluted (in shares) 40,418,065 30,365,506 38,080,658 29,696,296 X - DefinitionAmount of income related to grants. + ReferencesNo definition available. + Details Name: cgtx_GrantIncome Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Follow-on Public Offering Common Stock Follow-on Public Offering Additional Paid-in Capital Follow-on Public Offering At The Market Offering Common Stock At The Market Offering Additional Paid-in Capital At The Market Offering Equity Line Financing Common Stock Equity Line Financing Additional Paid-in Capital Equity Line Financing Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive (Loss) Gain Total Beginning Balances at Dec. 31, 2022 Â Â Â Â Â Â Â Â $ 29 $ 155,820 $ (115,401) $ (199) $ 40,249 Beginning Balances (in shares) at Dec. 31, 2022 Â Â Â Â Â Â Â Â 28,991,548 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â Â $ 197 $ 197 Â $ 318 $ 318 Â Â Â Â Â Â Issuance of common stock (in shares) Â Â Â 95,823 Â Â 189,856 Â Â Â Â Â Â Equity-based compensation Â Â Â Â Â Â Â Â Â Â 1,187 Â $ 1,187 Other comprehensive gain Â Â Â Â Â Â Â Â Â Â 4 4 Net loss Â Â Â Â Â Â Â Â Â Â (6,172) Â (6,172) Ending Balances at Mar. 31, 2023 Â Â Â Â Â Â Â Â $ 29 157,522 (121,573) (195) 35,783 Ending Balances (in shares) at Mar. 31, 2023 Â Â Â Â Â Â Â Â 29,277,227 Â Â Â Â Beginning Balances at Dec. 31, 2022 Â Â Â Â Â Â Â Â Â Â $ 29 155,820 (115,401) (199) $ 40,249 Beginning Balances (in shares) at Dec. 31, 2022 Â Â Â Â Â Â Â Â 28,991,548 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise of common stock options (in shares) Â Â Â Â Â Â Â Â Â Â 0 Net loss Â Â Â Â Â Â Â Â Â Â $ (17,647) Ending Balances at Sep. 30, 2023 Â Â Â Â Â Â Â Â $ 30 162,140 (133,048) (196) 28,926 Ending Balances (in shares) at Sep. 30, 2023 Â Â Â Â Â Â Â Â 30,417,082 Â Â Â Â Beginning Balances at Dec. 31, 2022 Â Â Â Â Â Â Â Â Â Â $ 29 155,820 (115,401) (199) 40,249 Beginning Balances (in shares) at Dec. 31, 2022 Â Â Â Â Â Â Â Â 28,991,548 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â Â Â Â Â Â Â Â Â Â (25,788) Ending Balances at Dec. 31, 2023 Â Â Â Â Â Â Â Â $ 32 165,826 (141,189) (195) 24,474 Ending Balances (in shares) at Dec. 31, 2023 Â Â Â Â Â Â Â Â 32,165,478 Â Â Â Â Beginning Balances at Mar. 31, 2023 Â Â Â Â Â Â Â Â $ 29 157,522 (121,573) (195) 35,783 Beginning Balances (in shares) at Mar. 31, 2023 Â Â Â Â Â Â Â Â 29,277,227 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â $ 1 2,304 2,305 Â Â Â Â Â Â Â Â Issuance of common stock (in shares) Â Â Â 1,009,355 Â Â Â Â Â Â Â Â Equity-based compensation Â Â Â Â Â Â Â Â Â Â 1,025 Â Â 1,025 Other comprehensive gain Â Â Â Â Â Â Â Â Â Â (1) (1) Net loss Â Â Â Â Â Â Â Â Â Â (4,726) Â (4,726) Ending Balances at Jun. 30, 2023 Â Â Â Â Â Â Â Â $ 30 160,851 (126,299) (196) $ 34,386 Ending Balances (in shares) at Jun. 30, 2023 Â Â Â Â Â Â Â Â 30,286,582 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â Â 8 8 Â $ 210 $ 210 Â Â Â Â Â Â Issuance of common stock (in shares) Â Â Â 5,500 Â Â 125,000 Â Â Â Â Â Â Â Â Exercise of common stock options (in shares) Â Â Â Â Â Â Â Â Â Â 0 Equity-based compensation Â Â Â Â Â Â Â Â Â Â 1,071 Â Â $ 1,071 Net loss Â Â Â Â Â Â Â Â Â Â (6,749) Â (6,749) Ending Balances at Sep. 30, 2023 Â Â Â Â Â Â Â Â $ 30 162,140 (133,048) (196) 28,926 Ending Balances (in shares) at Sep. 30, 2023 Â Â Â Â Â Â Â Â 30,417,082 Â Â Â Â Beginning Balances at Dec. 31, 2023 Â Â Â Â Â Â Â Â $ 32 165,826 (141,189) (195) 24,474 Beginning Balances (in shares) at Dec. 31, 2023 Â Â Â Â Â Â Â Â 32,165,478 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock $ 8 $ 11,888 $ 11,896 Â 381 381 Â Â Â Â Â Â Â Â Issuance of common stock (in shares) 7,557,142 Â Â 191,273 Â Â Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes Â Â Â Â Â Â Â Â Â Â (106) Â (106) Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares) Â Â Â Â Â Â Â Â 71,973 Â Â Â Â Equity-based compensation Â Â Â Â Â Â Â Â Â Â 1,171 Â Â 1,171 Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary Â Â Â Â Â Â Â Â Â Â 195 195 Net loss Â Â Â Â Â Â Â Â Â Â (9,151) Â (9,151) Ending Balances at Mar. 31, 2024 Â Â Â Â Â Â Â Â $ 40 179,160 (150,340) Â 28,860 Ending Balances (in shares) at Mar. 31, 2024 Â Â Â Â Â Â Â Â 39,985,866 Â Â Â Â Beginning Balances at Dec. 31, 2023 Â Â Â Â Â Â Â Â $ 32 165,826 (141,189) $ (195) $ 24,474 Beginning Balances (in shares) at Dec. 31, 2023 Â Â Â Â Â Â Â Â 32,165,478 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise of common stock options (in shares) Â Â Â Â Â Â Â Â Â Â 93,350 Net loss Â Â Â Â Â Â Â Â Â Â $ (26,129) Ending Balances at Sep. 30, 2024 Â Â Â Â Â Â Â Â $ 41 181,759 (167,318) Â 14,482 Ending Balances (in shares) at Sep. 30, 2024 Â Â Â Â Â Â Â Â 40,806,092 Â Â Â Â Beginning Balances at Mar. 31, 2024 Â Â Â Â Â Â Â Â $ 40 179,160 (150,340) Â 28,860 Beginning Balances (in shares) at Mar. 31, 2024 Â Â Â Â Â Â Â Â 39,985,866 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise of common stock options Â Â Â Â Â Â Â Â Â Â 65 Â 65 Exercise of common stock options (in shares) Â Â Â Â Â Â Â Â 73,350 Â Â Â Â Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes Â Â Â Â Â Â Â Â Â Â (22) Â (22) Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares) Â Â Â Â Â Â Â Â 53,052 Â Â Â Â Equity-based compensation Â Â Â Â Â Â Â Â Â Â 1,147 Â Â 1,147 Net loss Â Â Â Â Â Â Â Â Â Â (7,041) Â (7,041) Ending Balances at Jun. 30, 2024 Â Â Â Â Â Â Â Â $ 40 180,350 (157,381) Â 23,009 Ending Balances (in shares) at Jun. 30, 2024 Â Â Â Â Â Â Â Â 40,112,268 Â Â Â Â Shareholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â $ 1 $ 496 $ 497 Â Â Â Â Â Â Â Â Issuance of common stock (in shares) Â Â Â 673,131 Â Â Â Â Â Â Â Â Exercise of common stock options Â Â Â Â Â Â Â Â Â Â 17 Â $ 17 Exercise of common stock options (in shares) Â Â Â Â Â Â Â Â 20,000 Â Â Â 20,000 Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares) Â Â Â Â Â Â Â Â 693 Â Â Â Â Equity-based compensation Â Â Â Â Â Â Â Â Â Â 896 Â Â $ 896 Net loss Â Â Â Â Â Â Â Â Â Â (9,937) Â (9,937) Ending Balances at Sep. 30, 2024 Â Â Â Â Â Â Â Â $ 41 $ 181,759 $ (167,318) Â $ 14,482 Ending Balances (in shares) at Sep. 30, 2024 Â Â Â Â Â Â Â Â 40,806,092 Â Â Â Â X - DefinitionThe amount of reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary. + ReferencesNo definition available. + Details Name: cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of vesting of Restricted Stock Units. + ReferencesNo definition available. + Details Name: cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits Namespace Prefix: cgtx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate value of stock related to vesting of Restricted Stock Units during the period. + ReferencesNo definition available. + Details Name: cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-

05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands 3 Months Ended Mar. 31, 2024 USD ($) Follow-on Public Offering Â Issuance of common stock, discounts and offering costs $ 1,329 X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash flows from operating activities: Â Â Â Â Â Â Â Net loss $ (9,937) $ (9,151) $ (6,749) $ (6,172) $ (26,129) $ (17,647) $ (25,788) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Depreciation and amortization Â Â Â Â 80 69 Â Equity-based compensation Â Â Â Â 3,214 3,283 Â Amortization of right-of-use assets Â Â Â Â 115 117 Â Loss on currency translation from liquidation of subsidiary Â Â Â Â 195 Â Â Issuance of common stock as commitment shares for equity line financing Â Â Â Â Â Â 318 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Grant receivables Â Â Â Â (2,088) 2,034 Â Prepaid expenses and other assets Â Â Â Â 1,569 962 Â Accounts payable and accrued expenses Â Â Â Â 3,650 1,837 Â Deferred grant income and other liabilities Â Â Â Â (584) (1,426) Â Operating lease liabilities Â Â Â Â (114) (109) Â Net cash used in operating activities Â Â Â Â (20,092) (10,562) Â Cash flows from investing activities: Â Â Â Â Â Â Â Payments for property and equipment Â Â Â Â (3) (117) Â Net cash used in investing activities Â Â Â Â (3) (117) Â Cash flows from financing activities: Â Â Â Â Â Â Â Proceeds from the exercise of common stock options Â Â Â Â 82 Â Â Payment of employee withholding taxes on vested restricted stock units Â Â Â Â (128) Â Â Payments on loan payable Â Â Â Â (544) (632) Â Net cash provided by financing activities Â Â Â Â 12,184 2,082 Â Effect of exchange rate changes on cash and cash equivalents Â Â Â Â Â 4 Â Net decrease in cash and cash equivalents Â Â Â Â (7,911) (8,593) Â Cash and cash equivalents Â Â Â Â Â Â Â Cash and cash equivalents - beginning of period Â $ 29,922 Â $ 41,562 29,922 41,562 41,562 Cash and cash equivalents - end of period $ 22,011 Â $ 32,969 Â 22,011 32,969 $ 29,922 At The Market Offering Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â 878 2,509 Â Follow-on Public Offering Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â $ 11,896 Â Â Equity Line Financing Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â $ 205 Â X - DefinitionAmount of increase (decrease) in current deferred grant income. + ReferencesNo definition available. + Details Name: cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase and decrease in grant receivables. + ReferencesNo definition available. + Details Name: cgtx_IncreaseDecreaseInGrantReceivables Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of adjustments relating to commitment shares issued for equity line financing. + ReferencesNo definition available. + Details Name: cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Financial Condition 9 Months Ended Sep. 30, 2024 Description of Business and Financial Condition Â Description of Business and Financial Condition 1. Description of Business and Financial ConditionCognition Therapeutics, Inc. (the â€œCompanyâ€) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (â€œCNSâ€) and retina. The Companyâ€™s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.In January 2024, the Company ceased operations at Cognition Therapeutics PTY LTD, a wholly owned subsidiary (the â€œSubsidiaryâ€) and completed its liquidation of the Subsidiary (the â€œLiquidationâ€). In accordance with the Liquidation, the Company removed the AOCI balance associated with the currency translation adjustments and recorded a loss on liquidation of the Subsidiary in accumulated deficit.On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the â€œShelfâ€) with the Securities and Exchange Commission (â€œSECâ€) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000Â in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (the â€œSales Agentsâ€) providing for the offering, issuance and sale by the Company of up to $40,000Â of its common stock from time to time in â€œat-the-marketâ€ offerings under the Shelf (the â€œATMâ€). During the nine months ended SeptemberÂ 30,Â 2024, the Company sold 864,404 shares of its common stock pursuant to the ATM for gross proceeds of approximately $905. Please refer to Note 7 for further details.On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (â€œLincoln Parkâ€) for an equity line financing (the â€œPurchase Agreementâ€). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Companyâ€™s sole discretion, over a 36-month period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Parkâ€™s commitment to purchase shares of common stock under the Purchase Agreement. During the nine months ended SeptemberÂ 30,Â 2024, the Company did not sell any shares of common stock to Lincoln Park. As of SeptemberÂ 30,Â 2024, $34,795 was available to draw pursuant to the Purchase Agreement. Please refer to Note 7 for further details.On March 14, 2024, the Company closed a follow-on public offering ofÂ 6,571,428Â shares of the Companyâ€™s common stock at a public offering price of $1.75Â per share (â€œMarch 2024 Offeringâ€). As part of the March 2024 Offering, the underwriters exercised their option to purchaseÂ 985,714Â shares of the Companyâ€™s common stock on March 28, 2024, at a public offering price of $1.75Â per share. The gross proceeds from the March 2024 Offering were $13,225Â and the net proceeds were approximately $11,896, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company.Liquidity and Going ConcernThe Companyâ€™s Consolidated Financial Statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $26,129Â for the nine months ended SeptemberÂ 30,Â 2024 and $25,788 for the year ended DecemberÂ 31,Â 2023. As of SeptemberÂ 30,Â 2024, the Company had cash and cash equivalents of $22,011 compared to $29,922 of cash and cash equivalents as of DecemberÂ 31,Â 2023. The Company has incurred losses and negative cash flows from operations and had an accumulated deficit of $167,318Â as of SeptemberÂ 30,Â 2024. The Company expects to continue to incur losses for the foreseeable future.As of November 13, 2024, the date of issuance of these Consolidated Financial Statements, the Company believes that its cash and cash equivalents as of SeptemberÂ 30,Â 2024 is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Companyâ€™s ability to continue as a going concern.To execute its business plans, the Company will need substantial funding to support its continuing operations and pursue its growth strategy. Until such time that the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Companyâ€™s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or abandon its product development programs, which could have a material adverse effect on its business prospects.â€‹ X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying consolidated financial statements as of SeptemberÂ 30,Â 2024, and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Companyâ€™s management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary to present fairly the Companyâ€™s financial position as of SeptemberÂ 30,Â 2024, the statements of operations and comprehensive loss and stockholdersâ€™ equity for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, and cash flows for the nine months ended SeptemberÂ 30,Â 2024 and 2023. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of the results for the year ending DecemberÂ 31,Â 2024, or for any future period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended DecemberÂ 31,Â 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 26, 2024.Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.Cash and Cash EquivalentsCash and cash equivalents consist primarily of

interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.ReceivablesGrant ReceivablesGrant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (â€œNIHâ€) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.Grant IncomeThe Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company generated grant income of $4,293 and $16,516, respectively, as compared to $7,684 and $18,035 for the three and nine months ended SeptemberÂ 30,Â 2023, respectively, primarily from reimbursements from the National Institute of Aging (the â€œNIAâ€), a division of the NIH for aging research. The current and non-current portion of deferred grant income as of SeptemberÂ 30,Â 2024 was $1,117 and $0, respectively, as compared to the current and non-current portion of deferred grant income as of DecemberÂ 31,Â 2023 of $1,701 and $0, respectively.The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (â€œCROsâ€), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIHâ€™s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Companyâ€™s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of SeptemberÂ 30,Â 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.Research and Development CostsThe Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimerâ€™s disease, dementia with Lewy bodies, and geographic atrophy (â€œGAâ€) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to its research and development activities, including allocated facility-related expenses and external costs of outside vendors, including CROs, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.Equity-based CompensationFollowing the provisions of ASC 718, Compensationâ€‰â€”â€‰Stock Compensation, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company recognizes compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. The grant date fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to a lack of sufficient public market data for the Companyâ€™s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.Prior to the IPO, due to the absence of an active market for the Companyâ€™s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, armâ€™s-length sales of the Companyâ€™s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Companyâ€™s financial position and historical financial performance, the status of technological developments within the Companyâ€™s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Companyâ€™s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors determines the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.Concentration of Credit RiskThe Companyâ€™s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.Fair Value of Financial InstrumentsThe Company applies ASC 820, Fair Value Measurement (â€œASC 820â€), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Companyâ€™s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entityâ€™s own assumptions based on market data and the entityâ€™s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.The carrying value of the Companyâ€™s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:â—LevelÂ 1â€‰â€”â€‰Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.â—LevelÂ 2â€‰â€”â€‰ Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.â—LevelÂ 3â€‰â€”â€‰ Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.Net Loss Per ShareBasic net loss per share is computed by dividing the net loss per share by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. SegmentsThe Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Companyâ€™s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.Emerging Growth Company StatusThe Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.Recent Accounting PronouncementsNot Yet AdoptedIn October 2023, the FASB issued ASU 2023-06, Disclosure Improvements (â€œASU 2023-06â€), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (â€œASU 2023-09â€). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entityâ€™s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entityâ€™s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures. Income TaxesIn accordance with ASC 270,Â Interim Reporting,Â and ASC 740,Â Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate, apply that rate in providing for income taxes on a current year-to-date (interim period) basis, and include the tax impact for discrete items within the interim period. The Company maintains a full valuation allowance against all deferred tax assets as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As ofÂ SeptemberÂ 30,Â 2024Â andÂ DecemberÂ 31,Â 2023, the Company hadÂ no uncertain tax positions. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments and Fair Value Measurements 9 Months Ended Sep. 30, 2024 Financial Instruments and Fair Value Measurements Â Financial Instruments and Fair Value MeasurementsFinancial assets and liabilities measured at fair value are summarized below:â€‹â€‹â€‹

v3.24.3 Accrued Expenses 9 Months Ended Sep. 30, 2024 Accrued Expenses Â Accrued Expenses 4. Accrued ExpensesAccrued expense consists of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023â€‹Employee compensation, benefits, and related accrualsâ€‹$ 1,480â€‹$ 1,165â€‹Research and development costsâ€‹Â 7,795â€‹Â 2,520â€‹Professional fees and other accrualsâ€‹Â 230â€‹Â 370â€‹Totalâ€‹$ 9,505â€‹$ 4,055â€‹â€‹ X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Other Current Liabilities 9 Months Ended Sep. 30, 2024 Other Current Liabilities. Â Other Current Liabilities 5. Other Current LiabilitiesIn October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through September 2024. As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the outstanding principal of the loan was $0 and $544, respectively, and is included in other current liabilities on the consolidated balance sheet. X - DefinitionEntire disclosure of other current liabilities. + ReferencesNo definition available. + Details Name: cgtx_OtherCurrentLiabilitiesTextBlock Namespace Prefix: cgtx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies. Â Commitments and Contingencies 6. Commitments and ContingenciesOperating LeasesAmounts reported in the consolidated balance sheets for leases where the Company is the lessee as of SeptemberÂ 30,Â 2024 were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023AssetsÂ â€‹â€‹Â â€‹Operating lease assets$ 542â€‹$ 657Total operating lease assets$ 542â€‹$ 657Liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Currentâ€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities$ 188â€‹$ 174Non-currentâ€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities, non-currentâ€‹ 392â€‹â€‹ 520Total operating lease liabilities$ 580â€‹$ 694â€‹Operating lease costs for the three and nine months ended SeptemberÂ 30,Â 2024 was $55 and $164, respectively, as compared to operating lease costs for the three and nine months ended SeptemberÂ 30,Â 2023 of $53 and $161, respectively.â€‹The maturities of the operating lease liabilities and minimum lease payments as of SeptemberÂ 30,Â 2024 were as follows:â€‹â€‹â€‹â€‹â€‹For the Years Ended December 31,Â Â Â Â Â OperatingÂ Leases2024 (remaining)â€‹$ 562025â€‹Â 2262026â€‹Â 1582027â€‹â€‹ 912028â€‹â€‹ 92Thereafterâ€‹â€‹ 39Total undiscounted lease paymentsâ€‹$ 662Less: Imputed interestâ€‹â€‹ (82)Present value of operating lease liabilitiesâ€‹$ 580â€‹The following table summarizes the lease term and discount rate as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, respectively:â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023Weighted-average remaining lease term (years)â€‹â€‹â€‹Operating leases 3.5â€‹ 4.1Weighted-average discount rateâ€‹â€‹â€‹Operating leases8.1%â€‹8.1%â€‹Operating cash flows used for operating leases for the nine months ended SeptemberÂ 30,Â 2024 and 2023 was $168 and $154, respectively.Litigation and ContingenciesFrom time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability but instead discloses the nature and the amount of the claim and an estimate of the loss or range of loss, if such an estimate can reasonably be made.As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, there was no litigation or contingency with at least a reasonable possibility of a material loss. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity. Â Stockholders' Equity 7. Stockholdersâ€™ EquityCommon and Preferred StockThe Company is authorized to issue up toÂ 250,000,000Â shares of common stock with a par value of $0.001Â per share, andÂ 10,000,000Â shares of preferred stock with a par value of $0.001Â per share. Common stockholders are entitled to dividends if and when declared by the Companyâ€™s board of directors subject to the rights of the preferred stockholders. As of SeptemberÂ 30,Â 2024,Â no dividends on common stock had been declared by the Company.ATMOn December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate (the â€œShelfâ€). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in ATM offerings under the Shelf. The Company sold 864,404 shares of common stock pursuant to the ATM during the nine months ended SeptemberÂ 30,Â 2024 for gross proceeds of approximately $905. As of SeptemberÂ 30,Â 2024, there was $33,809 remaining of common stock available for sale under the ATM. Lincoln Park Purchase AgreementOn March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Companyâ€™s sole discretion, over a 36-month period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Parkâ€™s commitment to purchase shares of common stock under the Purchase Agreement (the â€œCommitment Sharesâ€). The Company recorded $318 to other expense, net in connection with the issuance of the Commitment Shares. During the nine months ended SeptemberÂ 30,Â 2024, the Company did not sell any shares of common stock to Lincoln Park. As of SeptemberÂ 30,Â 2024, $34,795 was available to draw pursuant to the Purchase Agreement.March 2024 OfferingIn March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of 7,557,142 shares of its common stock, which included the exercise of the underwritersâ€™ option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwritersâ€™ option to purchase 985,714 additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $11,896, after deducting $1,329 of underwriting discounts and commissions and other offering related expenses payable by the Company. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation 9 Months Ended Sep. 30, 2024 Equity-based Compensation Â Equity-based Compensation 8. Equity-based Compensation2021 Equity Incentive PlanOn October 7, 2021, the date upon which the Companyâ€™s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Companyâ€™s 2021 Equity Incentive Plan (the â€œ2021 Planâ€) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the â€œ2017 Planâ€). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units (â€œRSUsâ€), and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers. As of SeptemberÂ 30,Â 2024, the aggregate number of shares of common stock of the Company that may be issued under the 2021 Plan is 2,547,943. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2024 pursuant to an evergreen provision therein by 643,309 shares, representing 2% of total common shares outstanding at DecemberÂ 31,Â 2023. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Companyâ€™s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Companyâ€™s board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the â€œ2007 Planâ€ and collectively with the 2017 Plan, the â€œPrior Plansâ€) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.2017 Equity Incentive PlanOn September 15, 2017, the Companyâ€™s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The board of directors, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Companyâ€™s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan provides for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised shall subsequently be available for reissuance under the 2021 Plan.Employee Stock Purchase PlanThe Companyâ€™s board of directors approved the Employee Stock Purchase Plan (the â€œESPPâ€) prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Companyâ€™s common stock at a discounted purchase price. As of SeptemberÂ 30,Â 2024, subject to adjustment as provided in the ESPP, a total of 209,532 shares of common stock are authorized and reserved for issuance under the ESPP. Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i)Â 1,000,000Â shares of common stock, (ii)Â 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above.Stock OptionsThe fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â Â Â 2024Â Â Â Â Â 2023Expected volatilityÂ 91.78%â€‰â€“â€‰92.29%Â 91.53%â€‰â€“â€‰92.68%Risk-free interest rateÂ 4.23%â€‰â€“â€‰4.45%Â 3.46%â€‰â€“â€‰4.26%Dividend yieldÂ 0%Â 0%Expected term (years)Â 6.10â€‰â€“â€‰6.20Â 6.18â€‰â€“â€‰6.36â€‹â€‹Expected Termâ€‰â€“â€‰The expected term

represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.Risk-Free Interest Rateâ€‰â€”â€‰The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awardsâ€™ expected term.Expected Volatilityâ€‰â€”â€‰Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.Dividend Yieldâ€‰â€”â€‰The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.Fair Value of Common Stockâ€‰â€”â€‰Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors determined the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date.Activity for options was as follows:â€‹â€‹â€‹

Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Basis of Presentation Basis of PresentationThe accompanying consolidated financial statements as of SeptemberÂ 30,Â 2024, and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Companyâ€™s management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary to present fairly the Companyâ€™s financial position as of SeptemberÂ 30,Â 2024, the statements of operations and comprehensive loss and stockholdersâ€™ equity for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, and cash flows for the nine months ended SeptemberÂ 30,Â 2024 and 2023. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of the results for the year ending DecemberÂ 31,Â 2024, or for any future period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended DecemberÂ 31,Â 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 26, 2024. Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Receivables ReceivablesGrant ReceivablesGrant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (â€œNIHâ€) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. Grant income Grant IncomeThe Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company generated grant income of $4,293 and $16,516, respectively, as compared to $7,684 and $18,035 for the three and nine months ended SeptemberÂ 30,Â 2023, respectively, primarily from reimbursements from the National Institute of Aging (the â€œNIAâ€), a division of the NIH for aging research. The current and non-current portion of deferred grant income as of SeptemberÂ 30,Â 2024 was $1,117 and $0, respectively, as compared to the current and non-current portion of deferred grant income as of DecemberÂ 31,Â 2023 of $1,701 and $0, respectively.The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (â€œCROsâ€), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIHâ€™s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Companyâ€™s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of SeptemberÂ 30,Â 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. Research and Development Costs Research and Development CostsThe Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimerâ€™s disease, dementia with Lewy bodies, and geographic atrophy (â€œGAâ€) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to its research and development activities, including allocated facility-related expenses and external costs of outside vendors, including CROs, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses. Equity-based Compensation Equity-based CompensationFollowing the provisions of ASC 718, Compensationâ€‰â€”â€‰Stock Compensation, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company recognizes compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. The grant date fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to a lack of sufficient public market data for the Companyâ€™s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.Prior to the IPO, due to the absence of an active market for the Companyâ€™s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, armâ€™s-length sales of the Companyâ€™s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Companyâ€™s financial position and historical financial performance, the status of technological developments within the Companyâ€™s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Companyâ€™s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors determines the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. Concentration of Credit Risk Concentration of Credit RiskThe Companyâ€™s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds. Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe Company applies ASC 820, Fair Value Measurement (â€œASC 820â€), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Companyâ€™s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entityâ€™s own assumptions based on market data and the entityâ€™s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.The carrying value of the Companyâ€™s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:â—Level Â 1â€‰â€”â€‰ Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.â—Level Â 2â€‰â€”â€‰ Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.â—Level Â 3â€‰â€”â€‰ Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. Net Loss Per Share Net Loss Per ShareBasic net loss per share is computed by dividing the net loss per share by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Segments SegmentsThe Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Companyâ€™s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Emerging Growth Company Status Emerging Growth Company StatusThe Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recent Accounting Pronouncements Recent Accounting PronouncementsNot Yet AdoptedIn October 2023, the FASB issued ASU 2023-06, Disclosure Improvements (â€œASU 2023-06â€), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (â€œASU 2023-09â€). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entityâ€™s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entityâ€™s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures. Income Taxes Income TaxesIn accordance with ASC 270,Â Interim Reporting,Â and ASC 740,Â Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate, apply that rate in providing for income taxes on a current year-to-date (interim period) basis, and include the tax impact for discrete items within the interim period. The Company maintains a full valuation allowance against all deferred tax assets as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As ofÂ SeptemberÂ 30,Â 2024Â andÂ DecemberÂ 31,Â 2023, the Company hadÂ no uncertain tax positions. X - DefinitionDisclosure of accounting policy for emerging growth company status. + ReferencesNo definition available. + Details Name: cgtx_EmergingGrowthCompanyPolicyTextBlock Namespace Prefix: cgtx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for grant income. + ReferencesNo definition available. + Details Name: cgtx_GrantIncomePolicyPolicyTextBlock Namespace Prefix: cgtx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -

SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2 + Details Name: us-gaap_ReceivablesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments and Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Financial Instruments and Fair Value Measurements Â Summary of financial assets and liabilities measured at fair value â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Significantâ€‹â€‹â€‹â€‹â€‹â€‹Quoted Priced inâ€‹Significant Otherâ€‹Unobservableâ€‹â€‹â€‹â€‹â€‹â€‹Active Marketsâ€‹Observable Inputsâ€‹Inp market fundsâ€‹ 21,766â€‹ â€”â€‹ â€”â€‹ 21,766Total assetsâ€‹ 21,766â€‹ â€”â€‹ â€”â€‹ 21,766â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of DecemberÂ 31,Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Significantâ€‹â€‹â€‹â€‹â€‹â€‹Quoted Priced inâ€‹Significant Otherâ€‹Unobservableâ€‹â€‹â€‹â€‹â€‹â€‹Active Marketsâ€‹Observable Inputsâ€‹Inp market fundsâ€‹ 29,391â€‹ â€”â€‹ â€”â€‹ 29,391Total assetsâ€‹ 29,391â€‹ â€”â€‹ â€”â€‹ 29,391â€‹ X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Accrued Expenses Â Schedule of accrued expenses â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023â€‹Employee compensation, benefits, and related accrualsâ€‹ 1,480â€‹ 1,165â€‹Research and development costsâ€‹Â 7,795â€‹Â 2,520â€‹Professional fees and other accrualsâ€‹Â 230â€‹Â 370â€‹Totalâ€‹ 9,505â€‹ 4,055â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies. Â Schedule of lease cost Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of SeptemberÂ 30,Â 2024 were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023AssetsÂ â€‹â€‹Â â€‹Operating lease assets$ 542â€‹ 657Total operating lease assets$ 542â€‹ 657Liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Currentâ€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities$ 188â€‹ 174Non-currentâ€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities, non-currentâ€‹ 392â€‹â€‹ 520Total operating lease liabilities$ 580â€‹ 694The following table summarizes the lease term and discount rate as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, respectively:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As ofâ€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023Weighted-average remaining lease term (years)â€‹â€‹â€‹â€‹Operating leases 3.5â€‹ 4.1Weighted-average discount rateâ€‹â€‹â€‹Operating leases8.1%â€‹8.1% Schedule of minimum lease commitments â€‹â€‹â€‹â€‹â€‹â€‹For the Years Ended December 31,Â Â Â Â Â OperatingÂ Leases2024 (remaining)â€‹ 562025â€‹Â 2262026â€‹Â 1582027â€‹â€‹ 912028â€‹â€‹ 92Thereafterâ€‹â€‹ 39Total undiscounted lease paymentsâ€‹ 662Less: Imputed interestâ€‹â€‹ (82)Present value of operating lease liabilitiesâ€‹ 580 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Equity-based Compensation Â Schedule of fair value of options granted using the Black-Scholes option pricing model â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Expected volatilityÂ 91.78%â€‰â€“â€‰92.29%Â 91.53%â€‰â€“â€‰92.68%Risk-free interest rateÂ 4.23%â€‰â€“â€‰4.45%Â 3.46%â€‰â€“â€‰4.26%Dividend yieldÂ 0%Â 0%Expected term (years)Â 6.10â€‰â€“â€‰6.20Â 6.18â€‰â€“â€‰6.36 Summary of activity for options â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

522,155â€‹$ 2.07Grantedâ€‹ 873,800â€‹$ 1.97Vestedâ€‹ (183,482)â€‹$ 2.17Forfeitedâ€‹ (8,125)â€‹$ 2.25Outstanding at SeptemberÂ 30,Â 2024â€‹ 1,204,348â€‹$ 1.98 Schedule of total equity-based compensation expense â€‹Three Months Ended SeptemberÂ 30,Â â€‹Nine Months Ended SeptemberÂ 30,Â Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Research and developmentâ€‹$ 291â€‹$ 176â€‹$ 804â€‹$ 489â€‹General and administrativeâ€‹Â 605â€‹Â 895â€‹Â 2,410â€‹Â 2,794â€‹Total equity-based compensationâ€‹$ 896â€‹$ 1,071â€‹$ 3,214â€‹$ 3,283â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Net Loss per Share Â Schedule of outstanding potentially dilutive common stock â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Options issued and outstandingÂ 4,362,080Â 4,184,594Restricted stock units issued and outstandingâ€‹ 1,204,348â€‹ 522,594TotalÂ 5,566,428Â 4,707,188â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Financial Condition (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Mar. 10, 2024 Mar. 10, 2023 Jan. 03, 2023 Dec. 23, 2022 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â Â Â Â $ 9,937 $ 7,041 $ 9,151 $ 6,749 $ 4,726 $ 6,172 $ 26,129 $ 17,647 $ 25,788 Cash and cash equivalents Â Â Â Â 22,011 Â Â Â Â Â Â 22,011 Â 29,922 Accumulated deficit Â Â Â Â $ 167,318 Â Â Â Â Â 167,318 Â $ 141,189 Follow-on Public Offering Â Â Â Â Â Â Â Â Â Â Â Â Â Â Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares issued (in shares) 6,571,428 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â 11,896 Â Â Offering price per share (in dollars per share) $ 1.75 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Gross proceeds $ 13,225 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net proceeds $ 11,896 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Over-Allotment Option Â Â Â Â Â Â Â Â Â Â Â Â Â Â Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering price per share (in dollars per share) $ 1.75 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Underwriters option to purchase additional shares (in shares) 985,714 Â Â Â Â Â Â Â Â Â Â Â Â Â Â At The Market Offering Â Â Â Â Â Â Â Â Â Â Â Â Â Â Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Â Â Aggregate offering price Â Â Â $ 200,000 Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â Â Â 878 2,509 Â Amount available to draw under purchase agreement Â Â Â Â Â Â Â Â Â Â $ 33,809 Â Â Equity Line Financing Â Â Â Â Â Â Â Â Â Â Â Â Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â Â Â Â Â $ 205 Â Cantor Fitzgerald & Co. and B. Riley Securities, Inc. | At The Market Offering Â Â Â Â Â Â Â Â Â Â Â Â Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Maximum value of stock to be issued under agreement Â Â $ 40,000 $ 40,000 Â Â Â Â Â Â Â Â Â Â Shares issued (in shares) Â Â Â Â Â Â Â Â Â Â 864,404 Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â Â Â $ 905 Â Â Lincoln Park | Equity Line Financing Â Â Â Â Â Â Â Â Â Â Â Â Description of Business and Financial Condition Â Â Â Â Â Â Â Â Â Â Â Â Maximum value of stock to be issued under agreement Â $ 35,000 Â Â Â Â Â Â Â Â Â Â Shares issued (in shares) Â 189,856 Â Â Â Â Â Â Â Â Â Â Term of agreement Â 36 months Â Â Â Â Â Â Â Â Â Â Amount available to draw under purchase agreement Â Â Â Â Â Â Â Â Â Â $ 34,795 Â Â X - DefinitionThe maximum amount of aggregate offering price. + ReferencesNo definition available. + Details Name: cgtx_MaximumAggregateOfferingPrice Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum equity impact of the value of new stock to be issued under an agreement. + ReferencesNo definition available. + Details Name: cgtx_MaximumValueOfStockToBeIssuedUnderAgreement Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe gross cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesNo definition available. + Details Name: cgtx_ProceedsFromIssuanceInitialPublicOfferingGross Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: cgtx_PurchaseAgreementTerm Namespace Prefix: cgtx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRemaining value of new stock to be issued under an agreement. + ReferencesNo definition available. + Details Name: cgtx_RemainingValueOfStockToBeIssuedUnderAgreement Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnderwriters option to purchase additional shares. + ReferencesNo definition available. + Details Name: cgtx_UnderwritersOptionToPurchaseAdditionalShares Namespace Prefix: cgtx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_FollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Summary of Significant Accounting Policies Â Â Â Â Â Allowance for doubtful accounts on grants receivable $ 0 Â $ 0 Â Â Grant income 4,293 $ 7,684 16,516 $ 18,035 Â Deferred grant income, current 1,117 1,701 1,117 1,701 $ 1,701 Deferred grant income, noncurrent 0 $ 0 $ 0 $ 0 Â Expected dividend yield Â Â 0.00% 0.00% Â Number of operating segments | segment Â Â 1 Â Â Unrecognized income tax $ 0 Â $ 0 Â $ 0 X - DefinitionAmount of allowance for credit loss on grants receivable, classified as current. + ReferencesNo definition available. + Details Name: cgtx_AllowanceForCreditLossGrantsReceivableCurrent Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of current portion of deferred grant income as at the end of the reporting period. + ReferencesNo definition available. + Details Name: cgtx_DeferredGrantIncomeCurrent Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of income related to grants. + ReferencesNo definition available. + Details Name: cgtx_GrantIncome Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments and Fair Value Measurements (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets: Â Â Total assets $ 21,766 $ 29,391 Quoted Priced in Active Markets (Level 1) Â Â Assets: Â Â Total assets 21,766 29,391 Money market funds Â Â Assets: Â Â Money market funds 21,766 29,391 Money market funds | Quoted Priced in Active Markets (Level 1) Â Â Assets: Â Â Money market funds $ 21,766 $ 29,391 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Expenses Â Â Employee compensation, benefits, and related accruals $ 1,480 $ 1,165 Research and development costs 7,795 2,520 Professional fees and other accruals 230 370 Total $ 9,505 $ 4,055 X - DefinitionRepresents accrued research and development expenses. + ReferencesNo definition available. + Details Name: cgtx_AccruedResearchAndDevelopmentExpenses Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Other Current Liabilities (Details) - Insurance Premium Financing Agreement - USD ($) $ in Thousands 11 Months Ended Sep. 30, 2024 Dec. 31, 2023 Oct. 31, 2023 Other Current Liabilities Â Â Â Face amount Â Â $ 721 Interest rate (as a percent) Â Â 8.65% Periodic payment $ 62 Â Â Other Current Liabilities Â Â Â Other Current Liabilities Â Â Â Short-term loan $ 0 $ 544 Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=cgtx_InsurancePremiumFinancingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Leases (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Assets Â Â Â Â Â Operating lease assets $ 542 Â $ 542 Â $ 657 Total operating lease assets 542 Â 542 Â 657 Current liabilities: Â Â Â Â Â Operating lease liabilities, current 188 Â 188 Â 174 Noncurrent Â Â Â Â Â Operating lease liabilities, net of current portion 392 Â 392 Â 520 Total operating lease liabilities 580 Â 580 Â $ 694 Operating lease costs $ 55 $ 53 $ 164 $ 161 Â X - DefinitionThe amount of operating lease assets as at the end of the reporting period. + ReferencesNo definition available. + Details Name: cgtx_OperatingLeaseAssets Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Minimum lease commitments Â Â 2024 (remaining) $ 56 Â 2025 226 Â 2026 158 Â 2027 91 Â 2028 92 Â Thereafter 39 Â Total undiscounted lease payments 662 Â Less: Imputed interest (82) Â Total operating lease liabilities $ 580 $ 694 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: cgtx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Lease Term And Discount (Details) Sep. 30, 2024 Dec. 31, 2023 Commitments and Contingencies. Â Â Weighted-average remaining lease term (years) 3 years 6 months 4 years 1 month 6 days Weighted-average discount rate 8.10% 8.10% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Operating Lease Liabilities (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies. Â Â Operating cash flows used for operating leases $ 168 $ 154 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash

outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Mar. 28, 2024 Mar. 28, 2024 Mar. 14, 2024 Mar. 10, 2023 Jan. 03, 2023 Dec. 23, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Stockholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized Â Â Â Â Â Â 250,000,000 Â 250,000,000 Â 250,000,000 Common stock, par value (in dollars per share) Â Â Â Â Â Â $ 0.001 Â $ 0.001 Â $ 0.001 Preferred stock shares authorized Â Â Â Â Â Â 10,000,000 Â 10,000,000 Â 10,000,000 Preferred stock, par value (in dollars per share) Â Â Â Â Â Â $ 0.001 Â $ 0.001 Â $ 0.001 Dividend declared Â Â Â Â Â Â Â Â $ 0 Â Â Other expense, net Â Â Â Â Â Â $ 236 $ 314 813 $ (129) Â At The Market Offering Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Aggregate offering price Â Â Â Â Â $ 200,000 Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â 878 2,509 Â Amount available to draw under purchase agreement Â Â Â Â Â Â Â Â $ 33,809 Â Â Equity Line Financing Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â Â Â $ 205 Â Underwriting Agreement With Titan Partners Group LLC Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock (in shares) Â Â 7,557,142 Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â $ 11,896 Â Â Â Â Â Â Â Â Underwriters option to purchase additional shares (in shares) 985,714 Â 985,714 Â Â Â Â Â Â Â Â Public offering price (in dollars per share) Â Â $ 1.75 Â Â Â Â Â Â Â Â Offering expenses Â $ 1,329 Â Â Â Â Â Â Â Â Â Â Cantor Fitzgerald & Co. and B. Riley Securities, Inc. | At The Market Offering Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Maximum value of stock to be issued under agreement Â Â Â Â $ 40,000 $ 40,000 Â Â Â Â Â Issuance of common stock (in shares) Â Â Â Â Â Â Â 864,404 Â Â Proceeds from issuance of common stock Â Â Â Â Â Â Â Â $ 905 Â Â Remaining of common stock available for sale Â Â Â Â Â Â $ 34,795 Â 34,795 Â Â Lincoln Park | Equity Line Financing Â Â Â Â Â Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Â Â Â Â Â Â Maximum value of stock to be issued under agreement Â Â Â $ 35,000 Â Â Â Â Â Â Â Â Issuance of common stock (in shares) Â Â Â 189,856 Â Â Â Â Â Â Â Â Amount available to draw under purchase agreement Â Â Â Â Â Â Â Â $ 34,795 Â Â Term of agreement Â Â Â 36 months Â Â Â Â Â Â Â Other expense, net Â Â Â $ 318 Â Â Â Â Â Â Â Â X - DefinitionThe maximum amount of aggregate offering price. + ReferencesNo definition available. + Details Name: cgtx_MaximumAggregateOfferingPrice Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum equity impact of the value of new stock to be issued under an agreement. + ReferencesNo definition available. + Details Name: cgtx_MaximumValueOfStockToBeIssuedUnderAgreement Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: cgtx_PurchaseAgreementTerm Namespace Prefix: cgtx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRemaining value of new stock to be issued under an agreement. + ReferencesNo definition available. + Details Name: cgtx_RemainingValueOfStockToBeIssuedUnderAgreement Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe remaining value of stock to be issued under shares offering agreement. + ReferencesNo definition available. + Details Name: cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUnderwriters option to purchase additional shares. + ReferencesNo definition available. + Details Name: cgtx_UnderwritersOptionToPurchaseAdditionalShares Namespace Prefix: cgtx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of underwriting discounts, commissions and offering expenses. + ReferencesNo definition available. + Details Name: cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgtx_EquityLineFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=cgtx_LincolnParkCapitalFundLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation (Details) - shares 9 Months Ended Jan. 01, 2024 Sep. 30, 2024 Sep. 15, 2017 Amended and Restated 2017 Equity Incentive Plan Â Â Â Equity-based Compensation Â Â Â Number of shares authorized Â Â 4,334,131 2021 Equity Incentive Plan Â Â Â Equity-based Compensation Â Â Â Number of shares authorized Â 2,547,943 Â Additional common stock shares reserved for issuance 643,309 Â Â Maximum percentage of common shares issued and outstanding 2.00% 5.00% Â Common stock shares reserved for issuance Â 7,543,185 Â Number of shares that may be recycled Â 4,334,131 Â ESPP Â Â Â Equity-based Compensation Â Â Â Number of shares authorized Â 209,532 Â Maximum percentage of common shares issued and outstanding Â 1.00% Â Number of additional shares authorized Â 1,000,000 Â X - DefinitionNumber of additional common shares reserved for future issuance. + ReferencesNo definition available. + Details Name: cgtx_CommonStockAdditionalCapitalSharesReservedForFutureIssuance Namespace Prefix: cgtx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement. + ReferencesNo definition available. + Details Name: cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber Namespace Prefix: cgtx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=cgtx_AmendedAndRestatedEquityIncentivePlan2017Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=cgtx_EquityIncentivePlan2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=cgtx_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation - Fair value of options (Details) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Expected volatility, minimum 91.78% 91.53% Expected volatility, maximum 92.29% 92.68% Risk-free interest rate, minimum 4.23% 3.46% Risk-free interest rate, maximum 4.45% 4.26% Dividend yield 0.00% 0.00% Minimum Â Â Expected term (years) 6 years 1 month 6 days 6 years 2 months 4 days Maximum Â Â Expected term (years) 6 years 2 months 12 days 6 years 4 months 9 days X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation - Activity for options (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Number of Options Â Â Â Â Â Beginning Balance (in shares) Â Â 4,213,405 Â Â Options granted (in shares) 0 19,500 247,500 595,769 Â Options exercised (in shares) (20,000) 0 (93,350) 0 Â Options forfeited (in shares) Â Â (4,225) Â Â Options expired (in shares) Â Â (1,250) Â Â Ending Balance (in shares) 4,362,080 Â 4,362,080 Â 4,213,405 Exercisable (in shares) 3,599,654 Â 3,599,654 Â Â Weighted Average Exercise Price Â Â Â Â Â Beginning Balance (in dollars per share) Â Â $ 4.73 Â Â Options granted (in dollars per share) Â Â 1.97 Â Â Options exercised (in dollars per share) Â Â 0.88 Â Â Options forfeited (in dollars per share) Â Â 2.49 Â Â Options expired (in dollars per share) Â Â 2.66 Â Â Ending Balance (in dollars per share) $ 4.66 Â 4.66 Â $ 4.73 Exercisable (in dollars per share) $ 5.09 Â $ 5.09 Â Â Aggregate Intrinsic Value Â Â Â Â Â Aggregate Intrinsic Value Â Â Â Â $ 1,579 Weighted Average Remaining Contractual Life Â Â 6 years 1 month 6 days Â 6 years 6 months Weighted Average Remaining Contractual Life -Exercisable Â Â 5 years 6 months Â Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-

types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) tranche $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Equity-based Compensation Â Â Â Â Â Weighted-average grant date fair value (in dollars per share) | $ / shares $ 0 $ 1.25 $ 1.56 $ 1.59 Options granted (in shares) 0 19,500 247,500 595,769 Fair value of options granted | $ $ 0 $ 24 $ 385 $ 950 Options exercised (in shares) 20,000 0 93,350 0 Fair value of options exercised | $ $ 12 Â $ 58 Â Intrinsic value of stock options exercised | $ $ 29 Â $ 121 Â Restricted Stock Units Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Number of shares issuable for each award Â Â 1 Â Restricted Stock Units | Employees Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Options granted (in shares) 35,100 Â 873,800 Â Restricted Stock Units Performance Based Vesting Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Number of target tranches achieved | tranche Â Â 1 Â Number of target tranches | tranche Â Â 2 Â Restricted Stock Units Performance Based Vesting | Employees Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Vesting period Â Â 1 year Â Restricted Stock Units Time Based Vesting | Non Employee Director Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Vesting period Â Â 1 year Â Restricted Stock Units Time Based Vesting | Employees | Minimum Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Vesting period Â Â 3 years Â Restricted Stock Units Time Based Vesting | Employees | Maximum Â Â Â Â Â Equity-based Compensation Â Â Â Â Â Vesting period Â Â 4 years Â X - DefinitionNumber of shares issuable for each award under share-based payment arrangement. ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 + ReferencesNo definition available. + Details Name: cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward Namespace Prefix: cgtx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of target tranches. + ReferencesNo definition available. + Details Name: cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetTranches Namespace Prefix: cgtx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of target tranches achieved during the period. + ReferencesNo definition available. + Details Name: cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetTranchesAchieved Namespace Prefix: cgtx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the total fair value of options exercised during the reporting period. + ReferencesNo definition available. + Details Name: cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the total fair value of options granted during the reporting period. + ReferencesNo definition available. + Details Name: cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue Namespace Prefix: cgtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsPerformanceBasedVestingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=cgtx_RestrictedStockUnitsTimeBasedVestingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=cgtx_NonEmployeeDirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units 9 Months Ended Sep. 30, 2024 $ / shares shares RSU activity Â Beginning balance | shares 522,155 Granted | shares 873,800 Vested | shares (183,482) Forfeited | shares (8,125) Ending balance | shares 1,204,348 Equity based compensation Â Beginning balance | $ / shares $ 2.07 Granted | $ / shares 1.97 Vested | $ / shares 2.17 Forfeited | $ / shares 2.25 Ending balance | $ / shares $ 1.98 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Equity-based Compensation - Compensation expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Equity-based Compensation Â Â Â Â Total equity-based compensation $ 896 $ 1,071 $ 3,214 $ 3,283 Total unrecognized compensation cost related to options 3,121 Â $ 3,121 Â Weighted average period over which the unrecognized compensation cost is expected to be recognized Â Â 1 year 10 months 20 days Â Performance-based awards Â Â Â Â Equity-based Compensation Â Â Â Â Total unrecognized compensation cost related to options 628 Â $ 628 Â Weighted average period over which the unrecognized compensation cost is expected to be recognized Â Â 1 year 21 days Â Research and development Â Â Â Â Equity-based Compensation Â Â Â Â Total equity-based compensation 291 176 $ 804 489 General and administrative Â Â Â Â Equity-based Compensation Â Â Â Â Total equity-based compensation $ 605 $ 895 $ 2,410 $ 2,794 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=cgtx_PerformanceBasedStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Antidilutive effect (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Net Loss per Share Â Â Potentially dilutive common stock equivalents outstanding 5,566,428 4,707,188 Options issued and outstanding Â Â Net Loss per Share Â Â Potentially dilutive common stock equivalents outstanding 4,362,080 4,184,594 Restricted Stock Units Â Â Net Loss per Share Â Â Potentially dilutive common stock equivalents outstanding 1,204,348 522,594 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

M2+7&2*P#K@K)*DZVDT5L$[(MU44:NF%;EM[9M@"DJ^D^'V^"U*-4-L0"O2[6E[MM *0/5I!2%@K -FCE=8X0DXI7Q5G]T()L,UD>5!8WZU_'[@J3L5;]Z_QQ10# M]V?
XPB]/ P_NRQ\C[@*^BC.!$KI40^GGCIHN+_WRPO)-L4!]C.3DJ7%US4- M(LIS@'J^9$SN+_(!ZE]9)O\"4$L#!!0 (*X];5ETYC?6%A8 %J 0 8 M >&PO=V]R:W-H965T&ULS=UK<]O&?L?
QMX)1S[3)S%%$ MW,G4]DPL+(#%U<=RVNE#1H(L-A2I0U)V\NX/*-&" "P7@OS-M'D0Z[+X+"!J M_P*Q/RS>?%UO?M_>5-7.^.-VN=J^/;G9[>Y^/CO;7MY4M_/M3^N[:E5_YW]]
MN9WOZD\WG\^V=YMJ?O6PT>WRS)I,O+/;^6)U\N[-P]<^;-Z|6=_ OEHM5]6%C M;.]O;^>;/]]7R_77MR?FR;U^O?NPJ3\[>U*N M%K?5:KM8KXQ-=?WVY!?SYW]Z]3=X:/%?B^KK]MG'QOY0?
ENO?]]_(J_>GDSV M>U0MJ\O=GIC7_WRISJOEW&UNWE[,CTQKJKK^?UR]W']-:X.!^3NOWDQ+B\W^[6MX>- MZSVX7:P>_YW_S.!I9W9 /GL('3W:5C M&[B'#=SN+AT[:.^P@=?=I6/'X!\V\+N[Y!
[98'K88-K9P#GV8YT=-IAU=\DZ M]L)-OKURD\XFYK&C,)]>[.ZK;?G'-OGVIW&9!>+CQ7\8 MXA^_RD__8YP:OUX$Q@]_^]'XF[%8&9]NUO?;^>IJ^^9L5^ _-WCR[//3_K%G
MZTC/X7I9UZ;3ND1\N]MN;@TRNOK:K-8?3;.U[>W]9;W^L !2W* MX:O043^"Z#5=*)Q8[XA_WB]V?QI9_64C7*SFJ\L7'+Y\C3GJZ)-7]*!@4CTS M<)C9P$LPYH#R >OR\O[V?CG?
55=&4%TO+A<[!5*\"EW-]5F_SK6YRTW^Q.* M+Y7Q0[;>;G\THQJ\18&7>OS3NG=@9W6Y>ZIYUE/-LQXDW M,5UW:DW:S?)^LU/3=)V)V6Y7J-K-.GV6_4;.Q'*:5JUQ;3^-:WOLN/ZAKHC;
MFWG]@_KQ16-9"QOC8N M']]H;H^\T7ROE<86)!(+2$R06.CVSYQG?OMO;O2"-C&Y4[+?H6UV3@22%[1) MR9W*2"PGL8+$2@AK#7;O:;![KQKLS]\#J0:^5AT[\$DL(#'A]4Z29_6;7+O]
M2Q^2748D%O?WWYS.IJ[7(@!)]IF06$IB&8GE)%:06 EAK7KB/]437UM/'M^[MG.[G7J_V!>6N6FWG^XO-JB*BI<86$1(+2$R06AB8G%)"9)+"&QE,0ROU^?
MS6GG1"\G>RQ(K!S8_58%F3Y5D*FV@CQ. %VV)H ^JV=^WFNEL06$Q (2$R06 MDEA$8C&)21)+2"PEL8S$*F,E MVBW'E@H2"TA,D%A(8A&)Q20F22PAL93$,A++9[VQ>^J9OM69U26[+
(>Z;)4, M<_)4, ;9/]T[EM55-]21SS=/$[ZV,J.F)<=6$U0+4$V@6HAJ$:K%J"91+4&U M]*!IXQV'-JU3>]=WK,!K^=$#GM0*5!.H%J):A&HQJDE42U M/6BMK,?,\GW+\KO#GNPW
M1[4"U4I*:Q>D)DQJ_B5I4KTZN@ZA>5)4$Z@6HEJ$:C&J251+4"TU7Y K/;1I MGW@H@J6*=NIDJ;)A+UJJV#5-MM1LPJ7F7YXNU?LRC^5)4$Z@6HEJ$:C&J M251+4"TU7YPS1?O-4:U
M9+2VC6I"9N:C_&Q[TV;FF2D[1S5 E03]!:B6H1J M,:I)5$M0+46U#-5R5"M0K:2T=G%JP]>F/GTJ_J@VEXMM/Y"VOMO'2+9#P30] M/[IHH9E45!.H%J):A&HQJDE42U
M1;4,U7)4*U"M/&C/SS(G1]ZZ-M/9=RK[G'$F\ MF4UHUAQ(S?;GH"^JNY\,>Z*9DD+3LZ@6H)I M1#5(E2+44VB6H)JZ4%KW4PT MZ5X04L1+/I>"^^U.3=N>=*\P%S33BFH%JI64
MUBY(35K6U,=E7SL'C49I42U -8%J(:I%J!:CFD2U!-72@Z:?@^Y'3=5ST(I(MJGH.6M6P/P?=;Z69@[::A*NE3[@"<]#Z'L:.>50+4$V@6HAJ$:K%J"91+4&U MU.JG2H_,0:/]YJA6H%I):>V:U
1R+1.9@[;0X"VJ!:@F4"U$M0C58E23J):@ M6HIJ&:KEJ%:@6DEI[>)D-<5)\'\5S?SH-QU=D-@57=DE7=DU7=E%7=E57=EE M7=EU7=F%74DM0[4GTR'NS)A]LZ?/!BIF?YV &E!>"]>3H
M$H0&@E%-H%J(:A&JQ-@F42U!M?2@M69^NI> K7YHV/3#6TF;FAF9^A@<\&? [1[4 U02]A:@6H5J, M:A+5$E1+#UIKYL>JA[/C]ZZ^D/WFJ%:@6DEI[8+4A&PM?!>T7AU= MA]!L+:H)5
M1+4*U&-4DJB6HEEK]]6O[3[7HYTB5RQXHVJF7/5 V[)]X]%MI MECVPF@BKI8^P#L_\#(]Y-.F*:@&]"50+42U"M1C5)*HEJ)9:_05PCZQ\@/:; MHUJ!:B6EM6M2DW6U?&;F!\VWHEJ
:@+50E2+4"U&-8EJ":JEJ):A6HYJ!:J5 ME-8N3DU&U])G=,<\^T)/C2Y0:!X7U<1!:SV.HK,$OM6/=UKVI+/B9Z1NU3D;
MCM&=EZB6H%J*:AFJY:A6H%I):>TJT01G+7UP]K4/S="SHRL&FIQ%-6II23 MRU M5*2FL_N+0)]MH#2]>.>=B&WAI M?% M0#6!:B&J1:@6HYI$M0354E3+;,7JMA.K\
['%U:T'@LJ@E4"U$M0K48U22J):B6VHIX M;'=A%%L5CYU,7;/[!D:5>K4\JWOG<:%LV%L81;5KCCT]-LB;>*RM3;L-Q6.'
M!SP9S3M'M0#5!*J%]!:A6HQJ$M425$L/6GMA%&NZC[MWASW9;XYJ!:J5E-8N M2$T\UG:1B(J-YF%1+4 U@6HAJD6H%J.:1+4$U5)4RU M1[4"U4I*:Q>G)M-K
MZS.]8R{]>FIT@4+#NZ@F4"VT^['1SKTJT7"3&-TG:?<7'[7,SCN#Y'6-4G2_ M,E34+4:U M9+2V@._"<[:^D5B7YLZT;.CBP :I$4U8?=7[G3=2>??/T3[C% M
M5AR!:=6'T#D&B?::H%J*:AFJY:A6H%I):>WRTD1?[8'E:;_SP1MZ?G290>.P MJ"90+42U"-5B5).HEJ!:BFH9JN6H5J!::?<3W4<>O&$W\5I;'Z\=%VM#,[6H M%J":0+40U2)4BU%-
HEJ":BFJ9;8J=>WW9H700"VJE79_==[6$;0JBM,$91U] M4%:71-%O.K: H%J :@+50E2+4"U&-8EJ":JEJ):A6N[T,ZJGGN]T)Y_13LO! M3MLEI$G&.OID[&L>T:,G1Y<6-
"&+:@+50E2+4"U&-8EJ":JE!TV;1"ZN5%3 M]8@>13OU(WJ4#7M)%4KS2-ZG":QZN@3J]_[B!X]/WK HZE65!.H%J):A&HQ MJDE42U M=?HASB./Z$'[S5&M0+62TMH%JM1U"(W HEJ :@+5
M0E2+4"U&-8EJ":JES@M6B'5>N$*LHIUZA5AEPJY";8I6FA5BG28"ZV@3;2,? MT:,>\V0"[QS5 E03]!:B6H1J,:I)5$M0+3UH+U@D%NTW1[4"U4I*:]>D)@7K M,"E8!TW!HEJ
:@+50E2+4"U&-8EJ":JEJ):A6HYJ!:J5E-8N3DT*UN%2L$X_M%-GYHW*N:%*?(TX[S0)UL^[E*:'?]]%UHI\TM:>=2;WH)8UB=+\)DJB6HEJ): MAFHYJA6H5E):>U0W$5?
GKXFX.OW8I.^ZONE8W7&.IE=132@.PIR95G=)\1#M M-4*U&-4DJB6HEJ):AFHYJA6H5E):N\(T*5?G=0N\&O=W]8=?JNUN?Q&F_N;' MBU^W?S=6U6[_R6/I,;XN=C>5:LM]9 MD 9/F=#
<+*H%]"90+42U"-5B5).HEJ!:ZO23KKXYZYXJ9VBG.:H5]%926JN* MN4W U@57HM5;8TL/J@6H)E M1+4(U6)4DZB6H%J*:IFK6,?5[$7VT3X+5"N' MCJ!=49J\K:O/VWZL+I?S[79QO;A*"3&_.I_[[>
[VVKU<)4G_!4B\\KX_)^ MLZE6EW\:N\U\M5T^-EVL+I?W5W4EJD^!5H?H_\,ITG)1UZFKQT;[LZC[W[:+
MJ\5\HYS7TN_@Z#*%IG=13:!:B&H1JL6H)E$M0;44U3)4RU&MBVH!]@E4"U$M0K48U22]):B6NOUX M;_=^HMSR0_>:H5J!:26GM M@M1D@%UMC.^U]Q_IU=%U"(T$HYI
M1#5(E2+44VB6H)JZ4'3WGJT:#-X_Y&B MG?K^(T6GBON/%*TT]Q^Y39S6U<=I@?N/]#¥,'O/H6K.H)E M1+4(U6)4DZB6
MH%KJ*O+3ZON/TYS5"M0K:2T=DUJPL#N8Q3P>^_IUB3S%"8]>F[G:N\N:+=]>GYMME= M!Q,]A%*U>X[S;%F _=C%H0KK>N$5Q->MEJ@L#&K%%M0#5!*J%]!:A6HQJ$M42 M5$N]?
J;4F4PGWF36G2U^\U1K4"UDM+:!KQ[,S>C5T74(S>JB MFD"U$-4B5(M13:):@FKI0=,&ZKQ^?%49J%.T4P?JT$,H%=UJ G5>DZ[U1J^? M.S93I^]A=&U P[:H)E
M1+4(U6)4DZB6H%KJ]9,J1S)U:+\YJA6H5E):NR8U M(5_/0>:U/3)(>(YJ :H)5 M1+4*U&-4DJB6HEJ):AFHYJA6H5E):NS@U@5]/ M'_@=FM=6%BHT[8MJ :H)5 M1+4*U&-4DJB6HEJ):YO7SOI[;?
8^%+NN+:J5^ M_]M%\4I7^_IT\'>&9?3\Z *#1HM13:!:B&H1JL6H)E$M0;74ZT>+_5;HXU Y MT%PQJA6H5E):NQHUN6+OE8L_P5+@.IW973E0K/)]"90+42U"-5B5).HEJ!: MBFJ9UU_?
^M2RNN=&:.08U%*%)I!1+4 Ü@6HAJD6H M%J.:1+4$U5*OGZ1U[8G;FWA'H\6H5J!:26GM*M8DD#U] GG4 J!Z:W3I02/) MJ"90+42U"-5B5).HEJ!:BFJ9UU_)V#0=OWM:A$:-4:T<.H)61?
&;H+&O#QKK M[FG0;SJV@*!:@&H"U4)4BU M1C6):@FJI:B6H5KN*P+*_J2;=R[03LO!3MLE MI(DG^^/BR?.=D=RO])%D/3FZM*"19%03]!:B6H1J,:I)5$M0+3UHVBB@KU@*
M=SKI79#.%>U.3=?O/5:P0 ^A5'1KV9/D1N7?*LI!OIH\,"]"L.% =_*[JVCB=!\0'BD;=:[YQ>BN2U1+4"U%M0S5O9T?*S0NCFO 5:4K?-NU>M0*3"3P*@6HYI$M035
M4E3+4"U*M0+52DIKEZ$F7>Q_7[I868+01#&J!:@F4"U$M0C58E23J):@6HIJ MF=_/)YO=^6>TQP+5RH/FJ?>_752:D+*0#PE_[RT+>GYT@4&#OZ@F4"U$M0C5
M8E23J):@6NKWDZ[6I/ZO>ZD876T8U0I4*P=_(.TRTX1__?^?X5_];HTN3VCX M%]4$JH6H%J%:C&H2U1)42_U^^->;V=WBA$9_4:U M9+2VC6LB?[Z8/17;XTN
M/&CT%4$JH6H%J%:C&H2U1)42U$M_O!V6EWJB!'NRQ0K?3[BPP_/X!6/9DV MP=_IZX._^DW'E@]4"U!-H%J(:A&JQ-@F42U!M135,E3+IXH,[FQF=RX$%6BG
MY6"G[1+2!'^GHX._@VL1Z\G1I04-_J*:0+40U2)4BU%-HEJ":NE4$?SM+E*N M:*-U M5*2GLL2&?;FZK:!?/=_-V;N_GG*I]O/B]66V-9 M7=?\Y*?]]/AF\?GFZ9/=^N[M25WL?
EOO=NO;AP]OJOE5M=DWJ+]_O5[OOGUR M5OM?UYO?'_IX]R]02P,$% @ KCUM67;'0?MB @ Y@0 ! @ !X;"]W M;W)KVT[)_O[/39IT$_1+[SO<\]UQ\YW CU8O.$0V\EH70 R\W MIKKV?
9WD6#)])BL4=)))53)#IEKYNE+(4@SWLVW@7\(/C1N_MP5:RE/+%&M-TX'6L("PP,9:!T;+&$1:%)2(9O[>< M7IO2 O?W._9;5SO5LF0:1[+XR5.3#[FQ"J28L;HP3W)SA]MZSBU?(@OMOK!I
M8B^O/$AJ;62Y!9."DHMF9:_;_["(0)W ,6#C=32*G+7W \9P]%R=*PA!4G< 1)-%IF(@4T__Q/M72%A3L"AH&!PD?F#]#7O<4@D[0A^=X#,=')P=X>^V/
MZCG>_CN\M[*@!OY,C32OEP5/8)9EJ+A8O57S02H[9]>Z8@D./!HDC6J-7O3Q M0_>B_6 T'XKM']0Z%3KFHD$06:0R+(DQ=1%R[Y6H5F["-+A$31NVWG:(;YK>_1?>O !T M=2LN-
!28$;1S=GGN@6JFJCa,K%PG+Z6AN7#;G!XB5#: SC,IS&PO=V]R:W-H965T&ULM9QME.C!87&[#1W$ORM^V M=[E\-SA0EO%&I$6-;T(G+E*]"+*$XOGXN@Ü41_E(?EE>] MH>J12$14*D0H?
SV)&Y$DBB3[\4<-[1W:5(G'KW_0>?7AY8=Y MQDR6_Q\MR M?=6;]B_D!CQ8NRI*A^DN=]['32(]&N*+--G2Q[L(G3_>_P MI3X11PF28TY@=0)K)XS>2'#]!.?
4A%&=,#HU85PGC$_]#),Z87)J]"],Z8=I. M>.NTSNJ$675U]Y>CNI9N6(:+RSQ[)KF*EC3UHA)$E2TO89PJ[=Z7N?QK+//* MQ2^Z_R5]?O*_?[LDM)S?7]P'AGV]_OR=]\MN]2_[QRS_)
M+R1.R;=UMBO"=%E<#DK9!T4:1'5[?ML3?:<\B7+"W7!?'2I5@:\KD]?_Y> M?F#/H]V&,B3=SB#[,<9 ,BLQ'NQ_4"G\KWUV_ZJÜ/K"GNR\ZJ_/:E?0. PM.Q7/>^E\(BS59R6I>D%6> M;8@<(/*PC-
/'?86-RU@4%R;)[[$C,U:-/A?%-HS$54\.+X7(GT1O\?>_TY9FBZ)3I4=P0Q2:4M6"^(8Q.)Z-6_P,3 M;3R=S0YALQD=\[KV/JO?;W\KQQ+Y9RK+$B9R4E7E*51G B2UB=<'56O(U4# M=H58JG'NY
(P1A8),Q%PCPDC"-A/A(6@&":4"<'H4ZL!< 5$AK%X7YBGRY) MN,GR,OY?=< D/2ON7.DA82X2YB%A?\;']68V;!5K;HADU9!"T!=TF0R/BMU#$2_C,'\URVX)O79<-:J2KXAC V=4;MV
M@;JF"Z6QK*G5CESQTJG5 %VX8B7D_>&2 M/%:#5)S*B;HXJCM'TR6C@]!F.93F0FD>E,9KFC9JC=M2\H414=LT1/OS_"X M:6-R4[O+?7N89B[3SLNIC%JV*:[43W3%=/X
MW=1N>\]Y=F<43M0]QM*&X.^'Y&3XX;8QP M.CMK;&>[%&J&0VDNE.9!:1Q*\Z&T $73M=BX[-1NL]^%K_N5",K/ MW.:JDI6OU01*F9M;]3>C$J%^.I3F0FD>E,9IUU/O.^TJ9HCI/IM!]4M?9]B8
MY107W8> V58]:#:7-*CW#:6Y4)H'1'7'6-;5G[2D]M,4 1=/EUACD[!V#?#_9 M4MH2FVV2O0!GN-ROH;Z]&0#6HZZYQZ=G[+OU21'GU4"<^5V10IQY*4M@N7
M(6PVGK>7JZ/ZIBNH\>G9"3[]R8J!>O-0F@NE>5 :A])*"U T73]-=X\LWOS M;^J/],F#>(S35,W Y,"Z%7FPMFJW-..OQ#)YG/6FG"XT$8]0Z,C MVGFFQUG7-3?
TS3>$&6C!NV'ZE[H;V]RQV^:V2RK4JA7;Q:S9VNEGPW9QO;%W MX=S:86C48?/V0C,/VBAWND:VX9/ZAC!#WP+3>=.DH5_,QLEVK.[DXKHDW]:" M? GS[W*N<2OGN?
D;Z__MH'/_#:$T%TKSH#0.I?E06H"BZ>)KK&N'_9S'* [4 MK8;27'C-@](XE.9#:0&*IFOQ:*^2]Q9^'S]&B=_X'I51C-CM2K#[E6 W+,'N M6-+UK6?
3MFUM"&+CSF(Z5,=T[31VM&.WHWF6R"+6ER*YVSTD<60?1Z%^-)3F M0FD>E,;A-!]*\U T77^-O^W8=V/Y\^,HU-N&TEPHS8/2.)3F0VD!BJ9KL;'* M';M5_A?&4:@I#J6Y4)H'I?
&:=GQK2.EL/FF/I,A& Q1-5UECC#NG[-="/LO# MA-N^M6[GG"TJJ D.I7E0&H?2?"@M0-%T[366NG/>TO?31UNHO0ZEN5":!Z5Q M*,V'T@(43==B8Z\[[RQ]_.C+=15A])
<*,V#TCB4YCN&IQ'#>-1PG-,+?[]5=H/?[]S] M]J@<.6Y(O_ U!+ P04 " "N/6U9K,HTIYD* !!&@ & 'AL+W=O M^XE)=NIV]D"NT#1Z,"N>>^#N7G:^L^^151 M4]UU?
@71ZL0VE]/3GRVHEK[L6VIP9O"NEH'W+KRQ+>.=Z3ZNID-IF4F57;\XFA[U#SZ8YD6'4W-37>V$8Y*EX<74]_?;G@\3+@GX;6?N=:L25+:S_QS=O\Q=&$ M 5%%6> 5-
/[%#W;]=TKVG/)ZF:V_*_6<>P"@[/.!UNGR4!0FR;^U0^)AYT)%Y-O M3)BE"3/!'3<2E*]TT%?/G5TKQZ.Q&E^(J3(;X$S#3KD+#F\-YH6K5^0S9UIA MR!;J9>OFYSR_?DG #L@GO6(7\Z^N^
=M6,UGXS4;#)<?&>J 7-:;_\8B!LL M#F_ :?6K;W5&+XZ0-Y[C9Y]AWXBP'^XGNK_R_@?W^#Z5C]XI ZX M*IMX]7%%3K?4!9/YD7K;9&/UOK3Q6PV>79CZU8W&F;/OM%K;57ILFL
M:ZW3@7*%>XWM*[W6CE3_0G TZKHKD2!J-N58F)R/>3>5EE2&9RZ-;5<:R9L) M!(#,TNN<[E&06M.4*C>>D->JMKDI-OPD"&I#7@7M2@K\#!7JV $(H\JII(88
MR#WUTR,;N+$N)^>9)S8THR8X[(OA][;SRF]\H%KJW!/P_FXPGN<[WDSO6<+O MI^?/O&I-2^PUSEBCU3JM;9UAD"^ U34-ER(ZMS13<^ MX&D+0[BB>]CB3=E@:K#*Y$ +#E2#Y2J5NZY,#
S6L:G'!YE:Z:!TGCL.C'SC M'95=9*O58;76&]C>4F8*=D,%/-Y;A T/6)NP D&=LP>)W?8SQU'1[T$>7V41L/%Z?30D@M83FG'4WD6;I)I(PZYJLL?,P>$C%H,HQIQ
MY,T74D772# !LC"UM0T0CH2=W;DUY28S/&C+N6D""6PPC;%YEU$D>J16Z!W' MGSM=F;!1O@9!X!B-JZLH>F'K\C&R2/U#-QUOPR5P!ST]&1,&9AI*>8)'!>^ MD8_J]N._U;N/KX!>K5>6G6+7'
F^6WJ3&]Y@-UGOAL=[(\W;]&A*YGZ M.+PD%SOGJ,DV"AG9^"J"U/F?*"*0&2G&'?'V7'I491'*&/)]FXQ [NJNKPV(MDE.S>;2KF;[X M3R3X?J.0(B1OJ]1>>;SX]G9Q>7E[-
?]KVSHJK8%M+>YCL$D8/O4WUZ_9"M=%,*!H2E2*N^ M%MV]OAGF&U9>KZ">.95/,H!/K.)>#%$\)YV,YDI#>(Y_7R$+6], ^%(BWZI9QX)TM?EQR:@V-0..Z-E"J4;T%M89G# Y0Q[[L8 -B#@?6&]?
9LN5M$ MZO" Z=YUI2JKHT2,Y1$"+\2TZ57>?MIX"T(OSA:CQ62A/-H[^8.&M)UC M/D(?P$ @I)6.\Q$9D1YC+46=P\&&I_@X2>7D].QNJU$%$A8\PKO;2!U+@L4 MG>-H1' %;2HOJ?
Z;=ME*32/@^3[@1R$#7$A";D;[4?..E4_5J%NPBQ!J34#[M> -.1^K=NYLA37>'#6'!L'2C"(4*'4140A&%&6C>=<-MO_EUO_G6*QSZ7[]/
M(9=:O&3OGTBEGE685OO4")+^0Z?':1*08@UR9!Y5;6P02PKG_D@MNX!&&&(T M+RM3]H7>0@,XWFN/&FZ?/CT_/I:#&[V$%W",T> M8E937RT&?
9%QQJLGT_'YJ4*3CTL.P1'!,E#U>YJT]>\UHEZ[T&]_8.PHZ2FD M\1IUB74L/9#+C(\]UC@HB[XI#$ZXO#@=G4\7/V*=[7F=7?2_I#!,5@?97*L M7(%N/.C,$0R#?OTRZ ,HL/[

BYWZ=7\=C8B?YPW%.%:=9O6!TS,FYB&;4QR;=RG_V? M1G&,J=G9:#J['%KK?].;!#QF(@4N+H:9&](N31E$X'P:FX,D(K;[JSZWTF!% M^U6DAR^XO-^CKS>AQSL;3:;3>*AU\62!AY>CR]E,2N
W9VM9X "T;]*::.+5 M&I9:+*5DV0*%+^7>[JD#X]@ ?5 =1_33L_/1?'J1P'Q-QSX:SI<,T&%CBD%1 M* *P1]?3C[\XX)&D5=&%C@M&)/T]*KQL,IWO^*Y@MBA*FX(/K#L.]K7AB+.<8CK;E"@F=HB]6
MK%WCP@H+X] AGS-B6D+>@"I1Y)"X@2W+;0?E3@\0^X"XM%TX6,YC]F[VW"%? M:_*5QHN85D'2 P&WT"\Q>(YA%W:U/QAY)T NWQL-TB%B'%N[:%JDA2+]8A
M;K'[82>Z+^Z&!K%&%Y=C"Y6HJ7]@4H5U4-FBQ&4O[75T!&SZ!@%:#,[-_$" M'G#P*MLH@1Z/[R&J?Q240N&N>3ZMO$:I5B$M .V=UDLCQ4=4BV/&J+OSTEH MC/<,$31F?1S*D6N0?
=C*I=Z3)3'I445Y6"?Q M"#QR@H[%/-7BJ /3P6VK/6N-]I6#', _]5,LI3 Q>0<7W* S>EC8:^&2Z?KG0;):TIGU8IE@^.@32:G8Z=*ZVV#'\)%HF,LNGPR/_@E M^&3GLWY-KI0?+SCR(37B%_[AZ?#
[R'7\66 [//ZX D54&OBWH@)3)]!21Y'Q M_B;85GXD6-H0;"V7*]*@FP?@?6%Q_DDWO,'PJ']5?P!02P,$% @ KCUM M69=-P5(L%0 FCP !@ !X;"]W;W)K.XT>5K+R<36)?R\[>^W$(#$FL08"9
20SO_Z>TST# M#"A2]B:U'Q*+P#QZ^GFZI_'LIG4?_,K:+ONXKAO__&C5=9MO3TY\L;)KXV?M MQC9XLVC=VG3XZ98G?N.L*672NCXY/SU]=+(V57/TXID\>^->/&O[KJX:^\9E
MOE^OC=N^M'5[_SH["@^>%LM5QT?G+QXMC%+>V6[]YLW#K].AE7*:FT;7[5- MYNSB^='%V;9M^X$_7I7/CTY)D*UMT7$%@W^N[:6M M:RX$,OX(:QX-6W)B^G=
<_0MO6_JK);/3_ZYB@K[<+T=>VO?G) MAO-\S?6*MO;R_^Q&QSY\<)05O>_:=9@,"NM5?:.CX$/R81O3@[,. \3SH5N MW4BH_,YTYL4SUJYDCJ.Q&O^0H\IL$%VZ58^^[XI M;3F=?
P(Z!V+/([$OS^]<\,IN9MF#TSP[/SU_>,=Z#X;#/Y#U'OQ7#]]K/]R_ M-HWI6[\QA7U^!&QQUEW;HQ=???'VZ/3I'90 .'"A_>-?]?Y/RN]<^GV6?OWSV MTOC*<^ ;GK+IC!C;NY6%P17M>F.:+
<<7;>,QI32=+;-%U9BFJ$R=>8RWL/'. M9T96@8CQ8&[=(.<\,PVFM"[KL&BW;6TC76F MKK=<@ON6LE;@SL95.-^&ZV 3SGO?5!QSQ?/*8A=KZ\#5[-Y77WQS?G[Z]/WL
M:I;]>''Q1GZ?/;T021#.L/6'<>J1CTQB,IEY:KQG>L+I;R,SJK[.ST^'^$ MS@O7545M\8";OAT.E%T=_*,],!.I*4%QO9;%M5K99TW98M*C[$HRNZWCR9.,@ MD;;#4)S&V3_ZB@R=;
[/A&${^%:"VG=TK\5GV2GG3;]J&JX:-+E5KR(>SQT\] MO%V#\, I>N")7O6-Z4Mq;635IS4-(SI#X>-PIOPWG*P^[U:FRZ 966,+ZST- M /S,NF]97RJ&#VLP%$F(P"A'6!2T6WDZ9U<,?%#9NO7Z
M&*&@^+!JZ](Z'W;.R/AN^_>-0[8U?I4M$*3]L-Y_M J]1K&:,)2\Q/D,5 J: M4P>;*GKG*+K&=+VS,_$5X#'"J/_+)Z'0H+9118%A5$<"4%GBYZD9I!3U99"L;=[;#,1JU^U?0V+X*Y&7 VT[M]]
MHUAD\#51>>_PB*GWBQ1CQB[!08HB-K%*_5LÜ^;9S:JB7)R-5EU&I[2KQO=- MTX.$WW;3NBX#G=&7_#,'A34F#H33#V+ K\9A[?-'RK-9]MX+M[_W7;463T^A MJL-5SX&7GS90Y1;=#;5;]AS]2O
VJ5^@F:[-!YO985_RPGA S4UPC&+;BP7 M8- %GI%>>TVGK9SVWG8ZM:[,O*IARF$I3BDK7\ :>Z<.G%X$FL/M#TW4K7C0 MJ(*?$0;#;OL(=/;:-GT@R7X$,/?X4?9B3N,DB4!!52^*CB*-JE^(5I85&
'M M=NT:UJ?,&Z67=(/< /YXWLP^]K40MKP1ER%3=[P6)7O&/?6:GV@5NP#"Q_/ MH;6DJ;3B'H4QUWC4]GX2V$!#UX]^$$:/@(3U/E@&BW>CPNI^=(3BPU= WMBR MKD 1=?
O:1@$_]$1&]U^XI(GSM;4 BR'Q C25J<315OV5DSMC M'&ZNB:S S;HD#R< M%>>W+XJW+R(2R[>?=HJ\CGDKP12MN"^ZJW&7P+/#\58/H:2=4*E*C3]!9E0Z! M]-M^N8KL%%M8MM?6->)12'!+
(K-[3=L"S=Z/#EBME+_42:L-)TI ["$NEO24,/^ZW0A]3"BJPOKHUQ%3 M*<7H/)B+"G@Q6QDN=)F:5,T0.F#]+JI2) Z^0Y%.9-3&M86UI0]\'I4M.,/F\^0M0()0&&6_Y5_C/U)(A<91.'& M"Q*33
%G_/)Q_NB;AV"'_GI@Z__&EAYL+O/Z#-%!R//0C@(/OJ0A5\LZ4?N M<]QOL M7,()%4H8P:7\%H?$*6979**,8 Y09R6D%,BM 4+KK',(<3YBL;'HW M36/K@/T;!FK-F+%R'C;8F$H81-#A3-&-
UC3Q1H.KOWS[VH]J, S>C;$GD,.! MDH"U_9K Z[JMKT> J&P1,=U89DLXJBE28&3*-8Z(#%21ME ; 7)DJM/GV::6 M@/^1T(<&X_!^.4*^T6]$\Q6O%NFWH;%AK10XQ1W[F';;N203H*LK)/$,HDC
M:0DA>N<0AP5R^WZ##)E#)7NLJV(KX\3YEDPZ '-[02Y;B:JUP,'*"5P(N?&(M'"<>A)3[?OYO0;YMAJC7T4M)YG$K[C%)@]4RHZZGFHM=L!_9]F_5L@"0@RF
M)PD2#D6#F%"\MMDD,&4T]RF9A7<0+I3T+4!=U%MD,(Q
M#V[(HYHY[98)D:X!@V\ES)QGIJ*C*/^$N\GX.6[!+Q:Q3X"&"U47])_#\VKK!@,**.:C@GI71.;_8&TB[9U&0VGDEA[7@N^1Y]"%8,Y55N-\>!<?03(0AO!X8/C-#*
"QJW)051B2=R)>S:^A]ZR:+$BGD"=$'@^HL^PUHS%GZ M@+L!_2C. :@E!0N1K<8II7W9TC)U> T0(9F>FZ8%P?E3&2X'Q#6<M9 1"4)67K\'8 ")WQ'WQ*0(SWGR''@\3(WJ;C
M28+&QB@W%MX)XDN"@!0RI6!R6M"9+#BO:H#0Y6A.^9#[0Y;,T$>X]UF7-%+- MJQ*5H^?RS-9=+]#Y$[8ZDYH2=%=9<)E8!''(^QL58S1KQ@Z0Z5Y?98V1>DQET M1Z=G3\7'G3\-OZYHT)-
ATX@QB,%/[#U2J+J5TA@B2N\C9<2[3+&/:X%2'>#] M7%!UMK;=JBWS*9Z-"T^K_ -L*-M *NK$&]]A<0CZ'Y,JNFG64M0?P(:!MY/ MU$S@5>5F14D*C"]R@G4+7R4UBH5-0-ZT]G/@C)!X M 5.
<[>PPU+6K9@-W/8HV>ID@(Z99264[]>7WJON#OHE=Z^E)-#A+O"A1(\? MW9'$8 .^U6P&@\(H5_D/QPL6.6)-E\JK)8][U?7]<1GQ5 @RL/+O>DV@,YY2 M\>EB0=*G+?
#6%A.%6R1%":9* T)>^ZACJ:9L1+@,R->'8] MLY+-B^#HRU?KBDBI6!GF]= 6Z&?A(]H+=$Z 2P>D)0NZMD3^,PTX<@6Q@ M+Z5X9$AF0=FHMY20&[?
>HY9279G8!.D1DK%T[VPH44X7@&7!\:EN.U", M;0ENX7<#*U//HX<(>!P<1 ++XS"J:U,Z2I5YZE+>[0^X3LU,=Q\'K"M*O$ M1X7*6N;X'KQHA@;EI/L3+Q/&62.)K M+A=9<%.
(BP3&]B.O,%1&M@P=.Q6-P])1KJMN2D4L6= $G'C04A2371A#,X^W MXZZ"R*F7^/D#<#\?QJ]9UQ^+N MIM>^PN1]>JVZ,*:&)F.N8P&1W!'Y#E<'=<,O&%24>-4(MZAP2,@P /+39 [MDAXZ?
EE0K\Z!0]3*,#35G.#LDE.O1]D4^K6ITC0?-L7R%P8[MF=^VWVU1=/ M'CU^\C3[10@YR ;F5]G%_G8\89]HPU S#/_Z%LJML!/!,3*1]0]]_#[)] #MU6@STBR;5-/'VRANE"X 35@=VR# Y_BWVE7R:
M$Ö$8H])W$EG_Z&UH[P!+.ZV\-^TD![$?JUC:">AHGW+\AN&_L"OO#=S2U8I$ ML@FV .SIM%T/L0/>QVB#@R85>GLN^'8FF'N6!_1Z([WDMCR.$+7II0!..,EQ MH?\H28S2KI+0#R276[$-
Z+NJ%AKVD:@7D8KBK'1(Y;QZD+1CK"A!S*P9UV"2 M=05O(/3N$!3&^^4IF(X2TA':1(((§MR44J!%W.Z-!9.Y6)>4E$I5NN-W)K*PL:3H/7.;&S/#'>V%VZR MKK-(MBR1VXMZL/W/Y8H-
90S4L.A#=R=B(U_JY:'?WRP=*K]FN71V2> PE\U M:.N;WC&Z2_:@?;0']'VKI"B)4XB/1,_NO8&OCBRDQW=_:T;():8XX2E3BAB
M*B_\7PCS@TQ_AN>"^;HN>]V[[&5DZ!4?]1O/)CX2!L=Y/NGU^(GURRN^C)FZ\M.>]O&.-+2>^1Z.&5YU M1"6V@1X.EUL)$1G7J-4I2!%!-)?\3FY>@5]#P[7D."=MR&Z#75KC";@]#Q
MX5:/#X%-0Q=V*%T,K>@2,B64?LXYQ33DNE+KZU+%%@=)M2O%6KATJ.SHM?T. M[>'DPAWC -!=Y$VIQ0ZU/M!_S]QG/*I;8"%WAP*1['OS^VQFK42WV<6B%2_X MUNNVT*+RIF-
0&*^C#S)'JNR)@XDRD_M7$[QP?@LV)Y<"R;VR-O-(K [W*,H% M.:>*8,R:#\L -#7XNY@T0D*:-M=26A/YLY'*M-E?@.-_P??>T%EQX:OFNQU MT;7T^-J81:)^N+AZ&3'XNJ]0#D^?
90CA,;VW^P5K^FOPZKQ;C09/';>D F\ M9USHA;[.2SJ)@(D7\Z$,O#P<<#D4KB#;RU"XTV-K&"\-G!C'\UP"F":N:T5TX=5 V)#&EA1P,[:+8N6T M 7R^#7P'D_(86[1]7@++V R$64/0*:=?
T/N5GL6"7X!52YO[/3<,W# M >&*7,=85E4:\8T)!P:^[70SS$UMQJ+=SO'[)KE/X:9AHZ$Z6_1KT>9KFS1U MQ5VA:F K&Q2B]RYB*'"%KJI2]._5!; 3'VU BX/'/;,#",MHB\O5_:C=//M]N M=BPBJC3+>;?
KCK3N\\>GL(7P" MI\'MQ?ZO>DX7+_ :_=4P1B&[MPM,/9T]_OI(NX_C#[@L^?ITWG9=N8_5Q:9 MKN, O.=G9/$'-Q@^1WQ_U!+ P04 " "N/6U9;X6@.N8" #T" @ &0 M 'AL+W=O
MJCFBAKN<<=7WYEH77=]7R1QSHEJB0&XLF9 YT68K9[XJ))+4@7+F1T'0\7-" MN3?H.=U8#GJBU(QR'$M099X3>3]")I9]+_16BBLZFVNK\ >]@LQP@OJZ&$NS M\QN6E.;

(%14<)&9];QAV1VWK[QQN*"[5F@RVDJD0MW9SGO:]P";$#!-M&8A9 M%GB"C%DBD\;WFM-K0EK@NKQB/W.UFUJF1.&)8-]HJN=][]"#%#-2,GTEEI^P MKF??\B6"*?<+R\IW/_
@*946>0TV&>245RNYJ\]A#7"X"1#5@,CE705R69X2 M308]*98@K;=ALX(KU:%-H.==V$G.-Y20+LIH+V- 74*V!XB;L&SHZPAB%)8.S-*II1135%!7GFG0#1D
MEF3A2(C$^I6@/XQQ:I^.+NR\.XR"^/B?K4,%(@/3?!KS*[5A LB;^T%KM27 M#TSGO"C7++]M-ZT?/N,"&82[*REJI'@7O@IMFF;HFN;/%V^>%[PWCZ)-$;*2 MIP_AWT,4[AUT.FL**X71\59-
#:K2J'OW=2C?1A.?8E+W<.AZ./[?PV^ZAX_V MXJ/PN0U7@3;U\ LH:\5C?US^VB22HYRY>4M!(DJNJZ&DT38CW;":9:[,<@4,,P,-6@?['LAJQZHV6A1NKID*;:8D)\[-6(K2.AA[)DQ[U1L;H!ET
M!S\!4$L#!!0 (*X];5F"&%#GG@(,& 9 >&PO=V]R:W-H965T M AA)'V=:6EE" M^%!).D[^ODM*EITT,0JT%XF[W!G.DN)HMI/J4=< ACQS)O3/G,Y58JG\FM88V E2)ZRSE5
M+TM@A&RF(@FKN+:+I,K7U MKN!' SM]-":VD[64CS;X6LZ]T H"!H6Q#!1?3W -C%DBE/&KY_2&)2WP>+QG M_^QZQU[65,.U9#^;TM1S;^*1$JZ9>9>[KY WT]F^0K)M'N275<;C3U2;+61 MO
>C MZ([DV?^WTX DS"#P!Q#XB=[FXAI *&&IK/E-19:N1S0Y!099[5Q0] S+CB'^@.&2W$EA:ÐUN10GE M:WR :@9\\5[2,CY)^ #MB"2A3^(P3D_P)4.+B>-+ _]"%CB%]G\%>C*EN:0%S M
[]\#>H)O/S\++H(KT[H2P=]Z2GVO])WFB$=D;7!U#L9_&!N+D M $S&A_$W:1!]4'GI9V%V%*=^F&5O- *]+R\X,@(.:N/L3F,[6V$Z3QBR@Z,N M.B,YE'=V?$?
5IA&:.,*@0&H[&F4=49W%=8&3K;&4M#9J4&];X5P!E"W"^DM+L M [O \)_)?P-02P,$% @ KCUM654_^Ū ! P PP8 !D !X;"]W;W)K M&ULE57;;MLP#/T5PNOV%-B.D[1=EP1HNPTKL$O1
M[O*LV$PL3!=/HIOF[T?)CIL!;8"]1!OAX>B?#+?6O?;UX@$CUH9OTAJHN8B MRWQ9HQ8^M0T:]JRMTX+XZ#:9;QR**B9IE15Y?III(4VRG$?;K5O.;4M*&KQU
MX%NMA=M=H;+;13).]H8[N:DI&++EO!$;O$?ZT=PZ/F4#2B4U&B^M 8?K17(Y MOKB:AO@8\%/BUA_L(72RLO9W.-Q4BR0/A%!A20%!\/* UZA4 &(:?WK,9"@9 M$@_W>_2/L7?
N924\7EOUU2!-V+Y4ST!Z<%UZQ@L]2K*22)-'/,V+X$)25/=15!U6\ /46 MOEA#M8#DM!AQ3JG:*G = MLH6IN H[9"/4("(1#J%H$'5XQIZV=U?#5/J$>WP\3=[;=U, OJDR;S-(7+6/7)
MNG^TL<1[+'OK>'1PS:R0GM@?* TL DQP*LL7OA4>3O*(<3*;3D@V M43X]H[2&.HT9K(-"7W;"]!3>R?L7X3;\@OAAK#DU3\]F";A.,KL#V2;*U,H2 MBU[T/H<#P[0[7\"U!+ P04 " N/6U9?+:,5&(%
"R M#P &0 'AL+W=O6? @%!A[%F"H,\]7J%2+(A@?*UD=AJ5S-C^7TN_#K:3+0OA\,JH.YGX]+PS MZT""2U$H_\FL_\#*G@G+BXURX1?6Y=D1:8P+YTU6,=,ZD[K\BF^5'UH,L\$3 M#%'%$
78&K@)G-0\ZP62;OT_0&GQ1 MC>\R.BCP%O,>C 9=B ;1^("\46/O*,@; 8B]O<<,+N6-'Y?-7/]8>* MPJ&]Q\[\Y8OA=#/W -IQ@W9\2/KW1^>PN&D/#D]$OW*T@M?P 2G5'5QDIN"C M%G-C/28@-?
@4(3;:&243P;2%4$+""$+'5"G %6RKU.T&!A(;R[T!J0+2X7. M(8)P8)9 ,?:8+= V@88U\PF6I:AMN%-X^6(6#49O?_A[$335JT03#V:R%:7@\AC^-?A/ .AU=T(\(')U$>T(FT>)#VY#
MGLP&;3>><C)^$$1M7Y2OGI$\MIR05A::Z@:QL9,B-[-$4I?0\FDP"P]%P.NY2 MD;@S^39+JX"ENZAKA8 MUR'OL42Z96169-5N+C95M_CEM7I=&?\O"EO=&-OEM]>.@KY7%GG:(/+K5IPG M4]Z=-
)0H"H1I0QA.9DPXWH-Q,F3Z;)\>L0-ITEEZPK.[.SJIDK'0B70QMTF" MO^.S5AI.(S+"D7?>9WE1=E(2BVZ_B%[-HM=PPY<)%<2]4 6RXP]K>6%5NYS M],N8,)<7"X75["7_P[H-LRC"D87(UX8
:3K0G/GH7IO'T>OTD@)VFX>\BB<6^XKV;;3<^6.^L-?VMVMQ8/ M1V/A4EAR&4'A*$FX/YA=0773>%:;XF %;X5^-9S.JJXQ&>]VC0^43"M1SLI[MD\&U-
1EX&L>YE_&WNW6M9V(#"Z22XI6A1+>6!H]-=" M6AD24'B@9'183Q7&)E+3TX":8V%=2/M%XTID@QY=W*U&@C',\ M82R,3R&W9A%RGHVA*G9&TW(#5'(RXXTNF\
[[K7=4AG857HL<(W)4^:1J MJ,V#]*)\AST<+U^S'X5=41@(V))8![WC20=L^4(L%][DX55&N4IOO/ WI9BA M'0.TOS3&UPM6T#S3Y_\#4$L#!!0 (*X];5F.K#4HWP4 *4. 9 M>&PO=V]R:W-
H965TG MHY)+-;B^]&WWYOI2UZZ02MP;9NNRY.;Y5A1ZO"A^MD@)Q5MRL(9]$K,<]<+I].'7!>9 M,/8G]OY[+=WSY<@!F?I':8-R&U"2%U#.V6>M7&[9>Y6);'?^"(PZ6DE+ZS8Y M"K@0U9!-
XH@E<3(]@C?IPIQXO,E_"'-X*,X ,ST,0QGRUE8\%5<#I(5YE$, MKE^_&I_&%T=(3CN2TV/H/[P7QU'.AJP/]/K5/!F?731P[$Z7)26#RM@]_"^, M$5D8S[[E@KHKKIZ9M(S7+M=&_H-
^I]%@:\'JBIZ361S%L?C-N<0@ND52P.R M]5@;Z7+&6<4>^0%9F+ 23R,XS&KA FS(L]B? BKZJC].-RPCZKHW43(+N MA+!X?\$B#&^C[D/L>2#:5R$" _:5C5J2UD4X*&[$--X8KAR?(:5,C*X\4
MQ/3^&&G#:B6#M!0#EEA*U;#(A1%HQ[_@S).DL1*X\O4:]! 5^YFHTEXF\<6" M0O?/XXM?AM[SO@E4[%9>L5H)?UR0&K]S5>.\8D'22:L])!GNY POK&96EC@/ MN!*ZML4S64\0H%1@!^%Y 8-
S$ M:;_7U'3=K-%KHIN$$J=8,AZ[OUN!CT!#Y M/.0J%=Z[!+=GA9X6TR %&DB^'4.MC"Z9P^J-Y)^(1AYJ%W(0G18-G C?79# MM3 TFY].HVD\?:D$5+4AJEV&$'Q6${[A_52A;K
RGAJ!3XT!:^/C71ENO22I$ M%FQ0X>U)XD@6D/CD/)X=RRQO$K^])Y-)-(/X5KZ6B$B^YSY(Y<%7T)56MG+ MN]4! 0S9)ZEPY"IVS\T#NZ]-FN.3 !O7[BB2\#-'*$4U;Y?=#-SS0]4"[%EB
M9Q6BPA43H8!3N4 C;XG+NHOUJ!1*E]19*M#0',7;.//R:SUYPL. MDNI@,8;Y!-9 N1!A2?V(>)L84K138G"Z%!(*17" MAOQ(6I]%L]E9-)XF/;WV,QLE-9>($(M(7-24588@G85)I17LZ=0'V/@]TU=;U
M;IO.Y[/H;#QE/ L.012'-PK!.V]FV"#M2@@L*--P4H^'9[/^0=TO)6FAK>:!RBYJ.%W@G,B8$NY8D1J/H_GY M*91:@20.FJQ._?Z?C*-)PD1? D2MQ=-I*H M4I0WVT]_,T/JY7TE3G 'I/5*(H?
SGM^,]'RC].=+81A7[(T+U^+4.N,&+O7]JBRTX EMRM*K* @F5QF7^=G+YW3O1K]KBJ3 MRES<:%966<;UJK5(U>;%67A6WB5J[7!&UZ$*5C<:+BZ;]@D,A-Y
M*57.M%B^.'L5/GTJPO6TX),4F[+SFZ$D"Z4 ^X\6[Y,59@ R)5,0&*7#X MB#1%0L#&WX[F67,D;NS^KJG_0K*#+ M>BC9? MPLDS1GJQ2DOZU/O8M='DC,55:53F-@,'FQ(O;:DH@.DYNPWE9MUR:
[S1"3]_5? 5L-;5//V.CI*\$X4 M/AL&'HN":'2$WK"1=4CTAC]"5DMJM)\4ALK3LN"Q>'$&L5 *?2 .7O[\4S@) MGAUA=-0P.CI&_=L8/4YJYK.#*U%"OH7O,WN6QR#%"V$W*<_ 8>_L5&+81F4S)
MZ#&$S%BSA1K"]@,V;M8S7=]l)GS[!T^S*)P^*]FM6,G2:'O&G8$=$,6&P04& M$KN[#)G,6:SRW(7F1AI+Z=W->[;A)815G'(-[EKE4E#<>GM/.B+ -?CPBAX
M1LOP+EV'SR[80L0\$RUY'P7&'27>1B%(!()8D/96FL,1^8KQ#==)R2KP=,VD M04["Z5=Q LNZG/CL SQM&&2\,FNEY3^BI//I'*:6;*% 1:)K29XG+.;EVEW*
MYE#+FX=WTBH!;I^R@;Q@D$KBSTP5]/&2#8A@NZG_%&GG*O^[XJE<2J#>>WSA M <&&(B\@ F)IK:TQ"9;T'!9 9@M8],0[%D;R/L3ZL<-3EPJKJ]^UC66O*(MHP%L0HF9T@RX!\W3OEH?1-
OO:+\O4|:W8'9K0EBN\G3+C&(B*U*U%0)VODI3 M1]=L"S J-W9V>V595G!UNXNCR42Q#=*PT]PZ1*J 1Q06HX=EY >9"Q8H=6] M!(?!HX@Z)#B(#8RQ.LM9K^.KE18KC+2\HL>PMEQ#0-
"N6&49J-I)M^SYJ5ES M\X!;ZZ.FYV42'-8;CZ;>?#2T'KASD,MJ"8/"3Z0XZ'4_L3S6-CS >1442AGS M%)0+//Z;YQ64>A9:Z5A1:21D4(6P4]P+#9**W*]&^CUJ3$!Z6&S99#3TAL'<
M<>0!2Y1K;01&YR2[,CQM-.)45)D2);!0G!KV5L1.QY8+) _1'6]D.$(M%1,< MTAS/<_H7:(PN+"">Y0*"RU!/R .ZL0(#27:1H(S3*,F#Z,7>'5+4U&6]E", MS?'Y T,V&>Z V9UMR<RA(,Q;:" M:QM>%-
,H69F! 8&['UMFJ7N.'8H[7[H<<>+|=*J#!E/C"M M14HN^Y>D)US1@ D@A8UFB MS_KL8^%RYO&00$.P9:6IGCLYZBBI9>FZO+/]R5+S?>6]SD]0SELW'QC^&35%
ML<'C6%50;P\AKF<5^_94*W MDX'KLU!'R5% M .BAH0%BQ>(8!N_@ I[\596&^E=(>TX>+#P=J;DK:D M"N;>>|@=B@-TMJ;# ML[Y^"F?C$3YJJ.;(&L5:%PYU(&R/ P"/E$-
ECO@PALRM',KP!3IO'Y!'UC!' MH2XAUAM.9KQ'J*/)O W6G 5K@I]Z@, 1)3L 'GI!$.! ^[:ZCC=L M@F_0T&@= CT*R1Q%V+C; MHJL[=1-F4.,5^$:]M\FV//(9$K:FUIE-Q< RD]&=AL"NW5?8>
(XG*#N8(P@@B M3]J,/L')D5Q4YV5K071=N.(,F9GFY!F^N] ,;-50@-@I /]L+;!IC7D@(M3_D/N:CG9"R+5!I\C+XN'MY4>L7S9D<&;:K0MKJ7J4QJ0KCZLBKPE1POU7))
M+-1U8]L1AHE!1D5(25IA#! M_&"5G,C4:A%9RE,.(M@QG/7"!0"=)8(\>%PH@Z45LTE]%]"#K<= $5PAXTFW MAE5[\O[^YHYB%0&<]>,,L@LB*#@ .!0"H!X-M9^JYY+M88P70V-[%,0 R123
M5Z_FMRSV*P KA//=!D#NG!HK2PT"B9)C+[X)AN\&N?7, 8GHX",9,9-&V64FF$Q+6)568/D MURDT:Y=W\I10>BEMP&T*$3Y_\#4$L#!!0 (*X];5F.K#4HWP4 *4. 9 M>&PO=V]R:W-
HJ

@<*!''U#MP#>5$4-=&NEF?".C/N]UQI[J;C?]H+6/43Y]4)\!%*TM M3E/^,%QEVG>]W3*Z)8*BSZE@4E!5"T]@^V M3DE2RI_;. ^X MNK,]E#!*;"HBEB).5S>#C\ZU[^8#\HB?$3V(HVN4E?+ V._LYG-X,["S&=&8 M!C*#(.IE3Y'S]C/XI+UX5\T $7;+X5Q3*S>E22*!;OT!MD(;$AG H4I>A'&DGQ7CU4U]W;"=(&HJY)=4LLUQ64,[H MMI@1/C$C%WUAJ=P(Y*^;Q,\-X2[%3482?*;K%1L!
[NKU"KOT>81L/ MT8][#[U]H]5>O'3,='DYL-L+V'O)C"4G]>HS%R7P7V'F&OENM3[=/);=WUV M+:P":M@-E;7<:[$E ;T9])XJ*-_3P>+//YRQ_5>7=I!@'B28#P2FZ3&L]!B:
MT!>_\LY+PP]D3[GZ)D%KM:HD"HFD:$4BCO8DWE'T5O6 D,4QX0)M*2_6PSOT MW3*:Z1*PR#W_T!0+7U9^0 M>-IBWL&-DHUY^[;8=K[1M$$-4#Z-Q5G%XLS(XN=4\DCMKX.:2K6Y"WY?3NBL
M_8F8-0@U3J$OH>U\#G8:C (EU!AU['KO:ALY_4:%(C7(^LQ]SF6^!>W<9K^^(8 M=^,G6I1J\7ZRC=D3[=X'FT%[FE T6V^^'^JP"A==_)K3-%[W4.B>:!H/A2:+E9M+)T)8#]D"B M>:!H/A2:KDIM?
QVS_ZTW3Y+P-97//Z0*I/9-$=WGC]U\UBD4I,U=@J)Y)9IQ M_4:KMFI;,-C]LVGV3>3#FF%EZ!H7HFF_2#4)/TUC#6NC35^B;$^_:UQ;C]K M3M=7#5 T#Q3-AT+3A:OM-P:TWQC4?
H.B>:!H/A2:KDIMO['9?C]_2K:41ZS3 M9)L!>DL!:K+/%.>@)TIX)^NO8;UQ;;WQBZSW]RAI=Z^O+*TZ&/(B3@)NFJZ M-> ?L+12H,P=%\Z'0=/5J9XX!G3D&=>:@:!XHF@^%[JM2.W-L=N87=#)
(E[T$ M1?/.%&?H9*]AXG%MXO&+3'QG)ZOV8>KZ2Y1&R2[IE G4TX.B>:!H/A2:KEWM MZ3&@I\>@GAX4S0-%\Z'0=%5]3X -GOZ"/@;JVD'1O#/%N7D?ZS[6]1IF'M=F M'IO- (L;&7D|V*YD.AZ>?
PZM\$7!NND;F@AA\4S0-%\Z'0=%5] MP^\:K>L%C>WSO72Z7CN.==^3%Z?;B M1K)M?GS[@4G)DOQR0TE(>1:@WE\Q)I]OL@35_Q@L_@=02P,$% @ KCUM M608> H8) P ^PD !D
!X;"JW;W)K&ULM59= M;YLP%/TK%INF35H#&$&A(ER U[;X>*E6)VCV[P%_W7O.M7VN[V'Q8-, 11ZSC,FYU:J5'%NVS).(2=RQ M@>F;-14Z4[H]- M+0L!)"F-\LS&CC.VR?
*+=O5:QT+Q5B]>U\:-04Y9]2?/ M]4:T#@S<8X!K USRKH!*EE=$D6@F^X)LUI[.XTRU-):DZ/,G,I*"3U+M9V* MOCYNJ7HY,X$EZ)+G^K0E*??K#"U!*D%CI6=6BLOZZ *VN_VJ](5P6)(:YI=4D
M03R!%7UXYXZ=+P/<_(:;/^0]6L"&,D;91M_8C+ 8T._.P"NFE:^@]&54_!0% M&+M!, +.?.C@$#8=@D,-W09BY%T(/P1%R./%"Q^E&'C?(XT'D.WTI3P"/CX#/ MW-#S0]R-
/&F0)X/(.E&L@9X"GQR#AR[NV>ZP@0X'H;5PWGK>X1&^BQU?!1] - M8-HPF X*HDHEJ$HE<2N5='&8_@=UN,XAZ3G_K(]#CNA,7Y7#L+5I>.1,NG?, M;65?]XTB.0%?9W&W?
6BC:1\^/N#CMTGE!#P^ALWY87I5%UT3HJRI1!FMMZHPF6K:BJC2JCN)%^;K?< MJWW' #3U7O0'4$L#!!0 (*X];5G2#6> 9 0 *T9 9 >&PO=V]R M:W-H965T9V3E)"VN]
MU'/7;+VD.Y&E!5PSQ'=Y3MCC%63TL+*P]31QDVX3H2;L};(D6[@%\;6\9G)D M-RAQFD/!4UH@!O[#)Q M0P]_0.W05.%%-./Z+SK4LHZ%HAT7-*^5I05Y6E2_Y*$.Q(F"Q!E6<&L%MZO@
M/:,PJ14F'07WN16\6L%[[0K36D&[;E>^Z\ %1)#UDM$##8DI:HJD''7VM+>.5 M%FJCW HFWZ923ZS#'[M4/'Y4L8[1AN9R W*B*?S8'L*#>@;T/@!!THQ_D)? M;P/T_MT'] ZE!?J2T!TG1!, ZK2L5\O_-
G2WI\&NR^#G3EN"P5] MH8F+O;90."2TF#1"+:>GC=/35SB]*QA$=%ND?W>FM&!I:L17=61/=V6ATO^EZ*B-']L#D]P$] M@:4T1E0.T2%)HP2)!%X*?\UE8AJ"NX '<6'B!BUZ=Q<81(L&(\61H]
&,(. MRJNRXSHH)#FRTT9%:+U7G#ZGS4SFM@^DNRB*#.$^1 V'"!'D4ZEPN38(%) ML- 06(N.14/'PEP=79CDPR188!(L- 36XL-O^/# _JY+B]TK*S%UT*LJH,>>2
MX/2$S")&^RR9.]^!XR6N90B$$>1J'.YL$D6F 4+32%UB;%/9+BFBLJ-98I M5DRB!4;10E-H;5:.'3,>;0#?TJ+5B*TZW1QM M\A;^<(^&CYTI'F]-?X="}OM,9P@2YVF1X6/ND3]<[\%;[< MX('Y0-
U%Z./N(WQUD?&9L&U:<)3!O5S*N9A+2EEU-U -!"WUX?<=%8+F^C$! M$@-3 O+]/:7B:: 6:&YHUO\ 4$L#!!0 (*X];5E6\?L4^@("\+ 9 M >&PO=V]R:W-H965T>Y[C;&Z[Y>)&
M9@"*W!5Y*2=6IE1U:MLRR:"@\H174.+.DHN"*IR*E2TK 30U3D5N>XX3V05E M116/S=ISIS'>U@+/XPV,J=,=%2KCF_T9,?Z<1R-"/((5$: M@N)K S/(E*IM80XNDL*3K7%WR M[7=H!(4:+^&Y-
$^RK6TCQR+)6BI>-,[(H&!E_:9W32)V'!"GV\%K'+Q#A^ 9 M![]Q\(W0FIF1=4X5C<>";XG0UHBF!R8WQAO5L%)_QH42N,O03\6_L%)^WDV%9(0,/821-L6@?S
MG@DV(A>\5)DD7\L4TGU_&XFW[+T]E/O*. "JA/B.Y^(YWA!!Y_9RJW](W3\ M-IF^P?-?G,RN'-4803>&/K:GLJ()3"P\EQ+$!JSX_3LWP);$]NT,H- MCJ'':S]C3V![T]-
6>M1#U49]RNT);$_NH)4[>+NJ'3RM1C_RG*%S4+4==NXP M"$=!=]4.6RW#HUHN02K!$H45NS#4KTJF.B_FHSBO_7P]@>U)'K621SU4ZZA/ MN3V!
[FUSE8G^INT+0TCS!U*WE!Q8KAU9S#$B&=DP&2$G5W5D\4KTR# M<\T5MDMFF&%"'T(;X/Z28PJ;B0[0]LCQ/U!+ P04 " "N/6U9\!&XM2X# M #N$@ #0 'AL+W-T>6QECNJ7KPY;.
(;5TC\ZY1])U+3*LS5JP MVP5C)EJ50M8CLC"F^A#']6S!2EI?J(I)BQ1*E]38KI['=:49S6L@E2+N=3II M7%(NR7@HE^5U:>IHII;2C$B_#47^]CD?D6[ZGD1>;J)R-B+W9V]_+)6Y>A/Y M^\F[DY/._?
G58?S, >G@P@!BXNGSQ)_2QJ0OJZ7=\%,KY(FG M&&T0H-DL6R9T*#EN-F4|+)3<[DU"?,"JTY)%#U2,R(0*/M4<6 4MN5C[< |" M,R64CHPM"INN"Y'ZEX>[O@?UTNB47"KMGVP)
[F:33)7.F6[3=,DF-!X*5H = MS><+N!M5Q0 :HTK;R#F=*TF=APVC:5C9&1/B%AZF[\6>]JK8Y;<.[)ILF]90 MT_0RO@/ZNVI>>U>V]R+=J.(/RGQ:VNE(UX<"93>:%7SE^]NB-8"I=W%U6E5B
M_5'PN2R9G_RS$XZ'=,.+%DKS7S8;E,K,!!@FT0/3AL]V(S\UK>[8RFS*:57@ MGGNOT//?7_\JR^Z]R:#CHL7E#'KO)_FLPF;X& MDZ^B)@?';S+)CM)CW+R_=PX)>T>$-
AK!46Q$OL'!3FR31M,E%X;+IK?@><[D MHY."E3=T:@_S>_IV?,X*NA3FK@5'9-O^RG*^+-VU TL1#-JV_X"T^NF[3G0 MYN(R9RN63YJNGD]=,[(-F[6Y@'"(7+LKC&
<*B=A,\;4&)+QNP,BR\&YC>8"![0)6 M.Y_G =]*LQ)$MA5S!OV!.-(EF$(U&*X1M,469T4/N']P9Z2),FR,)8V$&2 M8 @\C3B".0 /&)(D[CUX\#Z*-^^I>/L+U_@W4$L#!!0 (*X];5F7BKL< MP !," +
7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4*NU"P>-8?
20$3;8T.P6BP^0"X99K>]9!:GK8S'9Z^_4[2<;JB/9H+VZ>@AWC?#F) MSV<[Y\]*/ZZ4>B0ON9!F$&RLW9YUNR;=L)R:'VK+))Q9*YU3"T7]T#5;S6AF M-
HS97'2C7N^HFU,N@XOS75|+W74+RK+4KY6FK\I::E(4JV$& 1A?>*.;JDA%S2 ME:EJ+%W=4@ 9!$<]Z'#-M;%5BZI_"HQ/#!K7I<*]*RXLTV-JV4^MBBV7#V4W MM08Y&B;7#N0Q
GGL%W+,3*KYMJPG M:DTN"\,E,Z;*1E?<33|G".2)7\BDR'.J7TO A#](#G^CD#&'::H*R)@.Y"D" M>>H7$])%97TP(FBX8J.8%.C',N%RH83PK M9FXW3)-1H74IPRFGU82!-P$QPX2^%;/RG-
OW1SJ"F0I,&A@\\R8D9IC0LV(2 MJ]+'C1(9T^8;F?PN8#KALF%B"3V;I:;IK*AA9?3R\OW;F^-@4@D]6V4&_4X5 M)+\MO(G)AFKFDF$F"3VK9$%?R9,A"Z:KO\N4D3$WJ5"F:$)B)@D]JP32'H?W
MCBPUS6!@D*'6%,9'-6)<1DPD89LF:4P<0DPE89LN:6!&F$NB+W8).8 %EF#F MNPN(227RO6[!N NIB87"+/AF(7$}-.Y%D[>!J8&+BB3R+9S\-C9FE7#1?2TP[D6?M?#JY MK5%=3$P[D6?
MX.FRX^ZB8-J)/6L'Q6P,\AB33JRF?!JC)\;D$[>YKKGONYCH MWED+*QO2^3?474Q,0'%;BYR]D1YC HH]"^ASS$Z9VUU,3$"Q9P%AF,/4NIB8 M@&+/ D(QL\S%Q"P4>[80AGG;Y,.
(,0O%GBV$84+1W2;'+-3W;*$/9L/PM"%W M9EP4C4W)/F:A?OW-:?>A*6-KF+%F,[B$@?J4BG2A27FH-\#ZA^7"=%T(,8*Z MN9PJFNV^6^V^N5W\ 5!+ P04 " "N/6U9*5V(H),! #B& &@ 'AL
M+U]R96QS+W=OFX'=S_(\#8Y M&ZQWRZQ;[R1S]8,4@C1]D$&0I0_*(2A/'S2&H''ZH D$3=('32%HFCYH!D&S M]$%S")JG#Y(1RC@B2.IA3:"U(-=^X+4@V$(@MB#90F"V(-I"H+8@VT+@MB#<
M0B"W(-U"8+<@WD*@MZ+>2]"WHMY*H+?V7K8)]%;46PGT5M1;"?16U%L)]%;4 M6PGT5M1;"?16U%L)]%;46PGT-M3;"/0VU-L(]#;4VPCTMM['$@*]#?4V KT- MJ38"O0WU-@*]#?4V KT-
J38"O0WU-@*]<]0[)] [1[WS=^H=XK7RX=GS6./] MWTEUO%WKG[>_+Q^;O8=PQJG!+XW5+U!+ P04 " "N/6U9B(RI-Z4! O M&0 $P %M#;VYT96YT7U1Y<&5S72YX;6S-F/##FTH]JY1)MJ
D[N;:U\N'6+IE1Z4HMB8G1:,)2W7AJ_-"W&O%\^D2Y M6E<^>MZ&QZ[4S2RV5+DX>MP7MEZS6!E3E:GR89]MFNR;R_#@D(3.KL85I7&#
M4!"SLP[MSL\&A[[7#5E;9A0ME/4OJ@Y5;%LQYW<5N:1?XDQ&G>=E2IE.UW5H M29RQI#)7$/FZ2O:B@WYG'TZ8]E=^M7\GTV<8*A=6&Q:?4$L! M A0#% @ KCUM60=!36*! L0 ! (! &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " "N/6U9#[J=.^\ K @ $0 M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " "N M/6U9F5R<(Q & "<)P $P @ '- 0 >&PO=&AE;64O=&AE M;64Q+GAM;%!+
0(4 Q0 (*X];5FN7-ME^@4 /4? 8 M " @0X(!X;"JW;W)K0I\% "#%P & @(§^#@ >&PO=V]R:W-H965T M&UL4$L! A0#% @ KCUM6=O5KKWB @_PD !@ M ("!$Q0 'AL+W=O&PO=V]R:W-
H965T&UL4$L! M A0#% @ KCUM67;'0?MB @ Y@0 !@ ("!7S, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ KCUM69=- MP5(L%0 FCP !@ ("! DL 'AL+W=O&UL4$L! A0#% @
MKCUM68(84.>> @ &PO=V]R:W-H965T&# !X;"JW;W)K&UL4$L! A0#% @ KCUM6?ML/4$* P = P !D M ("!X(8 'AL+W=O&PO=V]R:W-H M965TN)!8 *5# 9 M " @9N, !X;"JW;W)K&UL4$L! M
A0#% @ KCUM6?9T=2KE @ BPH !D ("!]('AL M+W=O&PO=V]R:W-H965T6H !X;"JW;W)K&UL4$L! A0#% @ KCUM M63G=SL4&!0 [\ !D ("!ZZP 'AL+W=O&PO=V]R:W-H965T&T !X;"JW;W)K
M&UL4$L! A0#% @ KCUM6?$)GM7? P IQ$ M !D ("!6< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ KCUM6:=_M.0= P A@P !D M ("!9LH 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#
M% @ KCUM60GY[!17 @ $@8 !D ("!Y-0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ KCUM632# MZBT-! ?!8 !D ("!X>0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
KCUM67(%QFXV!@ ;S !D M ("!;O('AL+W=O&PO M=V]R:W-H965T 9 0 M *T9 9 " @1O\ !X;"JW;W)K&UL4$L! A0#% @ KCUM65;Q^Q3Z @ +PL !D ("! MM@ ! 'AL+W=O&PO68>6R , /<; / M "
2D(0!X;"JW;W)K8FJO:RYX;6Q02P$"% ,4 " "N/6U9*5V(MH),! #B& &@ @ $>$ $ >&PO7W)E;',O=V]R:VO;VLN M>&UL+G)E;'-02P$"% ,4 " "N/6U9B(RI-Z4! O&0 $P M @ '1#0$ 6T-O;G1E;G1?
5'EP97-=+GAM;%!+!08 ,0 Q $X- "_ %#P$! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 153 229 1 false 30 0 false 6 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.cogrx.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.cogrx.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 995210101 - Disclosure - Description of Business and Financial Condition Sheet http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition Description of Business and Financial Condition Notes 8 false false R9.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995210301 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 10 false false R11.htm 995210401 - Disclosure - Accrued Expenses Sheet http://www.cogrx.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 995210501 - Disclosure - Other Current Liabilities Sheet http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities Other Current Liabilities Notes 12 false false R13.htm 995210601 - Disclosure - Commitments and Contingencies Sheet http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 995210701 - Disclosure - Stockholders' Equity Sheet http://www.cogrx.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 995210801 - Disclosure - Equity-based Compensation Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensation Equity-based Compensation Notes 15 false false R16.htm 995210901 - Disclosure - Net Loss per Share Sheet http://www.cogrx.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies 19 false false R20.htm 99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements 20 false false R21.htm 99930403 - Disclosure - Accrued Expenses (Tables) Sheet http://www.cogrx.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.cogrx.com/role/DisclosureAccruedExpenses 21 false false R22.htm 99930603 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies 22 false false R23.htm 99930803 - Disclosure - Equity-based Compensation (Tables) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables Equity-based Compensation (Tables) Tables http://www.cogrx.com/role/DisclosureEquityBasedCompensation 23 false false R24.htm 99930903 - Disclosure - Net Loss per Share (Tables) Sheet http://www.cogrx.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.cogrx.com/role/DisclosureNetLossPerShare 24 false false R25.htm 99940101 - Disclosure - Description of Business and Financial Condition (Details) Sheet http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails Description of Business and Financial Condition (Details) Details http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition 25 false false R26.htm 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details) Sheet http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails Financial Instruments and Fair Value Measurements (Details) Details http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables 27 false false R28.htm 99940401 - Disclosure - Accrued Expenses (Details) Sheet http://www.cogrx.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.cogrx.com/role/DisclosureAccruedExpensesTables 28 false false R29.htm 99940501 - Disclosure - Other Current Liabilities (Details) Sheet http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities 29 false false R30.htm 99940601 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 30 false false R31.htm 99940602 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables 31 false false R32.htm 99940603 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details) Sheet http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails Commitments and Contingencies - Lease Term And Discount (Details) Details 32 false false R33.htm 99940604 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details) Sheet

http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails Commitments and Contingencies - Operating Lease Liabilities (Details) Details 33 false false R34.htm 99940701 - Disclosure - Stockholders' Equity - (Details) Sheet http://www.cogrx.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity - (Details) Details http://www.cogrx.com/role/DisclosureStockholdersEquity 34 false false R35.htm 99940801 - Disclosure - Equity-based Compensation (Details) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails Equity-based Compensation (Details) Details http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables 35 false false R36.htm 99940802 - Disclosure - Equity-based Compensation - Fair value of options (Details) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails Equity-based Compensation - Fair value of options (Details) Details 36 false false R37.htm 99940803 - Disclosure - Equity-based Compensation - Activity for options (Details) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails Equity-based Compensation - Activity for options (Details) Details 37 false false R38.htm 99940804 - Disclosure - Equity-based Compensation - Additional Information (Details) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails Equity-based Compensation - Additional Information (Details) Details 38 false false R39.htm 99940805 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails Equity-based Compensation - Restricted Stock Units (Details) Details 39 false false R40.htm 99940806 - Disclosure - Equity-based Compensation - Compensation expense (Details) Sheet http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails Equity-based Compensation - Compensation expense (Details) Details 40 false false R41.htm 99940901 - Disclosure - Net Loss per Share - Antidilutive effect (Details) Sheet http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails Net Loss per Share - Antidilutive effect (Details) Details 41 false false All Reports Book All Reports cgtx-20240930.xsd cgtx-20240930_cal.xml cgtx-20240930_def.xml cgtx-20240930_lab.xml cgtx-20240930_pre.xml cgtx-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cgtx-20240930x10q.htm": { "nsprefix": "cgtx", "nsuri": "http://www.cogrx.com/20240930", "dts": { "schema": { "local": ["cgtx-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["cgtx-20240930_cal.xml"] }, "definitionLink": { "local": ["cgtx-20240930_def.xml"] }, "labelLink": { "local": ["cgtx-20240930_lab.xml"] }, "presentationLink": { "local": ["cgtx-20240930_pre.xml"] }, "inline": { "local": ["cgtx-20240930x10q.htm"] } }, "keyStandard": 199, "keyCustom": 30, "axisStandard": 14, "axisCustom": 0, "memberStandard": 15, "memberCustom": 14, "hidden": { "total": 18, "http://xbrl.sec.gov/dei/2024": 5, "http://www.cogrx.com/20240930": 2, "http://fasb.org/us-gaap/2024": 11 }, "contextCount": 153, "entityCount": 1, "segmentCount": 30, "elementCount": 442, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 455, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:GrantsReceivableCurrent", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_TtFiO_LW6EaKAC7Zp2ihvg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R4": { "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__3wTOSNKREO6QWFM2PvYew", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_cgtx_AtMarketOfferingMember_qr-U6ItWlkiHxoBuzlyJHQ", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical", "longName": "995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_PNA0vdmycECPO-skrzsZtQ", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_PNA0vdmycECPO-skrzsZtQ", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R8": { "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition", "longName": "995210101 - Disclosure - Description of Business and Financial Condition", "shortName": "Description of Business and Financial Condition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements", "longName": "995210301 - Disclosure - Financial Instruments and Fair Value Measurements", "shortName": "Financial Instruments and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.cogrx.com/role/DisclosureAccruedExpenses", "longName": "995210401 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities", "longName": "995210501 - Disclosure - Other Current Liabilities", "shortName": "Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "cgtx:OtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "cgtx:OtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210601 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.cogrx.com/role/DisclosureStockholdersEquity", "longName": "995210701 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensation", "longName": "995210801 - Disclosure - Equity-based Compensation", "shortName": "Equity-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",

```
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.cogrx.com/role/DisclosureNetLossPerShare", "longName": "995210901 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables", "longName": "99930303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)", "shortName": "Financial Instruments and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesTables", "longName": "99930403 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930603 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables", "longName": "99930803 - Disclosure - Equity-based Compensation (Tables)", "shortName": "Equity-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareTables", "longName": "99930903 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "longName": "99940101 - Disclosure - Description of Business and Financial Condition (Details)", "shortName": "Description of Business and Financial Condition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_10_2024_To_3_10_2024_us-gaap_SubsidiarySaleOfStockAxis_cgtx_FollowOnPublicOfferingMember_bWyiMVBhB0SWib_VYAaBRw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R26": { "role": "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "cgtx:AllowanceForCreditLossGrantsReceivableCurrent", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:ReceivablesPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_1oNpADoqmUCgc6yiuw_xlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R27": { "role": "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails", "longName": "99940301 - Disclosure - Financial Instruments and Fair Value Measurements (Details)", "shortName": "Financial Instruments and Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails", "longName": "99940401 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails", "longName": "99940501 - Disclosure - Other Current Liabilities (Details)", "shortName": "Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_loDmmG1MYUKC0oObsvsQJg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "cgtx:OtherCurrentLiabilitiesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_DebtInstrumentAxis_cgtx_InsurancePremiumFinancingAgreementMember_loDmmG1MYUKC0oObsvsQJg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "cgtx:OtherCurrentLiabilitiesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "longName": "99940601 - Disclosure - Commitments and Contingencies - Leases (Details)", "shortName": "Commitments and Contingencies - Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "cgtx:OperatingLeaseAssets", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_2nGO32PcrUSJkfPpWf91GQ", "name": "cgtx:OperatingLeaseAssets", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99940602 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails", "longName": "99940603 - Disclosure - Commitments and Contingencies - Lease Term And Discount (Details)", "shortName": "Commitments and Contingencies - Lease Term And Discount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails", "longName": "99940604 - Disclosure - Commitments and Contingencies - Operating Lease Liabilities (Details)", "shortName": "Commitments and Contingencies - Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
```

```
"Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "longName": "99940701 - Disclosure - Stockholders' Equity - (Details)", "shortName": "Stockholders' Equity - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_lSxF42PatEmgNGzgvTYZDw", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:DividendsCommonStock", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails", "longName": "99940801 - Disclosure - Equity-based Compensation (Details)", "shortName": "Equity-based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_LUCDPmDV9ESixaHlClsfgA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_15_2017_us-gaap_PlanNameAxis_cgtx_AmendedAndRestatedEquityIncentivePlan2017Member_LUCDPmDV9ESixaHlClsfgA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails", "longName": "99940802 - Disclosure - Equity-based Compensation - Fair value of options (Details)", "shortName": "Equity-based Compensation - Fair value of options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Unit_Standard_pure_2nqoTBQ4Ik-4oSJdbYtOaw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Unit_Standard_pure_2nqoTBQ4Ik-4oSJdbYtOaw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails", "longName": "99940803 - Disclosure - Equity-based Compensation - Activity for options (Details)", "shortName": "Equity-based Compensation - Activity for options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_12_31_2023_2nGO32PcrUSJkfPpWf91GQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "longName": "99940804 - Disclosure - Equity-based Compensation - Additional Information (Details)", "shortName": "Equity-based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_TtFiO_LW6EaKAC7Zp2ihvg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_TtFiO_LW6EaKAC7Zp2ihvg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails", "longName": "99940805 - Disclosure - Equity-based Compensation - Restricted Stock Units (Details)", "shortName": "Equity-based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UyyL7n_-4kamGFoSr29NbQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UyyL7n_-4kamGFoSr29NbQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails", "longName": "99940806 - Disclosure - Equity-based Compensation - Compensation expense (Details)", "shortName": "Equity-based Compensation - Compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_MKMkPZaDQU2yHJ0vWj5CFQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_VROqHjElE06_3uDUtLuvHA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails", "longName": "99940901 - Disclosure - Net Loss per Share - Antidilutive effect (Details)", "shortName": "Net Loss per Share - Antidilutive effect (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_BzU6E3kbY0Sv8pUcAbVz8Q", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_UY3-nGdBeU6BvLp-sQHEYQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cgtx-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r44", "r46", "r50", "r670" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44", "r508" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "verboseLabel": "Professional fees and other accruals", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46" ] }, "cgtx_AccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "AccruedResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents accrued research and development expenses.", "label": "Accrued Research And Development Expenses", "terseLabel": "Research and development costs" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r60", "r103", "r380", "r397", "r398" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Gain", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r9", "r17", "r311", "r314", "r360", "r393", "r394", "r611", "r612", "r613", "r620", "r621", "r622", "r623" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r557" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r55", "r508", "r698" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r407", "r620", "r621", "r622", "r623", "r671", "r699" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r570" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r570" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r570" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r570" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType",
```

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Equity-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r34", "r35", "r243"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Issuance of common stock, discounts and offering costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r10", "r77"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r603"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r529", "r539", "r549", "r581"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r532", "r542", "r552", "r584"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r604"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r570"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r577"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r533", "r543", "r553", "r577", "r585", "r589", "r597"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r595"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total equity-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r275", "r284"] }, "cgtx_AllowanceForCreditLossGrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "AllowanceForCreditLossGrantsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on grants receivable, classified as current.", "label": "Allowance for Credit Loss, Grants Receivable, Current", "terseLabel": "Allowance for doubtful accounts on grants receivable" } } }, "auth_ref": [] }, "cgtx_AmendedAndRestatedEquityIncentivePlan2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "AmendedAndRestatedEquityIncentivePlan2017Member", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2017 Amended and Restated Equity Incentive Plan.", "label": "Amended And Restated Equity Incentive Plan 2017 [Member]", "terseLabel": "Amended and Restated 2017 Equity Incentive Plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive common stock equivalents outstanding", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r149"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r21"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r21"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r305"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r81", "r88", "r99", "r123", "r154", "r157", "r166", "r167", "r175", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r306", "r308", "r339", "r376", "r431", "r483", "r484", "r508", "r520", "r639", "r640", "r683"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r96", "r105", "r123", "r175", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r306", "r308", "r339", "r508", "r639", "r640", "r683"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r321", "r322", "r500"] }, "cgtx_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "AtMarketOfferingMember", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to at the market offering.", "label": "At Market Offering [Member]", "terseLabel": "At The Market Offering" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r592"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r593"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r588"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r588"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r588"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r588"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r588"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r588"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r591"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r590"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r589"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r589"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r182", "r693", "r694"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r36", "r37", "r182", "r693", "r694"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to

```
prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialCondition" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business and Financial Condition", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r43", "r69", "r70" ] }, "cgtx_CantorFitzgeraldAndCoAndBRileySecuritiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "CantorFitzgeraldAndCoAndBRileySecuritiesIncMember", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Cantor Fitzgerald And Co and B Riley Securities Inc.", "label": "Cantor Fitzgerald And Co And B Riley Securities Inc [Member]", "terseLabel": "Cantor Fitzgerald & Co. and B. Riley Securities, Inc." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r19", "r98", "r473" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r98" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r672", "r673" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r20" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r19", "r66", "r120" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r66" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r568" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r565" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r563" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "verboseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r100", "r101", "r102", "r156", "r217", "r218", "r219", "r221", "r224", "r229", "r231", "r402", "r403", "r404", "r405", "r492", "r608", "r617" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r569" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r51", "r84", "r377", "r418" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r72", "r184", "r185", "r469", "r633", "r638" ] }, "cgtx_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of additional common shares reserved for future issuance.", "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance", "terseLabel": "Additional common stock shares reserved for issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock shares reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r510", "r511", "r512", "r514", "r515", "r516", "r517", "r620", "r621", "r623", "r671", "r696", "r699" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r54", "r419" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r54", "r419", "r437", "r699", "r700" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 250,000,000 shares authorized; 40,806,092 and 32,165,478 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r54", "r379", "r508" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r574" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r573" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r575" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r572" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r108", "r110", "r116", "r372", "r386", "r387" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype":
```

```
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
"terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r42", "r91" ] }, "srt_CounterpartyNameAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": {
"label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r124", "r125", "r202", "r219", "r361", "r367", "r375", "r475", "r477" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } },
"auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year
in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis",
"presentation": [ "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of
debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r15", "r45", "r46", "r82", "r83", "r126", "r199", "r200", "r201", "r202", "r203", "r204", "r205",
"r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r487", "r488", "r489", "r490", "r491", "r506", "r618", "r634", "r635", "r636", "r678", "r679" ] }, "us-
gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount", "documentation":
"Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r199", "r348", "r349", "r488", "r489", "r506" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as
a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r48", "r200" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ],
"lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "verboseLabel": "Other Current Liabilities", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r126", "r199", "r200", "r201", "r202",
"r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r487", "r488", "r489", "r490", "r491", "r506", "r618", "r678", "r679" ] }, "us-
gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular
debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r126", "r199", "r200", "r201",
"r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r487", "r488", "r489", "r490", "r491", "r506", "r618", "r634", "r635", "r636", "r678", "r679" ]
}, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit",
"presentation": [ "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Periodic
payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r15", "r41" ] }, "us-gaap_DebtInstrumentTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of
information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r15", "r28", "r31", "r40", "r75", "r76", "r126", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206",
"r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r487", "r488", "r489", "r490", "r491", "r506", "r618", "r678", "r679" ] }, "cgtx_DeferredGrantIncomeCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "DeferredGrantIncomeCurrent", "crdr": "credit", "presentation": [
"http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"documentation": "The amount of current portion of deferred grant income as at the end of the reporting period.", "label": "Deferred Grant Income, Current", "terseLabel": "Deferred grant
income, current" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of
tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r6", "r154", "r158", "r167", "r483", "r484" ] }, "srt_DirectorMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [
"http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r630", "r697" ] },
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensation" ], "lang": { "en-us": { "role": {
"label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } },
"auth_ref": [ "r241", "r245", "r276", "r277", "r279", "r497" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Equity-based Compensation" } } },
"auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit",
"presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock", "terseLabel": "Dividend declared",
"documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r4", "r77" ] },
"dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY,
Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] },
"dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the
document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
} } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types
of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting
or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentQuarterlyReport", "presentation": [ "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly
Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r524" ] }, "dei_DocumentTransitionReport": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r556" ] },
"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such
as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity
Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r567" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "verboseLabel": "Net
loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." }
} }, "auth_ref": [ "r117", "r132", "r133", "r134", "r135", "r136", "r137", "r142", "r144", "r146", "r147", "r148", "r153", "r301", "r304", "r318", "r319", "r373", "r388", "r478" ] }, "us-
gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "verboseLabel": "Net
loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the
reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding
during the reporting period." } } }, "auth_ref": [ "r117", "r132", "r133", "r134", "r135", "r136", "r137", "r144", "r146", "r147", "r148", "r153", "r301", "r304", "r318", "r319", "r373", "r388",
"r478" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock",
"presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]",
"terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and
participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and
reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r21", "r22", "r150" ] }, "us-
gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.cogrx.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The
entire disclosure for earnings per share." } } }, "auth_ref": [ "r141", "r149", "r151", "r152" ] }, "us-
gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and
Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from
effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group
and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of
demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity
that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r340" ] }, "cgtx_EmergingGrowthCompanyPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "EmergingGrowthCompanyPolicyTextBlock", "presentation": [
"http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for emerging growth
company status.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company Status" } } }, "auth_ref": [] }, "us-
gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit",
"presentation": [ "http://www.cogrx.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee
compensation, benefits, and related accruals", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations
related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or
within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and
Capitalized, Amount [Line Items]", "terseLabel": "Equity-based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award,
Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period over which the unrecognized compensation cost is expected to be recognized", "documentation":
"Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r278" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [
"http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award,
Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost related to options", "documentation": "Amount of cost to be recognized for option under share-
```

based payment arrangement." } } }, "auth_ref": ["r669"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "cgtx_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "ESPP" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r522"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r522"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r607"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r522"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r606"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r522"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r522"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r522"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r522"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r561"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r602"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r602"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r602"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r94", "r112", "r113", "r114", "r127", "r128", "r129", "r131", "r136", "r138", "r140", "r155", "r176", "r177", "r180", "r232", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r304", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r341", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r360", "r385", "r393", "r394", "r395", "r407", "r457"] }, "cgtx_EquityIncentivePlan2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "EquityIncentivePlan2021Member", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": ".Represents information relating to 2021 Equity Incentive Plan.", "label": "Equity Incentive Plan 2021 [Member]", "terseLabel": "2021 Equity Incentive Plan" } } }, "auth_ref": [] }, "cgtx_EquityLineFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "EquityLineFinancingMember", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to equity line financing.", "label": "Equity Line Financing [Member]", "terseLabel": "Equity Line Financing" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r571"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r529", "r539", "r549", "r581"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r577"] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Financial Instruments and Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r38", "r39"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Summary of financial assets and liabilities measured at fair value", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r38"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r207", "r234", "r235", "r236", "r237", "r238", "r239", "r320", "r322", "r323", "r324", "r325", "r331", "r332", "r334", "r362", "r363", "r364", "r488", "r489", "r493", "r494", "r495", "r500", "r502"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments and Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r327", "r329", "r330", "r331", "r334", "r335", "r336", "r337", "r338", "r370", "r500", "r503"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Priced in Active Markets (Level 1)", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r207", "r234", "r239", "r322", "r332", "r362", "r493", "r494", "r495", "r500"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r207", "r234", "r235", "r236", "r237", "r238", "r239", "r320", "r322", "r323", "r324", "r325", "r331", "r332", "r334", "r362", "r363", "r364", "r488", "r489", "r493", "r494", "r495", "r500", "r502" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r8" ] }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "presentation": [ "http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "cgtx_FollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "FollowOnPublicOfferingMember", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to follow on pubic offering.", "label": "Follow-On Public Offering [Member]", "terseLabel": "Follow-on Public Offering" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Loss, before Tax", "negatedLabel": "Loss on currency translation from liquidation of subsidiary", "terseLabel": "Loss on currency translation from liquidation of subsidiary", "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement." } } }, "auth_ref": [ "r676", "r677" ] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r533", "r543", "r553", "r585" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r533", "r543", "r553", "r585" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r533", "r543", "r553", "r585" ] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r533", "r543", "r553", "r585" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r533", "r543", "r553", "r585" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r566" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r62", "r441" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r62" ] },
"cgtx_GrantIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "GrantIncome", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Amount of income related to grants.", "label": "Grant Income", "terseLabel": "Grant income", "verboseLabel": "Grant income" } } }, "auth_ref": [] }, "cgtx_GrantIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "GrantIncomePolicyPolicyTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for grant income.", "label": "Grant Income, Policy [Policy Text Block]", "terseLabel": "Grant income" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r242", "r244", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r242", "r244", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274" ] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Grants Receivable, Current", "terseLabel": "Grant receivables", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r610" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r181", "r182", "r183", "r326", "r328", "r333", "r390", "r392", "r442", "r472", "r501", "r695" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r182", "r183", "r326", "r328", "r333", "r390", "r392", "r442", "r472", "r501", "r695" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r111", "r289", "r290", "r292", "r293", "r294", "r295", "r401" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r5" ] }, "cgtx_IncreaseDecreaseInDeferredGrantIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "IncreaseDecreaseInDeferredGrantIncomeCurrent", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current deferred grant income.", "label": "Increase (Decrease) In Deferred Grant Income, Current", "terseLabel": "Deferred grant income and other liabilities" } } }, "auth_ref": [] }, "cgtx_IncreaseDecreaseInGrantReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "IncreaseDecreaseInGrantReceivables", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase and decrease in grant receivables.", "label": "Increase (Decrease) In Grant Receivables", "negatedLabel": "Grant receivables" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r609", "r615" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Shareholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r533", "r543", "r553", "r577", "r585", "r589", "r597" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r595" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r525", "r601" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r525", "r601" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r525", "r601" ] }, "cgtx_InsurancePremiumFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "InsurancePremiumFinancingAgreementMember", "presentation": [ "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to insurance premium financing agreement.", "label": "Insurance Premium Financing Agreement [Member]", "terseLabel": "Insurance Premium Financing Agreement" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating", "terseLabel": "Interest expense", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r483", "r614", "r626" ] },
"cgtx_IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of adjustments relating to commitment shares issued for equity line financing.", "label": "Issuance of Common Stock as Commitment Shares For Equity Line Financing", "terseLabel": "Issuance of common stock as commitment shares for equity line financing" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease
```

cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r681"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of minimum lease commitments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r682"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r358"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r358"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r358"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r358"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r358"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024 (remaining)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r682"] }, "cgtx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r358"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r15", "r45", "r46", "r47", "r49", "r50", "r51", "r52", "r123", "r175", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r307", "r308", "r309", "r339", "r417", "r479", "r520", "r639", "r683", "r684"] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r59", "r85", "r382", "r508", "r619", "r632", "r675"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r47", "r97", "r123", "r175", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r307", "r308", "r309", "r339", "r508", "r639", "r683", "r684"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent" } } }, "auth_ref": [] }, "cgtx_LincolnParkCapitalFundLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "LincolnParkCapitalFundLlcMember", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Lincoln Park Capital Fund, LLC.", "label": "Lincoln Park Capital Fund LLC [Member]", "terseLabel": "Lincoln Park" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "cgtx_MaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "MaximumAggregateOfferingPrice", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of aggregate offering price.", "label": "Maximum Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r240", "r285", "r325", "r368", "r389", "r391", "r399", "r409", "r410", "r462", "r463", "r464", "r465", "r466", "r470", "r471", "r486", "r492", "r496", "r502", "r503", "r504", "r505", "r509", "r641", "r685", "r686", "r687", "r688", "r689", "r690"] }, "cgtx_MaximumValueOfStockToBeIssuedUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "MaximumValueOfStockToBeIssuedUnderAgreement", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum equity impact of the value of new stock to be issued under an agreement.", "label": "Maximum Value Of Stock To Be Issued Under Agreement", "terseLabel": "Maximum value of stock to be issued under agreement" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r569"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r569"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r240", "r285", "r325", "r368", "r389", "r391", "r399", "r409", "r410", "r462", "r463", "r464", "r465", "r466", "r470", "r471", "r486", "r492", "r496", "r502", "r503", "r504", "r509", "r641", "r685", "r686", "r687", "r688", "r689", "r690"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r588"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r642"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r596"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r570"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r119"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r119"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r66", "r67", "r68"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r61", "r68", "r86", "r95", "r106", "r109", "r114", "r123", "r130", "r132", "r133", "r134", "r135", "r136", "r139", "r140", "r145", "r175", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r301", "r304", "r319", "r339", "r384", "r439", "r455", "r456", "r518", "r639"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial
reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] } }, "cgtx_NonEmployeeDirectorMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.cogrx.com/20240930", "localname": "NonEmployeeDirectorMember", "presentation": [
"http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Person serving on board of non employee
directors.", "label": "Non Employee Director [Member]", "terseLabel": "Non Employee Director" } } }, "auth_ref": [] } }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r569"] }, "ecd_NonNeosMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r533", "r543", "r553", "r577", "r585"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r560"] },
"ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total
Compensation Amount" } } }, "auth_ref": ["r559"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r577"] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement
Adopted" } } }, "auth_ref": ["r596"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated
[Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r596"] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang":
{ "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a
component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other
components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to
the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn
revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r484", "r625"] }, "us-gaap_OperatingExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating
expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in
cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] } }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from
operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r87", "r480", "r624", "r626", "r627", "r628", "r629"]
}, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLossAbstract", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss) [Abstract]", "terseLabel":
"Operating Expenses:" } } }, "auth_ref": [] }, "cgtx_OperatingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "OperatingLeaseAssets",
"crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of operating
lease assets as at the end of the reporting period.", "label": "Operating Lease Assets", "terseLabel": "Operating lease assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating lease costs",
"documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r680"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [
"http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
[Abstract]", "terseLabel": "Minimum lease commitments" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesDetails",
"http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total operating lease
liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r353"] }, "us-gaap_OperatingLeaseLiabilityCurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label":
"Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating
lease, classified as current." } } }, "auth_ref": ["r353"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
"http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-
current", "verboseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease,
classified as noncurrent." } } }, "auth_ref": ["r353"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": {
"role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows used for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding
payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r354", "r355"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label":
"Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets, operating leases", "totalLabel": "Total operating lease assets", "documentation": "Amount of lessee's right to use
underlying asset under operating lease." } } }, "auth_ref": ["r352"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel":
"Amortization of right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r616"]
}, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"], "lang": { "en-
us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted-average discount rate", "documentation": "Weighted average discount rate for
operating lease calculated at point in time." } } }, "auth_ref": ["r357", "r507"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.cogrx.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining
Lease Term", "terseLabel": "Weighted-average remaining lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r356", "r507"] }, "us-
gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Description of Business and Financial Condition" } } }, "auth_ref": [] }, "us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign
Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment, including reclassifications", "documentation": "Amount after tax and
reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a
foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r2", "r385"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel":
"Other comprehensive gain", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r10", "r14", "r107", "r110", "r115",
"r136", "r341", "r342", "r347", "r371", "r385", "r611", "r612"] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherCurrentLiabilitiesMember", "presentation": ["http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Current
Liabilities [Member]", "terseLabel": "Other Current Liabilities", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] },
"cgtx_OtherCurrentLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "OtherCurrentLiabilitiesTextBlock", "presentation": [
"http://www.cogrx.com/role/DisclosureOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "documentation": "Entire disclosure of other current liabilities.", "label": "Other Current Liabilities
[Text Block]", "terseLabel": "Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other
Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } },
"auth_ref": ["r46", "r508"] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrentAbstract",
"lang": { "en-us": { "role": { "label": "Other Current Liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-
us": { "role": { "label": "Other Liabilities, Noncurrent", "verboseLabel": "Deferred grant income, noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the
normal operating cycle, if longer." } } }, "auth_ref": ["r50"] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncashIncomeExpense", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureStockholdersEquityDetails",
"http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Noncash Income (Expense)", "terseLabel":
"Other expense, net", "verboseLabel": "Other income (expense), net", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as
other." } } }, "auth_ref": ["r68"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us":
{ "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified
as other." } } }, "auth_ref": ["r63"] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNonoperatingIncomeExpenseAbstract", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role":
{ "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other
Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r569"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label":
"Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r531", "r541", "r551", "r583"] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [
"r534", "r544", "r554", "r586"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [
"r534", "r544", "r554", "r586"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember",
"presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]",
"terseLabel": "Over-Allotment Option", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": {

"role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r558"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payment of employee withholding taxes on vested restricted stock units", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r118"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Payments for property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r64"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r568"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r568"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r560"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r577"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r570"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r559"] }, "cgtx_PerformanceBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "PerformanceBasedStockOptionsMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to performance based stock options.", "label": "Performance Based Stock Options [Member]", "terseLabel": "Performance-based awards" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r561"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r605"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r560"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r53", "r217"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r53", "r419"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r53", "r217"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r53", "r419", "r437", "r699", "r700"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r53", "r378", "r508"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r104", "r178", "r179", "r474"] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds", "verboseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r3"] }, "cgtx_ProceedsFromIssuanceInitialPublicOfferingGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ProceedsFromIssuanceInitialPublicOfferingGross", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails"], "lang": { "en-us": { "role": { "documentation": "The gross cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering, Gross", "terseLabel": "Gross proceeds" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of common stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r3", "r13"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r359", "r374", "r383", "r508"] }, "cgtx_PurchaseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "PurchaseAgreementTerm", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The term of purchase agreement in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Purchase Agreement, Term", "terseLabel": "Term of agreement" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r558"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r558"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r233", "r240", "r271", "r272", "r273", "r285", "r325", "r365", "r366", "r368", "r389", "r391", "r399", "r409", "r410", "r462", "r463", "r464", "r465", "r466", "r470", "r471", "r486", "r492", "r496", "r502", "r503", "r504", "r505", "r509", "r512", "r637", "r641", "r674", "r686", "r687", "r688", "r689", "r690"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r233", "r240", "r271", "r272", "r273", "r285", "r325", "r365", "r366", "r368", "r389", "r391", "r399", "r409", "r410", "r462", "r463", "r464", "r465", "r466", "r470", "r471", "r486", "r492", "r496", "r502", "r503", "r504", "r505", "r509", "r512", "r637", "r641", "r674", "r686", "r687", "r688", "r689", "r690"] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "terseLabel": "Receivables", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": ["r171", "r172", "r173", "r174", "r631"] }, "cgtx_ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ReclassificationsAdjustmentOfForeignCurrencyTranslationIncludedInNetLossForLiquidationOfSubsidiary", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "The amount of reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary.", "label": "Reclassifications Adjustment of Foreign Currency Translation Included in Net Loss For Liquidation of Subsidiary", "terseLabel": "Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "cgtx_RemainingValueOfStockToBeIssuedUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "RemainingValueOfStockToBeIssuedUnderAgreement", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Remaining value of new stock to be issued under an agreement.", "label": "Remaining Value Of Stock To Be Issued Under Agreement", "terseLabel": "Amount available to draw under purchase agreement" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Short-Term Debt", "negatedLabel": "Payments on loan payable", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r65"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r124", "r125", "r202", "r219", "r361", "r367", "r375", "r476", "r477"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r287", "r472", "r483", "r691"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember",

"presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r286"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r527", "r537", "r547", "r579"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r528", "r538", "r548", "r580"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r535", "r545", "r555", "r587"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.cogrx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r98"] }, "cgtx_RestrictedStockUnitsPerformanceBasedVestingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "RestrictedStockUnitsPerformanceBasedVestingMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to performance based vesting of Restricted Stock Units.", "label": "Restricted Stock Units, Performance Based Vesting [Member]", "terseLabel": "Restricted Stock Units Performance Based Vesting" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails", "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "cgtx_RestrictedStockUnitsTimeBasedVestingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "RestrictedStockUnitsTimeBasedVestingMember", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to time based vesting of Restricted Stock Units.", "label": "Restricted Stock Units, Time Based Vesting [Member]", "terseLabel": "Restricted Stock Units Time Based Vesting" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r56", "r77", "r381", "r396", "r398", "r406", "r420", "r508"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r94", "r127", "r128", "r129", "r131", "r136", "r138", "r140", "r176", "r177", "r180", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r304", "r310", "r312", "r313", "r315", "r317", "r350", "r351", "r393", "r395", "r407", "r699"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r596"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r596"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Public offering price (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of outstanding potentially dilutive common stock", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r33"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of total equity-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r33"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r242", "r244", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock units award activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r78"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of activity for options", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r78"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of fair value of options granted using the Black-Scholes option pricing model", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.cogrx.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r26", "r27", "r28", "r29", "r30", "r31", "r73", "r75", "r76", "r77", "r100", "r101", "r102", "r156", "r217", "r218", "r219", "r221", "r224", "r229", "r231", "r402", "r403", "r404", "r405", "r492", "r608", "r617"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r521"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.cogrx.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r523"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r163", "r164", "r165", "r168", "r169", "r481", "r482", "r485"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Equity-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r497"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":

"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r261"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r261"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r258", "r259"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "RSU activity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodStartLabel": "Beginning balance", "terseLabel": "Ending balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r258", "r259"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Equity based compensation" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails", "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "verboseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Equity-based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r242", "r244", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r498"] }, "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward": { "xbrltype": "sharesItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuableForEachAward", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable for each award under share-based payment arrangement.\n\n\n\n\n\n\n\n\n\n\n\nShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Issuable for Each Award", "terseLabel": "Number of shares issuable for each award" } } }, "auth_ref": [] }, "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetTranches", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of target tranches.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Target Tranches", "terseLabel": "Number of target tranches" } } }, "auth_ref": [] }, "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetTranchesAchieved": { "xbrltype": "integerItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTargetTranchesAchieved", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of target tranches achieved during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Target Tranches Achieved", "terseLabel": "Number of target tranches achieved" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r252"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)", "documentation": "The weighted-average price as of the balance

```
sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r252" ] }, "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the total fair value of options exercised during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised In Period, Total Grant Date Fair Value", "terseLabel": "Fair value of options exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options expired (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r257" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r256" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r254" ] }, "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the total fair value of options granted during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Grants In Period, Total Grant Date Fair Value", "terseLabel": "Fair value of options granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r264" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r250", "r251" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending Balance (in dollars per share)", "periodStartLabel": "Beginning Balance (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r250", "r251" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Maximum percentage of common shares issued and outstanding", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "cgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesUnderlyingPriorPlanRecycledNumber", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares underling the Prior Plan awards that are recycled under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Underlying Prior Plan, Recycled Number", "terseLabel": "Number of shares that may be recycled" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationCompensationExpenseDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r255" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options expired (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r257" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r256" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r254" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r241", "r249", "r268", "r269", "r270", "r271", "r274", "r280", "r281", "r282", "r283" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "terseLabel": "Employees", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r244", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r271", "r272", "r273", "r274" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r270" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life -Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r32" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life", "documentation":
```

```
"Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r79" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Offering price per share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "cgtx_SharesOfferingAgreementRemainingValueOfStockToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "SharesOfferingAgreementRemainingValueOfStockToBeIssued", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The remaining value of stock to be issued under shares offering agreement.", "label": "Shares Offering Agreement, Remaining Value of Stock to be Issued", "terseLabel": "Remaining of common stock available for sale" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending Balances (in shares)", "periodStartLabel": "Beginning Balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/DisclosureOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt", "terseLabel": "Short-term loan", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r44", "r82", "r508", "r692" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r69", "r121" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r54", "r57", "r58", "r94", "r112", "r113", "r114", "r127", "r128", "r129", "r131", "r136", "r138", "r140", "r155", "r176", "r177", "r180", "r232", "r296", "r297", "r298", "r299", "r300", "r302", "r303", "r304", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r341", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r360", "r385", "r393", "r394", "r395", "r407", "r457" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r127", "r128", "r129", "r155", "r351", "r369", "r400", "r408", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r438", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r457", "r513" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationFairValueOfOptionsDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r127", "r128", "r129", "r155", "r170", "r351", "r369", "r400", "r408", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r438", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r457", "r513" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r530", "r540", "r550", "r582" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)", "verboseLabel": "Issuance of common stock (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r10", "r53", "r54", "r77", "r402", "r457", "r467" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.cogrx.com/role/DisclosureEquityBasedCompensationActivityForOptionsDetails", "http://www.cogrx.com/role/DisclosureEquityBasedCompensationAdditionalInformationDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "terseLabel": "Options exercised (in shares)", "verboseLabel": "Exercise of common stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r10", "r53", "r54", "r77", "r255" ] }, "cgtx_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of vesting of Restricted Stock Units.", "label": "Stock Issued During Period, Shares, Vesting of Restricted Stock Units", "terseLabel": "Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r53", "r54", "r77", "r407", "r457", "r467", "r519" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r10", "r54", "r57", "r58", "r77" ] }, "cgtx_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to vesting of Restricted Stock Units during the period.", "label": "Stock Issued During Period, Value, Vesting of Restricted Stock Units", "terseLabel": "Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.cogrx.com/role/DisclosureNetLossPerShareAntidilutiveEffectDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "terseLabel": "Options issued and outstanding", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending Balances", "periodStartLabel": "Beginning Balances", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r54", "r57", "r58", "r71", "r421", "r437", "r458", "r459", "r508", "r520", "r619", "r632", "r675", "r699" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r74", "r122", "r216", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r230", "r232", "r316", "r460", "r461", "r468" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.cogrx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Description of Business and Financial Condition", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r576" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r568" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r575" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r595" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r597" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.cogrx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r598" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r599" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r599" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r597" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r597" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r600" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
```

```
} }, "auth_ref": [ "r598" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r305" ] }, "cgtx_UnderwritersOptionToPurchaseAdditionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "UnderwritersOptionToPurchaseAdditionalShares", "presentation": [ "http://www.cogrx.com/role/DisclosureDescriptionOfBusinessAndFinancialConditionDetails", "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Underwriters option to purchase additional shares.", "label": "Underwriters, Option To Purchase Additional Shares", "verboseLabel": "Underwriters option to purchase additional shares (in shares)" } } }, "auth_ref": [] }, "cgtx_UnderwritingAgreementWithTitanPartnersGroupLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "UnderwritingAgreementWithTitanPartnersGroupLlcMember", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to underwriting agreement with Titan Partners Group LLC.", "label": "Underwriting Agreement With Titan Partners Group LLC [Member]", "terseLabel": "Underwriting Agreement With Titan Partners Group LLC" } } }, "auth_ref": [] }, "cgtx_UnderwritingDiscountsCommissionsAndOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cogrx.com/20240930", "localname": "UnderwritingDiscountsCommissionsAndOfferingExpenses", "crdr": "debit", "presentation": [ "http://www.cogrx.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of underwriting discounts, commissions and offering expenses.", "label": "Underwriting Discounts, Commissions And Offering Expenses", "terseLabel": "Offering expenses" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r594" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized income tax", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r288", "r291", "r499" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.cogrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r23", "r24", "r25", "r89", "r90", "r92", "r93" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r564" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r143", "r148" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.cogrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r142", "r148" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r562" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" } , "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" } , "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r211": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r287": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r608": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }

ZIP 61 0001558370-24-015436-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-015436-xbrl.zip M4$L#!!0 (*XJ;5FWL3BPU T !N(1 8V=T>"TR,#(T,#DS,"YX MIV3C^<=DY[EZC5^B1EW&H,>!P;26%GI]V@X,X7Y]C7 MJ-MMP[^SSMD%ZEU?GE]?=M'L/B"\A[JMB)+RA1G73-]@2T-?;ZW;[^2GY5'?6] 5^6E)(W<.]FN<4[)T.1XYU!K@E>:-'K" M/5 M3*D:FLC$HA%B!)%B:%;,74,58KJ>ST\=N@9%G6[H_O)7-8N(-09=2]'A=R" MRY*:IPSKIVOGJ1V4REH&+"YK4:]HVM37+:G-B,:[:.]R.7J$=NZY +X$C%*(Z.[5IG M:6/KK /X<&PSLC1Q2Y!AJG'PRJQRVQYP>M ;8M9 <5L4"WEGK>|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l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|_!QWBS:PG)ZD:9*0 IU]< R(ZK#*[DA8@A4 MQ)|4NT9S5;QD MQ.P9M>HV_%4-UDOLRSR7S7>S.KW^[_KN)H,*-IYRA>'K M4VR#KH*G8.,7(B4'B&+B@+^G/!ON'JU^PM_NPA%V94|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|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|LO6G[;D*F%#L@HB[M.#?TSWQ&-D;GQBY#;TF*/*1O_XV2-AGQ\?.H;,9F?ZQ&MRAHSO9|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|W2&P2T[O'IT7R7V2J_K MH(O;<6]&1P]9.'RE,&T E#!PJ\V@G.HO"KN%52U+?CRRF%=]1Y>IB(160HW- M.B%=*\GZ4[LD:^"4]T,"> 6(_W[=*$Y"N>N_'LBI]V, K_-[D MZMWYZ.$7Y^IF -O#WO?;^WY[WV_O^^TSOG$?P<4+?U;/DM9F$2E[CE[B>8I3@@50GFP MVG@@"-9-B\]-D-N?-;1;X)M+9IO3!ALQA%L<>113+GV/F!UWTR4S1"70'W$W M:MK_M "4NAO1Z9]4<*3Q BT(\H*L,#Y:A(CS+?)'XE$Z74%8%"&MTKBB#.D1!XX[:X1NV-GJ?3"=T;TPQ744QR@I MBN3E*X-?%M(S*P; ILJ&1)@3"HZLB#*ILBTH(\|9FM#?Y;E'VKT!7(RQ(1G: MJ[D/U7%UPC*>%(11C6+V1\!IDN4&4W@%01U1=*7E@!NS0PI#UV0#([-J&:' MK_&HP(+?RN=8H^"9Q81$U[%T.D%8+M@+LP; MA=; $++6WA&T<'_ DT079_|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

S9V@>RN>H(/]-X*DP5B;% 4(\$*45ZF7/K>>;GPR$3! M7_G\$*YEU%:WA^[&+9I6'5C1&++KMHD\T&D)>52E;WB\7WH>,5HB_D/W)S\] M;2%O"]U#&S2L>]>D(63/.!)WH%
<*FHOL!\3VK:]#8_@I^)Z0'Z_C^^@Y;+-" MI>5,/')?.ZD_%LUFX(T284N&$_9'.)Z_@FCI[\T%7/297-9^*1_M"CVE;EEK.P/?5$D\EH/F,\Z,@V$OO8F2U
G^C[]M7#AEC1^&+M3_#]3Z9'GE"6.EO,#U,*F%?GV(#,*5F MR(5H FMPLXY"J9ZWI E<5U+ID[E3_>\P74HI95^W8@01HVAL[2OVV5__O!P M[Z?2+$))$[BNI=(G]T\1#)-
ZW^'ZUE233*WJOP1ID_)1>SM4)P:XN3,X=39B[LF$f/%F9RB&5RO M:M*KCEGE-C!JK%'2@4?!KEBC<0,[F07QSA,>6(-C1>RMMW)5N8+]DE\<*".OO$?!*G3NH(<1H.(17-H?MHLY[U
M(V)96\@^VB+QX$/AG#K-U'(RIS69L16?."E^C.)7I0WJK:![I%2K_=2MO ED M_Y,+.M#M&%&4437E;'<;)PB.=XD?XD0]5M=;07QL5>.] >J99VJ#N^E. ^+<-K&AN4U
M#H(V@*PU@NY_IUJ8W'*I!62?D\HY=$2F-$U#'F&WH=FUD?O;W=HAAKK>I;0] M#-VP5.\0-'>"[H8Z.M B M]/#+?V U9NZW ^^OY^0W3:5E M]EO"=<46[>JWC6O-8#IBF["#;QR7'9&1-
NV%?,VDYX75MG/Q1(F&%5XE?_(WE[E,)KE?G?N8$KD_B)N+;18K* MEAV[PO3%/0I3-`W2#YX')Y*^]U3R^NKN^O+H=$8[=_E'HJ.EY?+JY,S=/?GL[/[M.ZN>+BN?
J6PT$^_=*YDI;S$#CQRG3&9.;JS:F(,\[E)1([.QX4P\;T\WJ?== MPJV(J2'K"%YXJ2R .8IB*8X3?&E).QNQM4P2G"8M,Y2)1K!C2JY3.9ZJ+>#& MDD+.WM-
D1DY==MM,"$VBE+W8$3MJ6B&TWW8.D:30<#^@:@VAQY5+W&&>N,CS MFD'$V=A*9LHYC/HO-N+NQ$G6R]"C_SG{^|Y_<@(B4+),3YPX?O7#QU^=8*=:
MF.CVA1V7G2Q0CE.MCG#CMIOXO5V(P:8E!55O8$=BH83G^I WA M1E^SN'V=4E!%@JS=R)M61L MD:B)]L(XM&;)2;BW?]/Z_1ZJ27!#*,4]FGK SMNM30N!VYC![B1JR=V7S?. MJ2-&?H$8@Z-
H=418(,;#2NQ.JW6NY(XHZ8BI1)2;(] \ZX.OF3G%M'KS.49- M4>NS]<;1%7@Z:(3%/8=;%U M%'@$(^F4)7UM.4OMT!UV*'6U0SG8=/O"#M91//8*0&R1M_?D5Y!%@]F= Y^IE=QRNI:B+]YA
M;Q]GU*90M@/$]JF:'L':6WY.IQU:D M/6#&%2HQ?&'9|^/G'#PP_Z& _^=HI7F CFL901 ^]FE1C%]M[>&B1V:6E+D:&EJ M%S<|<1V:O=S8[=L,][DU1LZ&#G3TA8/L():58HY"^BM/\$:/+//(9]R1D] L
MR)1TQC0/8L5^C/,2SEMVH?O]%/$1]FIC9211CS[BA.W [+&5"U_[D7F&/8/ M^3+8?6V>"+5V@HEHW716G_/5>|"=%VG*/=)7)\[!{AS)F-K\L"LHSPUMQC)- MF-->S:A;
X_>9BTK82MO"CA>6P3N[;$LE1+,&F9:-;-I5BDL8>R]:^]S@H]! MO?";4^1-X(W&PJUM33W58AI*I"F&^ROBQWVFL95^L.-06W.-R6S1"6Z4ZHL^ MQ92V8 -
I5CN()*):1B%1Q.JKW$CT[8!L&P7Q_+4HAWRP8.81!O%+ (N,,F$ M'&'>8'NZ,-(\P?+\@-9,]],-N[X=>B=12",&& MFX[0O7-#"MJ\0D&9NI6!WZ2V;IDZ>G<5I1C][CL{)>DZYJS..$NU6U[]'#-1
M)TR^Y.06:)FFL?^P2VDZ"4HC=.- R&*;4/%JEBEFQ*VDL=W$XER+2=14&TC> M$G9P-FA7JU50;P8W')N$'7")7YQNBM=I&-D%NDB2':Z_Y&4F^*95, ^%]_L\/M[S]\^(BV3HR>N,8?/RP^?
&# AQ+^0H^S2]=1[/\#>_].%M+9;WUF&5[LH'C" MAY[JWQ&?Q)L'*,?/RP0#3C6ZA2[XKM5G MR^4V<"-<*>F0F6+Q\I3]V)Y*0654 _!38UC_ZX?%[S_\;O'AYQJ8J/[XP^+C
M[WY:_.N__7Z\:%\@0F>+V5/9@94>)4O/8Y77G>#&\;V+\,39^F2%K_A$ZM:P MD:!%?RTJRK+PI7%QH$[AW]FA.%U'"R ^1(&TG3792-6G%HB.BIBM5TT@XWN+4 M\4/LG3EQ2+
D6;KN;K,+G!1[IWCEN[YK:S5$7:0ZNM>CM?V7G!#MX/LO:L8 M"!8HXX'>E;@@P::^'S1,|Y^YYB%^I#R:@MJ IRF%?P"H;JI6SB9&"Q
MAS[)&^,U#A,RR^'IMY=1DESA]'IU[[RH|+XS%=CHUM,JM7L\74C Q;V^BHP1 M&#REK,)19*BC=Y3I=ZP6%3T7)IQM70BR9AU1HK%BG8 P@W%>H+TC"QX-U+HU MGPO
C>D&6:N8O7OFL>WQ&QS?T7UHK9.RALZP@[N;#=3'MZJ>< .] MH_RC'?(23BB*$>?%CX7HB].(L;.4*&S<%N+,*#\L0N_\$'E1$#AQQJ]K\R,@ M*VE455LPQ9-E?FRE94!)ISFA@$IG=?
37>\PEZI5RCQ;MG ,J6("(\ GU9I&] M?]P+)9+Y^7L'(^4=YA?!55W;HI>WGE?DUF0>.VK!)&)-I*T8A2OI%E "];K(M^.A@HF]O^86L1.NVN"UUF5?PR@0?.X)+/,"$\31Z5V,Y4NIM.N.QX():KR?L
MP.Z@O2)52M_J:&UWF;RG;N,:6=UZ9H&J7ATKFLXH0$=:*WE.S?3'JHBG<*&T3N+>W7E _=75]>G"[OST[1W3WYS^>SJ_L[='V. MKF_.;I?W%Z0!6EZ=HI/KSS>W9W\^N[[^/4,75[?
W5FM$5=DQ+9XK2/T\#[@E5OD\4DS*A\]MY_L%)*XA8GF#C2>AEZI_@)!Q%[M UF(I#'!+6Q_8L:]ESM0S5G^O/)\CVM6M9;LX@T"3"CKR\M!MO(^1'B2#]&EG41:&=:*/7DZ^B
M,*KJ*)"E;?]'MS/PF.QD@[W7&)E:Q/D&2Z6HH MNX-|;IRD%27+T\0KK$[UT.H*&YBZZ%|- FGO!Q>N.DG?U],S)GN@M:BLE*Q
MF%D#8.GAA9'X/H]B[#^&_,U'] 6>S'@2LLXCTWFZ07.,5^3OZHJ*^KUA1WE' M*Y0#7;,KW%COJD!?;Q=\4,8(E3@ARFJ!'ABST:LDZA>/-64+MOE)U'8S6Z24 M4\"6T7Q3-
/# OO_] @NRXDUV#XGO^4X\3=6D-CB& ^F,3HGX#.4Z?0=-K-IK(??N!BD>8XE"5$&WA#.YZ^0=2A%2J'5'W?N'9 M/#.H=.7DE Q(YES!CI4&C[$:.$GBKWS77OJ-Q)(M*-K< S84:FA;N.7_ZE (QYES!CI4&C[$:.$GBKWS77OJ-Q)(M*-K< S84:FA;N.7_ZK:@X7 ME'2$'G#_ 5>>-
#9/U_5MG?E/:@R^F7!!O:V2O$&5U?XZ=Q'<5-E&UA1V]C1J6 MXU;:$&[$-HO;US?SU\'R"E4+Q"A;&KBGT3);O!05]!;H@5(&5)ZJKOFI'^Q2 M9;4;=>MY16=-
RZ;X%WGZ%U@<>,44$;2)2.I:DL3CU.&U"D_H7,X=+$[!6Q ME/.(KW;T:=_KU5XAD:.QM2L-V%'=RR+E6.]$ "X"]%.C;[1DW)!@AS@_.KW> MKS([X;#>>C!IQRQ'CC"+*^KQ[!7B*4|"^%\AX8D
5=U"6]VIS!)3VJRB@2HJ M$K/#E59%#"'+A).1OM@RN6ETT*4|=;&(+WG-* *Y>T]M=4=R=T^T+&TLZ6:#Z M$*=&1[BXT4W\"2J(W=U?G_S'GZ\O3\]N[[Y%9 _YY>+^UU9"(,] NG,"+*RQ
M?/%5"05-[8&{>INF%?=6-0;LTJTB]W5C2H^-<.RAH*^49OV2IQE?+?2Z!4'T?!W> M[!X"W[U>K7!,IC^?,9V)U;36:0 30[4US>__-C4&?B%82_3^U$Z8EW&J$5XT]SC+>[!I)
CX0$9J\.3VH%3SOH.D2F#T2IC;Q9@IM.?4T:4-,II6X09 MPYI:W=#E$M'XV?4T>4)$?(L' ;H3:TMK.>SYTSPQ[6>YO8] J&|.. MUF8=JT_WR%K"C<\6>?MO?G"R*,]1MQJ/$VFY=-W=9L?+V)
[BE>_Z5BIAE,10 MW6]M'DD[/(<=IYTM41EA=3O#C>;N*O1V_>N3"\4]3O"CX MB2"/I9==8TP$/<7\OQ?A2'JK?;10$YU"\[,2Q^V3=]Q_C1#T--50V=3!+DO$B2'79.=S0/XX)6YO4-+J#9VM17:,SAKF?
0[W>>9=0K;* 1JK6>LXM[E?Q3!'XVF8$9^:-;@E\T M];DI)I[::-0",:2V"O$@SWC8WZZWK&S?V0N.73J1%O3I0V>6F-AN&=U9D93(M|)!20Y4)9TN\B>",0).E1V4L&#)#79Q1G'HV-
VP*>R!&&#JEM3,2#9SF*NXV-8VXO^*$WE^Y M7MV2'V+?I=5T:/,OH3 _#B<$<=L:Q47YWJCKANO5 ^VC^\3%FT(Z> M*#/VU24+FM*CTT]< OJW0@8QU[2(_ /C.DE4+Z5;_9JECWS::P?
FVSGOD+ M7O;LI=R#V&W)CV5'N_N2L >3F$?R#9MG/UVO<>"A510CO-D&T2O&*'5>]K:K MQ@=T/G*-A>AZU.8'Z1VLU(;I&J3F">I=%!M6+S _,2PXFE1W//;0NOY8AFI(0 M6V&?2+5
3H(<,APDNX %8^MH +[35A99T=]/NAOPF)3P;_M+>SBH9OD/E)< M:6#VI6;PRDO^6WJS/2&!=H?C)] %_%O<8C=Z#!D5-B@K5ED&V,(<@TS;O7]] M:%]><'?*C&G>>S%S8[E$6//
MWN')^(\W\;ZM/]-5&.5Z)7NQC_Z=<%F+IC8Z0JGXG&RR^+QY.M54>)Y2-A@: MX0H31 U;/9_P3\|2^,+ H %Z+R#(VL#91+N03<#]+ ^B5'MJC?UXUOB*67(JGIY(],"OM?E.Q/'X=A3\^3'NBR:O\[
MU0OS!E8D_P&TX8 M">"!SSX.YLW*FOHK_L8+_Q7+#M)W_N$LOVAW&G?NVV= M@!LT0_45RT=+=QZU5AS%1E6V4-72ZI$Y($D8:/#&;JO(N@H <734;1JG^Q MCYPY;/6LU?Y 1>V/+&>/"
[% ^:XDDP/N!L!4AE/MRM+G=Q*7+@(2]E9Y5MB7 M--JWD^EW>$Z<9'T>1, ^)_O,[LBZP44='7\5C.WOMX:*&EM2]"W:IG]8Y6=[] M&9U?7O_ESH8ODVD%U?8FCIY\LC@X?
OV2T*7,J1;'K.SMTDW])X(#N,W#>Q&" M[??]:5..ANY4X,;(%WZ1@Z=DE.>*&-*4U+74;YD+/T.Y:Q1P1M)S;C;*41@ MP4K.0BL*68CZ,(IRLS@YLU\LS_"O2,01,2\(RI+I3T<"%T_P,1:Q2KG/AH'
MC0RPA8U=INRN6$U,PA,N+AK3?(15R0\$1&3<4%7*;F8; >DLBE"_SPS_)W3 MUZ#FC7/KY_NRY+?T9_:9=MS6<##]E+Z4X/ILQYC\'&#ZPS+TEILH3OU_R$Z< M.G:%C:U=]"_CHTX_N!C72?
J^D5%FLD Y&[;P+S.R@BO&+<#4=M1JFRLO=5S/ M^% MHE6-84=TLXYU:,V6L*-VA9YQ(@[*,UNRN889R^4*;9S"VX:WD5F,,LDP6D9F,2'4)T\=2<#.Z+[V]5RIMJ1!EP4Z*U)
M_]N@V5R5<5P@OO,H6AT1KHBQ78@L==\ERP)OYUH;UHT;ITR3)39EMB$S?>10 MKB/>),J.5:Y7I6CK/ MYAE(TX-CMLK=(6*V?8=3>AJ, N/Y2"]ELVU3L1d GS_6W17%%GM*5[A,,:>
M6+Q.#"8#CV*AY[J-#:4[SH$[ZC#PG$KRS;7.&J#QA?RG; M%YH:1RP;*;,&YM1%_B\S1^]ML@G@9NGRJ.0;YY6"(#T1=-UX1TQ:S.*T#;M) M;&YPT\5&S7"C0VE.<--)GY'A)N.-!'-
^SL[9HQ)_(,LQ(Z;*;;(MV<01-LF0 M:,HU68:I;'+%TY3XM=/ZODR?_C!QH[LZ+H-8U/E,"MOKN0D-HUC991S%$H_S7(A+[_779$WLAINTR:G,!TJ3LD Y M8MC>X&9'N]DH42_!TJ< 3!SM;0G-
W>UJYSG-LMI4F&QOF_'+YU)FRUJ8-T>A M=|#TMHP(^C=Q%);K1 VG2W1;];;'1H8<.!F^M38(,M)K$S(8-DGK?09 M('$1BD]@0Z_-A.:)6AHV$8#/!JHS Y$='29"$QRUH"N8%FP4OT*K)^;Q?)U
M*9$?3TMJN'_?^3$F5B'0E[!>$$W39>C1/*7M9G]_IQNCO^_A$L&)U:#@SE'%;(,9OP5;O.4M+QTLV;$)3\[:"#3,"5A@!V!QD.,"" MQXCNMN@WUX"+$3UT,#W@+10FXA|-UK M45^S@^U4_>
<7](V6: M^:>=Y@4"S"B.#@6"&.#>4L;,R#S!G##I)V@IN@/#/ MQ)>'BH.-+\XWV$[5;SZXUZBY"N^:7\X&C7/3//I=]7)^C3I[#SWG8AW63.A. M7_/$+4^@VSR#N>7O2=]'\[+7^A+CE%
WQL]C^).9:X&D ..#0/M)#NMZ4H+ M,)(,U6C@J<6"ODR"2AQ;GQFT?*!CIX0 4>O*W69\+QN*=5O'**S9?+R&*YZ
ME;R&:P2A;O%6&.UZ=;>.XO0>QYM3_*#:PVU]#QMC6C4M@XBR,5R4:!>YKW<7 ME-E;:93V$26.*'5+H3Z=MOE1+0G7('+"[$(.[*.7P?O,X..WNRWZ';' C? >
M.A@\4H%T/CN52=CY[+9D$MDAB@V@.%NML)M>K\Y>7%;BY9;@YW5(34/_C^:Q M/#D!GQIE,P_ZAV7H57]1:JFP^#2<8$//A-8M8]0$;. ""V93*]BZQRV2BDYQ, M*D3%HC,!RFK!
(;'<8*8403FM-5^V6UQTD4IGZXHY@A\MWW-R?,[-+ _@0X M^P0Q_02NJ%Q%/@4#86IF]@,NF-L WD'6XI5HJ2]) T1=SB7^4OPNWB^)#&A<" M-ES;^29E)#+G@ M&[@1@9BK9J26UL,C63O
1MUWG.D*J>|!&- YY!R7I44 ^N0XKMA$53>D.)X+&7 MS8>]0!Y]*7R@BUZ[:ZNQIC=3 -"632+.PL9-?_OFDV(4.D*8O1"..N!;3V>)TGA9ZP(]^&-)9K|I.9AXNBA^=4#R"5+LA'R:KD'6]$GO(
M].EY\4)WVR1N+-JPL7Y4"U;>/1J#,%SL'U>]_K6T$C?VM]D;0,>[Q]QPDN< MYGSI'J7GVWI;+).I)"HQT;&3^,GUJFRI>_R2'@?J"R*]",$.OOZV*4=:=RIP MPVJ +GUC* ^;TG""MI&JN0?L<-
;0MG:#3=4<;BCK"#W@,13V#,19_V=0QMHN:'P$IHCG MMN&I/S78GC[02(I=B*ZDX$;(4(4&ORS4\MI2:9"T/T9:-)9UJ&%OV97T%. ^H MM)7^MO:"#1V:6E=.#)N[P(4"7<%[OX?!WL415,LQ7G|Y:<
+8HR'8%'BH!KY M=/O =-).&N>O@[5U /XBF+;XO2][A"DM#NT5XTZT$F\Z9>] _!6K?G2Q*S2BO MC%%(@ZJEQ:WD>D:,C9_R'(O0XW>S'G'H5J87;, M[J=&[]2Y@AO/_R[SZS-JFXF,MG5N9R('$!N-
J]IN%&8>'>.-&8W4 6KA"LDP M5O(1=#:T6O>(&(KF%)>O5U':-H*V=H(-"WHZ5 (.&GO #7N-N7N?KY?(?XLX M RN#GUQ/_7&O2)Y^K;F:*?=>6X>/P64< ^KV1S!&5O"LW"4:T%
[JQ6,;VA.6P$:=.S4H9.T19NS+=*/*30S&64)/3",J]Y#<%)VX;#IO;S#Z..B*J"LJT\A3W5/LCS73:PHA+<8.R=N'DE?]OZ^5DWQOG!J*.H-K+I]88=C M)PNT%U:Q-_6 7@2 MO[;XO4L]5;+WG:
(4QI:'Y"]*T2,5 OE,"K-I).KSQ@@S@',[,&DZORKVIDH M))B$/9T?G>(G'$1;&@GBYAY75@G3.CUAHE@/[:MSB-9ND"<3^L+W'VYDX(+'$&4FRP8!@B$V; ,]$>0D8BKRY]AN_>2WDQA[?DI_4NW,-/:
#0\| MVE8O+2F;PPUW':[WHIT4:4Y)Q\N(?P*8(YFQ!EH E0UBM%E B?&H3Y!EW-S8S[N[P(X616[R-XJX)=[I]88=U M)PM4EO(Z'>&&>#0R_7.1>4LP$7YT;M,.)!X]D&QX]$WDJQ])RNZ6K?"74.
M&S7[P0S:SIKGAXXZG8 ?/'928]JKY+A:L-).$9'??.BQYB-#2'C0QM>I81 M0-46;J2WM5793EA1"B#"U\#.EM^>.GX]=@A.RUQ2B8?NRT!#>VW:MJ[MPP[9KG:0GCVT](4;TITU&+[/OD
/KT@P0XP;RMBAK_X"%;B:O'>8R! X,.211QA$6SQ&9!+ E*8YE=J MX8"Z->R@;]&R'.&*IG#*N4W@OI[*Z"Y8[BV4.)U*U7)0!10'<@D3. ^%(YA+X M>HMIIE/XR!3.P.CULY/N8O)?
S5#M0PEZ&/>V3C7$.Y.!/[]E>D/#93G N5< MD0"+G/$"I1%ZP.C&\;T%RL2 @R/F;5;&F(T?^IO=)L>:O+/JZW<7!7D&^Y;,3 M>ZQ^+D_23N@:BYW%+9-DM^&_Z[B &
(D);*":QJ;RA<@8'.#"VT1ZCA%TFL7 M5*8%8E(A(=8"Y8*ADF10P!"PA8M=$_9FE[;N^=+;+Y+Z,B3KC&QGN/^=D1Z M$H43T0YM8]^E#3:1AP,HP%J^@5(V[-)-_2?=[=THA.
<'H/ULUP::W:C."RA[MZC;1/;2% ,0%ROA#AD#3MBLVEIW,.C2O2(>1/RZQ4E*,)9 ,;//E]!/$S9B MC IFW;G,&]EZ6K4+S'5D,5 ,ZZOH9 !8"'2FB%2D^>&A<;N6YH1Q8<*$F7!'
MN2.'LL ^ATRY@TA",W=#L.G@(M"[$):Q-(V(^A,LE%-R25-G!I>64AC#U/3_8T[<^M(>UY"X5YNOZSL$DC.:"KV/;5I%*,1*7.2#JZ+J.DII1&@H54]%,+$3] Y4$ M8[6;98]! -7D-
:.=FF2DO&)WR!*:4?X%Z($0L3&;WEK!UMU#0LSF MQ*_7,:^?|QFGZ\B[") (Y)L,50Y;&E#QCE_W&V?-F#.H/M&X+(#CZ03VK"#1 MB/0!8^@46O;?
KLOHHR@6CXHB+@_*."T0%8F=%%&A%NB>V$5@9!T8^|=U$]>E MF";_*N*9 ..-O)W36B^.M$Z>O5\X&+U_|^EL2#KI/UK"M)A5$$:6*OE*ZQESO%F^)?=9$EN5CC-D"K:
[G:;1Q_/K%WJY3II9PMDGJO= M$:8[=Q=_1! GE/MXN:*]P(D3D]:G?OJ/1QP[@4=?2HC(_QS?^@%^+::5%Z'[M&6|\><%RS2&|B,!U[F$WRX@.=*0"O1-!?G_[W1K?\B:H$^>$]BC=\;;;%<4H"
M@.5&1(B+A0JYRX%*%/%L)D&V3'B E77O(1\CA9= L.U= ,,I MIKXY>+:T!PZ5NM)/"HQ"'"$2ER$X*$)5C@2XO3\BOX-0&4>I*5;6(;2;UMK&1 M=OV$8WITPY*[>?Z0%,!TVL-$+VU-R_M5RL;P5C/Z(O?
U44KY*"UN<9>V#0ECK+-Y9E/>!&JZ; Q3<'"'2]]4)1B/HE"S^\9V8H%P6?GA=Z86CX^QOC1 M28EF*QRS^DR^6S]CTNH ,U3U=/8/S:[. MF)%_<&[LIHCA%^.FU5Q01SEYE-%'C('YF?
ZT^BX5WW1T .!'E[1FJWD?^")) M=MC[$GIDPI3M=#>HKJD=/C9UL4,=]73ZS@.(W.FDR>)9Y%A[R-UO'94!&+[]+IE M=^.' "S2H?F]:Y^)@G94%C(Z$]03\EB!:.,&XF]#7&=3LOL('9,I&;<'8XER
MGM9PT*A!?P]#[_G/W;>(;]HN>&7M%V>S#? "27OS|:|_ M??[XX^FW*'YV>"D,QJO0/*O*@WR)B.(%WY52OOIE:.M\ M,F6O*YM2- |!)>R^S#LR]?6B('#BI/CM=^/-;QCZ/,<^U9V?M=U'^23-
XWOT M3L 5EX%;Q_XP@[6W)?+)39?.P.C32WDWNX? =S/X_A1'B10F.U, #)3]K%%L>G7]#APL>RHS9)OLD5)"KI.L M:>IB$#W3QP4BUW?H[M:SGZ[9?I:OGZ;H)4?)VEQ$E;> M^*6=MTQTPSM?
9BV9L>.&R1@BP1%QEOF9Z (QKA;VR|Q:A5$AO;>|'U]PZR3^3IEY:S$@U8H%0_ M\|Y_#/V5[SJU1Q7I>W!^KU=6%'L'FLC\3 ?M\R@^B3%9K=#'ZS_1|L3)+9N; M480YV<6QXOHPR*P&8D=W?
%OFRH5-OX*N&?KH,/!&@YZ,97W9J[C+.**!3/K*N M9C6S$[%BH/P7R W(TH+$"2V61I8<7!ZSRP+#IJH8B/-#E"%= ##SW);,([B: M7Q78-
(H7[1[2U2[('CF7^XZ5JU1DZ1J7GN6Z(G@D!5:M#C"!5% _7RFTJ96NX M4R(-F7L?ME#2Y4?F%JB@;GA/U8"ZIWB%8_K()(M2Y+-':A)$,%S9T&+/\WLGVE$SA M IDYU<@OT-NHUEVD?
NZ*Z=,E]_%6X@9<2M :$+5*%"?W>>3G&(5[YRN!4 MMX8=FBU:E@-3T11N6+8)W# ^QI*"+"&&44;82D4:TY.L ^E#HO-D(QGQT]SUY 1T0)246=;J -O/VW4M>[>Z-5R?UI"Y?UG%
M9"V>I2$_E*B/79:Y@_,6#WG)%9?_MK&&V4"2L -@#'N50V0(/;A!-(I6$X19 M_\K0@P/MWA*N0[?(V[M R6+.%U6 MCC.Q6_=O4C4W7,T5)6QYC9+_ ^&I9K?!%N=VG"
.%CXQRMN<=,G%^MK=35]YO/P+$;A!YZ M3XJ37R#&% 'VT.X&;4NG_W$?3,)R-I=9NL5A&,"Z$"NOHP8D0Q1*8V38@Y_$+ MG&//'-Y/_ <0-
(@JBG0[:Y/UA@TYG2[2?D4HZPX61[BJ,?K1325$N&%H!!7/F M@+&OSC%(/_ ";VL,.]%9-RX&M; PWD-M%'C9.F8S2*'6"IBB=3M=[RII6[<%V MU@YGFVT0O6)\BP-:-
*ATZTQ^$;U+/]CQJ:UY.4Y;.\&-5WW1>U_&$!R.8LZB M>JW2Q@UT\[HCMW139H$>1/HN+R:?V<5QW7CG!&/6EJ 4L7>+$TR/2.Z*1#_]+;^>L)#F>(8L&1>;57 M\$18,#5<&,*
('007E+%A#X"7&*&,DX4B$(8<0?'5W2BQ,WL1>M_$T0HG"2O^ M>8[;IBZMG6!B73>=*XN+QAYP9RR:<@^-YS)]1!E,.E?1N'8[L=X5?5>$,(OG MB!7"&# S&1S,I @A+;9&FVX!R5O"#ML&
[Z0W1R^C M\/&(/>A#.56.X"Q>X:EJW9 &*FTX)R]5I7?NMYJ+CXZ2MEES1HN9FE7EKIP- M;DS*;&@^)[?]$=%9CA,T(/^3O/M+J1&QGC5[M32/R M>R$+VG)AT"J3QM9:;,;,DS-
"@A/*617/GMG).@5H"!M#=CG%XY)RH!65U'/(MAN8PX5!7S_*0K6H+=|ANE;CW\B?/PB3KGR*UZ29*V.,V*&-69#G9FWW*C- X M_VSL,#]W5L]!U:WGY=(CS4-[.+7%VSVL_*K8;"N=%#;>[VGK
]NYM33>*R*L MZ@#7Q?7$'E9*6) OGWW;O>5C26G[VR&7+==UU*UA1VN+ENJ]D$0X=V;:!!YM MR^YRVILM&J<|4ZD*.\+/'!?S%RBT;%)I/]>8W-=3'9I%V[E$I43BT38H*6W$ MB5L9+"?
3E"GFR!2S$(<7(3$$3E):@IG-S;T;3"P9ILZCWH%K"X$YQ:J.+=31 MV]1[+O&LI<-H$9YQ8\7?%_S6J8<*C@#"?E*#Y/K'A#!ZYR3(H8^Y4_)6[L)7 M52>*^'7GNZ*8NY:Y]OO,*?
X5&J M#OM9A+E&N$GNTP,X89,]! CDL77.5=Q* M533T6$X4IS0GYCB*X^B97A!5V$+>$G9L-FA7?4)FKQG<.&P2MO\S+81FD1IE MZ1&5J?1*J5Y!Y(0V NP2)PG&EYC(;52E6DJ-7E-IOK:([
[@%:5%34=M Q3 MM)U31-8T5,>C:#B7:*R+.UHL"L)V'V!]))BZ-F>>CFWH/?H'S"Z<7R/5MA/7+(@^BMV8O3927CB^7O&O1S]>XU%R3X*PP66X MK?:3!?I0@PL\(^AD"H9R*?@MXAR3[$Q9[-F-
(@)Z%S(:A+65K'$M]0D$7^&7 M]/X9!T_X,YEXK9LSCWJ1.P :K!39_B1T)HY^+I19 IZV-3G.K2SN6;-2B3J M?X(,+O2KW#]' \U64#D,**E9I0^"'!+S!XZZ(D;gO2C &C1=C&8?$[^_ PP3A MV9R^WXW.
4%%V3*]P8(2.1"X]*AB%C H:_B0,8]!2#3_&W30.">&'L%@@LSA M0$;9+GT1@](X#,"H:&(4+RAG|' QBGE(&/]^O*LFC>+?1\>8VGBY(F90H$!_ M*C!!8*!5\DLLW4D
O^(R0*>KY+DEU\"QOS;!.U"ST]<'FOLH>@A!]YT>-5 M%(LC"7$?QZ*VFGK?F3!RJ(CDK[LX7:,5WSI]1"RBH* 7=U%66)MZ:_ OT=F+
M&^P\|3&LM$P+^AAVA.F&X(RWX+9L$/;]QF/\]^Z439Q=RB,C4R7+Z2;D6Y"JO M!;G-:D%ZK"P&^3P!J>\W<:1XZZ_,WN;Q\]WUQD![B-TG(T C+NE<<"6C>[7 M,,;,ER%/'0<.FF'!'B;YVZ#-
%G/_4T/"4T$H"MC%;\(SLRCA8&?C@'<1_*0(4^2I.F+2PLI; MO:,K[,1*\DZC14X%HM+BEZ+L91_#RLG,&%,:[**-*1(:,\64)DVFPY2,JZ@= M*QA;JM]NW#Y[N))-?E@I6?M DBWXM.Q5:CPG4*CKJ
[JK.5< GQ/WM'"^$:^ M1K!D51>7&WN M 3M*;;2MU(]5-X<;KSI"JZZ[2BDN$*.(#V;8OVW>9[TGM*]7R>[95 M;6&[;*.&96>5-H3KILWB]K_'&1 ^$875)XQ*U-FI9/G?_/V;=.V$J-K)WD.)
M)?&29>A=1:%3_;>_)0X+CW\;'YCKCL5V '0TRKET.A(F[0]%7$9CB-_HSX M%W15ZCGVZE7>9Y+T@YN[#5*V]4"B(/NX$3XWJ^
MVX!5QJV:T",HL<)Q>93/3X9_=8)=MN=&TUHODF2'/=ELH3^"$$)$Y,TX7(6JQ&SZPU+UN)L M4<:WF% O2BDJOV9&O"L9D0M@?M%AR5'%-8@=7#Z*<)]RGAP_H".[A\!W"T3?,F7?^2'RZ!9MG-
#-*([[?1+,-+9GL_P6-LDC MHPW=FEZ&7@9:H@*T] &O>F1@QN20NTCW9C51)\<#=%HR,RH>#RLL@6Y;Y4J1 M%9);,"%,._(PPD(.>_NPI@Q5V6(\+4Q38HL(WV+6E'&VNP5KRCS7=8^?G,!#
M@?R82.81O:E +.C*1X;'KT4;D>.T?'9B3S/=9S!]F.@\F245J43#B ._>LXVN M8N])GI"$3?0HGR/&")6E*9]>)^CAM=)0B(283#;SFVZ(!:Z<#6Y(:ZHU@1UC
M,GW*85+^.UQ/ETK9>Y9. ^P%*S6+F4:80S]5HT3IO-]7J^HD KZ[U>0< MP>%&S\U9$MCTL$=F6[>8E?#P^,'714CO-QA/F+#_XG88^33YS;HEQ"1$4TN_(S;;7,#LM6 M.W"[VS]\A
!QTUI"A5U$=WO8-:W*Z@\|(BAMMD'TBC$_N2#66=.K MA3!,"!S?=17M|<%4X6[?C*C;H.RFEDWPECWP M2\N/?P*P(I]/'3WLF7%6&':UH]@M#FF2Y2Y=1[' C[U4U2GY'"C"M5EV%,!3 M,3E
_&M5U1H<+A"7+3](@3% AWKS@<3(C%Q82F<6.RD(#U]"ERP-+SV.EP9W@ MQ-GZJ1-PC6[)(B-^PMYY%)_OTEW,\F"=L#!_><([C!Q,6!O+3OFZ=@ MX&O> M,30;'BY.SCK/K^8!%
OF++|ZQ=BS%[*W^QZV*:ARC>7%JA@CP3#)!OR];B M,J!,"/-:+9L66^X[V-MFD+F5+[<0["FM*)WG/.+KU?4N35(G]SPD5GL[-'
M'^4>>]C48PES1#!I[U'FO!K\#G#ZVT5KBS/A0DPZ>)4$%9N90M1YS8I-V%[0 MH:D(0-6AWQQ0X_EGQ=B6"GC4 Q@O>,?0^C AM'>EJF4ANA*!"[@]5=EG"DA MU'F@=?
M,,NMKNB[?!WFY+=AUCN"58-U-[$"ZK&V"Q82&;8QO@"1.) MC%]\>EE_0H; -PN,J3_L-:2PO@W'[KL%(A]C1%CSL^9'2HG M7!] ''YD#PF6J@:]J!(V?AW)6NU3ZP?9!-K,7X5LI8^%JU*
(+X.%]A2_0'(MGV!O YIY]L9V15Z,;,N>>U3Y'ME=?;.B8.1LKY AS4#1H[5&/]M3LX$[Y32@- MXK"OM)5Z(_=^$UI>>]0QQF&@'(&3."VA+_E7@;SD'W^[11:1W*L_PTFFDDU
MH+A3^0,\A)"+U[^F(G'0)/7IT].?L9.013*+TY%O3NIXDC3)>?^OP+UI/W6Y MJB? 'C52$JK2I_I?CNSE59]D&X'*_VJ_G>XGB75)/.MRA]A>I=.G.' MAU 6;6!Q8X(*+:K2EL1>H$QP5$@N'D.5#]
]RK,?YO<@$\Y^07:C#$U 0;R MTR3*]1'@GR _01)=9^YO& ^3A)-CU /DYIMR9_S9RD#^0F?RMG_QV'F-\$9)/ MAI/4\#R^F?T; GB-[S 9O#?P?B/@KF,!@-!.Q494;10)?FC3]RD_#*5]M*+6
M\S/KQDMMY#[FSX]5.G.1Y/-J:FZ5TE?,V"H+S**9_"M,;&,V X2=S,:C-0% UNGTM8BJUQF,E]]_?Z5"(B&EK;>]@=]\2(T6?&:.IM)+F5/R>3,8NG_Y #J(]/49
MZ(A&NDN=.)V7F8[QHQ^&>I:.Q>CRB31,DXOPAGV13W&C+W&YUN9'388\P#=8= M$\H:T%:?1(:1,[SAQ R5IEA7U: M2":WTT0?0\[IL &TP;IC JB$S>$":).R$ "T)%^!HJ/"Y_L,0C&E?0@
BF/73^C[Z9-N$L #A-UO^, ^AH/H5+.#_FP?]V2+](>1]3/IA)-D@'ADTG#BA[ZCPV?^!)(9, M:D=YNDBK*6$,DTFGP^$1ALI1)9CY<#G^U^@T9([':2L;#Y@1&F'+H3/JGK%@8 M0(?OB@'Z/+(DEP.!_
OK9 <0HD(M^1 .! MV8]4'#9SJ@=W&75,Z"C# 8*2T!8ER0YF,>Z,A@ M^D//) QX:>WV7D]4(G&0YX,.AK"1!C@S31$#'!M,? M2I:D.I.103_S<(>)NS[WF8]#XWZ%B3)>#Q3U1S8
A!/V2G;L+!$>R$>D)],> M!J@73YR> ^HD;1/2)OR3+]}OHB[7Q/&P U[+XF+#=R/!PP5I/;0@077HXN23J M_!-;_I_T"R\)?'F-UCH[6"8S],?)<7KYPC#)=2FW)MF#+3IU+M\3ML^&VU]$0Y
MJ55FAPN[[2I#@-Q*WFDS?LP%;.F#&9=D:NALY^N,4IN\OQC $=V2,,09\G3%'C!YB'.Z(,<08$$:,YCWS QLQ M,'RL#B,&.BH):&/XN,4)6?30)S[NTLC][4OHI\GMW9?/N*%D3UL?V)"LI7$9
M/!L[P(4Y/;%[O\.54T>,/&+TT3O"(?D.?>5<)MG:,84,&XKW"'%WW,7UA\?CA MYQ_L)BDOY%*?X/C511OZ&5 !NV_DC8$3.1'VIL(S*@=9A,.QOTHV(UK+W)W M=*1C@]TH'W@$Q\]235@>5KJF;.
Q7FP.LL5Q*L;W.*+_RL1 ,%1&3

*G=G.2/$03=8PATT;Jl^@"%\CW\v= M!^RD/83-/^GS# 8*CI@]NS?MER@,E8-WPG(ZQX#PL1AjI Z.!Y[SP.QH(%-6."?,&%%M9`MF/!!#F6$=]&7[=D?\73_K8!,IU#D_;^4_U]OO=G_B QQ#FP?Y['4,?#!1A@8 MBV_.Y407Y6].1>4M9[28 10ILUK(2")M[+F*G 7,07%*>XZR)'0\"%11.6 M%G&3_2>_R,4%F]>Z80K#9O;8RNQA)KYOY{5*

M3)@S8=_QYOUR/H<^YV_1>O@L)F4,4"HX($>P*)\XS.]<86++C3?QOEXA+B/* MA$29E#.<HAY6T)=-%YJS"'=#CP^R'A>F<;E;,+6=_

MW_GIZ7681#&+^>2:$1+A*43BA.=]RBD552P+QL%P7J+:.XQ^TUZ& DI<\'Q^TUZ& MV=3I)<$!,OL,LX_%W.:"HY+DB(E.UE!.6Q)4*Y)+MN"_4I60T,GV3<%9?+?;

MNR]D*9#2X3W@0X"W$OL?;Z<_YN`_NJ7.(SZG/F;!OR;"6:(]5-_M^>.PL]MR[^TMAVFHS'PFK.W6,2TJ]FJU-M'}1_!S/#8)7W6QP%%1:./PC6;]T?V+)FY,_R]?250, (_BL;[:PA^!{[MXK@

M\N]@!L&KO.\B@BLL !_!N> 3(?C/_).$[%U32VN8D;\,)W=8$'X>Q2OLVT1Q MF01O%(05_5\E&%Q'?XE SS%#PAZ/2.8E>14,T=?F0L-=)#_.4W.BG%M_I@7U# MMZ326QWI '_W?XYI';X?

M(`LGZ,7]&K!4PU9AWV2/?VC;3OD?CL# [0!%C,? MXBU7\)] OKK MGE_2I.O,%)>K$4T$?[RJYV^\T?*] <^X#20'2GT:,JCL*]U8&JSSB M)=E;*)ZV0?^~%12ZXT.348_K TT%G>-O5V KU?90Z%W]

(%H%RN,&S QR$_7 MJUOL1H^A_P]B6S."GT1)FMS3XINJ[S41+ ^ #QY06KHP#4S "#.N3JCO=.\0O M5"3R5R7=58PZ=YAJEY=4WLB?V:<[/BV;8JBC=TUL#6A7?TH2ZQT20-8_U>, .XH]9Y

M!>'V+L"+.G=08(3G:OV0,6.[P%LF!LVD_'1/8&%9!AN(*/0FR"\UB_BZ"LMJ=X,- M7]UL4(8EO9YPT::C_%.#B!5X,&0#]LHRPN78MWUQ5@L8\WM&++#,A86J4_T{! M\J1*_XK3

C;+L\@AH#P"],JC(9_0+=9/#64,%_?,JC)9,.825E^O7R,]&OEK MBEYQB@KILCD9W&F8=9MSF.Z%<4Z^ M/D'\2R,0[H@&$W,L26Q4'!'y_UGD>Q M^!5MIWKAU@!Q0,Q30&[^)$6272O &(;

[9#N:P7HGQ7$#VP'A)Q,/" &D^0IY+ M{(A<8EXP 47DG^AY[;MK]L!IR^C@)PB318,K1H@'C(KF=E-HEV']>WZPH^=' M=]C=Q<1N.#E[<8.=A[US@F34[KM4|(.<.3'=L4^(L=F7T\N='8D));)R?

QJ;R.M;-DQ.,#%Z8cT[L!92&OD.*5;E!P*=#9S1TZ<0)W%_"(MY@-]>QZ]R @W9 MM_RA!WQ!JQ=V5F%^ M.@,X&!E=P{$G>_DRD'VU5!*&7L7)Q*$;/, Ms$.;XZ=DTILYt'S3

52TX(KIQP@<+,37U+...U7-D&):B5),!'&"X!7E%G6C MS8;8C"'>STU2?)R=@J?#RV=T:OB_T!CT[VY_^)?N-8/.G_P]02P,$% @MKCUM68J48AOC-0 -@P$!4 /!C9W1X+3(P,C0P.3,P7W!R92YX,6SM?

5ES MXTB2YON8[7 @YCYTST-64A*AHZRKQZBK6C0*%44,QNZ,WI0P"@R2V0$ 3 '74 MK]^($ "!.(" D @1.N9+(J,R]T _][CXA.Y\"0:#H^%/YS\ ]?JP!E^__IVT<6F']$[@#TAC MQS\=I3]

<)CP<7/ULG/UM'@'J^M:\#L;V\+EO<1_X^2 M\3 /J,=OW][>WGYZ. DI@$M4?7CTf;_^ WS\Y*[\"V MO[I^&-F^ [X,4/F?0 +E?>8@$>%0IOK[_32!DZ^;?NBEL!_24V+?<5??3TZ M-GIP-[./^2#!'_+-

!)6ORJ4#ZAZ>CBXN(,^75;%#7D,IK>DOWW?QL,_@8# M#TS!8D":^#GZ>_&_? G=]8N'NR;?K2!8_/+%64;O7S'_AQ"'@>?:,5XO,0\$[6D%0!0*D272CY/=H0_,P"D>O8GB(*]]KL MF-

SME^%D,7D!D" K1"'[\"M8O$*R_'[JOX#X(:PA8I@^_V/$4!L&,(@W(--<>D==NZ'A!N(\'@&H0. M=%^]P"DX6EYOO]4&(=?'6]9& 4C$I7C C$9RS?:!<%,QM^AU0TDRP@B#]N%_[2]#?@.;%R,

M2"]}MES37!"A W8'[S_H)F%VFQ%FIW0<($64 XM8'8+MZ[K/K(>V1)H7: M2ALSI 2Vq0 3*MU%0] BO+I%!/IA989D]04:NL[>S4ZB_5G_IO9SYXT$ZITH,',5HE62AN: M30F52!'H3R.K6HE$3EL.6-

A*9%':T'N3= TBV_5D2.W0OKZ33C462+.M^Y13 MC0F5>M@TJE&+.T1C397U0CC-;,9O'J/4%655/%F-2 :.,FZDK, _PC7[M%;!%;4,6M$XT8TARY>

OR:.lK*WNMGO0XF:@X8]/;T6A%78TV7F,;$;A=`.#+ M-`*3II1D1O,;,6'L1.XK^N$V@$TP@=&\3DR8QWL$'O'S<>@6HY0.5!XU8,05H M_>PZY*H.6:D?OEMU25ZE XT8D?

V<++25\H'5O@8'#V,T&\]=;X/4%]PL%L"I MN/01,[8IHG&#(6J1M!8"YZ=E\H-./B\(4_$(X0;]#-HXLFY1FTL>?:&&(_ M+14@HUWJ%Y&CAK!0D"7RI(§0U"4+NT6\)5;@?1!Y/&:Z!]PCXGI MA75^?

GQQ?G9A64?GN[%EH3"&^7':T$F,1A\|+Z,CS/BGQ[84XB7QU5]ZW%?L" M!NL"=\Y*>_L$!!Q"A_YE(Y'O6%_G.[/>[.6(0N:+%8^68 M44KY'LE4AH)$FN=-]D>9X/H?8U2#^^#]]>@R.]}$O*]DB*HJ-

/)'C1,PE>H8\3 M. O>?)[\=B7S!]!9H^,SS:7'&7NZ,1 V3'ADHIC 1QB\NG&P)5."'>\7(}T81-M E)9]N ,)D?,8Q!&MO=_ W1?F>]>LG,9@VS*&P*,(+?MS+R3% M'7 JFQX'0<^]Q%?CT3?

M^D5[(2&C0J9QZ<+CR!)P-1+@[.GZ>X=N7$CGM M%^F%G(0&GT\?Z.?1*A)3O1<2XH\X%4\/3E)2N V\.RM\\THY M_"HKU@M4\0\\E5EOD3d<]2!DZ^;2NBEL!_24V+?<5??3TZ M-GIP-[&[9#N:P7HGQ7$#VP'A)Q,/" &D^0IY+ M{(A<8EXP 47DG^AY[;MK]L!IR^C@)PB318,K1H@'C(KF=E-HEV']>WZPH^=' M=]C=Q<1N.#E[<8.=A[US@F34[KM4|(.<.3'=L4^(L=F7T\N='8D));)R?

QJ;R.M;-DQ.,#%Z8cT[L!92&OD.*5;E!P*=#9S1TZ<0)W%_"(MY@-]>QZ]R @W9 MM_RA!WQ!JQ=V5F%^ M.@,X&!E=P{$G>_DRD'VU5!*&7L7)Q*$;/, Ms$.;XZ=DTILYt'S3

52TX(KIQP@<+,37U+...U7-D&):B5),!'&"X!7E%G6C MS8;8C"'>STU2?)R=@J?#RV=T:OB_T!CT[VY_^)?N-8/.G_P]02P,$% @MKCUM68J48AOC-0 -@P$!4 /!C9W1X+3(P,C0P.3,P7W!R92YX,6SM?

5ES MXTB2YON8[7 @YCYTST-64A*AHZRKQZBK6C0*%44,QNZ,WI0P"@R2V0$ 3 '74 MK]^($ "!.(" D @1.N9+(J,R]T _][CXA.Y\"0:#H^%/YS\ ]?JP!E^__IVT<6F']$[@#TAC MQS\=I3]

<)CP<7/ULG/UM'@'J^M:\#L;V\+EO<1_X^2 M\3 /J,=OW][>WGYZ. DI@$M4?7CTf;_^ WS\Y*[\"V MO[I^&-F^ [X,4/F?0 +E?>8@$>%0IOK[_32!DZ^;?NBEL!_24V+?<5??3TZ M-GIP-[./^2#!'_+-

!)6ORJ4#ZAZ>CBXN(,^75;%#7D,IK>DOWW?QL,_@8# M#TS!8D":^#GZ>_&_? G=]8N'NR;?K2!8_/+%64;O7S'_AQ"'@>?:,5XO,0\$[6D%0!0*D272CY/=H0_,P"D>O8GB(*]]KL MF-

SME^%D,7D!D" K1"'[\"M8O$*R_'[JOX#X(:PA8I@^_V/$4!L&,(@W(--<>D==NZ'A!N(\'@&H0. M=%^]P"DX6EYOO]4&(=?'6]9& 4C$I7C C$9RS?:!<%,QM^AU0TDRP@B#]N%_[2]#?@.;%R,

M2"]}MES37!"A W8'[S_H)F%VFQ%FIW0<($64 XM8'8+MZ[K/K(>V1)H7: M2ALSI 2Vq0 3*MU%0] BO+I%!/IA989D]04:NL[>S4ZB_5G_IO9SYXT$ZITH,',5HE62AN: M30F52!'H3R.K6HE$3EL.6-

A*9%':T'N3= TBV_5D2.W0OKZ33C462+.M^Y13 MC0F5>M@TJE&+.T1C397U0CC-;,9O'J/4%655/%F-2 :.,FZDK, _PC7[M%;!%;4,6M$XT8TARY>

OR:.lK*WNMGO0XF:@X8]/;T6A%78TV7F,;$;A=`.#+ M-`*3II1D1O,;,6'L1.XK^N$V@$TP@=&\3DR8QWL$'O'S<>@6HY0.5!XU8,05H M_>PZY*H.6:D?OEMU25ZE XT8D?

V<++25\H'5O@8'#V,T&\]=;X/4%]PL%L"I MN/01,[8IHG&#(6J1M!8"YZ=E\H-./B\(4_$(X0;]#-HXLFY1FTL>?:&&(_ M+14@HUWJ%Y&CAK!0D"7RI(§0U"4+NT6\)5;@?1!Y/&:Z!]PCXGI MA75^?

*/?(*CQH,^WIXQ$UYB!_=/S'J 4&#<<7 TSC(#!V>)6M&0P.(,EOZP.I(P MK@A,?TR3#)X23+IROI4N\/Q0(.7BQS\X9,\X35,)^J^?.P,\Z'@SKF7!P>94 M6Q*U/A MSI"S4,NNA^S:I"@DJ%Z09%YOL0""?XN-J;MVM=22V6,N-8XI-T2'8D\1JK!!'PT6O^+/QJ-N_+3'EWM,FX M-$[%RV41G\9RJ07?;4Y{ER@T6B;U MC?8T9[9%H 5O@^U3,R,MIP"22L\HD-M9C<+7+_Y/JDB TG510VJ%4C9Y_S8@,H7FG=,CNF&Y[,Z^[#M(NR%S0N-MD3Q,W99LO%)YP!'ITTKI9S]8=^ M,2"V2L//F>US]%+,Z*6$?+ ^*UV1,;. D(R 4.L&G6?*UE?.F7+1M%\BP>SA, M'], ^$,P?ZQ/T3IM,$M2H2F_0XX%G4 *3RCA2!%,QIY^T^&MR) -^3 M@IG.5PL]r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}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|-/5=50=5N6QOGL0"M4:J.F$[XM13CNN_4L?OR#/NY,XS=? M47&QM:*%1"R1[K,N/D[D;<)L4L7!(Q4Z,7UH1;>G\:U7]-G-%*_QZ/3){126MF6%[3,>5Q 51'"$XF-1S^?,MD6F:H/0<6L(E_L*5G M\'ZM' 9/7%<;MA5+F,/"C*9K+WWK7X:B ^."@<!TE^J0U42B+BR?55JRP8.$4X.,M%L]PD3YOR,"-6ZJS?;.TJ$JCC@K=L 8ZV7 -^T[1R MJO.T!):HH7W*C G_2,=4#2S,0'(M[P1TT9">s"<+W71HXY]H=ND/PDW&"P+FD M4EFDVG;HH(3LX$,T"U#T9[)}7/B%[! +!$&OfCZ1V+-(V[5*78<6,YMIF2$UO@,2VIWZ)#QTB7L[[VT5YIP[6RQ-74YW5'B3*Y,W[LA+]U\Y5?GA@D3 M+VBQD\2ULG/F& MY5$U/E' DS+AW;I@]]J.*Z?<.QX.W=P/A\,X?!FMC(7]>0@ M.2(?9B:>T9;-Q^I]HT,WPW![S?NM^)VLD)#X@2]PU:.][4WS\2'#M8>,L(G5 MJD,O'FOSCT*MXIZ5S>X'%YWOE7DS.KZRS0H'<+MLQD"W%>9UTM?94=(EQ,.11 MYT-),)ZN)([]^=2#)ZLVD)*UPHE8H,O63&/&@-*8FHVD36":WR_/H%#M$^ MTZ%-A0T(2-45G(G:GM5;A>;ATM]RS+F&_/Q2 MBIRH6O>BYH+T&_P MCH32*\$12ZH.P=TN62C?_]H=BOC:?]IF*X^E@@F_SOA+%1+NZ}OSBA2,]F,MPL<8,\F5^\U):Y"V"B4JM'9.^-GZ\AKIC(M/WN= Q9Q936Y0[$XS@UXM\Y"* M%O_K&?_4X"$HTG0*<-(>R5QARD\>Z{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}<,MIK%XA\^TRH]SDSG^/0ZO,PUWE_[B]L5WI_U;,DF3,*C@UJ/@5"\5ZZEM7L MASRO/N5ZXSS_E%2-T .LK@M*&UQ\ H1V1."E;YM@,I)2'-2,,1 -+%XQ&8YRD MQ4)H39[K@M ;1-"FZ7D@A&J#Z,2: .;16]1FP6$TS'33YG:1<44PWVC71;?'U-M&B' AHTYS1#"YG>F%HX*=#(VP53X_[4'PN31D\7KWGIXQ&C3(M MA7E\"B]"PNQ#?6G]T(-(69LUE'+,2UVU/&2?7)7&D8.A_JZ@O'!F< MD^EZ_9Z,#E*=#_%;BJ51,,V^L+/8=>]#P:JUT_ 46X .NLNVQY88BW.NO##L MN"$\CNAK%\[T_R>^TWG4,_[B*#Z5F=$,%T2C\(W-0?WXE.I'=[!ZA BXKJU MR3XBBKWJ8ZY=2!?&Y0X]K7%/;5M0KUV#?"HB/EUK/"]L$.Z,!@F%_95 ,P+GY\2C$[&VV.9[fMDA5*5 M'AF_KNJ\Y[NC^7.UTQ=>#G[:.>M9.L,5\,R\X JJS':,=(%/IZ\%&E%_B3==MD%Q1#QA!:D),1:57H%K,Z0Z M9D>QK"_%(>DJ/(1[\,YCZ=I'MVE6KU/C]}XNZAL.A/L^*Z9;H0M@A/U,S]=M M,*_00&U#@_IJQ&JY!V*F\&"9DKW_<3C(M MA7E\"B]"PNQ#?6GJT]+(-

*T&=61_P]C79W#;,A MY^?NWYP3CV\CAX7MP@O6*_Q*SN?OP$%7MMC# O*K]NM"JI<9%ZZV36R,2_% MX)_N@,VFH?_[NSI1U/.98G^I"SAN(X$"@WRSL5=U9@?WA'WN$[O:=86Z@K0@]E Z-]$D%K+W)Q MLB$ZG#ZLY9^<[_(3O_@KAV,"B*DSO$C*PAH_]P&\YDG8QH64M(R'M41O8'9L_E@D_!GE<'563_MX9W\2!N3^?DB-U/$\@,_%Q(HO9DD;W"""^.OG+B&N 7!R!>S^^2[E)_%{^+S" M3^)W@O0R]7&2$D@C7Z?(AF3Q[=)8:4RZ2HK(_S^=X1.#.).=ZX["Z?8L2_8? M0!/00\CP"2 58BFF1TMEE87<"NT$ MXH9DCOD%WR+#$\>\G2L*L_AO MZ)B,]%/W*+/J]!5P4.>DNR7,QZ\3/7'U%B@D:VU\D\Q#A*A%70:$K0Q_RCZPfY_M;&\.1;DR7Y\K0T$Q(Q)$?@HWPRYXE^NJ9AT "7C@KZH"DLWC&+C4:W1(' M&H6E6FF64UJ*]40Q=_^3-W3R@DF^D4AX3V[,MY0))^7^%_)8RX=),?X?R_HTJ_MJW<'HH;7];)T M:+#$;W#Z_,+5UHC6: 2 H9&WJ%)55#,G5PLRl]$/E,5Q#:"#\!HKC(.TT5 M:>@L[E8LZM6Z*WH,^K+X:M5+3*/QV&MP^-)32TI,O7*O0_&5],C1'!TXN_M-<:CRRNBJ,I[[92WL[FB5'BZQ+H!*WC4>YJ_"6J4,;8_O7*62?S,E[.L[YY;.MW$X5.+_Y$KE@7QUJ"3}-HA#-I0\QKORWY6E12Y?=^3?_C{T!=TS%L[P *&27R?XM"!9^-'7_2+!V MC8UTTDF[,0W0-0V5C&M\.>/P2I.:YYJZT)[W"DS2\?.KZK!$.?PW[-.AOH3R MCBSTKXYL1$DDUQRA.$F^62,EN=:21S7'-C)7#1$N.V!X%7\AC}^]\ MG^!++%'0)2,'';ROZHHM1OS!H,5?22H M&SP5W0#RY=&:WT0V1>B?F6TYY KU,[:B=:4, <=M_K%)/14>IT611<+!#_;D MF&\2%O'D#%U'7770_2E+24>T$/#]P)!0Q<<._J8#L_22D;MW!<>$HX4OY,:<3T2M5IV_%U_%U'1/>&PZ5!P9>>*?%>%HO& 4T?]_H=E_/6*{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|QX"6Y I=>_A?@Y*[M= D^%8_X.4T2=8:,'718@F_U]"^), 6&C_0I2RPC0K73V0['0D5_=3W_T {] M_"\9)UZP&%RLPR>/S94>/WKYA.UQ1XXGF4 W0<&>4WL^3Z*<&YR>0Y4>M3%) MU>4'!BP9H,S-H7)>@\/V'2%]O Z_(Z6'*#K/%V4GU;@O=^XRLOT@B'}ZD_[31=B4B+6,-LFAJ75[K1*IAY2+/,(' MK]$?$;J?KMH?H_CG>K#B _^AV^AZTW%/%6%IX40Y,@Q!,&X2YW^;T3G5'XCYJRI20*]Q(QCZ@)#$ TZJ5N?JXP+]&NWKMIA7+((W+)G60T;#:F&,EPT M=\P%,+&#$^072^A'Y.EU1HMMK(/T,4PW(6H^&U?']FS!7L+H?.'B^12W?^<_M>BC$G-S+0,3^)E-63Y,_N+\2,WQ5])6B_M5;U@6 MA3$L;UO,=K59I5LP(Z%I_PK\O6*Q0+=!GL(UYRE.'? 29.N]Y[G7E)[QVXK_KZ"=F*;_V&"AE.09%71B!,P"U^~ M!2&K.\!"OW:SXH>F]6)%:SCE@YJ]@C\F8FFZH2X04UO!86_O-1PWL2X.32>* MR_%O/5[L-)L0#EJ=3A4U>L9'$ M0Q$E,_9U_X^~^A>CG*$=6DD0(U[PN:$8H%)$\&C6';N(>.#ZZ]\K2%YOC&1BM8K@&!:/H!*C#=>B1$T? #5! _\ M",^O!%__>?[B?$};/-Y2!M^(CJ.@$W%^3=>X<[.ZF..D4BP$64]E?+ M_9I6Y.28>MH2 J&SE=3_^F#/E>EZ*$OHOUE) 5QC0)5"4*7P!N(O+XNEL*E] MO],OFRTVJMU@,V#1D%K!K4$X[D1Z,J7$U8$_X,435F<&" &*%8)BA9>TJSZ$ M$59IMUOR?59E!XU=B%+M_A!Q^ 0C8HL)C3'B5EI>OC207M1M3K,;SV PW3?V M9?PB6*SIJAO.+ "T/0/>?I_*)G) -'"#:.4HS,X[Z(7AS6J415]F;%=C6G7JD MZ\L^K-)XL8F$#]H$!1/(CF;B^gFE3[K'KI+I3]+S>6;KU]"8X_M!LU,7*;.ME:5M-[8]4D\IF,25W`3GW!4M7CKO+[U4M0UK1)VG]HH+IA:'UU5H]K.Z!LT\338A>1Y_[S? 9VLJ1 \@D17_%GC#@V[.N M)ZM00."O&/%?A1?.3E8CLY2VO(-+.@C1$"6.@^^/2[-TV>I?C]_Z/I4M EL_M_(?`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e2(Z7(GKH$@<I'J)3U#2(Z7(GKH$@<I'J)3U#2(Z7(GKH$@<I'J)3U#

P]!P&\B@S+U%$!IC[_$L_7M%;F"C%WZE9"D23[KWC*)^! 50% ^W09^ M@9,=: ,0#* 90#/RL"C7H1E7G?YW 3O5:?$,$NU'CDG2EBZ6X.VH/>,3.S7) M%GS?*
4/U#1VL>FT8>O*Y=+2A8K@_2_X[E.LIOU\S3NU?O=>\)??:F@?S+0#A!&-MSE-SY-RO4.Z,+@,% 0H"%"0?7H&G++/;!QK+/N([7,.N>%0M-S]5#S]^<-MS1^XUM^X@OQ^!>Y=07ZW0KE7D(N?
S4=VFW[X6/6KJ+FWF/+2)'E.HRJ:M,%9 M/3U6J0\\DL_E3[TT3O>VV@!HX5M4]ENQ#(Y<'8UO=2@EG_3 M\BIEA0L#/V$N7OU77CU;%(OA++$D3,A?M^*]=%HRPD@HEKQZQN&'(DP^P#3ZMJZD]>=28W!^T;V;L7E69WENTC[3J!!#SAWTZSXDOQ^_S6=4Q4T [M18,;=-C M9XIW>]·BB]$C"]_U+_J8_<9@"OW0T+X@S>7 #%^Q=#R2!(SV$JR!+.G+-T79 M"@QN+T
0!NNGA9G(F3=*.*]=L(.;P#6 MW"O6G-YS\G=@\T88H^JO*EJS.1W#T51=E.=X&Y>B(Z/,FTZ78LV-/#N >-.0 M\0&-^*LYQE^$3N$EB&0A)/6!(\8^B&0!P_.#
<..*PGL+_[G0RW$DJ]Z/.U@^+^.=ZZ_0&HEA@,.> ^(-MQ9].K6>@IGZ=^OJ}Y.? M?^\WV=K*D?_D+<>?HO'?G@^K9 T*Q?\J//Z=K&%F 6UY![U8IL>S#;*T>9!X MX)_^GQY*Z0>NGWIZOGF.)0?
&1DM&_6H=!<'=_4-1;XF+T[L^+/;.#(5XHX MT,{\8C!@/W;A?^7"PDO.N?\0N/*KQE?R[_A@B<\S2E$L]C#?QX^^?1>2@R6) M%)>38S.^D#Z+IOQ2/.\5S'1)
(20^R9]G^[BL/S[\>2\R2WWX87QT*O\D%(7_M5T#3W_SWETWX.1>1%S,+XQ<>/GIC^-.NR\OEG,4VP-OZ\[1SY//&E;E.MR$T MN&Y!J+-
]IL>*0J,\>"@TNN6O!:9,*0S$TJ!1.3#]R1&A*CO!]RV!V4_?^1+5 MA(/N@&LW*HS QK,5XK\Z,%<8%+AJ_#^NW*IS[0K;'Z37'>L_*BPO-H1)X9_$ M.#.
<4%/__GAT3AH_)\>S2@K>Y:&4P@6;NC'-K' 4·!VBA;+5QK3 M+\AV#+Z!?^SIW\J1*Z>VN03+ "HW-5%E"(9NX?&%29IA!"Y116I.%.$93*#] MEP,2RD_6/-XIC_H..U+@:&>
(J$_4IKTZ+R$2@OU*"K=#KE@N#WTQZNSH>=F@ MT&]'EU")^1429T73*'8&+57O MX%1I&U-F9MI$]Z@QADL.O.[P\!BM&>&@Q<>4"/PKZ8Y@B/5*GVS@$%LCFNCW
M7:R:DR:80A8N24X,I@'1'S<:N6U4UA%-3T@Q3>,-9633>*9%K"&/5%C{$#RF25MF5*%]?5\E(*<%BVT%#OMFD+?+B3>^,,KU:'7[BOOF844FVS*,E'K$?Q,F6%-
ML[4:URO],8DGE%GV68@(>NIBRL-E7>H1(J[P_0-IAOWN)LK]? MJR*TP98=%%F.>=KN{<).89]JSE>5!I176!MQ1TSUIS2^LY6(J3,JY>':EO? M[,"9.7)VO4F3@:E6AXDI,^S3KDU-\ UAQNRC{0Z-
[_CB+*',L$\/# 7G9X$M-MHNZHUW)&.RVD})@RRWI'Z.^LIAWAK+R8\,U0KN!3 27-LK^!QB$3;!TSW/,9DC/A&9=W?&++}]D("67BW_Z9E-09W$!1TX4Y965,_H0W-M\>AM0II95!
[;-1DJ'%7,5F,]+85F/>(Y7]*R_^TXFSVQ43{22XQP^-6D$9) M3B@S,^T,:3J<2.L%:Y>@0-?{7QBPB1)FIF9&I@=^K%* M9Y %!&C?;2$6+@[A]6+6:MC%BBLRAW$S@$#O-01=T03.AJA,LL*B..LP\,BO MV-]XI.E,8.-7; N?!5-
H56\QL4V$O&) (,2L++!OB%!4AFFWM666!,Z5TU*QX-M*0Q7V0F.M((UR3/&BWVCV$OPX&430I "05IMC0*HD<*RM72]C4XSGL)K-D2_ MT5,0V<2C-L<<%.%4EIPLR[=*4B)F#[FFW05(H&
M,7'UEMB2,6<5KA>HX*8SR,X6LF9-9B)#-L.CFQH:(3M(IEVV,L:\0RFC#,. MK,&N17EA*Z,E(1,3)M 9Q?%%H>9T1Z,NK/&&UN/14>3Z3$*:W89UO\)NS,HH
M!D4K@(:M+K6OIJ!90O.J]2[:N&'3C.%SN$ $2.Y.TAED&1/7I=UP8!8WL-WF MZT5\O^>=+9.T]Q:-+35?S!I M)<5V4QCyAILO)(0TRQC$%HBJ8&C$EH/08I4?·]MP.FH&$<:9*M(.=A[4C
M65J1Z:A9OA9;PH_'HCHF0*Z=CF>M%"U,BQQE39^EXQ#V1HC:!H2'F=?>*P<$M-M)B'C+KUMKJ,6^,>RT70CH/QC=_.Z0E!A$\O]XK;[=EQN2XHCUT&*;+<"EI-M%A%&T;(ZFLIMEC6"LK&/C-
8",=(99!%!MATODFR\%,,R\:U_NB+74EIE]!D1 MTL#?LU_]$,M57,N25[[V[>D?+QTDB6/ZT2F=>%V5@UOW9_=WUF^:C2D$WM.W M/HZ&'.PM1^HM^<*G^V)\ QYS;KG;/^_T_^A)-+]I1
BV,:.+\%MG_6.LY"=O M$S72L,3N,:?MLG]8+PU$D0+X)"IZUD!3;8!\OQ,O,[L_M_>YM(]FOA@DV M N#2'>W"[RI3@(TX'RZ]VR0,>3N>0)WO-_"4BXT T:23C0#0 ME)N__"4BXT T'3H;G>QW\-M=G? Y\CE8>
M[$WR\R,$BO.O@O20*9!XV +FXX*]\'Y(Y+T!<9@V LERH:',.0?1W5N0·'IZ_ML}] &V S+T VG!$T5!<*_GP__N"?OG#!:%/K1G%#ZS'>\^&&44)[3"^
M(6O]\^M@(, $?.*B&?!/^!*N?HK,[@= E=*GE8%N%* LMRZJ70/YO)S_7=@ M+=^]M7P9+ .A3M0CSM 2"Y8:!X QSO=?<$-?CT.P67ZZB}·?RKG^)_*.1(+ M.IZGKJN?5H1##()#&\]T+CB
Q@N%Q*11%&0X8/ O=/:]\A 7(0 +@R=.6FN,;.M&PU(P9U*P%+*[C85Y^=_9]++] MU)*T!.U^IB=IR@L7!G[^7,SVSRU)X>>6I/128(I$]PW#QJ"R52!H_ O.J4)+HLT!RJ50_+=(QNA+GDLOCX}?
GVA&?%3R.W\]X MK0BT[ZTD133:\V%06]2V09.T2@81*TBT+ATI_\@,9'6IM?/VA\L)4YP(V/:MXL:/'.8D-UP'OTXCQA20MW&V"@)@3G2*A89LG37F/.GQ9)B4SFRU'/$T.T MK:L8V@\K9F*
%+]\1PCB(58= "0 2.X/2!+P^"=?Z-'7-MEP-)65/2=>"?\1 M-IKFI%-S(DABB2"KK'$*$DZ4B%T]FH# M 4 RNT#RKGO-JV=V#2A)>29]F1&5J-I-".[) 9I8'H3&I8GS%9$E^*\69XY MWJR4M-5&]"_?04R';
[A^V$2#TEB(4KJ48]_+EZC M>"/C-2K$ %V0 RC^'XJ',+6@ \C=/XM^/&2^059]I[04\!*3ORCGR$,WX]7 M)/ZIHQ9DRW*5!.H++??
S^<^89JR%XTB&60FZ\]>K"3F*\3RBDWG*8.27L0K_%_$59)O371'4V.^X^_IQ=_FJH=P2[Q?Z8_\5X(MD+R= M;AJVC;)&Q5LNFF6[5!LG/>O1+]_IQ-6!G2[0 M-S?/D^F>]YW,UXOXVW@_?
UG#]JBGX_LN-+]*)*.8&291GWGEL*)%37K M?WGISAZ40]D*M>PY^<,&W-4X< K&VW6[F'AH!.AE?F*C_))"9 4Z>+!]R5-MT@&'[EFXHJWMFNNPIKKP&HCEHY.UM^<=2%77Z3.#\MT-
XIXC>#HZ DK,E3JJ))E*QHZ,MHLM0?IB115=V2 MJ,29 D=!)NV1!.,DS4WYW0E3WU %)YW"=QY@-Z>&V532YIT=JZKQ4BTTDR_M?(,?]:EAAZ4,U^.Y,1.2K:QI3MGJ.) ORN33(62L7B0X?[A&>
[?.A>N73J=_M6Y/_[N=]·(WA6^W"T1R'ZR'\++^_J/7X_3]2%W)(J9H);QPL5.?>\Z-,MC[[%!I??\U)C$ MFSU.*C9+D2,6),$W?5]5O*W$77(2X2%O2@!@,YU)FHD/.$@7#'+GOO-)!HF? M7XAX@X2 +
[_D("'@7-]'Z5F,]+I5:T!+S?OSZT\!12:=]+M5L+3X,)LXG&VV MJ2-OQH$WK(-D22I($V++>)CKOEF0L%$$BNEM3$O21AI^"U;:@#VIN1&K02*2D[W<3S;?,RK.I.*Y):#),(\S$#-?1,P$UV1
OP']O3[799\,?3[L6I> MMEJ.6#EZM)BTRO&'6C9GC9>>WQ]G_0353"B.DTIEEK"[VWUA=XR]=*Y'R'5 M#"=]OJ*;W7S.)T8JP6XV#Z]$&F%T)M,$?MHC.#K8?MSN]:^>R E2.W[=E0? M!%&#
(.[M!%$##P@\(/R#\@/ #PO\NA'_5X9LW0U_&%]MH,]DUG^FUR%8BC_>1 M>>>OE_?Z"8V^#-D]5*#-M\ZL# G\F/4].PPDZ1F=,;F.=5)1$9#X31((4Q.*-! M5G8@,.)A<[M.Q/<*A=Z#/.*7O$:7,>G%FI?
EA97&0B%O6C<7'OCDQY!M$.4 MBG8J2-)ZK\/D9C!N@W2\IWW<0!DW^.+_KG'>@/CWM;]_K #80?T/WT_<% M.H:BHR37&B4%5:RTGAZC{$>.D'J_L89-J0GJ
J3\%6(=^*=0)IWFJLJTUMB;1]@&QD M4R$VD0BQ[*4JP@*V.I[.>4T2]AQM^*$YRE9_=@^\CA,1 > 21"T'OSJ!WYU7)C=.E[?2@'Q]$V^R2+HS,YQ%B[O9J M\/[2]C?)D-@\LI[V'ML#NI.JI+JIXB0[KHU
AD-U>BP1BK'[%DT@2)!\N4% MR26\&K\G/8X$!28ILS4H3ACT8CI7&ST5TKFE_IN@9&_N(&(/)P\RJ]!-SE,E-MOEB<-K),@/D!T0&&)8)Q1+[W3Z#-N*!! DDR"?H'V_.S=9E.Q*CQS.>JV4B
M5G2Z<2%?1IRJ5$*<<9DS"F]*K/ZJ(X58]/G5IV8,;2@X8B3):?T%>K6)X8MO'2R$^4J3;?&2[4 ME])X.6!8W%@K1-.I4"2VKY0$'/?^B,RW6O(M"IE?3N2X30GS,7CN"E.SGWB[-MS;'182V:.(H]QC^^
=F2MP>C[K#;GK08>5C7!\:]5L5B)OGC'S84H2]8[?ZM^"X0 M-9\N:H(<[(!^__H-Z/>[+/G:Z/>35+UWJ6=+]JVO:]*FJERL?
M;P4*LQ>UG:,;+,A<>T\]VNDT11:K9^#Z!OWLE(OIY%&'+]_KZ[N'}KX5@&MP MW@%LV?>C^B"!(<'5^^ZX'>U;"8.K2GD+L(^#?,V >(-(\;=8\K5%B@/Z M#+>@WH_^ ?K_+DC^,?
O^^>)%GG66(O;RY2%Q\+86C*A^5.=A(38P+,4F/K]P/F MO+\7T-&RJ4A,HVNYO#CC"NGNNA!?&H*$(6LX2LK6 X3L0&8$.N.3G&._RJO1 M,&SDBZ,RP.)F.TO/1(BI-8W8#W;B%=
[^>]'_E^X2)MT]Y;>.U1DD\GU]D-KK MVZ6KVZ@ZOK97'U2$;7MTM? 8I8)R <0+&N4XS[BP(IZO'\'HYL%,]3IAF MTV4N-XH6N??[>=[<[8591YXY>RC?<\]D>V^TNGTF;R*C+X,!3:..A!!L/D @#
M,12(H>#^OB:2"!CGBS+.[,MAWWSUIL?]$2U;PS6MU#MR=OYB1]<*N7H3;[AZ MW^ESW3KY"#IY4,>]GO ,=7N;4VD(O29NZI]*XZ_J9;TE^J7=C[HO38,K<18 M9BYU%'JD]!;C<6)1O'"_M"&
[9!@D0A;<.K&,&T*5?OCZ:,#$ 8D3<6>;C(=B MR4MU+/EN#/XG;\E[V[3W^3]A?34Q&\6RX@Y8Y4M>#3D^,)V/+ M]K!0%AH@ V'@ P(_NZ_1A_F2HA!^Y^_*Y09ZUAA=.?
Z*E0&G;6DTHJVKAP M][+42[XW&_;?62Z4%+JL5}:25#2(.[@C#U.AY*Q #XWD >W*P\N8?'_GA X MXJ(7*NFUIM^W*W2\D*K5^0Q=3-L2U2\HSO$QJ2-'UA,V%>W1#6T49PVL$9 F
M9/$0F]IOAQJD7P."(! $'Y"FO.S5&HOTXS\1<"1KW-+F'? M/0A[[,"3% ^PEEO!%$E-7TNFGT&X_=&O+5JG3>ZP/EL]LY[XE_DZPXKV]Q.IA M6TEDK4JE$Q,H]B(75ZV!M$2B#"(8L5",OI0#,^#)
!#W)B13D X4H(\%>$ PSQWU\R?98#T^M\,@>6W2XN1Q[DQMTJ@_:DX:IW]>9BPT*S0ZG4Z1+%QZ& M\:7:*!GMQ ANYN2/?Y(!FVCG@[SY?:HNYH#P \(/"#(@_]^^) O#D,Y+BXPO
M(L8J.GCL<-)M!"O)&+F,/KQ7;QTQA*GULH>3|JTR.CC1*/)+K 6"=[J4VKD M,<'A'O5*&Q*."5*6CEW3$K8]*%71)$16./05-,4@'?>=CIN;$PTWYS\F3WU MY]IWJ=6M0A57S>1HO#
Z]G,IHDUBBTI!_PP7\HO)\@5YH58X)9OLMOR^DR^3@UDV)Z MDN4F8^'EI5I-#7ZS-.0=^GB6-7+]8C\VH*5Y1VF5HP]Z2U["99G\\0_+!.4B M@:SY(K(FN"L#^@WH-Z#?[[+D;Z/?
JW26'M?/9LM6&KO]NJO^@==6S:*2F9{65 MC_>75LS4XX2-/Q,H6C(9%TN/%,/=,H!^!O[2TBX:S:?VDM,)XX9LN+68VY$+M M2/D+DMV"]PY2/.J#P+J04_A_OC\PSNK*6.?5.=.T:1[]Q_HHU],?7_GU
M"3,69=7&0.HP&3PF 1(3IQ0:B([\Z:@8"Z$0$5W,P! MX0>$'Q!^0/C?A?_5B4M1+IICN.+"G==IQ4N453K]\[O8Z?H$9NHG.13<8Z MC0Z?G;BV:(6$SI8C<2=X%[1(\!3/R%.[]*^%P4T"DYW94?
JN3_G0@W>O-.MDN]+_\S-!T0_PVZ2@7T']#_=Z+_OR_9.;4]7*ER\,%L_MVBTC\,QXOW7UYFXMM7:\HE>,OCYIC9-#111-EAZ%$5H8!F"-AQ+1 'XUD",?M59H$MVE__]^9 C_A CVSF_'
-%V&D61/6/:.9XWKMEA*UM =]U4SCBS#QAHOP M, F-U]S)K"7+*RNG+^=V7R?!13<_.5T6^+H[6!3NA5">2WNSU M"MU2?OVPO&S3LT8E'5M%=*/=D>Z3SQGTE%@OA[1KQFEZ%F42(?
J23<^^.UL=-M32]]FKC,W^=KC79U]_QL}/.%![G1T\?%RM5+=[+O71X=6R8Y9;-C1,_$!X7 M[!86"(WKZ)\R18)5[?06Y4;I _PVT5[-6T-TKG.NC*3VO54+RYD+MQFC3.T
M2:G+)9)GTVFNN2H6!&)BA40W&-.#3'10) $@N0;"I)+N#0^3WHUR?AAA'/%G/QZ?QWT?>W(-)+'FC>FX<2=\)Z9D=CM*/N?80RP_3)XE9KQfFYQAVXM4P3QO3Q>ML1]!,TR'0O
M0?,.T1N_]R:M+?FVZ M3O:H&ZS_Z=T3L =4\M^4\R_LP=X&3OE5V\+=SK425B790I_<16*;S_"=X'VH MF]B?]!,C)V(7.9Z>L)+(YC?_P MU-B V^9?[5KV{UB^.#!K:*2QR(?)V/D,@ \0[^(
N7%^)VCT1Y/YF>)%"\ MM6&TC9O9.EN[^7#{3/:VFOP176#"'S"'^E^*Q=_|<^<0=DYSHS9X9PD?'7F\ M>RP\OB '=$P08W1R.(C$A=@@*B?908}}1P,11(R.QT11$*/2#{(1YSE(_P$,
MT=U}G/>PZVW^O<$EEIMU1Y*.MN72,0\MJHW\]7+7=HFIY%IMN%:G\0ZW7^L]?PX^[BG]M_G_8&F^+2%,6_[SF M62H.4@!TVT2*K?CG9$]T37/ZVOE\+23-++E!M[5G;O92F$]T37/ZVOE\+23-++E!M[5G;O92F{J H]B5OY,CJ?
K.K%V6B 3.W'JPA' M=]9\M3\TR@ME^9@=>1 ,T[LA$1++)4*9 /CTVMS(3B4DBE4H/HOLC[RN=NJ2& M9P7.7CR5&O-6?:H]+]'(O7GJW&(Q]R_F+QW}JD5*.FS92IKPS+UY=@?=*),R
M8@QMBTD)7.Y%^_EZ>A#,?WM&;5?]":V0!]>]&H]/X]&.33/^/[(.5OKA)O& M2XZSV^<MB>UE8QJA%>I#8'SD]FO6A4K&3'++^Q8 MGG1]=B>M=;E49&XND7FV-W(QB*O,R.ZN)S6%,1:M27K T
>6U&E%BX^U%<.^%8W95!,IVQ7YN5H.]1&0JG]H,/>20I13 M?^&&$WZMU7KWE6J],4#4?("@ZMEJXBDFL@6.[]S'TE*UWAY.T_#%++4JKZ.9 M6&=^C^@Y-
PJG'1,%SCV:P('COV]%4]5B0JS12D=@-:ZS>N;C#6A.OC?TN;@H MF6+\ODVWE'8D,37-]C'G6'VAJ8Y?C)*CR?JI"P-1\9CH=#M)7""A[VA19'1 MQ-
J/.IVKA4OH1,8\K#^.T<3GRWM!VB58[2"NM=!0VU9F5IXG2(H.3$ ->&]D8 M[;E9D,MT9,R ,K:FH-&+I'A(U:/,,VB]P+0.EYJK()WGY 3WUP,'&7II-
MT2A'1++]@*\7[<"1%C_M(3ATX6$EXZ<,JCXD*5RN_Y*K.FN.?HVD8NC>!>252 M&M%52HF6N%RDS?(1KYI(:]D#+ ,UXP.IMTZ9S#Z,W9>^T>.3 M,;>[?
9KM%")6M/8+_XR>>H"RK''U@5T]X0%7F)32Q9=&U=1,Z @.4%8M)S0] MTY>G=B<^&,Z?)DM]58VAH0HDRY73]T:ABB9P@+*TQT9.
M7E5:.4X1^,&@CXRG50$/W;M:>HT\/V!4^_5..R8\K2;+9.>B-V"H>[=@?Y-G M4!++W(3(F57YF2C_='_SZ!EABCA4&9H9 {)@MVX2W+7W,,,&?:!D3^[,$OKUM M&>[$G!V\1)OTJO7J M:$],YA$__
'75MG;.HX]$Q@*0Y!;\KE,^,>(?6' 0'W80T9-5.<%!? 1!,*^T MR.M.XH .@KV+G,3\" XBD$W?[*#02<2+DPQB[=QII?7CEIPZY#__H"2. MT_KBA8 PK^[*!+VX';]#@P__[$?OQWDL]><=$/K60-
O6OE^ZY"E]T*^GQL M4IPF2N*FV/)__L7$Z;\C=(C\X/G%]ZY2MYR60@]$_[V&N8_+%0Q[E_Q< ML*[?Y0]69J/;]'XQ/?:+G?OGP@]'%.@_9F4;.A3 M2I]@<{]Q<2C(>5L@I4XR?
YZ)\HG$^^3=.$#HOV,&76D:[SN4G]_RCWS\H9[. MAS\]U'Y'9@>4^]4H-WXKE'M=VO4V.5X2T/DCS,OKHLI7G&OG%ROCJ'%XU4O^ M 8QS.7PHAN!#1?WX4-%!YJ43YR*389]N+9*SCI
>=E^2[2];-#_^5.)]R2.L MQVR7MH44ARTU-W'TS ,E*$:2NQ0,)>QF:!9,]Y;#&C+UQ>BB+\Q^C{(O6IGQ[PV M0H_:SO3'(0B528R/YA)N,$#E,&'Z.1EF@$'IO6W6'}@ M6I _M'X+.2,;#A=7Z<)6@'Z'&.@U"
^E&J3A[Z\4-CAJ4%@1$ MCY9)S?@U;G^%41$P,"EC6X4^%RNTK+[PCZ7+Z[1N%Q7)TP'A>*$Y1XV',P# M,BDZDIOUDE#K3.Q\WK8>T\.\DFM @TQ5UF4C5E?3)NSK M.#;'S;WM@G77QEN?
DEZE9CO7'I[4>&Z^KO0:]/1 ^:.BC 1,G6!27U&P"5O](M=KC"+7%TFF\M(C[:(0.3P)YFV]#]I'# _5\ (S\YP95,&(6'/MF:YL:< M07^35E>O=K<(/# ^7MNZ^M%)T=L!@$%*6#M&I _>A\X
4*Y,1YO3W?6TY< MO$/8=8>1$]JG4,]_C6G32FC866]DVR=862Y 36%L*Q0YD\=R(/P@>^2M]Q5M M(9D7[3O]#67@S0]T#SBN6RCV#4CV=DCVLJDI5UU[>Q4I&:0!99D:DXZ4 ! U M,\
>M]8X(P/0HF;PM\ >+#_3LP!Z_$7O>VGA80 QM2W>'INLIK5EH3.9>M M#ZC7M:DA6DF]E^KPRXXZ>UR6!LP8J=<8,W(?_#^PP+^R9+C"70HLJ?^PW']+
MHG"-2GZ>'AJ1CO+44I+QO#0HL&F0*$"#!Y*^,6"#(:E%T'I M7%S,D?6=;96!S^)K4NX5UH _5Y+_MY %XYJ/&AY'=]-2 VMR02A?Z68 M-ZC/&N0QL)6T.F:UFL-I%6DZE(P!Q^@<%>
[++*Q&@[%EI[O^($(P+R M2 (<;!QP0'=N>CJ4H&98TE*MVN4'2 ",%CPQ)@EC">2_]0%?`-KKZMS5F9 M-W'KIZT*;TPD:^>`CZ?E@ES-%5]F=[;ZPI+..+26V0
MG$R4TO*)SZ#{'@-Z)A.G&@ %9OS-B88KW(4K^,%S[K]T3*6.1H=MI7NQR;MSU7;2CQ<`LJ_D8/P#I$RS#V[Y)CP*C?)9I90/5Y>_*%=)8@4#(4>.U!,^04\M+*!.22O)$!1S7^/29[#,
("DA,)0"7HGI&,ZA!@66C7"CIS#KN(!(6;+E50T M=E\W.ZUIO +IBE6VKHP&+,8'39Z"+ Y\(%K!SZ0*[F5P,FQ=QL,DL!;DDA9 M.KFU+]]=^]LK^(&9DW.W}?[V9QY0?F#@O]_/]#
V[QA1G7RI6:*7FQXE12,X>.PQ8#_`)%TK$O8N&3"@Q0 M(*3!3-77DD0M%6L\UE68!&7Q*_0>1#*0]H@4"@/]8R@"_.A&6I0S=C_[7G+C M>YH&07O6LU1A-
HP*W];_*]WX=B\;K3&O"%E>&3U(PD'/7GP[-Z(N(2:RMH/M$SDQ*>B,FLH,T.2EP.68$BR0=?6@-$#'\"5^@!<;4DOE0=;73D2LPZH.R MZ:LP^K]W;=)E58"F.
/8'YE48]VPV!(QS4G#0U72ZTI7S%>2^^LBA)UU.[0]]TS'3FH58\5;$;6; M!4$2__%//'+ +L(@>T,+,J?.DANN#E8F!A^,W).!7+ <&^:K"%+Y72<*0:VW,; M,U5C[\]O7.N129M6..N9SZIU7M2?
6*71&+!)XN8(,0?Z@ 6.CH#?;PMRX4MU_M1/TM?F](_%*,QKIA3EJV7B)'1G3T@CX'6=GTB=SFV[,+0$B>RNS]0+\S2 7Y*MST?N MT@UZ.[Z49D%NRYK,.7=E$U'5-0V4#?@?M[D:FUZF
_PAK8G;'_A&'E!!'B*Y M6):C9XD)RZ3]PW#]L;F<+@WL>G =Q,P]I550 EAF4,GR(IZ;:0\'[(:DCX)/ M*O>YZIYC'WE7'KT.\7J8O[%,E_R#?AM*Z)L:I'+H,C7#.DK@C A,B]MR1ES8
M_YHV!S5YP+*#B&-DL%JA%F'K@M%IW4_D^JPGIYC")WDB#E@T68^DKPO%!C.MGNFCQXABLV*Z,8A@_$XV%4JQ 79%P/2W[D_X6*9G!^55YWX2?@X,DVE_&,^O MG],#>/63G D'F-
Y<%I_P9T?*0:BTD#TT_A3G8G2N67Q*_IN9(M.:#Y%9QOK^B_+.(=9$1.UA*GV%2/SO#\SG^/BE2K.$W,1U-8J'V7KO.5_M1)7"RVC1[C_EKD=_3L.E,#WL]02.3:=#CWDV1X,
(1CEEV1!(,P2.$@"M27&A_)7O*RDB]FN/*Z?TLT.5UB.X[,_*.UDZWKLITZ,#K>, =_]*')%+41> M5E6!,H"D0*I4A VEX]^BE_YE0:WQY5GYC;_UDZ3LF MMC=995OHP,|_%0L]1$!_;8\EBA<$?
8HFN@8?E*9,@$-OH(^AI:LEC0Q>I6:\ M@;-WK,%D2D!8V 3!\&U.)1(:9%KH URO=8<.YYS+_NW=_TM4%NY_T7_<;PNJ MQ!L@3\,.*SS1 *]RI F--.U+N$>=
W36!OE*7O(266AJ=^K_Y9-[1KR%!5W5 MC9^N#/,M:DRB="P69R,I/#0D?A+F9?3>{GRZY->F:TVD[CPK_]&_U06$CQ] MZ[GX7^Q]]I-E[@:88I(^=1869>X2L0N=U$Y.661S+O_AJ,$!0O5?[5KVX,6.
M>4P#X.G^[0^7.A\aM@/9! R5!1F T\\<8N7]!'N25/'6AM$V,F,K,.WFP^TS MV=M]\DIB!1G8WQB M0,MR:A! 28E!DI%C SHQC">CPR'#)H0?9^,JC/.B>==P[ZJP^TO"B M*\0HD88AV4@1,4
421/NL.F[00 #QT;66 49:NGH;)% PA W&WF9=\4ENL+/-MNLS35\ ^%#T5S\<+ &!._\PI,^.I4RY/T7GS_^A;QAZWQMHA1/'/3YPE)BB& MW0B/DU-6 '3%ZK:)2 M1F;02)/1%TIFK%P
MCIR^,04O8YN*)IEF3C(%0\ S4BER"F8M,DNH&T LW'.VFCUV94#%>'=,GA M(%[IC%?]JM_IQ.U\T1+#'.3/+.>]HMF2F+9.C!O ,.8'A=Z+V. _?EB&+9U- MQN\=B<5<[6]XV++>TZ:8.\]W02#?
W7W#Q[=A(! 6*¥<5$5\MDU+D=>OZ(B[M%'I2YOT!4+V@8+'TWUFB >+?F+__I):\B31&03=FNH$%!OJ=1QNB\DL@6?&C>T RM%3D96RD%1] M!QJ]]>QXMWNJBVBI& X0SUH!
8,6*%FX2!XI/R[>L"B>J$\TR\!7E?IV<4 _H%-M:T"FH^12P V@_J+A"\25E+DVD=RC_G WH-K%@_?_^:E _0*L \T\;=)S29 MA+& !302"U236DH&GH&@(PL7S0QH901E _Z-#D=#PL0
%]CY:$R_K6)HJR(1: M4S.T$## 3+06R% C(,H*G" . Z3"H]VA1,>.3O@K0Z6&CZX4V/>HM"5,@"I MBFO3D$8VV:T9;XU!4.3,&3+]9#@&% M^,0 W#M=?AQ#YN1[O/ND+#"9JTAXM9K MF$;A*
[ZQV\LUI"DZ3)&T8ZME2]205_%7=RD=BP7,."1-6%-(.&BF2B,)BW * M1/","_X/4A!2M5- H)V'D#@S$ 6 $)2]^Y];!01N?#*7;A#X67@\ MYBN?G /Y*Z'I'2 .,YG3?
U\[@#H9$Q!!_;VN1CFVH.5'1,/4D=8>IQ<&:CM2B M_N0^"GQ5^14SM:7HT0H<]6W.J^(?95V/8)5M\'#;=$:1)1+T=$"W]&\)"MD(9]F$^ IQC.D3J@:O<=+Y"
[*%,5OHG0O%0>SE?"Z=YP;>D;F4CH M.P)H.YCJN.SV7886K%,F6H2*CD5"Z@&2>]@. FFH=/D=YLZ$A+.(HI!5)%7 MK)<1$]*J2/T/YW]C9Y+3,K,'=5$G+'VT?D!Y.N%'YT>N?%63.($(0BN0G0(
M>-.;)M)>`TIX!V{(X'S,7<_%]-!G@$2\$@'O9].P!EDP9B0#O(SK*]*1#262 MS=KL%3(ZLCI8'GB+-CN$]LLE[>MW7\^$X_Y@L3WZ/Q+N\ M:KOO;^L9"<"!),$#W3_3+F4<)/AYKHJ(X*.GZ!V=
M(DB;K4X,J6,6NAJPW(-$5#(>0)*HQ?4U*"=OX23#=KFPN M7'3(CDI)..#FHK=,8Y,B.E,+F%,X?]D<(W2(_+"O=IC('GMK[,PN:@TX^$ MM8*8D3KQS.)A%C8;1.[?^*6ZMNNBP277:L?.3&*=P)?
=']A7.;,DD.5>OM#U%L34R #U:.8VC(%[Q M08Z5)SAK<"92"7S4LFV SH-F;_&*>EW6$)MT0D(8XJAR<6_+9AV;G9$S$CK M!)MT^W)_>(JE%U=)CHII^!.XC*
(RD:HAX>LIY>ZA_FW=ZP0[QVN!'2EN"M MNR_W[H^-' 8-9?_O+G8@,8BQNOH,@##P.*Z*E34W"'", <4\C@ERR8$E&Z#4G9 ML9C0*X@.#'NNT/U1.[^>M/ALR@:.MG0P,Y63IN3K)
MT+>6A&D>C3G]HJM24B].WM%*;L'T^7RN8TL)76)9;O4_O7L,7QY-4IKT#Y MV NOK_9@T525%)^;K!O*4V.8'UK-)%)/(\%0(K6OH6+7#[] "BA.P@ %Q>"T7-M>^,)/4]%4=5VZZKTIT7*^/^VE-
]HZ% P0-5-2&?)NJKJRS"B[YF-E#S!\Q2@ M']RZ%W({OOK*#[@3HOX[(?I6LL_C-=;T.E[ACCTVI*V52C]]18KF%+!AL QUR*)M97:X*$7Y_AR.IMXFK'*.M>#$ZY 0_+QD\#F./9CF<-
#NLOGY$$RJ5&MR6 &1_A0CP8@@58AW(@++\V<%S MG^F5QP?KL=7JS".UY^!++ ^$'+#N!"OTL<.OCW2T>^23!Q+54B%F#C*P-DBUDYI M]_0D+!3SD

*1$,O^-B7P)(V'TB1K0P#XC+=]_\&)_YYO_^"\A'SSO M?F]2+],TR#VM:*5HN3*NEY\>E^B\F5 RM>\E>///(.D·Y09H4:(MX%P\3QEP MTO<$G,GJ|@ Y&1SD=QV;5)[(=S/X("",,K?R{KB@ M%"0H!?
DZI2"()YWL;-)&/)D![F2 GY7O7-=)|HYY0YVN\E[+V7\H·0C>880 MQ@,Q5M!!>J'S%23C$S*^MQ89WQ,NK\QO9_G,KU:&4&-^@22S)&F02#?#>5:0 M)DF.
\&X(9#>H(000A*CE6$$Z'[Z!IY#>+)'@HD,EL)&0) ?XY>,G;0I.ZH_^K_]\+A*T,T9W+BG33=FA00>6H4!&7JV86*.'#0^A M\ ^3O2"UQF%+(=Q0]`!$7]L.4&2)WHZ^H8
^350N8%#*79OT9%!VG%'HX?]];OOV M.C&>JY)5TM!V2P]TSP,JH<&&]%)5S>+,66"-E5[#,<[G0:?_O$/&P\Q[*%Z MWU]2.=V,N%\+(6!JN9JC(IES&Q2L:6*8&+-

*/"YW.]NO&N$C['@P9=)TZWE9[3].''Y%9M(':*A9*)'_#\^@E+J[1'>> MR-N",]MI"^+Q)@"?RI=24:YE=ZW8Q/LOJR-M%XU-[1TOSR!V/'6L\;E/ -IJ?CD;,\LM-S[}CT:3^4?E@^K,!WNLXN7=7M@M]""N=10_[JW[#A'/HRS-8RXXR7-;T/G=H/G:I!Q#1G5^ 4RLH(=#X^_H@2_M-W[D#U8^?&5F;$*44)-$CC<@]&FF-\O/D=6?%K]&G)^4UTV/F4F\|/5&_?5Z-MK5? 6H\|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{[L3^N*>=M#]CL5=''R-VA0!"K-U9#0K261ZH0CI=WRI2-2P$0YGZ=E'1B.GC MU=4K&KHB;<&YWG62M<[0X0:>9QKP'-$MQ=#PTJ;W(*H5?KS#+-O.V)&ZQ@!}.M(]T1*Z[DLD9;CK0C9^6^%SMGHUL$PLX Y1@V=+BFO&7@Z;M X>AZP Z-/N# M9XKF*]3? O8<1$?,C7\;[%]UYR$/>5KU.?2![X+Z&Q?FQ! @TAP&Q8M;CCF312.=,#-M+:,<[AY.@R&-)X,EJ@ &]!-QA8^^01$J!SH1P<)[_&8X,5ZWCH-M!&S5,L^P.CA<1-[N 2.!B>A&1'Q(2M)EMY9CZW6N@Q2F==Q,@PX4DI-Q9=G:.ML;<=TPZO G=%W>5FW_&;8U=3-"0>"R=$!\.BLI&.KGD?D*N^B7GVYR((2^<-M0S@:VY66[NJ;L&V.1!"/%1ZE-;2;J4C"8&O)K9Y!SWLO&7G\'_(O M(ZZ)GX^WGL25:B,X*1 EX4L57+*XC-NTPD-T!>$$-EK1Y@Y%N@C@'GSZ[5H M3I:)47[0K8[T48*6L9,7X%,&F5B%_U P=>U-/]'G+"17P\#B YFSNJ&,,,C8 M%)0*)6!*!&.[H!N2Q6<),LQ& A..C=VU@REO24>9I2OD?[&!.EO02K;ET]_M.^V'^P6O'7O\'2?OH$]P:3;1^H[D&**!H]?KP$ V;D-6'KAU.=WJ\\ CR;-\ME4XQWV+.>$7N3^GX# H 1T==0AX? 4(9*[F]LIN^D?.PAFU!) S;NZX**MHX M@H%&*=.A,9A8EF]%)FCKEX,Z+-@(HXP5)\+2>"DC%=Y!PZTY-ST6!85)5Y% ME[3K!:N6BEM(E1C-EC<,!;1ARREC2 $X.)N/,]"'X'/0$_V*=BWWS M=6(!\SO^,+![S,>71EQ;9@3@?$!VQ!(MRI2TK<(5](=:@N,3V>E90T*C"*EH MF"S,#55C,?[FX6+PC%S.MZM/'7K2$N7X!#H2,_SQ_S_%,C/'U) M9_.+>2/"?** <=2]6M_$ANYNI3:0%6=H9Y=RA]Y1)AV@GJT9^X6 &ULW'5I1 M\#]\4+@CK;!)/),%PT[%C95,7\@B@EO_O(GLA9&O:.D1"..!4_ _53$Q'NT(M_9TXR\@SG+_^X9CN?[IN-"?W_U&7&W$E/?)6/ ^8T<9!I;V!871EBX4P>D@ MX^6%>3X$.%WLON;7>#B>%R1R2R) ISMPJUL;8DB.K]O=**]>C'#711.[.XL, M/MUP81S.O)0[\"#^EKMW.Q#O4L'.HG'JVX5RB1,)4FE7)G4G_AGA$SF'\,.X9T;L\+-*9UWN,$J2Y0NE/)+1T1";BNSC=9 4[%M, M@G_3,C3453Y>+W #SI[&+2-6;3WK;.BTC(=BS'[E70@CEQ.X6E {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

12!;"1TJCB/'US&D(<%8*8F>09B>!UG=.RCD_Q[{10K^';TU\MJ3?*N'6\ [I@:TL9@%B"_&;!Y3*9D@34=\IS4QM_$-<<1?1CRI&P=J;]9.M-*/4J'G>]>2!- OX?,MPOH\,WK2@9I;U]@_BOUJ)L/A ;B""T/M@8,.> (//4>P<<^OM/HR1@P/+.0(4^>)4*4$[U1X MIW. M$28C8B&H>VPIRYX+$=!S"N(7CQO5Y](M>ZIX3]$0GH1Q>-T0+D!7GA C1%]+$K[<%$,, M8Q!D"M$U3 ,TG"W*#=_F7?> [S]+!?]Z9%V@4R^<#DR;*6_N#$.@]O'?ZB+_I 3ACG MZU/2@E? MK89XN*H,DIZPQHT3]9V_>LJBQ9L3TS\!5_=[PSD>G0Q^-V_!2AR* M=36>3:D!.*5$4 C]ZK/?L-C.8]QZ(#+T5%SEY[)3R LEH[.$@.]&]7]3J0I. M8E5\) >2RX28I&%C,^H57CV>+[:= '*;&6-LD#$69(Q]YXPQ]I4BQ(&HGFH-W M16]I&\1]A8LQH(J/ E5(.M!B%$QK/!94MB7VE/C,8Y^BXBP?,LW16[>?])9- M)+XEYQ6^?D8GDD*<=VT<-4A/!^<^+NP?NH*:%\8 8T)Z:+2/+1WK> 0"W*F1 M00>PR:IS=LTM7B&/V)QQ1D5W>K@EC'7(I',PY0$C'&,OZ$BEQ:D;LN3S"VVG MQ!Q9(SIQ 6EL5]708WNQ7@&2HLULRT=EKE[LD LXB7TE2'[KXP_E3X_TL2;J MM&S$&.L+\'9A.R>$!NZ.! ^2YYTCOE@TR!EE*.8D+$/ V2V\H#">""BE?RB+ M/S>/P;HU,HM,Z/=#W/\4K))XUSS &@<%A!1@ #'P7F#[=(,**(5R'N<4ZH8] M@V*,3%;=P,$";&^!+Q,8R5LW?M$!AQ?>:*=+$MIZSY#Q5N5[A$._OG?Y_P@5 MIUZF$_'G@X(ZP[8(6?,&A@3["TP%$1^R[05T'R+[!A&:B9NQ._X)9YY;IK:% M]%C\P -H'J163$;"##8:0UB*B#:- -7%E$+X]/'D%8(E4P4'OVIAW+CP340;VMR67;;IH(&:^&1D.!LBN+&1Z+[Z %GBV- "62'$%*3@6 M72<"U-<8DI-$MOT Q%E(!A/:-M",T6O!'8.N &M^^ R4Z] <='>$OQ20!H!J\WU=J81+4W" M4;UU+P[[5HU?GCF=:[?7QI$DY=-*:'KC%LBL-T/J)- DQ#?N41]<=1OQ+;P0Q MY^Q:SMFT)MI6+PH<9GUAX!:_%-;%?B$Q64L/E?Y3IW%? @3#PBV3LIS>[_IVM MD "@,Y& (IB=P'1@^B!=X&0L8D\I)U*1(\S1WM(/@XY>N5W4WUOW9GZ5Z+>3R M%B;;H2DY+AT,.H@%K7.9O.4>V;X#;!" +YXTTE5]I!!PC4,('K*!2 C1T\3E M(0=L0]M.CM,M=%"D$P3%MGVY+Q##.7]B**0 P]8[[%SL85:=:E*!,''IS"%U#4Y&?: D@-=/29X3J(\; _G0"F]DE;W*W'5PY M/!P8R7OMSA,<'!#O-O1@OHBFHWKPZ%! #N%&M,*1X_EV=@=KZ(=6= C7!"38 MYH[TC? 'KBT'V<0FLP96PBPK;+NN3=> ._1RUZT:*%[ ]Q?[NP-(1_]OMKNHRR M63/A0&BE@O0M:=."$4MO^&&HHZN31.,@$ (3\#C//"" \$F?:#6Z68_Z.18 MOH[R),O>,:]ZN>DXQ9L;* 1'IZ_RILC/*>+((&W<<;? O/4/_<\ ,=(T$*^%) M3:0TDL(J^&D#87!?YI'&PM3HWDN['%F7V+4=71Z ,#@X[GI#UUMKQ[PKD>=N^@OZKX"2AHP5 ML"$,;(**6/- TX(,5M[+.>RL.;.F2F^>"D7+1"K#7:+,WN-&O7]QM]FHGI]> M,,BQ^=J!L4@0& L"8]\Y,!;YI):H"K(OJN]K=!C3=M[8KOUE?CE/VN27DS@%LEP1\ROF&" (;/D\#&-7$U@4%UJ M,J]DQ=&@H>N"IKAZDF^H9PVA^]U[\IV[)O(]L-]]#S>Q4;-2+* (SN[-43,<8 M!#T:/V^Y01=T:GD)5"%!,-CR,V^QSC;D%S#>Y!FZV.H? U[V&3Q@"NG*O+A MES^ZK2!5S_'W*!I!8<+V@!_'&\W'6H)U[PR$Y# (%GH=1S[03#@3?'HP5I/(@ MFV_M.QL<6'+W;8/5ZL5O8-.0P"#H]SAE'I$E?IU- $/7T(80:L9AW8CW8HD3G MMCO2UO;'8ABI0]1P1]7V!CM)2:ZS=QNW[M#&D*.T,:"D%WASODV.B@(0J![,= A,29%:[R9MC/\PFXIO;.=Y]M<>1D97E=#2ZV8\1]?F#?L)D,,8 M1-P%KZC.%A!35C$$ M>PHI]X*; 79%8E-P6N)L&_+[']TC!DK(C?QO8#="NVER(3EU6]F=Y$M;\ (J;UK5^23"4!-[A2N*70*0:QK&4;> W;(&SP^2T\QWGD.P&?L"93(=- Z;0I$0IF"H0R!TQ#'+7_BD[P2[DF M$[Y!PKA]Q,R4?KH__'T&0^$]@DV6O!!PB3"*K]&,N"+U]W_^LD3_U+8'[=M,9]!7CQM<>"VB)#@M0W8,YMV_

M0NK13^)\1#_M_9F\#&?]0OM0H$]2:L,<0BFZ_.*[N5I4^C"R+ YRV1H!
MTH:0S=S6P;/BQ':0]N.X2[=#;M+*\3Y#A C?T2>9EX!S[]{K(5)}A93.
[9\D,;5$'%@^+DK"W6=@0,;SG!(S1K1{C@QZ#%7Y6DH -!\4T%1>1&!
<4!_\2&53WP]]!V MOBKP[$91QP%\96Y+CF<#R0^+%'5K^I;=[O0<=/-[?
O7>/QPWP)>S%[/XX)"N MVS:T+ADXS>P8I&-OF%E%,W*YVID^I#7M.56W*
<1)P=O*A5U2R)=)KV\+()/ M MW[W),+S=LPZHGLH@V78'$)DGF"(^!)PW:8_NQUL
MW'1FA;1KPELSG<$K((D6'5'8?9KC%OI@T=.2L+.SZ7I<3V/*/O/)QI.AUA7. MIKOY)
[&M%I/V@=88A\==;UZ)LPM7&WB"9 J?+NZT#W9*DASMER2BF6_-Q3;)
MD@>,7IVE<_I\VLF.A/A:L9>#E3KZW'3L*N;KFEQS2Z[<_'2J&E?%G5B;18: ME/%Y6S
3C#+R[?#8&[8+>_V0<;I] 9X MYJ8JOV;-M@.<69V<2= ,'9I'$7+YV2DPT2(D)
M4F*^J8B@D7\&=N]-@7G#+#K$"(F/MP]%L[Y$A
MCXP8PZ)JMD%EW'NS!1_9,Q,ZPP&GLC3#;B$#W]],C=X-&Y_0),?>RTB4-Z0937_:!
M.PD*GJ$2TP@7/&+]':Y5'\;=;*8Z#5Q)VWIOGOO9L)*#"H-&0_S8&N/,5HM M->-
\%9*NXY19>JUML;L4NU'?LDZL&V)@NWZ/C30;L0L;H(CW:J4$G]Q\[<
MG97CW>-52VEN66:[OJ)YK_'_R?X)Y1=6TD&2<("*;]Q_!/Z)"H8!4&T$Q)
M=2ZR,!>Z0&KQ$65"RH4'_'=TZJQBY8HUHN=0K'_,G@:+IN/O:OL6-
K$L8FM9O%;ZSRW$'Y[SZ23"8-51(]] M""(_\D$^W,JYP3;X$WZ(_?3F,DJ)WD>
{[.J&Z]FM>CWLVV\[I;;U7F(?47:NAQ MMA4LW,DN\WW#D1]X%9#*Y^\?_/],/\[IMD
'3R$IT5+77KT7HC/?JC""GVNT M8UO/\?
SH6VF._\]\8]=67W_8JTKU0F3A0IN_2A>IT#8QH"TB\.%4FU_Y2.80 MF:0V&D-
[O+F$T04^QOEOY)H Q': P$4'Z[;@04_V]]8=NBF:Z+Q"KB%-&DMC
M*WH#/HR^Y5G8XG8F'DX-Y/.EDF[/Q,)G;!0@B(KII_KGS)@\CY@]2FP@PC&2,!&4\
M&M80?#O@[=L.8N:05_E-[?7.\FW-!\8"+W5>Y*MOG-K$W/&!2+MO152/MA5
M,%T=1G 5*M@:Q;^].V7>Z$6(3'%5,MKC>P!\1H\A0+2Q7V7AU-M9V,^N)#
M,OU=V*Y''.["!<#%PB93>-6O3 W!5G(H[&O<4)7G:RAQK@P 0XUXUM88AK[-
TBZ#6R0L*6'L;6QQ_;$_O3%=J.E,.= &!^6!02;L5=_A"# M&A*\%TF7K5S1[>
<=JZ7D*=E655^\>M-$D!_!" OW?_2@6>'U;DK,ZWUI"!3S MT?X@V/[V59H?B03D
MC&OFL\F';D9518Z/CY,OE5A:#L>/->[:H H@670_IF^,6Y_9D[UY3
M@(M("CE^CA41W0MN DWD;_^%Q./=&"!IS2;8:'*0D/G8("HEY $?E6A$F70T
M(3,I7HHF?A 7-OE&6QC(]6J)4QK<,]=+]^*RR:::V:<&J >[(X7ZXZ!"VPUN
M(D57XO#15N?A6GK #I*[(\TN\WC/U&FF(_76G>=(]SFR-I:#R/XS:Y-$M#Q[
M3#UQV57]*3L/K^QR!T;&=DGT#Z/[;VSJW'E>EP9"VQ<%+L9X@R.ZVFTX84:*I!1Y4I;O
[8;88 M5<3:O=;I/='T(F\5EL5U XW<>WMZ6LW%[@NY.&WW,_QJF;G/RX4E&KGW]L2\
MF62SDZ?FA!^;29J/S!:/ W@FP^P.?4S%Z_7E**W3-A-=MINLF7Z(+P?Q ;T[
M4G_JYI<*>A)=>Q;+R[HHQY+CY2"Q/[(_+UGMC%V:3.(]OKAZT3K=,=- (_<6
M_U*A6_,'KA^E:UTM4[>>&256@V?N+7X57L:G]+J6F-@CM#V/X]1L$8-GQG='
M/LS8OOX4SW4G]J184XMVG8FD8.3>-JE/;=IH3 MACHTEPUI$Z#[2]30:F=H= M*2E-
1BK45V9G7JI4G]+6.FP^P,C]#64>)\:HW5_(G;5<;\U:U8%:4I>#Y/XV M:3S?-
^8OBU@GN^XJ2FK=*%J3-!JYMTUR_K'9;=>Y%C>/*;/T_:K4D;LC-')O
MF]I*W>U8:NI"CZ^,&&KFW M3?.Y)E;J\>0CM^;:HM@=OT
M437,/LM^WS*1\OU8;83^1DNK@IQZ20K*F#^057)XW.6S2E[S.7J)M*\9,S_^
MB=P=KGC&"N#A>N%+V3BO6&>;16TF?"3%VTD&Q5:$OVP8=TN:0E?)E^V"JX^B
MNLPZ0YP4K;$D604
X$3&QCX!RIW.RXL151\GMMQZ,IJ=;"R7.@"77W4L(WTDW)UDHSD,BR;O8O_V[M9,]
[@O3^QX/ M:- RT*FS9^[O8!B"5VRL>"O_=V M,O%G
NUDY1\YA*,9_W=T/#B7ZSL7YBZ>",[E"L\EK!2LQ6%LX7_>N?LL]>_5 MY1CVCHE>=
(/.K*OYFHQM*V4!B9Q5OI[VE7S'/7G-3W'#>Q(8-(',..^U02_PNPMP2Q?BT$$(J-
8!A"Z@ET%D/48N_ M;5! (X'2&BBM@=(.**W7=Z_HI: .@(]-=!3
SWUZ^JIORXPR;VY_]\+:*!?)ZWJ#W_#R3]OY4*Y M7N(@:N?7I \VH(\S*9I?DSXB
7W\+GVD[A+)KT0>;=WBU3,DYFY:L?S\ER!(
MDBQ_JO9%>B'_/!NI7]GR#I#V[^3/7MGJWH//=Y:4V4_8!Q\K8^B<-\NX@+3? ME-
UZ9:O[!-(F":T!:7_^X9^1M&.?#L@[<__#.2-AN0MNO)O4W*
MOB%7;1R_H])KTMIM2RZCW39OP42^0JIUK(G/,XY?W9/_/J.Q\,G+/,6ID=UU
MO[63\'L1^1VXUD&6-\=I381_N+FM+'@54&_3*\7TAF!N([D6>>"U"BX7]O[L M WSU?
BPJDL$;PGB-?5E;3_/&D(K'L XC^0B8KO3[B2S',OI93,=*=-*[U2; M (#+%W7+^?
LN%.WAM1V 1=[%T&\+@[*=Z_?JC76]T^*22K3PE#7H%8!<1W[\ MPS*A1#Q^
D_D'O-_N^N@QRK+J;DD&XHQ1[/AWXNQ%V[I._.*$[=AT 6%_
M(\)FOP%A.Q;=3='UU2N-U6:O9<>R#R(=KZW5Q9-<*E92IYHB74[#&PFI+E>Q

MJO$.W['387UD5Y?K$;0Q8=^@XGV%F!L.)3I]);ZJG^O3;.K];=@6)1$D2D3=
MA@807T5B'@_*??K2KU*,GM%RSJ:R;_E3*+Q;Y.C
MR4=CW'ZH+F<=Y9Z>E/*)QU%'ASY''V I!\+F6,STTSGNHPSJ*USZY]HB 4\< M"
[9^.F%\E"U^A4L/>.(:3/8K)(P/,N.O<.57I9/^&L?B+>@ M2KP!'#!VYNA1,
[S[$BC>1Q.9V:C+P!]),K%=:.[_VD(@]U@2>A[JQD^7[WRK M7_
M\9WZ25K%6QMF_)TUG:W=?+A])GM;3?Z(!(KP!XR@_A?X$GWSSYU#V#G-C43W
MSG)F'7V\>RQ.1W&9'XK)F)08B+(4&T298720Y)/)04H>RD)"'-*"O-<'F==J
M+Y71:/Q$M_2$8 ZD>KI13Q_J*)Y'C_I MZGRNR)U6492K]CKZ$HLU#G44OY^,IFM.K?
8Z4OW12%8>>^&!?K"CN#V-E1Y7
M3T^IR7PPZLZ2YM,L_-0XU%'\12]'A)K1SM#A47$YB_3+UY:'.HHO%]%6M&L."W3X<94
<+LKA:HI;Q#K3 M;'JAE-/59K>?/M11?!SIU'/K9K-!AWM,BI4GR92Y2!_L*%XVPU:
[]BRD.#O? MRC*1ZBS9JAWL*#Z2$]5\+2F:W%1)%K5.JMF>-AJ'.HJ;8T-
6D]%:KM.C)V:X MU:MU;7MYJ*.X*@\S1B3>CW-
E*__45@JYM2PW#G44GS0TMBBV$JM.39^UQ6YD
M,K>ET:&.XI6^F1K:R_6,ZZ64QWNI'ZFE:NE#'<7;=R(VX:SL:+E?_/ MWG?
V**YL[7Z_OP+-?8\T6[?A.)%FOQK)@,D93/J"C&V,<0('TJ^_5663VG0F
MF&Z.=&9WTZ9<52O42O4L>V;G).E41_%)EN+YZH:G,+'02)4Z&A>ODZ<[BLNK
MP<3NC/,*FZ.<9M>*RNGU]&1'<;J2HU9,<<2QGNHH[CBK+M:-
KD3%4<52JZRH:J)+G^HHWK#D1J835RV6X/)B M.+EJ8&/4>_RPH[C7-
ADU.BF@!#BYS81#AHA M?F[7X(!1XJ&; D*(G]L7.&"$^+F-@"]#B(#?9GYYT=\':?)-U-
&S;L*/Z.T+ M7_)V,]^,R!_V\L7WO7S)N^KE^Q"28&S"[;OU!F$3;M^>-P"[\)"'0#3@#<(F
MW+[C;@!VX9O)PW?H^/"6C?0=F^@&0!)NW]@A)MP^TX.Y]N$AW/PP^3^[IN(
MO:7Y?T"KVZ QQ,V[A7W &OB.S6R#Q@^!MPZ_9;O:)R5#_/P81X^S,.[I?9/ M,
^_[(!Q!WSZC=J3WD:%!JP?Z;_JP'IA=&F<6)(XA!NF@QF
M^]$!3D^G=F7H*%QXV";6*CM9-NB;-*=*MU5*])AU"M.LEJ/KY3HV&S:\JJ/) M)S*)?X?
VHS?2,<'J-WHN'7,G#4:_0Q/&&_%ML-J)GHMO[Z1_Z(-OO^9@?3>^
MO9/VH/=DTC'Q>K\S-;IE9=[?2*G*M(@GQOVBBS+<7$XMC13IJ.6%:J?32
MN^:@;QE@=YDK^G[=0&_IP@:PW]#%W-H KC6 >O&,CBK1R8IE8V$VF'6A.T^/
M>M7T('F=9DW#J%PAQ\XTK.3"A=Y"T1F"$I=>M\\+.Z8_49D$O[WGF?W7 *[U
MAK[!3V3YX'?O/+/K&\"U/EC^^AYR -G@4EYS)<:((N1T',UDJCS)MLJ*N/Z
MK#M.XKG&5_;B?,\MCH^@Q3[K M=77JD^LU$?
V\PMGWMYN/&ZFN&5^SHLCK\;1NQ9:T=*JS8 EO*(Y2IB6LMDK9
M(V/(ZH588TCXGVR76W9U865R6'A5<2;R)M8P4DOPI*\?&I4SB$V?Z@^PG.AT
M=#;+,.H"=A;T=6-KC#.*GF)[&!9;ZNW28C4M;J;TJ6Z%JURL->)S+5'IUBV.
ME/*2!OF)Q1P+;YQ:H4TG MB.B,!D_Z5K2@LAU,&:5&#$%N&D2;'>5B^09X(\-
MQCJ;'O958Y\2G!>Z[I#P9_R#;0Y3QX@(J$O-6&F-5,U"W1.A2DJP@[=C3E
M[71$=SJ0WI9LV0C UYZ(0+&KJK&$!QR:X869H\5/1,%1Q=K8SQ2HRZN?'S+Y
M67*IY1F*G>MQ-;P1PW+*6EZ('SZTM:=Z,6]C\\3NRQ]NSQS,5H<1G#Q#M\,8
M%DD^VAU^P:(X9VN,!R&"0 @\DGBTQ@@$(:*/YF[!H,1#-P6$$(]VAT$A1/0-
M(*,'):Y$"2R"/;H3GY$0'ZQ>>=.!^)YP+E=8\O5AO**?O?%/QB+)^T;]0 V4
MS@3U\)9&NB?V>&B#VVN#X"![X/%(_+[EO"7.[,,>:9C7(RT$8Z;G@WKY00R! MWW?
GO!=ZYH7\3?,>Y\&GSX-;%W4PVDPUUB),MF@PZX+R)D^AD:B+8]FVGD*<
M+H20@2*(0XF0CCU3%70 5C]30H7 W"K_BQ%6M%;@:_;S]
<9;86RZ\G:0<$P[I@E4UZD+&3.MW-WDF@(C*]R<87N; M4FH)JP+
(7W_Q)RJ!7:CL^*=*;P#PALXDO0B-\N=)[^7JR3XCOJKII!@N'\^S MW$J>CS9,K5RK-
8#XQJ#XXK'H)<37-;MNS<:?%M\[\+R;HB7"^RO(?!+@%15C MI@$.
/QHG>L6V4VC"5XJ0_']7K'>J]-#"AI#\:=X\B+:]*>(XA6X^6*B>.'6 M*H$0Q?,;-
E^2Q0:EY?*QX=1FYNF*)92X<+=!-X L LN&>(H2%W%,KA-0NJ49 M/RK^"R.^'E2B]
(()J[/:JK^6#):%X@_L.#)^02ON;L7_#N)3 M7A^/A^_[
9OLUA>Q+Y;!N_7";JUL+VUJO2L1T%+JC6B],4DRZ15KXCUY;F5WB6_5L7I8L:@K3-
=+1>KT5:C MEI3A779@)E%/6/2"B;S[D-
_[P,#8WRCW_W[I>]NO+^+$K>UWKNO:_[\3"]T MI1_%L6LP1.G)[^%5?
M\M_DK5S*I*M#?&B%&M))MTNC)N7PW5X4";3AW+EL?K
MKP(]1",AM/:0M_C0P>HOQ";'\S_DG.V\7T9]*>BA&F\;(S!AJ-.?$/1#VM# M/-
=KLZ>CMS#_E2-
3*:EL,K?;:4QHS:R%I8C:+TZ9/O>#Y97[P53G3'#HSF6TWUJV%4HOWZI39CB:UY/+7WS
IQ M-J#..[=ZYI@B..?G1CO5H I*F#):16'4MVO<,CA[7:AF/[W9!<3BEMWD;!&L
MVA:%NFC"NF5.V@-3A8F#_:]6U$7=$)8X)G8RXTZG.HY7VF#_Y3Y4/_6*C

*M.YP*10B])P04JQ@)N2C',VX-YX @5[C9S#168,*VJ*[/+@I[A>YI=/)8HY^- M6GG9'*
<;U5B!$?%%3V]VXUFF_WGP[./Y -+(AB#S=7??3HN'3HRZ52,151XC!+YS\S_KE
M?)G15OWV,$UJ^0XF\[&E:&8-*X]]WOEH30S3;HNFEC),$\$>^;+LB+TV1=7I
MIOFUP7(81PXIKJ37*T#Z_9%91-P+'6E^6.>@D*6"91N9+B_F6,TQ\6@YG4\4
M6Y_&=]+ED1Z(DSQOB)A7'$RH#*ED9RC@-1'*>J$V -!GXD\O$2MKMT[%[+E
MZ0)D[7@)=MZSX-3]=H4 ":'80; LF")!%S5&[MZ'++CYD9/.S1[8+8ZI\1G!
M24HK5X@SS<&FVXW3T,Y^#M?&,9DL5RL4UDRZFEQQT7ZT'J:E(>%_LH-UFXOE
M>%-3TEBZGR:7R;C:AT]2SY\<+(61TF@4]\\Z2E5F94:"@D M.Q\FJ+5:*H?
K*JQ1\G@+*BQ:P22E,;#"& MJ/67W-H,T_6E!)[TO3T]**0VHU:!4-+%9K5,S+KRAFV
)WUO'_7B]7*I(--L MEYF3A1@I=C-5^A3XGE7GV"(EZBV&R%1$(]F/QE1L.8S[G^PD*Y-
U(2OF62(Y MC\W7V74E*T# TR,)"RK7S-0EH=]_;9\O6,+,,MY=,>C:N MKJ/+A-
1FEM"P\ST]=/@BP_?X+-N*EINB3@T%[E"?3T8)!M31%E#0\
MW8D.+;Q((V/D^:.K_CI7(]=D69&CY5RTDQ#,? R-NEW5A9'H@%NBR3:RRV#; M#@-
BJR<[\0D5WO+NB,*M/W*P;->&%V0R],&Y9] M"N4P!RS+V1
K#^BP9B9%EDOG4ZUDH2*8E<8SUGKMT2%Q253$KX0?7#_7 B?R
M#!ST[N'[^OEJ0>,AI"(RA9;@F!:/@@G@($=FL6A9HACBWC;!EW $SO+@+JT_
M)X_O9^"\;](&;OC[J4.>+W8LZV$/7 :+O#?"SA=HI%7NP@^Z'(K>:%^*$!YBT:(VS9]?
0OLZ,2.?1#T[L$E9X#$(H(- MB?5!+GG-
C3\30M9;MM+E$;+>K8*_@J_Y>9Z*16+1[\13KR1?+Z./;GK-XL-J
MV6W"?";1BMT:S,>__'/>K;IUS\#SGC]?T9^/;4"N7<"VX9R\CMT:5>^,5+YO
M2S.&7K'/7Z'$2(CS-/>YM'9@[L/ZZ7ZFNQVQVZ_RS9L=A\N^D[M9;BWXECM1
MKM.U*D[*=396":1QQ=.G143'-&;U"I,/PDQPJ*__L:B\;>Z^'XGCPM= MS?$N@X>,"Y_8
6QM?:53/(K#X 6N-BMZV,]T(3+JXU93R.<4 @*&[,GK5*C MB[5$3K,JHUE*&\#2SDN?
\H'1 X'S2F\N']-'?SM=S7^%=M_NNV;-;Z>_'-CP6N_?
MP'(_7[CN!_C75PJ];3W$]2O8TE''[%,]9Z2TAGJS',Y.IJL"O#!,_/J+)Q*/ M#-MW\3[.[
0)ZK0#8.R2T@//3=2\%IMLJIYNIPK*N*DTHH5$@H7$_EL6W
M=Z&JAA[F'V[4PXUZN%$/-^KA1CW<*,^->@KIES@9 EP5=;-CXE%"=6T/#A@]
M_(LFHI9FY\.>7:79V##K9#K3#!%G:8C0!+PX,OFHD_PQ=9*W.R,?*N'J/N.K M.J'?
PV.60Z0J&#%SHLQFDM*J/83:!OS&UYL_?CN_\=4RRTL$8H-85O2HM?Q! MYL()A1!?
+_)+2HV-E5:KG6I2#2*\RB/ 15AFF;A('[&'._THLWR460;'8CBA M%H1TBA;8]:K*S)-
Q9C4@YE9?06H!5E@FWXPO;QO*_/<9(.+ENYZ\BO%Y_Y+O_[BL7? H%M@B=J,
M@PU?;,-G.9^%2TD(QWII)CUJ;4$.%ZMKQKGLL%>(X;<
MULKS;KR5P31F/10HJMC"!I!)R=LPZ?-]Z5>PJF!Q38R8BO@X&F-3-'&-?8DG M"L-1O-
XP&:(L2&22U^U5D89,ZF]@<\RDD2"I\4]9EL]|GAV HQU P/% Y$QH M;DV\]^\L)_CJ2V#
O0BI0U!;:W&W<#SV'-CM_QSAU^W,/P@-;)A_MC;>P:H\ MW#P"F7N2&';A\;@Q>/$?
3EUR:\M;93P9V6%8_=F9B20B!18AH_\)'?P,M\.W MEQ!V^&#'CF"%O:\=
(PMO/WP#IL\CC&W,_A!X!.8K#L"7*3P2CUZ(5,\XDMP3 MYG^Y$%#+0/+_;
[N6/@DEW#N :52>:BU1;1.=G%H[-09FQOSJVQ6"/>I>-:
M5!UEEZ>Z>!2$R2HZ7RH+S&E4XMUVABG,BB<[;H0+0L59% 2%U=:-E5@2Z,*(
M:9SJCD'B!6?9S#@%I2L,M ;!B=-UJ7&J.X:87&9:QH)L842K3POYC+FIR-*I
M[AA8SQHJQ6)JKL2Z#%8CEHY!K)=N"=OQD_4YVX_F.DL;6U=G#=.)AV71ID_V
MO.!8;,1J8,STO)WNQ$N8[M3HDSTOTAP]*0H;NJ/45AE*'G7&Y+JR])(O!X\. MH^
02(A)8)+$J-&02F+<<"0(P L4Q61L'(]S\43,QRM,+-V*YX:]29U-K9.AS ?
2FG2<4J&T:ISBJB)=*0UD,2RR,N"4?K]7W?-XC[;U.#BC2Q@ MRX478A$5=_'K4TTN
!4SX<&:F]HC4LDM4BS-I&)#L7&I)J!O!!G@_U]HAG)L MC*%$P^&9!P?
[P8T4O$$BL1*-_Z<6PX>?#]CG_'FHA@/Q2//V"$P"-)\D&(M(! B&B%_*++
[92CQ_MJ!]YT-7UYUTK?HUS 5LEXPLP\\6"O$H.#E%A X1.)/ M9P):>$L17QP3^:U]<
U'_[^^]9\%E)R\;9UE\HN;M3-PW3W:]HL[W*G/B<5- M$^=@3.0X_#9%C0-NAR[]RF]"
[&"TO4G MU$FUDNIO!O5R"RLUFUF-6V5278Z^9F1[#85%^L31K2:,F#:-0XR3])6K?
MP 9*/&R@.[>!;J:I'L;2;917UG!.Q8-
F$T+H85RWK:0Y.N$,NIPO6%FM75RPZYZX=F*J12X7L.P; 3?
I3ZB@S1RHF&18'2%:YT#8>EA<#XLK*!87U%V_OY'R8@^,"6;% M@T=I#?
YV0I.ML_8B%IOU>FQMV&M3R8&4CJZ6<-Z__B;\BNR?>[>VZD!] ;T>
M6G"J@VZV7182Z&%X!0WZXXJ6V0CWP0)X=7M0,BI:>NP>4 %\Z&6'E AS4S*;)
<.I]J)0L5P:PTT#V_M\]^;>M^5-_?Z&52UWGTG1P-? -:J.[:U;_P-30=;?M$18"E!;?<\L-?
FE; MK^W]'3_FCC&#O@3X'M7$9S\VM6KEU15E(PDHC_SQL,;4&"WOHJ2C)#4@S#!
M(\Q#6@)(% */Q),/PER,,%_'@'WSH DVTN/N8A/YV8M-5"R"4X&^V/3!AL,T
MM+\^>Z_IF[+)E\[Z[\,:KQGE9[HS^>.8Q#OBO@^3O.*874BK! QYN(NV0Q3"*

M'%@.)XFAW=7*0\?W]QI>/C['9"JZ"31T733YPSYF86+?_[JI$PM'3,>Q--'OJ869$)9->'\%6&:) MB/_RW7\>IMGW-LW.S/L?:L)S;>9OC$N*D6ZG-+8U MG>\/UYXSIJ$8,
[0"CF6**#^)||*"/=-43[8L >6KZ">*!?MW'.# M#C7;4OJ3W3_FPAP(6K=59[0A-
B(=HEW&)=3]PX_E\.W:HKRZ,V4I+?#U%C-3 MUE9K$VY'Y:S--R#*Q5O->|
[>%^5S0NZ.!'_^(]M_OBC'A->7J LV[+DUJY! MZJ:1GI)$G4?UMX%3!5G3T$(V> ?
LB03_^X1$/0T[)>GKD,:M0R,Q).L+0UV@ M^Q+0&85W)ZP0T
JF*#DJ9QOF&OQE[LBFC$K?.#O$F;(%O^<"P9O@L.7 0^"4 M,"U4I3QR+*!-
+"L2ZDY$_>B=@@@S!_"OWE AU;"LD&R%8!>.T,PT1JC*#6ZO M";C.T,&OZY
(EJ_!/SS!;VPK*.'73)&':2=A5X4'QH-K<5'J.51)#I\#' \V MF5/15L#R/C!I0#?
P@66#/[GH]#:G@/D"C<:%EA-#%;T%C(_6,7+ ''7+%KG]&MPR0QUBS[O;<; >#X.?
M5SG9+3\$?.QND2UN_XAF"LG(@9G"#^$'3W!C+(>?'"V#![_0.J^XI+?%^3#N-$;_
M\X$B[-0CT*.<8T\,6&&->OC)EN6((6<&?O9
TMYG2ED3#I@70[9/AO6(8D\8AO[O,Z;,$DS M\D(61&20>CO9MK-R;5CNQABN1*?
C@QDA3Q;2S7:RSIDULP7/;*$#UP1\4K2Y M)W?48:6!49KI"JNE:FIU5*L."N3RUU_@K6-
^G]3=2V#TAM#2GZ" W2OO[?3" M^]G/SM/I+CDKJXRCM7)K(B=VR@EHP[^?^V8[;?
3-&/!X.S_$@U52'*;T>=YF M:C&]MN;;;$.=OI<'(Z'[4.7I [7CG;7 31!#8 S95EV-
+B#*ZH(%C5!X=BVA M<0TV7$5]6T?K0WO9.ZFA7P D"_*-(
/+&;@C%C!@1U/PX]:41_&X76.J9RSH M3282>MN"?/J0K-\JF('RM(!78?
&W)>K/&36SW>0#E7G28Y=ZZ6QKV.8K3%AM M*-WINEN6-T#:=<,?RMA3#NS'T0DS
1[+2'R9C'N;^/Y;A\8?K4,?K4-?YM5[
M:QWZ0E/"5YV^:_M);QT['W>=Z';EKGRDFKYOZP.#&.#0((X#2V,9G]\'@[QS*5X>GZ^
M/@'-/[)#X%#R&D0^A9;@>.& ##W!@]KB37F&1G*/:614_]2 \C#7(9W9#_C*_?
Z61<$N&"$+K$P%M!(-QX(A783.@U!Z#,B]8&7 9 03RUU5
\CUCI8&T&&96MC>2:'*J0.M"V@#_I)I M->MG6@5=-[C MN:]Q;$OMK >%#
(EC\QZGJ,:ZW&.T3X+H>1R+W"#O_1 ZKP"C-P(+N\#06Y]>
MY%]6C.5H.I_J*.%Z,M&5VGPAM@'\2[W OH"(4&\<&:'CYWD.R.1 T>^8PX*(M=:++,
(BGC]G3 D?#>S$E/N#BOV'Y!XLGEDRK'6WC[$R)X1@3'Y=7R9;U!8<9 MO=7E K
/4(6!MQF"&X@)ROZDW7284Z1B4*<&4D51E:ZV?J&)M64.&
@]I"2H@71<$]O&;@MQ5*HP"=
M=N5$^+UQT(>2SW5OEV$2L^"I]MKX+:^V'%O,#2NC#S%Q4ZZ/8^VT8$[H7W^3
M6-3'-^^*"1QDC:Y,W:]1(T:/<^-JFN;9;F=CY19%>5PTZ,_I^%V%]Z>UO-DH
MVYNB5.XKW7)L/182>)B&<5B2?$I@?I34@^MFSX6:6W"RBKPU*)#HF-_K=B#A
MUPF87=Q-*O\N#I>101UB6XK>N!C K(M<[: 6V/#=
[FF]"G*^O'4P0OV$<@GE,:'&7YDEXY4+[_\Y,8^8?#R>!'@X]UB
M+VR8DA!#:ELOM/_E]0/$FRR<:YJ;05[- AJ7U0\>%VZN%0PF9KC-A:!>9
M5ERRN!$_S=3J]$F]\J6\^]MQ,C(61A;33O^@_X1FR+9#VR B D/G\%CFT6$+
MF6P;I_<+Z+%LH?SO1Q6*JQGBLTPWU6+&Y2(FB\-V<]1)=I,+(!-X(OF4 M.-&A\T B?
#X:A\JFP):(7F)JO!#=;@3%/@UV48:^U!#OB!M^\/_A,8_#&^D
M]\.Z:S\.=6S9;E=/]M#%G]'%N])1>%Y6#1W6(,'P]!$9C43=>MT$$LKACDL
M7BVM@1U+JJP:UK/D
'A\)'ZBKA8PA0%'#XGNB$\A783E5K'QP614.:S+N&S^CY90(>_):HJBFF^P+!@^H=L_SX
(AT*!ZDJ.L17+3 M<"V+Y8H)8LE;CCI??C(^Y5)Y^X*=:GC#I3G)I?
HJVYYI73FOR&UM;DG3ZB@W MD@"74D_QI-^]1#[CWEV!1J#)+7U1";_:.F?AY>T\&/?
X1Z&3[>[?K$3ZU=4] M+S4M;$T7OXP?NRJZ>_@L(?,#!?+,7VF#K4$B;NNP&
+AG(;*Y32L8(;Y=,O+ MKM H)PX>]?3Z[BM/[M-
N=@8J*.-8H[T2YKZLT43M@A7[7[8"WU[/@#31)]HZ MAINQ%W;V8+-VO-
X%6X5V:KMJM$_[%4557V' NK]?K2CS*Y6]D#1%M MHY5@5U,VIE/A/I[OU?
0DL(;B3]%H_FG_/CCK]A#3Z'E1 8\!DX"U8$'#:2@ MN!)-7K9VA]6.O0XJ5XW9-
E6WLXP>U#ZI^=F#W:NA76L;6V5+"ZZ'SZDNY4\2
M7(R+6G$YVBS9N5'KVH16XR436"7)1/0ICI^(0W.[45\X_)]"Z,K#S!D!I;G+
M3H1F,+MWX=*XRQ//&=<'V+!07; <-HMIA6AJ;3)'IS;Q$4'=VPLH^?EJB5V\
M(">THD+.F3F]C]+PKI:86#E8B1^XEP^**X[M/R]FR/V!%[IV))F[\=23Z'= M-0-
T@<0!=EX0)99('$CL]I=+$9WJI:H9U1KD6'F3[2DY=A.7]4^DC2(C9+L**GH6@3^$OY$$
\X]">W@+C;(/RN_>CW]T0 MP$Y/(RL9EJ=X$X+]Z)#;]5(YZE6O:.TO8R&6AE-$@S;=6:
<-R[:06DL!32=L M+]KZ+VYU\%0A4R[H?
7:^SHSZXW:T6.)I_\6MT_=U<6M1,2[I!4>P3T)'6[; MA?S("UX^L)%718:@PKJ.HJ=ZFU?
E!0_5>-N %8=Q=-#AKA2"<^^$CH9J;L;'@QW"1QTX_+R(&E&!-(_+SE^!
V%840;^.P/#XNV8"'CN< MB6L^[":XO__F)A71>]!U:G@S6CP4!J00.6OB_2KO7NK.

[/]^9\G,..!N1&C9@ .$.ZKO!'\' M#\#&>T"'7VKL!ME/[+2]._-6M!OWM;56SQ>["\ZA@-/0;?
GA64 ,"Z3ZT?>V M^X'&CASL_O&:O)ONB(3(D -V&+#'16VF&FL1!H%I8,R[X]K@9';--
I?.VUOR M;CK]\%M/^RLI3RBY@Q]:1P"+_E^>) =V'^IM<| H"$#5M'F T_X/3?X*
*MC%9:9TG<7+ MBLYC4S:\I@G@_Q!/42K^E*3($S504 ?Y* S[SID+#S-F%W$\ M246=-*
*UT%"1L'@I%@E^1-CQ3@_,PZ M$ QBZQV=Y(!6*3FGZ[.AQH03M;RU*,QQA0*
.48PBG\A3E5;N_L$P\|QM-@B/ MN'/C5YTTHK],B/F8G\49*E?$TE@Z9<8GIC:M2I\%P?
JTA'J@6)P$C/N:8UMP M=\ F(IIZ52D^P"Q$J_&D2A?[Q>8%V');N^\&RD(I%K;>WBM?3
*MQ/OWP=#B*_7K]"_HM27,C@"M](<$CF$$:*#730>[LC: M.6!$5X^'5 B?*
*(G#K[:"RIHF"[;!H-DHNO&O1LC_,&^>\4FM@B\@*H1T@Q3A.:+_H,LDX,3Z OG#E4.*
M%PML2^295GUAKYGYW$BV&B@Y!DX>/'$B#/\"4[UM.-H3TW"D%SV8B%?9\;S M\T
IN;]Z[MB6+P@,>Y\;AQVY<5YT"K"J!VBV=VEWKW#?Z U01\H3?KSS<5R3 M65S-
9(@ZL56H8N@;79Y./"Y//RY/?Y_+T]P6]][0\71C)&3Z1E6X^-I)RVJJ8 M:M'0
/GE;L#NR5E?&C2'%6N&R7P_W;$YK"YCC2'A?[+&=>E!ETR4%2<^'PJ-
MX6"9UVCP)/7\RS4K^IE'JY/IFB,"+2>!)W]N;B[DRP(8MCG7 4321 M8JGIF((=*
*WQO3]:=9"R7[E&*DVZKK!.66%RGAU'_VZ.C^F!4QIMQ-ISG>]TN M-*
*:SF&&D8\S]9YPLFJ5I4C05'?*TX),)M-M$ 3_KFFQ;LT8#=85 M*R,T(=*
[M=IXO7]_/33_@4 ^<0D]OHTBO1PEVU#I2W;:"O$A?2Y":[S 4Y](A@E-]P%/03/!?*
^V1[@6_/O MZ ;0:\$)U^=Q_2:?%8F>5]?;TL_]J;P-_!V&L8)N>;5;>77B;G#RD]Q!3.8
M/\!TW!=6?L:1<:TS=K?]:.?A3)O>)KLAKY-
*FYG*2I)YPTH^GY)'[GE!F7\XG!#-9M(LEA_#H$S)Z3V=L3KADJ#1BX96_*
M'9C+;H)I=V%K>]E_EX.!%76GK?\GF+P(OY"]<&LF#](1S^+YO&C:G)N?V@;S
*M/5Q9;*N1O$OY FJ09C! +,%>XE2T3O7\FEW3PS= ?+2/#9*05BBBEP4Z!_K*
*M"&8)S!Q-:SDQM.TLH<;=)B_0?+;N[\'--3 =-V@#OW*0 7(+VWT^M%?%9/$3*
M47!47U[/33Z-1%BY;VW+G#2C838F>?@OZ[3(2%"8\=$:1!O'5LUOUW+H<[V*
M:'_;_,AS[GXC9O:U1,C6_[QH(@2/#N&;7CDS: U==:!U ;C\"-/NY"F"Q[U3
*MI,RF,W4MTTDR+7G%Y=6T:HVEKY3D7B4U@M=C=F9*5Y/L/$SWQ^2 'K+Z\M63*
*MX[?-*5" W&IOWNW2]-*MCCVIHK2\G#?Y>_3/7EYV;*!O<=%?*
MX;!=8F;/2,_5K$=/).);BKX2W/"EH8^TKC<-O\ >1#$\M7%D%C[MC<(G:!A-
M(#&1L6@YI@DG"%/\,%)B.#;0CPNXT0A(;EM2 > 5 MC8*
#:4=X^#T_QKW'T/N#'HG&_C=OK/U=)0^V5 =FP\PP;:B,UR_<13PE@,?W
M'FUTW\,M90/[L!L#%7V_[_;702"3$R"Y4$T-MX5#!OLUG![RX:/>><(-Q
W?"NOQ90P35BI5GB1HL.!3[%OQO'%<-+G;$R>2_V2
ME%.9"@3));#D4Y1\]0[(,5^8XB'@M=OOX/6D.Z1NL,RCUIXQ72EUQ1WPGI>5 M.:$1
LB.Q7V.X +? JY$/S<")X$QS4#A"NIK^8B47]%02BTM,6VLM8V"+%8>'Y>2?
@E]W2^4^1,0KY+J_M3,)@9[NKXW'4G-:P%1:.1[- -IL:WYL:&:^<%H=D
VH&AX%UM6&7INO\+!-& NOB@^^\N1O2^0E. E<#RR$$,_WLY M$=&GGJD"60A-
EK,FX APS&>BLQL%'"@ST;37_\ :)=[-4,L;#UG'7:,U4V4; M_AD>$.+S#PU3XO3=-
S31E$33K=INLB"K[B[" M>DJ.*
(^]LFJ7"T>B+HX1FBK8+@.FX&!+FMVG,LS"6[QJM?;Y\"+^$=> MYWZ*QW;T_D[?*
+K+E>RMON,!04(6Q9%\SSRM?/RB@['0)6TUI,J:%^;C 6M# MZV*
$AKTG/]/UO=SK=4%H6N;YDF-./N@1L8W7;N,.\&+ MEW53BD)7KU?]!^7+IM
*MDQ=Y}?P.?YH$TLDC$P2I<$_._211UMU_1%P&1Q*O M]FX^*%TX&!\J,]C;*
<[MOV]_#L#7N'[+,FQ2/'4=$#-P)GHV,_+WJX M(1_$&8(!+F(3#!I,M#8"Y&-2_'/W_ M/*
*?^S38A\8%-N*BFN'!]\H7W!!BD\$-T_>AS^T/&(@2^+6'>& M8[7NT?9]!*
4&$(Y%X,$)/Y83R',HPT/L2YX7Q6-DSZOK1X@8A' ?%@8T%E74
*MAOM,O!ZPI9Z=MZ^_O_R\W63G&^W3J6ND:K,MSN,41L-&*2IIACPA \D(B<@"O[ST-*
*K/;36NX2&/!0:Z> *]I+:G:HNCN2E\J+;Y1G-D,7TG8$M):L1/'QCV[UDW94L)C4Q11*
M10.$$ L!0HOWX"I=7>O^+!5[/W8)Y.$L8.&"Q\%O*E@BW$T+0G>VPKA--AQ;
*MC'2AEP8*EHH00=&O=[{[KVG7:,S*;5(RE61:H[XA+4KYUF(,[YM&J!/P.0]- M].,UT?*
*W8&A_61%2UE^AMFD:!*447@W9L'3,W#.R0%Z'\2-L/2^_,FHBIKX1B*
MFC9F;&FLCCO=6776)I$F(D[L_C<+&F:VM<5K652%A^?]\+PO8YA,ZB$I%SHX R\I
M9-_B.^G.=,YT)^,$L\JFZVMF"22%>D-2[B\NLDNIP;M"H=_PTI'US\,7N1=? MY!,W#&"
*[SB:4'G2O#_[F6>[>)3ZM+Y;KC7"WJ.0R(S5?KDX:MM4X$EG8:?J/ MX)B06TX**
[.AM@1U]1&#;@#GQP[N6SB@]F7-.A@VO!+,KQ-?+,0Z1JB,X]ASS
M\C5GXCS;YYK>WO;E8^%8JD\[F!++6;C1(NC;Q#$:3M' MVKB/\&W?*
*0Q=\)UWP[*Q^2Q?,-TX[OTY++84(9Y9S2I!:?5L*%C.O M2R/-*
*BLN2C&D]5I76O:XDSFFD"Q+GU@5O;]^1+JBJ*2S68P@6'%?%,36K-*
^#VD;&7=0$R=/Z+KE;Y088O)0.'-\:. M)?Y\M\7.?[?M4C/U-R[3W#GY*

*/<^0'N_#*OWBVX@:125=:W7HM3KK,=82MI;T#9I?:4Z[GM0)5DOWK%*O*
*MLS#;VO(DP#)968^+/47"TJTZGY+I6F%5/@FPK*VZ@\:H/=;95H.5Q-R$Z*44*
*M.*9OHNTZ528SR1*FY(@"F8Y*'2$9A4#0_HDR7).L=IJ2A:T%V2:X'_VQ)JMV?*
*=Z1.FUF')R5F8-8$=@*C*
*M8KZ)]D4LGFXL*PMF3I;3X056+"L9&!7P3[0R%E*%L2B(BI/MVYVNQNKB@#X%*
M<E,TW+YLF%$JY)U2PKAT5^*!U-0>^>C),Y1ZMF&(N-S;O%L:Q3M=NR5-%0]##N?*
*_N<<6@[WZ3B6"W=3XL1PF_&,J!A'6IWBCJ&AM,X;K5&'J*2+1M22P). ^,5/%6;U<*
MPM8U15,Z#E^.3P;CN-1(=&)0K#ON+86RA=6F\7Q+&PT$"5O"1WVCREI!;]HJ
M]QWRT\#KQ(>-U\E+-J]_$/U#?AGZ-MXR*
N"/T%8&L>N4[$UG6"X!OB401QUPK,!2V>@;D;@@O-XL+9/&^\B,#L]F,@
ME)D#=!4$1?G3IV3<@(C."&X4FA>/V#MXCB%BR-O/PHS71GAC"
MV0%>+D=U5"4'4\NA;6XYU$151B5TZ>X@K;*05";6WJ%$H&1OB
M'7.!H(Y<..B0QR7'X"R0A!O1-(#@("FCP>"6$P0;#L$/&H'(6,#YD-MR2! M"T*W/NZA?*
H28Y^='#XGSF.1W1,=X'8.[LB\0#YV%G* ZE)W+7MQ\K!G[U;D*
ME@@M5%ZX^S>!A'.!S86]('(AV^00')(KA^OG\$Q(D"'VT].Q#.ZO\G@=?,&+
M(%:B:6@NF/A"-(%3=RC>KJCNOBCOT52? VI;$-4+?&/FC%04VH$+DCWN\!"V
MP+X#,ICKO9+:->\%K(7ZKGIJ"7W=1#X-^ #"CHV@V", \P5$L]JJ.PAEM8 X
M;KO^42^KG&==:-N'^PXQ(;>'"QS)W9R3>X?
VZ]U[M5OS3(3+YV[3C4P]X>P#4".;@CR=D5BO3=0I'WG'G"47')!]#8;U4P MB>-NJ-!*
*5P3-\^W>H"K+,IVB0)NL6&RY7)K!*E,WF"_O47JGT_*BYG^7@5*
MZJ$9)WN:6LBP(8/O#Q#72!:=Y,*G3 MF_*
[45($:AF*_!1(&QYTIA,'Q!QQHF]>W/?/LT\GM$X'N^6Y<&VNV"-'&PP#9'5]Y9EE;,$;NX!
MPU=<1BB7T]L_NU2"-N6EH!9/I1_!_[>B_>LO#8F+CFD(\^GA$T(&YBP/1?!V
*MN(&'BOX0-W-[YQ>P I=9G1]%!36EE+IL*5-I1\3F3G;@R^143P!UT"2!>8>*
(H]"!,\PCP$)IAT MP2-Q_$&7 -(%CU#Q!V&"1YB'(@LF7? (^9"7 -(E&4D\R!(\LA
1XD&6X)$% M)R/X0UX" ^K\9OSE^R//OF7O?!-0Y^1G09VCU#<#=?:"S.
[%G(,F;5]"+7T(MTC<7I N%ZW[BIER'4:ZL7XG/ZMROA_T%>:(I:ARZOO8PO.Y!-]Z9-
%S<\#IW/T!GW_K/ M&)]-33Y.S3O6D][J^N^)FV5$&W35FW9-Z](/6PJ!X6E<<9$)*
(WB=T.-4] M2,KR^!'6"KJV#%;34-=N^G8I^7LY.A-O2,.[2'\V4^G[L &S$DU>ML10'=ZW
M?'##9TRD[\,-OV7=W2@P;0\:!>#WX4A%:SCXKOIB=\%CS/Z'F;\UXVG@'6**
*M2'$JI_/B4R@C\N(^YD#B3^X/;I?M,^G&@*W]|&;23;MDH'O3A^LEGZ_WO;@M*
M+JS!D.V383TGI$0VEEJ49V&KD6?
ZC6/D%MH:UL80]H[TL,)/5%9>@=EEVY,;0?.@NU:8>1Z,V$PP-DHEI;%9#N:*
MKXC1!$2=)'[]I9X(G'RB,'\WN^]J%4<>UG4\:W1S,F#;\#_G6)A[]?#.]8(+
M;31D6YFM9FC;6;DV+'=C#%>BT_'!C) G"^G+FN$J/7/\>F$;5_7"JEO? +D& M)
[2%,\P81JK)9C2O%8=S)W586D6E*I;3: K"=^_<6?HO'D982=")PTW, H\'S)@$O/*
M1QNK',B%%A_%)\1@86!I==V85CKU=K1QA<8S;YZ NU,@PP"A$C>-X^3N"PY*
*MP7/+(KLNKG5VN1AV:FTH%Q F/A2+1-_HJG(G*8<8>H6W7UNDY'N(%%[=]0V4 M3%*
*[S_TR0NEUO=X<9%6KH-<13FW.-"SKA"5;8,VDVLJ%94QDG>*X*3C&J"8-*
MX]#O):CX4Q3S-X+\%MQ_*Q?WWNW9-Z%T@B?LGW->@]4HV?J0M'_0G:4ZS2@?
*M):I]3%SVE$ERTN^8'=@>!;BS>"09?VB-7*62*
*M*EA+OOX=E@L2_LZS?,*Q#L.ZM)2.1,V9 .N3))\(J-^ M3^8<'> #*0./!-XC@??C?*
"M4#IA#(U2"C;-#(4&-H\MQ7(SSA>6+&Q%[19$$OYBR/,Y4S], MKS_R0@^?Z%
(^T0EA_Z!7E!OTE^6LC<4CLL7UZ.^-=$XV+T>>$5$A+I0^=-/ M5 ./Y-#M[8-*
*'@.X4_$([=TD]S2K87M=KFG6Z_\X8=]-#?E M4S,?],/J) 6VN&6U6*U-)?A)9;W@ITNH@I*
C%HL]TE/73T_=6@R#M4TOI:]N MO4OWX $^9.S%]-;/8)]
[2G^YK]CAAK3$F7T('(+M@4.H;Q$-O"R8&@DX6C"<
MD2H&@J6OAQFRM];4UBI+$77.9C2IFMM(BW9_D%D&&S(D&ZV7K%@Q5()2SQN3YV
[RUX%S+X[OU.F_OWWU<1=P'=DB'UALF
MSIAE3.8T8SFC9UV=0&H#@8=1@9^;HR,@$41 MO+.0@VS)62%C?!U7,6"
[H1YK]UGO$;&I'O333>N6;YCI[H@6;YH">:K&%K MJU8H.
*(I(,YLL.26Y4I^&^@9XHM$(=L'2SH>]>5]&\1NJFOT>TK-9&C6QQ6BC96#%M@I[*ZA"*
<)&[_WK>^],!)1UP+GVGV/.?\[J[E]VJ69B]NZ64F=GM:ECV?)X?31Y HO@ MT>
<+:$_$T'+;%Y!S2>8"588$SA9#8TXV0PN(;@L=< NB:82,8SS+T!)XY_]S
MT2JM^$F>KY0J2GW 91HLLRZ <'KHOYT2DA $#,A&\B-
/3%%1"Z#_=5%=+41"SK&X;8 M]^;]+-
EIRVGZ953E%TX%S@;;'N(DR10E_TGRAM[Z<..&+_/XN]HX\)].C,= MVH;-J:^H*?**
,E(K,<53_,!0TAUA,2X55%X0&I\UT3Z_QY_E]WO88ZU93&:9 M%$DSQ+(_-

*[$Q:V$CL,=DXL0)#!9S;FOL>L? AZVI8*JK:G4ZSU:;;)--VZOV*
MP&K$)]4P\%OPY&EM=9VSX,,F4S WM\--A$II/A@SM28U%MK+U3 /SX)H,OH4
MCYVPC8)X%GR8T>]!3RE.(M4A:L95:9#D8$_8[0Z,P ,5N];1Q"YV5<)*
<+EF(5RRE,0DWFZ\ M"%/\[#C8(7@_A9:R/3D^$UX,.OU@5V%'C,\H+[+85JA-=1Y3Y+*
[$=Y@A&4^4 MH&%$/-R%<^ZS4M6J8F'>K3&.O;)=H;I.O M!+4MG-
*CE_@G,7%;20>\+\+Q<"RA?(X_]MU]+/4O[N(/!GP*9 T%1W6#>;M_WH*
*MU]\V*F('FAX604# CUWRG_M[0/57>15M;1A6<>]FZVWM_L-CFOBVVOTCD$#^ M-*
*WPB]/]"!/KF/\^(\(R:^]*8'2WA1R\,OR4+MZWOV'1DOJN]206+V44LW$P8*
*M.4%:#M%-5[0!NR=IG5G5UW3'4&)K:MAIA&G@7M/@2>KYD]%.(ZY1C%)GUU,^*
ML^S)1)PTZ2'A'U/+I)QXUV]),O2D!QBSY\<"STFS%MLF,WEJN%Q=#B?3-
*KP2=^8>85I)L,.V<9*F5Z7 M;NH5/I.1AI1_3(Y(,QE!4PRF9DU2Z7*
SVL[WEN!)WYB+#:5FA%$89[A5NI5I MU9?
*ZIM<81OUCFIM54LIDL9C"36;Q;'$2SQI+&CSI&W.-%YXF3*GNG(\7,K2=*
\^Z1N3D20C+LA:4A&3K;6=R57 M2:$!; ;?F(L1D9EP67T#3L8Z/6[)T4Z_*
*OM(^L:DF7&'K/2EHL*1]1:?6Y.+ M^9P^Q4N-*
3J[54PKU/E93HB.U5QB2L!\##CLO'S_9T=E-14RK,NOJ(F=K
M74#W$[R4JBETLZ6H,28LUKM32HBODRG(==''G3PK8L*@6C3*AM*9$E=9F5#GL M-
*,"3OK=/-ZUERN3; [96ETA!;>+M6@>.B>//'TV*1$VTZX3)2 M/;4F516-3V"6TRSE'\%'RO*
*;)B_5@Z.2#=6NG"CD/CCH9&'8R M?W34C0Q5 -]HBA:P]W@8;T8!C1"T?*T*
E+H]7QKTQ/8A#G2[K-EBK1 P<$.H MR#$$&-O'P+C***]=]C@'Z"5S.EK5,H;_]*
*<"EKL&O+*M+^=^&452P/,HKA() M,1P_@:\!1NP,V+'0$ AQ(9<9)/!;"!VO(=L #_*
B.%]RU_7#GQY+L$0F??M M]4RD5[*U^W1/8T1B1&&PJ*
*IR08>+Y(*I83EAQ;1DP"YZ*L^F4O1K03-4EPI< MDR4P1\&>G">HX-*
*Z3JHW=X!H,ND$3+&N8D ;HB9.QM71^Z$R2*1'8*;H5)^NL*
*M:G0STJ^_AB[Z?!&7.&C7W\43S@S\N ";!X@=<;D-1>!LP.F(Y[9_A*029#<8 M*
/:HC93C;4(N!0^ %Q-H#E4=1TR%EN7_TA0X7Z&Y578+3C]DT?_&5:HF5E5
*MLM1(*47#@YK:S.438?]DD']6*-]I#*-0QDXEH/^XJS#,(W[_1!6T9=K#)F0-*
MQ+#PMPJWDC5'\YCS-&-#3CO)U7"YB+,Z+F&>C8)B4Z((!-!VK",1\?/DGF,9
*MCYK>8'JRF)IMU!S!S*N&'AUOFG42IT\6;C\3D"\[[N@?;VFNRXX?B()-\-0Z*
MP3=55HXGB56J6K2#/WK[]APS!"L(;>>%UQ[5-1#(M1S@$V!!C,MSEQOQ0-M M6*
A&\U"\!(D 9' P1GC+Y"%!!LK/-DR/VUU-^E7&N#3AT4B ?EOB9KQ%>%_4
*M9I5PK%\C,44KC,NE7K1;PMC3U?G7)7(_4Z &K0P[836,*B]'LV1%G[CZ+@QI*
*M?)K$KY+V4+7-1!,M4>?%-Y3:3W MD$Z'N+]B(9V5KZ(E*8=59T*1J4TJT8':*
*(";Y\1T4M8@8/IQRC93*B+4\41K& MYTVA"4X7,OJ$!R8!'!@J\[2]63>TO,Z*
8V2Z8)M:$AN]:E0'@\HQ2AFU2DYS
MP(A4NU_*CQFUO@3)1$GGQ(GR.Q*,_20./@V"Q'+O3YVK%\ -^S,9N&4W0Q\ MJ-*
T)\SSC%R0_U<73ZO#$-"$(5<)OE,*;$ B?B(.9[E63ZX9BP73387EZ$IG MJ7CE'&+PR5-*
U$TMH!-52!*;F$&52'O<(RKZ=?]@&E!'MMKM9%NV>6Z=]0VK0
M&^&Y<3_!A.VFO)F3O7A;)SV#;>'XH-8ER/622(E-Q)C+3JM)!NF"@DCLY;Q*
M4@YH''MI^(ETJ%)L-';(HX1KHQ[\/>QJF@/5!!/KGITC1$+TFP!%Q^:+(-JB
*MJ0'[!RBR"6>COQU:31[_@-TTH*YS9[6+*YR8.)S.S#1&+EP2_XL20!/B3"8*
M9$@ZT%D";-$"]ET\2V4!ROO^1MH'&./=77:[@^6XD4!0$-5C27:"+1MEJ.!
*M+X!W6">C.8CX\!21[?6NTO!CF_8';<'9;WD_.]T!JPB.*GK1+Y_$G=(#KJ?@*
M+0ZE]M@3BD5_/W7-D)MS3N]TK S2"BYA(YO4H234"?@[2*0PQEXOVTZXOGR ML?*
NT[V'\]2]Z_TWL?=?N?8H[B77790 'O #-[/$/]L?#B<%*
<]'>A&"BE7/4+/KD)WJSZ;NBP\2;N;4-K?S\MZ'NVM^/YC;J["&!XG>@_%A M,'$,I&&*
[:=O?PQ!FX8];20"5^IL9?^FXBA%S(TL0W7LYRGBF#(;)B^I"A+.&0W*Z%?:-F_C*
*)EU4:3]VZ'7K MXLO[DWBMCMA[R>CH)<_HP=#?(PA@!\(/T1@*I]DCFB$"C9_M;-*
%:PAY0J'>L&W;5P7JI1K(A_:]E?:]8V8Z)F"-R!#Z!K5 M.53T33%CP9@'K3$@-*
*$5&Y+U$)XX2G>399.76"SV/^. ?\8J^KGVOOV=OXN1> MO@$$3@Q)#T?C*Y4?*
*['I=CNO#,*5P6BYKM$PB61W= G.,F3N 50HZF*R#VDS7*
*M8$ZP/>%TKXRC:NBP=$(47NPJH3%IK%V9YP;,7.TSU*S/$%6'=B^21 GB"8_Z*
*M$9F^I^1>J9DO#,S=5OI.'5'G@&[W8EWWK%J^T@'B:LKE*KB?[U]6!PH_V3&XKF5S*
M-[HF8.6L'[_6=2O-D[L'5R5=LH7!^+S4AVV5HZW>80WLDF7BY,_08"*
*M>D4#YOM8*W>C+BZ"]7]9A1$,0^6+T.5 GRS-\M#.*Q.3G9>TT6PBXWFNJ3 M**
*0O3Y[?6@E NY^= =-!1M[W=/GNQ*0)ED<%5=7OAVES$5WE"MLKI@U55E1L*
MF1Q1BJAB8T%(1O.Q%>U"7^)\HE^'$'__F>PON(USSB-0^CZ"R*YC-&$2/G*
MJLG.8K-D:DH_2>7+>F))-EQH'2"?Z,03M8PQZ+\".+\C.* A_ES.ZVTD[17*

M+!\)I/,K5O4FBWAV&9L%HE5J@CAZ6!PYPD_T<+K?/;/SS!V@B-[E[9\@K/2*
*MAQET2X7C@"W[5!IKW*UTV^--6I$WA7BU6$\/:],&T$7(!CJABNXZ,.2OZ7GM*
M(NSW=#KOQ7ZZQS[9EZ__.8]RHU-\S%I:75F9#S"Q.I/6L4I;"J(]]7;Y#]-H
*M8!I5("@F5ABGG'%_L"I-((0OC"<]$1CU1%+^#@O?4[9O&U *DGQ>/^(4I-7?*
*MKH3H6OHI&,;7ERJ($LW.P.*Z)LMRTWBA*ZT(*FY!Q>7FY%*
*[36J!Y1QR1(AQD6=NO8KCQA\0#^:]9M>-<&O^*
M=:%JMKA!$,O'%!#J#B!"2#S<;_YPO[=(/[+1 WLWLQ#N#_R> M*4[*
*X_)"#*F&91UB^QPW)X+/F_L++AZR,=0P(<[R '6L*Z/<;,'R6J*YD'GQ*
M!94$9L:CGVKCY@X0R8TCI0W+MOQX-]EY@<^GBJ4D]:%RKJV'%!M7KH0WLVU*
*MV#B0N#?)2#)Y!N@;,ADADC_S.KUK@42PZ&O@_3?#.< CB1*P1)TNI")!UT" M2!<@,*
_"!) P1(2@'G0)'ET>BBR@= '.]H,N :3+PR +%W(!UV"2!<\0OU0 MH+9@$X:*
(X+$'78)'%Z#(?B@(<<#I A39PU(.(&&P'XO)>A6Z?+"@ZLU(\LTV
MX6HH;&^Y")C95'ICU MGK"%KV3]PKJ&@&W#.>YZ>!5.0407.5SJ>^^:P?LVR
ML\C3GVHK7]!Y0T,]PU'-=MFK7'Y^RP,)'ZT+F;WH>67VWET/D]8J@^FD.%=B
*MJQS3L[5&:BX>H<6&R0]<]O!JJ$7A=(FU]^[==0QR=QV#8WOUE#*U;86;E\Q<*
MNID8Q_GED!R20.\G\4O<(',]A(!)SD.!G%.!W.9 #)3^(_U!WEV_5$I]>EQ M9Z!/QRZA
M/QX&R$%!4L"VX4SZ@PHHO-E5%,CKJ!JG4B"K!#WN\WE%5W+Q6FD]F:=B8^P&
*M"L21A W=Z@@E)JS;)I<=BJE"!O:Q2/[ZF\"HRQ@@,! 1,,FYB0*Y-3+)Y13(*
*M3_9@*M8(-J@W8^FG'Y.Z4H+OI],=(>3Z0T\&%+3V U>:Z49>3(?S(5V"\-Y*
MJ$!PXM=?*I&\A ;!;H4N>A$-BZ!8G:+(N6[:)BJ?N(5<1
*MS+/@MA4.;^[)B5#]U^);0<>0NY-@ER>*X*2@CP3Q^+!8]NJ-:E/"6ZQ34":5 M;E%*
(V.WE]0^+20M/)I($A3'I+C-HTS&]DAW C@#DK[\Q["(=TRZ>$'^HDQNK
MD]LF_8.G3;Y@>+Y/F_1K0SLL&GE#(:Q<>EGGL4FT?0/3LSGBERTUNU:9-!'N
M=;N497?C2Z!-8L!W35Y$F_Q0XR0 T-+7TB;4/0#J 7;A
**SAZ;E9L=@>*W"]5FQ[G;^9B__\">)D_]%OK5JGN9'#SS9>E5-.@=+:/I/=FT*
*I@2E6*H&RDEX\#DY__+U]:LM>#ONU[,WWW^_/_0.#GN?!L/OPX.HP/T M=C*
TUJKU]S<27M]XC5?9(F$EBP.>7CY_L,K ;KR"8^M#<;=7([;UK9=#TZR.
MJ[W[X]VW#_^U7_[YN35_\WL#U$+W\-46_-96[SQQ)R=)O'7EXL3 M^^*LBU&PP?
*Y&BC:JHJ]*9*Q6E5O?>:DDQH)M^KK]JX.CAOW&.YK.#[RC_AO_MPX_MV!)_K?*
*[8A*G7_X=?WY]U'OSXC\S^\6/QA@D!I9YU1K]C12*5F;&Y85> M6^><[56";7WKY1 :-*
YO2?>]FQK_WVT?_^?[U]>-=Z[L?VQT?HJFJ-N[_.+@]86 M+
(W__/%W\\4K_TWGVQ^OA/?N8/Y&_#U 2P-C5B U!NVJH.M:8:S-'11B'HJ0 MW\?
BPOF7'3K7@Q"!ZY1H.(CQ9([+CLRKR3,_1BF>2+CZM_CW(Y4'I]CV7C< M3FS-18)?
#P6=(<+'7UC#.9T.HDX7N;!CZW"!$F'Q["+_TX]7G=8'.SF:CM^_M_GM\?OK7?
U_>7@1/;+-NZD"<>[=E\Y!%<,K6] (]5Q&W@?V=T< F2C#V;1>$/ $TB_+E5
M_*DK!B;V8N$\<]-H+NSHWO# 1[2\"B/Y%5[7-- PG?WYU?O0;K>/O/,?@_"T M
[E[T!KC,4]95:X22\Q,N/RX;G$$.PT,^%^;IP#\!)? $3+X+;GL/CAH]>E? MSCCY0?
X[^OC!>S$6 MYY^/ION3-XW1Z^]#<7[QZ+=>:_EXK])SW]UP^N;WWX\'W?G@VV?
Q<=QVFN_B MYLODH/R\._GPW^;AEQ][<6-^^JK5'DQ>'_[XS]?
\Y/WW[^\ZRU?.7^7Z^_O_CZ9^M5PSOO#%_^^_A+WSZ\@"L[MBU=&R?B-\]^/)^-
OZ73T^^'1^UZ_6&_QV#/@:XOV6 (#\3D?_,9'JJ'0"8W3E6"8;9F;/068&26Q-
0)!K!.HTQP_Q5%\HRBW(&Q@D_"22.0.R(^DEM_!3M'N94F\C2XJ^G;?O.A-*
>O\F$X:)ZV7]K=O M;_]^._SW07407/$'P34. 6NWZBWFM4HY17$8MQW?*
3HI=%9_-1.^A'AIMNK]
*MZG"+$B*F8IARX@49ICIU1#3#^J]4^%N=DKSDK]Q+9NXJT5&RZ?UW!9*>I]F^*
MP_CUWH.:MGR]8>L5JY6?U0HFC/4#:HL9PLS6Y,-AI&'$U>DLF1'/2A2:1Q^"S*
*M^/%Y-M@3WZ;ODS_/VIBGZM3:O5:M,=A4T^X#Y\KMU'"6C2O7=*INARN3WOY)*
M^[C_XN+HCY?->6?OQ8?QZS?C\G'EV^D?)^'W;^=QP_OKX]W'Z(W?_[[=QQI*
MW4&N; XZM>ZEC:_7-PS6$?!6?3%] $ 2>51-P5E'),Z-VPFE\3[OI\9ZZ_Y4
*M*876%DV)C.I)?.&6XH^?/BNSHO5YU/[]^W?1:,43]^C-]\^SKR12'G\:'*
MG[_T6LZ'WX>!,_PW]D&"/N_6NKU>K;.B,+IBG%N'"2K&N6NO7SD8)_[/ZX]O MG
]O]K[MG8J#3Y-A>W \QEY \N3[C3YX\Y;+,&Y?([K8
*MU;?!+K^UNVW[!&\^)GM7]CS6*4;]^OZ M0)YG.IJ.8+":C7][^XME?$9P+,$2V]0-*
B.7:T.5M^4YT]>45_7<2,4DX>]9J
*MUK$4:@I_RHUUFO5^=T.H6LAXM#/$_-.V)A$&Y?]Q>G*X?*
*NI%@,%V/],C*67\XZ+9ZG?:9W1DZ9YV.VSH;-OK# MLY'HM9KV?FO@MMW<6);C1$Q;*
*[^P "!A/\8A?>K&3QC&\R0[<@\#VY[$7GPW4 MA)9[G'RR0F*Y7CSS[?DS+_"]*
!@.9ULL"3QYU@37]2TT.=QIP6L)3_9,("BM

*M5IW;)HC@,KBBV&SVG\=6!E^J*E001FI]Y0','<_VD6Y=PC9=\U'$J9_0)2_?-O8?*
II$UTC!P% QBNC#*@!!J(%CQ)$Q] MEZ=?
*V3@(:RR2B8BL"R^9T//@*5281'//LH?'ZM0:]7 >C!:$"4#.GLU &N!B MA1^+"WB>L+S*
2B:PS#]3.P+Y[L\![,P2F1I:&39*:SVLG?PLW%U(@DMFW:" MWZMA-*
*#04RA(!SK1Y*1RJWK':S9J%*4BZ$CZTZ ->KI:\01*KP:[ED!W8/F[R M(A2N%=N?*
*>3Y\!.!&E>493+ID4<_G(D=C&DDX]3CY3S!-;8:SS\='=*GYO.G M-0N^?*
X>'9UNM'FVV4[>.856N7!X "P"?A!&FNF$AG&6%7VJ,D74$A?E=VP,:
M@1MPSM>>'X;?$*D&7I*)G< CST/_'"#JQ=]@SVG@B COU#NQXSB=SC)2#(G$
M1K8#BY+/<(@,'3N-A07?(Y 4P<+Z76\T@CMPM%K$DX[DT(0+I_:KJA9LRC*
*MRL/<@!R\Z I_6*H:1^-@GJ W"2 M=5RS2&PV#Y0$6*"Q\!)(A\3?2>0-TX3F-L4ID!'O70 :*
<<:.5Z2U?0.]=7. M(^C$19GD]!<@3I!EMN6_^J3*$2 EX-"A%\XF-*
*K"5(U*J**'QD3A&501CN$!3 M(E(.SGJ8$Y[=[*A(1)X7!.$YF28U*P85Z5O3T >9*
88,HP]HX<#&F%]@H8/ MHM&LY)@KQG16& W;@O<@13[P1]D.9-THD%?*
*\$(\S1PN/P]34 +S&$E("9?# M]Y^4<)'"'5YFUZW#-_*J2(*
7['/;\\E&Y(4AHTLQ')LO!UCYWA3%>HW%W AP M=>#_#?;Q%+O1I;R5-^@%'+S4[T]
+27$(""M+D(>LGB.(QOU#_3FL0C'L)") MYUAV$@$VYOIIKP_TTV!2M$&*-002P8*
*3LI;X=&8 T!*Y[\.YE#BC!^K6X MQ-&>S5M^*R[FUC!T 48L;<8ABF&6:TP "@![4[AL-*
$?,+CQR9F.ED@C,?J0LH-YG/A-9_^.I I!&8 MQ*#5YP&.$X,?234XJ-WA_ZUO8@[O'>,
*.G@Q4"H^AQ%B3Y')>*8=4E\X@1+,CV TWGJ M'ED1X0_*
23(G0V0Z]T,/%0(\"NRE<3A%1)P#%63L2DJ^]9&$@R]^R#7(X7D(M@ZE E>_%4ZE8 ?
*F@39$0Y7@_G#GJ)*R+6(LZS)1,C+8#5(%X5?(I)V*4H:1I MBZ;\K0(4\+IZ@%**<3HC?*
4(FPV0^P[>#E5#3]IM^98($\TX!!3.!@S//5=8 M O\-.H6W)H4A."..4$O)P$;*
[4X1"0)3H8'%-V1F$T!4K1*V#KJ?N5+>KT%8 M+Y,F.6;>^_3^X ,L*'7G-=-*
9PZ[0+MYE@Y]+YZP"GD'E@E9LY)UOP+@@31J MUFED!S&/;D2C
WDM)\8026#J7Z"P0O#;5@S(01\?]8"+1@UZ^PQD%.@NDQOA M)[9
*@NYW>L_78HB4%SCDG@N6AQ10!R_)#*5='OWY^>BMVF<2SO;0^\Q(RUC8*
*M"$GI0HAOS*R:4NF1SAB] ZGH-Q'*)-[B 5P.6QA[H5EG,NW338 1!B.@5UBI.)*
M@!0HZEV !=K6(%[0 D%1I2=XXE]H]P=CDL0 3,0ZX$Y\3^'=& "(/>B/A!98(&5$M#-
APD:4#XD7.A 0"2PXGSX8<ND[X)>]=
[!H("CR[,"'!WP%TI1\]^[3$=B@3ABAAC5<]!I'-9ADP0@+4(BB M3,V#
(;,%LN4^.7AY^&GOX.5;CE3@'X>OCP^?;I5V<.04X5X$4>@38KIMV"V1 M">$-
%N+N)2$:O$CT@H%C-0=[K=
[3C!/_7^8;7$Q"A@]H.C>XHX#@-29.@IL&8#/V5.^BTV6/0)TPF80Y),T,)FZ@!??
N_<]E.XW@?3 M%I520-7S_/)P""'!"U0/X-.B#L8\[!7V$I3T_H!P"OMT9Z''Y@W^32]P#I(D
M"M,QFR_@CT>L?O4%M3S%2U&EZ3>:6A?@SH.\&SK?J_89%+\QK.C#/S=7"
MXG&1S4&+R)!" ':R0^F?AQ-+3=, "5V42O>'V2CIYGCE9D> M3=&[XOM N?] ?
=!\|XQ18"6?Q:8AOA%LR#Y(LR#9#T E$=>LKAZ2YJPL?<# M:#A*
2Q3HE6"063VF^).WN1[%,4$&33R@7HI$H5&/6A9?ZHW@(QK)H8Q<>5&L MB8>
<.S1[M!$[0T@,[@ MK>'P*QE80@8Q !T+#D)=@(4SY.V1T+:9 DL)E*]$@@6
Y^U)44(CM"YA_$(M;7AD9A(O#?["V(6DN]46%7MG\%X7#2E!0B(AO,:2X,!'NT R6R:CS-
*Y$@K*> M]'OU[B]/=6,!>$PJ"[AF2*K=%(/X'M*J!R#?QY>9!AR9-1>HY>@>&*_1&-*
<&:]+ MB;4225$S1!BS$YQ@5,D!"RG@LR$ YC.9KT)!//%FX&I@R@9@^P2M>%?*
*6UBO M&@!(8_8D^G4D'^S ML?USX8*G5\&)HQ B^'L.?*
FTBXHSTWKXZU:0G0P[HI8R);"(VI]L_/K]]_Y3C
M/7$ZC#V*HJ".L!RPN;,#2*)T3)9!F"99^!!^4-3/R_""KVE$1K7VH8+0@H68 M 11MN.=
*($ %7*B\|LI_($2"SQ15H&2J/5X>3(K$'0B,@)X!2MH)2"J,THK@P M.N*@JD$ZJ(-*
BM/^CXQM9N!DCV(Z.%-+@)A ;3H)VJ JO#SV 0?1-1'LNF,3X M7D >\0<("2/_;=/:8DR
*CCQA))3Y=+0P3Z5R,=;0#T.7O 2I6(@4YQX^8F3A%@LH'+G M"Y%,\&7@Q_5I*Y!.$S"*
(QO/<6@%SH+-]SDF#S\1/,3;HV_'4SO:9GG; ?A\XF^-?IV\7E--^-W, ,?
2.@_S.3IJHEQ"Z>28KBFU9!,1 M-AN#7Q:O1(]0>@*L+R_9 :UX3ZY6[T-*
[L;8_#4%NM96[O'8M\EQ,C%'EG?@/ M4F6C!]HH1 M!JJ97CA?
3@4IG'%#K9]YO2J+S.YKYNXYX01DBJQ6R?MY1BXL\[(E):C744V& MZ?
#.)L!X#CG0,A,A Q$RE9U1@QT#I<3R:[SUPQ_R"51/$+KS (C"R:1O1EZF M::?
*%COD>.M$P18).28]^(VU@QE+ ,$A6@^I"*I>#EF4K>^ M"'D6)-*
*[)^@735+DLE0YO2ZJ7R ?Q@(5G>X+KRSK,UK*8=-1H-KK]4>NL[_:' M9YU>9W V:/?*
Z9VUGV'7[S;XC.J-"ZT+O+ @^>61CI6A680T F@0 N%:CT:>H M/TD)^ D-5M>
*;Z**"H&V\+ X57HBSL.$+06T0V1% EK&LE@)PV:J/!'^=H19 M%Z%*%GPL300*<%/*
D(/FC$NY*I8V-6N8@K!1%P-&!1%BRF2#U0YS"U$Z"GTO M1,GA41K,

8V)D7H@D>I1ZN?ZGI]AO 1F+NAPV,1EPDI5+A6(*1%5."57Z-
MDYL)B"Z%4!TGG::J7F&$M01X^^-FKU]OHP#UBW
M\Z\O4EVJ6(+9JG&K0QF!4HD0%6.,4MH5DJ%18\MQ4TQ$R#!GZ CA2HDRCLAD
MH3.#LU.XWZM4_C&ZOTG*%M0!%?$\X:(='Q]D=3F@(CWTW\) B??EQQ#B
MW@C;AX7D'_3&>%#@+JR2&>])Y<3W"'TZRQW"92\).EV%C-VLK MGLX%SGOH'>2?
CRETL,-T@7/N:,M$)E*H]O'T'3C=L:6\$S(GR[='=#4)XR&
M8>;00]GK&9S(T(S*NC7+D8 M+S>.D1>1X5&>S0MYFY(1E6-[Y4I8'V Q-;\5GJ$Y9CJ
]0?2DCJ F?W!E M?4Y<,\A2GP *Y,38URL 6;GB_2!F.N;
[42KD49H#N@1.K.N;\Y"6P$>8U=8 MJF8!9 MA386V1/0*-U S(_^JJ0(S3TR?
P_;!R9ZY25_CS&LXI"92I%*CL=1D%!)O2CMT<&>Z)*MS6AYM8.-)M5%8&JCT,
MPJ#7J74:'3YM-V;GV7@UQ7787069YZ:1*BZ\F7[GPEDJAM#,NW2.^>-&9F-<
MCU^,1&K^2>UV?6""-+>G[&3UK+@8UT?(R6UX"X[S-7B .S":#6XW6<4 ,S!O MR8->X
%3(@%#L%'Z*D4G]^W;PRRR:ERF50M"")VUE?+.)+/<2SZHE1RHE60D MB#
[X%1>KDDZNE*VA>[I45)^&B!B!ES@U^F!) MR9--N8[>9S&*]6II1*7)%)SW:!VR(0R?
^ I(ROJTU[:>O(('6>_!*&JWVWNM MWF!_OX5)C'.A53]LQV:R6[,WKOO&3DP^DB/3J5>
(^[KU\K86!@EY5?,48U\(M5N:L6V!X"^/\<;MC&!5D=&2]2=CC8U\@,:"UIQ745?
O=&;M;4ERGEE7E9C[W MI4YU+0<453!MGM9"=FBOUNTW<5BT@;,E0YC:"1:# N!
<MWFLI0RIA=/WEX1N]@#O? J(U8IU90A\XF';A\SX M<),7-SHL=J7BW\,4
(^UT/"8&!F$@< !3L'->Y(U9-YLH_4,$]GHLQ:LRS!< M2'UY(WSQK9[$H MIQV3]*[YB?
GK/!$&%CN.K2P>\!//'$F['/J+EB
MF1,TZ1LU00N9DN47./9,%=X:J8L<])&0,%!!,BVC8M7FZ%*G$;AF%.;G?*:W M,Y+F
,F3L]ED@#';PQ6*600DK6Y;SZ3(J!;:0:KUS M?+\,%QB14U<,DRQR$./%K&AD4J[&DP&
UV=A(E.RF.^UAZ'J,,S"XASO)A!@ M.S;H/%PO/ .6 01,((QT-
;8=13CE@F^56A92=2G'V12HD-!BRA%# :#&@'2Z"<"("(G"N MM;(=3"OP>S P0TM
R\CWN1T=%XX*!KT1%GPKEXZW\2I5WG3%XDPB8#HP5\.3
M)V11DYJLD96PCK!R$I>,&%1*)]?8M\!X*T;=[(A0>B'D_U." 1XB (6--($
M%:D%E9S(V1\7/)PB(RK,+T=L?X(%XWH.!]828#QF09O.P>#N72[5 MS Q)HE1 'M&+-
\IDYQ";'M4+N(N%.CH2J6;JUM$Y]O"0*G777*39!M6E\<08 M@(HD&$9Z2?
D;B:2Q:U<.$:+X)\T[&8)]B/JGDJ027,+!D#<,R8P=_C74%)
(]51S73=M/65ACE99I)_(FE2C^YGE#. M4LA4G;%&>
(4C2V)R11@1>A\$#Y0+J"\6WU.V0/N*HC5I<&&]9!AIDS1OP\ G
MQ"GIDB\T]TG6,JSV0/AW*@ 54EJ^M%2XI7<$8R%
M\%,SFRWW<$_G,5RG%EIVAZE#<$SP]ON"IN5LW=BWZ'SS1[#!U"QPJ=L+#E0
MIADH=-T-+'%Y35B+Q2L6+JT/'D0"0,Y]H)HMMH]0"847,2;>:"'*F[&FV/-' MA5H>]
[Z.L#\Q2ADRP[DE<*Q,8.NI&F30(3#Y45YPCD7IDO^0.M:11(V,(2E! MR9K33L[%!(-
N!%V!?$Z..N?40R>-%X:IY&N89#7IPH ?V?FXG7E*Q[*@&Y9Q M\N_CEWO-?5PE6@
OI,@I4T$JKBL7?%\A&1[]IH7E!'B):J&JF"G>9Q).KZ>M_#J MY8&*%P%SJ_2IP%I:TY%-
DTD826%XH.T\?YZEXW"<6C92QT7TR5EO;(?K5^L2
M/EUVCYE(4FEX+5@19%9.A#&'0N;;J4YVL<,)?P*F]K"H5UI"U/3");8@+ZC#
MTLAV:V1Y9.:&D4M^D8[C6"7/3:H(H0+)#W'+3V:1YJ++T&Z>NI0IQ,&^;B3F#.296#)#
=MUY'Z# MFZ#"BT8DT:;@;.;Q< Z)7Y83FB!CQS;7\$HUS#7='MA=KAK:E+U889S2?
[G(M'4=9'&/?:,$N5G.K,)A\^?K240Q!807R3J9VZ"^!(!A(VNK)5,9I@U/'D'Y@:Z@4*,HV=
[7 -40,L-2ET5S8'XM)6ST* M179F"?
JPKD@Z65'M%UUBYQ'(Y=,DDSV@*+A#T^S9>$T/9FPJYX6F\-HUV?\ M#/2;;O(*".47;=
:NO5.;H>T$)W2="'F)<8S=5,_()R1,D6YNRNY)9G%1D"O MA2?
3@)W14]UZ'X)1)3#"3TI&Y:5G]MR89QN&KB1Y'(/LJ+&D*@2;4BLUEB51 MZ3&#=QU*
(QV9I+%9LN$)6Q#ISUB]#1/7@IKJ!4VLL&-96L2TIU>"%P(UXR!Q MW,\QV(TZLX/\9!
+;Y_L!=#WZ]B/Q5V2Z/RIEU<1HVT9W)+,,9-B2G[D@F2GR+!]GR2YZA^//&,ZFO
%WGDG2(JP1 MB[MJMIV>Q2N?0QBAP".:/#4-GEA@K(R!(X/%B0U[.] V!<4"(_4L$&B
A/- M 0(:0B0:2VG!LE:K7:/R MH$8U;Y=HP_+M03P-)];_HF^N!O6>#$GDC&(3S0]
<.,RHD6I0Y-V^"1]=@Z M:T>@.M4S0X04BG9O(9A?4E.+(")U_HHT*TUU!%EU0\K*J+
ML>.U11I2UE+*\A(0JYHA:IB6L71ZEH_#G%?-O!GU?
ZM+5#!=Y99JW$$M%;0(*"MTO6(AF5JZD&VH1@760E9R
MXD4+>?,LF+Y037%52JSP&/G-O(;7S&\4]/%H"07Z)Z+3?@-FQ"2Y@[L_XN
M=QF6K51I,V>^0+'F*:51M(F]FO1_""?EDQ!4N0OMQ*'*2"W393%$?G]JS".(MN.M
@1(\RD;/%VO%2:SK7GPQSOP'#V/;M"KY16YA>)"-GA%O_]# 85=CP??@ M\(&J_/
&$!LQ<(:^UE$=HC]=#8]E*W2@#7A(_H*T?!Y2V M?
R*9[>F6%O.:2GYX,5N>I\M+\1@N3% Z([/00LYMY>@;!%.>16J M94UQIXX5X

MFMN>JG#J&'3+6"Z.QK8:NQ]D9*A]/C%94?;$G^_!U#=.OH3QB
M*TJ\=!JKLY1T#)7@DB\9R,N*58Q,((TSH$;\O37S4[C?^\&R*%\V!N_3;0 [MG-
_J5OFM*K]5Y;?N,L*41+[4!QP?!L]B3),:U@M@'8JJR98[KI7ZX4W3J5%G
M*&S,N"A!;#3QQT5G%$#*EP"@EY/BV-Y6 R.G)6J;>S*]9WAH]T2!O$AH(B'9A
MO$(]@Y0)'*HQ6QPI<.V&>SPCD,X;RPIAI":5.D"5C=*BN'U1PIGJJEV=-\,C M9N2AB?
U<:S==QX.W3I;'B1CC"^40G.'\QF-+,OV?N21J(Y.)I$'3['BIBEE
M"V\8F"^0!=O&;)/[)XO#Q=.4LN^7A@AA+F
MUE8LI=VH=V^YE.8>C0"]YE*6!NWQ>MP5:VKMWVY-3;FFM_R6(%*HK],B-
=K4^ZZ.A[!S2$Y2SAE,_ MBIX63X?
F)H4YEYOITF8]QKHFYREOVSH+_O%2:06)E_89$@DKOJ>9J/A^;(L41@>\BF] M9GT 3J
1'I+ODZ$BTPDQGH\6YPBH1$%-_;UW$=FS9^SE7@"2H&' M[GZ%B#(@
IR>BB7*@(E6O=NK$%$"1(!L&E2(* ,B&A5+E 03E=E4$CPT*H8H M
R)Z]7[%$04BXM[,(?Z_G8]N,&N-RF#2[UC)_3QRW\]ZCZZK77OHTVS'SCUT',M516P0?
@,+BMLD"\9YEYBQE8QZG?M*.4_?QW^[!2S&?WX M +=\E2;:
<$5/H4"HM,#6>7JPN&&62,O_7BW?6[>5[\U6O=G;:?F.J:6"!/=5 MH:#
[V.L]XKVSZWAO[XC"WA9S]^N#W<;QX033\7DLWTY9F2TACB-$OD%U_IK
MN=O_65&$N^VMK2#=NR2GMKV=G*5Q/[8%YX*VL'&#-RD#OUY*%:9=MXW>(JEU
ML/WM;(=:MX/'>Z76AR9:&R7@O?LG5O;2=X16R^Z&ZY*TWNRR23L[8)"7@32O
M*L79P"8?%V>L;)%_K':ND2V'.7/9LTA0@@>NL9K-6GN_51SR-AXI* F%7EJ0 M46(*O0?
D%$^AO=[^[@0LRT&@]YYV*() [SUUL,("N19-/FGU^T\+RA9LU?9< ML%S6#[MX*
([#MLR9%?O>8OAQDP[5VIC-MO=;L%YJUQK]9M&&TT_)'JNC1=LF
ME\VQQVH\;WN_&V"/7L%6V_('6O"4]NFELUPQ]JHU+:W6X3-V"W*8MR">4AM
ME(]^.PWIU#:=LA/F)+O*+;NF*?@@65?9?>5EU%L%'SJU3J]=A<=N8](]6#+?
M;EG8ALB\W^E6,;9;F&8/DLJE'59>(K]^H&[0>A"!.GCF6QS+3I-YPOS(D\JS
MVMF:JGL(N^T"E[*9MKYN.F)A1>8J4O,0(S6W M(>]^K3?H5"&;*F13]I#-
M<.0[5I[O[G#M4>]I; -'651^3%5P*:4&J35+K#N MM8KO["-
[EY37;M9M(WSX$FT"@=MWE3I#QY$L%KNYB[3U(SGV8[7*=
M6K=5!;^J;KF'W2W7K^WO%SW:X,$3>=4L5WZ+JUWK]!L/(@('SWPO$CHJOG*F M-
AQM:P.MNV&*9V5OA9$+'-Y9QKT6P=C[M?WVBH%U5;AM,^&VA\(1UPFE["A'
M]&K]SGX5;[NG>-M#8(AKQMIVE!_:M>9@7?+UU\2&[92&8HM9!O^)#WKF)0 |
M9S&,AR$\Z17F!KJ_S :ZZR-K"EP7(=,+8/?)LS7!Q5:CWNQR?'$BK%'H^^$% M3N,B-
%EQ.H5[X'FQ%::1%:T91J]G=UE/O,!*)F$:PQ6Q;(3\\6('W9-:I% X<=*5G4
9/8L%L_4!W/AF+.71^1.[1]P;9# ^G.OM],D M5%\0Q_$WDKFS):HO^!K\AD7) #;=I,-
PDT@MS3B5]]%U/:UNJ]YN5:?^ZL?R MA=>GC>*.7V[5F^T*$25 1+.^?
VFY:X6(^T)$N]ZJ9%,9, &(J/!0 CR :+JT MRKE"Q#V*I@H1)4!$9365!!'-
>KM"1!D0,:AW+JUXJ!!Q,T3<,'5Y14-]?[L>
MW&Q7"A<#MYNU[=;JW#7P\%/)Y$0UCOX81);1X$K
M7.N3F"5B.A015SVT&S55_C"L:*BP7,CE2O2G ,)5"FR7@% IC^TS_C5DH3G<
M;.V@,ZT66K=5"\UNO=7<:;W0:K0Z!0G*SSHAX7VYG;KWM7]'QY\+Y?
M[V^W^>"N:#^MR065;E%Z"D7M%47K94'H;0N_6
MVKT"";T2ZOE8Q$,@=0XH[#ZIMVJ]9F,70PP?1!2'02#\7? ?-MG+>$5ET0/5
MF5>5\924V;K[!9J-ONEHQV:I]AY&ZY61:G>0:%O-0@=K[I*LO>=42BFH]MYS
M)X5,DNP/"K)JMFVMOK.#=&0[21K!>W;9&]FD_5,N0WR;)E&Y('$K[[M9X)'/ MVXI(;-
)L*A>*MVA)E0L0MW2_]_8RJQ!10KAA6B0%U&U;97\[$5'KEB@!7B4F@7
&P'0+46DNR<_?CQ;;>Y/4P
MVKK*L$EI:VY[>N/&RN"WO;&B(Q;-6KO(D,7]Q]FV5O&^;4K85/W[MO=5/(7W
M>H4G*1\\B9-EMVU2V%3=^[;W54A>LK]B]GP9)PN;XV.,J3B.+^P($3:1K]#X
MP%=M8BS.VGZ25L>8G:^! ,5K-1;W=_L8S/"(XE6.)(70-BN9&Y
M\K;\U%SUY163BR1BDG#VK-6LXPS?*?PI-]9IUOO=#:'*$/DD]@V9;UN32(S^ M]>@?
IR>'*TP#&;+42M-F7>9PL@9I_!-GE/,$KK/_#LS9.WC-\9! M7],X\4;SW#1J-79Z
7OK9GZOG)M](2)A/6XVZQT+UNC#EJQ1&%G)1, _.(%G
M&M($'G'I!!XT[3D!=92\8Y!7,3F3-GJ$:[U88)/:EE) MY,%=M@-R
(0",I673"R2HORO.WY.2YMG% >[BI0TP#^T+3-
FP\HC3VKY<'3F0I]9+K_K^SYEZ+0(126%WX$X!#S$(3_21-W;2U%U<9'.Y=GZY"TYR
MVR#X8GSDNS]1NL@.C4E#-AQ?9SO@-P=A8L4 -6\$; *6(-B27@@< A),?]YO
MZ9PR+BX\#@!2PGHB2>;IEA;S.D+@\&)*1;6T+H^!A/A\W#$"(\509[^H (Y!
MG>:RO1C>%RF[BPRMQ SWP/4"0.2A\1$);SI,HY@L$;;,#(,M;TS%^((TPFVX M;*CAYL
[RFV/EE<"$J_!.Y(RD18OSI.+"T3"]-4P[/A"Z"M<>L]B?*^8J"&0 MT?*K<$MN!%(Q,,R

X5R:_AYF*T2<6& $!/ V6 N\7#V11P#*L%Z B07K$F]Q1<"*17Z/B"J ME9M:5*,HLSRB-
JE$K1W.R?6KG%R5DZMR3%'BE HO?>":YYYP28-&/D\&-O[K4
UK5B7X&CV[Q_+)^A8=2X*%;G2-7"D2 M>*[.02X#)EKU3B6;RH
(D$W5J:^E0$0EF\J"B&M6IKV5 1*_>KSBB M0$3(4(+O6.[W[4;JM;WU]JY-
NI4]:N'W8LZ B^72:8S6C' M![CEJ_30 SY%M](!&Y%Q*\;J;/[H5-C84F_N3DGW D_,O2H.]
(".3D6\[[96 M+_#(W(?*W/WZH+/3."[@?
%S65=L>DG7"6>%@K(N$GQ5%M]O>6H'SO[HE&&>V MA>D8'&LMW4#
[M8+I+LIUV^@MDEI+,*BRHM8-4>M#$ZV-[1R9L65B91]]1VBU
MY$ZX+BOKS2Z;O;$#YG@9*/.J*IR23KRZ,B]_M3KBR' 1Z[SF'(@CTWO,&1=!GO[;?
6B;/W0O%+!@QZ[NC M'XH+L2W+IH33R3?D6JWUA[>]WZ)/+JCU6\VB;:B?
DCW*>=!%Q1YW9(_]=H%S MH7]:Y;$F4+5M:MD,=ZR-3VU[NX6,E&
[>_2B/K06YY)BATS !\S#4V3MACOBI
M7+1KVH(/DG>59BLOI]Y&C77:M5:G787*;F/3562^,V3>[M:Z[6X5;[N%;?8@
MJ5P:8@^+R/NU?F/YN,'="]K!,]^&<6R-HG!JS->HO*S=KK2ZAQC#+KA);'$M
M>TI59&TG*[(JJB:J9@.K0*K^:45U&2]W-A_PV@6:)GM]YT):S_,S3ZTG,H;U MM+ *]
?/@O=>JE6T$BECN6,54BI9]55%=#^]H+OW@JJ"#8L261$;;[\N51V5 M,?
B^LO6KL$QY'=A;G?G=JW6;!1;G5@&:BKY+1=^#6J/P9-BVT5R%:G[F4$T3
M)/;^SH5J%JRJU6$;.N&E\FBJT$TI=,FJ$U@I]4 G/*AQ4'MFY MWUGN4=[YT-#BN6*5?
U&%A\KK/E];G;0:5<5.%1!Z2!2]JENG$M%5"&A7Z;FU MZ^$?JGD.
XL.>PZK=BJG9\VHE=1=KDH&\RN7J=?U:/=.33W M$ A[5;1M1^EZ4.L,UN5=?
TULV$Y1JY4@T*8FQL5,@W1$_[MD#_P_/S,2V#; MSG7/D2UF_9>N58?
ZE"OGK5_UPDD\+[.3>/11@__\U;O?I>,_+1#770Y63H0U M"GT_O,
)JD0%5IQ.X1YX9&R%:61%:PX3TO-6K2=>8"63,(WABEB.KMC.=G)4 MQ%?
N^6*4$)%=DX8D$/@9DO,=)$]B\4S]<%<*%8$3/AHS*G] ZX-$@#/<_/U
M=IJ$Z@MB8/Y&,8I>HOJ"K\%O6 P-8(>_X/Z22*U,OK')^[Z>Z]-MUYN7ZB+7
M.U_Q_!">.0(246!3?Y-L>3:,A/UM[P(_]7P6QAX6/#R+A$\G-2P\4PH$>K&Z
MU!Z"&YHF0EL2C5\V%Z6O-[JK8S#&?=>GE%]A:_K?=S1^FY?VPE1XV0Y>FO7]
M2_L_*KQL"2\M.AF]0LSF$'/W$Z[;]<:E_4<5CK:/(Q!PS0I'E8#["1%S=^:I
MK+;RXZA9;UO#!)L#0B#&P!AH^YXX4%=1V G[CW! M1#-L_];6?:O>:6ZU"'5P<_@-
<^^\8$$R#'T7$_1>(*QW\/TDMHX"5[C6)S%+ MQ'0H(B[,:#=JJD)CN
::&S,C'@BU;4R%_^SPN4I]{C!*M55.F%R<\EK3OM= M._FW #'1J?>VVQY2L%)J-
5J=#:B;J\)RI:>0]ETHI// **2]BP;)IBFD_\&>FP5$MZ"H+J]O
MJABCS(S1JPWZ*\\^V8$8U[;_LX-T M9#M)&L%K=SEL=X^F78;= XWU
M:]U6_X$%"+=D3):,'DHF3$H9)+P<1I<,S:N MX<\7%^D/JG!A%2ZLV&*Q
J*VWVQ4X<(J7+C+X<);VFZM6K/5*\IV*YESPVS5\'* M
H*59::6DHFJM<',W87A^F#GJAF_NQ3JY(,H^;0A/:/S?^WI]/G**9T/(OZY MM=:7;0\
OJ_N@&WO0,)MY4%6AL8G4]+]P(@S^29&FN^@$%S]OPM"+QP$']-
MX\0;S>^R]!5CWA=&YZ^<.W\A(F$]EIMKM^O=JQ]JP79].J,]C*QD(JP)S]-
M0YK\)"Z=_(3C.&K)-.9'<%E26@];G7KO;L]L5VW< 2_%SB1L&.!)\6K#?7K M^S?
8SX4=6]/(X #/BTW%;C Q)SN_^R60^[O)GARAT#(KY)P1@Q/B]CS[7F8
M)L]&W@_AKJ(K8P(?+U0)B[R?)B_#^0F/?C5_N-,F%@0@+0^6?XG4'RQ)M?_]
MQWZOO_]\T0A9$'TFJN^T9/X3'P0KBZ:VS]_(N1#RJT>_P=MR5-=LU#N:FKS
M6BJ@,XF';.HE$PM/18C@R\Q5#:.Q M'7A_VSAO,Z N;Y/#: MDTPR8JW1;^)
["FIT;TATC1(?] W1J=(]%;E6Y+J>7(&V'HW)S0:5D!0$ MX.2F'],_C>L='JZ#7NQD@>3:"
(Y-C'I>.]2CU5$.N7:)6H/%^U_M9+\P>J;<:6-7Q[+7?;WZ^V,2]2BVN2D->KM
M[B^6\3F#:P[V/_8,B.6.LI*WY4^S4E]>,8W;P&D+1"?* OA3;JS3K/>[&T+5
M@J_:SA#S3]N:1&+TKT?_.#TY7#GB\TH>.B4A"NQS&-+I8+&F;_LW ^N7TBJ! M=@_:
A(!FWV91XG2Z#F'X%5G2=XA?5_5HON?+J A 5L9H)*XW*6K'U\L6BY
MU6&"EY[)]UH$(I)Z\< %ZO)BT+.X@4V=RK=J#]>,H%RU57,S=GXS"W&2_7J_MV.C'?
GV_D.!'3KLTZBU3NXROLST[MMP(O@JLX5R:4:")1B*.X2EHYHCHW'-(MJ6P4I7^$:.
[22U;R50U6?8U;=X>B67PP:=2L0"1, MUHWZH%"J7K#J\3TLMIO%!L*!>$-
C1]83H1&G]B9E?N98@/3WT,86<6*!\13 M&V$YL (Q!Q\Z^@;WC0!^&.1!I>C[%@?
-8;USN#[3*(97CAMYBVOP ^L#/,/Z MD(*G@BL\&$="4/@H"#&L.1-T#RP<<(,8!VZ
M11*6Z:K0P.CUX'_K?4\]UTOF9(H=VC.D)>NCB$/@!UE=5N"BIE,(I4.UJPCA!M;HRB<
MLA$06_:%'>&M(/60^-X?'W#P.G\Q_A3;/H,W^* 86JT!" 2Z=>'(?1',D.
MH]_Y7\5(D(40)Z'SK69].GAU5._8+$R'BXBQXOQ5DXT[N&7%#Z'%\+M(+?@ M-
UX!;C6B11R!EYV_.&D;GT"Z2OH3_Q K\W %PE' M@!9PI65$,#'!IV$ X+'HF')AV6.0W&/
@F5/0?B0 K-G (L?<%+%K5X^(8$**H^%' ;DIF,!]I=,.IA@)TS0.R^'MX1CS7QF

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|_WXH> UC$7CHSIWTL3E\P0VX+M*H)638-YR(R\-OT1L&6BMHK M:K\&MN M)ANFN?F)FWO0H,'Q&]XPY8BY"LFMU21TA0YKR%Z]|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

MD'^KUABT'H"/=23[[T:6^.%,L$7(HG)Y_DQ=.&N/,:P,^]=Z#8X-E\^]!.'[O!3;:T8&
(XM)#M2NW;]-N M7YYGVL S> :Q+THA'S:;7]OZUC<0+.K7]IO-
AYY_*X_3N'42VEK>;NL[WP#S M#&K=_14)@]P(I4TW\RTN=D7SWC4I?
*G.#G*Z:T/1/+U].B)]55^BCWTYTFE"5LIE53^Z033*
**M(I5Y&*2ZM(L7;.NK!CZS&NQ()]^S29 M09WP'<1>C VFL\C#IE2?*
AK#:^OAH_.MQJV?>&8Y&L4B,&X9S6A./PLA&WNP- M[5CPF<,BB/5X]\?M>DL]C&PS?
ID,8=#KZAU]01X0<2SDO"K?XY$1/'$(9(] MXQKW$$2R':@3.P-UG#8]A,>:\(H9%*
()#!,6"W?8#AUQ#(^VY]322OMSG"@5 M;G8\-P.A9SPE9[320%+/S1_G+<=(\6;P 9
ML,#'->I]];@B9S+M L-
*8P"L65A,RFX!FZMV.39I]\\Z[LTG[/#K*3WOV>&0CCR79(W7#@T7QEW=Y54R1%2BJ22*
;]G0H1 M)4#$?KU;<409$%&)II(@HK:2H*(WD\[,'@SB+AA@?Z5:8C[VS4._EI*\]U+*
*M>>U54GFW8'#W&7 #&@RX07A<->,-7W+94+>W(HXY"8I%&87-_*NH()\%Z&YW*
*M,N955-"4)!#*Q'A%!QNB@\%^J>F@G:>#;D4'&Z K/>*K= >!=&(E,+%344*
*MWX9TN=/T,\#@*G]E\Y/8-PB5RGDHH6 8+('@,AFX?CCH<#-N0HE'15_3@/Q+ MV-&N:*
(G2$@-["SM,#$@%<44&A3@+%1G\Y&0@?84=IH-Y10?%:(7.3I/!:9C8
*M_IW.CY!&\E9G6#PWV]Y]:FLT^DR>%4;BV]]D-B9SK)EOM.UA4#FX%#&*HU_6*
MG5XY]NJ&@Q];O:=PY^2+5;O>]O$4CA;<$%R"7=:-%L,VA5;5&QQLV+8$NZT*
M8+9H=BNV&)&8J>4Q%(X6W A9@EW6C!;;&!^[L_*&C^/QKC6G,R=9XU>[\YC*
MY;>1=Z- 2'&1@H?/MKWM#X3>5 S@83'D!AS^AT_=VTW\;M25?V#47;S?7E'W
M;E)WMP3',93?_7[PU-W?;D9NHX[UPZ+N#7G1#Y[""ZC\WHFCE@IRAHN==W]G
MBKS7 :8&2/&?YAJ8KIASBA-]K1,G"7%>-4X=K5D7P]:!YHTJX:7QVE$(S\!*
M%5,OG9IC1,(!XY.X1[KPDLFEFWY@H9[7DS@(<,Y/I O%VYN'CC-#P62MGEV*
*M,SXWMNP$'C"H]IJ_P(L#G&_IT6+BA$ZAJUL?[#F^BP9=KINR&PD:*4TS5_TY*
M3RXU-PGW !C&$V-6-\[&K%L'^?F9:H)WAP;RPE-Q)&L06K!86#3N/DR3.+$# M9!L%
(SH FF_JA'=2M/([=P

V ^?WX7D&40WH@W0, M](O?
=>O6NG94H\O6\84=H82;2.+6!W<@76^BS79MS4^K8PPP9:YJMQ;7_C^Y M%F'-9SA[-
*(R>*5EK[$JV)K=([([%'G<@VR-X\3/;O[#GL8J@[-*
*>U!OP9GQ$<2[#$N:8&Q')S2^5M^=&EZLLK.J$E8I)P]JS5K.,@U2G*3?6 M*
;.QNR%4+8B[MB'N;&L2B=&_'OWC].1P9>D_?@8U&4UM/U?^+[]Z]-LI39 %
*MHL>IP'RDEZ16VZ382VF50+L'8,Q6*T&;?9G'R1*H^4=0]LX3O,+Z/YR="W<^ M74#"*
C8S+:YQ.4O6/KY8M"R."+^5 H/E?!'6Q#Y?%I)AOB"-!VR'HY'G\&A] MWP8NL9,P
DED.VJ\/@^:ML>1$"S/0(Z!C$L#+9O>V7.KW21!O\\SM.TI'P, MI.0+)^&9ZRAV>;PPO
>6)\]N0%+!GT9IDH(\!!;PIB"_N69NIH1H-NXZ"(,] M!X6T3_BZPP9'V]R:OL-4'+530
*EU";O62LVF 8_SQ'FSK=K^H&'%WU/4 M'R,A"(02CV3P(;0_>$D2#]-H/*E9'T00Q'/_W*
X\FQ'$#YJ -K8M>-\4G]#I MJB'K=#!?.(6WHBH,,_TK%RJ1S&H/3\D
1,,",QSQX[VU8_PEY8#R9ZJ0]"W MP@LP^9&A'[4D3IQ8?*
3DI4GB!'O0.A@C@#3G6]OUY#;>P"M;3T/5&'FV1)!9. M!A<_O-@HVC3H7ML./L
*'M))+_&//9E'XPYN"S@<-WJ[U&[U%U "A2KS8B6%\ MA Z?*0)X!?*
*(!4\38$&T1_P7V'%WDX@G"9!_\GL)B]G_NN5R3]%W< M0*9C@/!_3_TY5T*
S.IK7)_U!KW,EZ:>1 Z0M:K31O\+HVWJB'^RO)?J7PF%#
M;)_7>&>J5^<9C+P(*)&OQJ)W>C7<%J?#KWAR-.U>FI1\) H9D4.17 @16,WZ
*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*M""!7/W47M3V=&?D$?GP.2EN';Q]07'35N/YC2%+]S6?Y];RP8;7'Q_7K.-$3*V^*
*MXJE+EC?R?+A5Z^=/1X?X^SL^,*7'$8@MT=I'@8,*
*MB*O8B;R9.NXLX@W8V09FN0W40)()ZWV8R#D0+:4/@%P$24MYW@I%3>E@'!F: M*
63&"7S!M)F7'; -_P0=#\0&E,8HWQ("CZ8"?QI;KZ/P K5". 5O=FY]@J6G MI4+?
%Y;0H+2%6O.8U^SPFFMXO(TK /R9B/X]G3%)_RA;GW6MH_ZKK;FY2@
0!S!ZWWP%FTWG!$M!0"> M$/7EN8@48UT^:3XD\ C"E0Q#"\!&T]V_@6I[;?JI-^MQ!
*M;1/ATV%P&(M")O$]8E7Q T]ZP^Q!O]'(CLF4Y*6AH-T, QS@M86!JZ#RG74?*
M_DA"#$$H&P_S?@Z7,2)%)-3M-39=<.3.@W,4. L#"@)BOSCBF&BO$5D(3>E MH^;*
*(I0&V18B!_[U'&&)&?DXRX$GG:HP*SNA0.%[^.,+45A /T6Q'RSCMMLG-EM MIW?*
*FBGY_U!6MKFOW'C$@^ [T,MM_8EC+2^BY(./@3U_^]1*DFA_&:21OVI # MLD)N75-*

&N5X_YOZF1?XH%7VACXH/-Q"-2EHR49=.W>;,4XACOM:2UMRND._MY-.WZSS?*
@6C2!#WI%P/XEH8^K.1@B-;F.];-'[WX6YG4!AFRTE")8>]@F(-
*MA'XKZD'E@!FF"AFL%(7VENV65FN_WFP\&3T%ZZRFK"*T@",\FCQBVTC%[^A(*
MV8!"D&1TZVOH7'-X.L<=:SD$?SBK%,_HW-;0S_.\<.9{8RZ@WW1.&L,F^VS*
M3J/=@]]:]ID]'+4{0^$Z;F>PQ$$=]2S X<\\=9%G&V69^[,(*5AB(I)$ J2 MQ
P9+._OH%D3D)=-:CE"]E6@:,5:VU.QB6H+9K#96LK.W"F,@'6+GGJN#] MX<03(_*
CP&PF 75"N2=.X: YR[^_TEZL^IT3\@PPP9D^[5^2+Z!\=H'GC_/C M._
*T,5GNQF$'1/",PUAZ\DJ)ZAM[S6[3\13NIB_ZKKR*_E:TS%Z:O@KF)64 M'Z4O[V :UA*
*N2V$ZZX4=X%5K!E M40',VP9T \GRE2*875CY;%Y#JO-*
/K!]B':)!=Q;C%7$ZG'K)&K<5U07XP.DT
*MY5/&5=HR#3Q''3N.^P$.LCGN7Y.Q52ZW*P@#-B^2BMA2(^1&UMX M?*
#LG\>6OGXX.J8J[_QQ6 <3.:$3<8 AG(P6F=Q>E[S2V]-JS1,"G(!P%[+
*M52J%R'#R41D:99.PV;:0; 'Q,ZSY0=\$B4;$F"#TX@F%"@!)&,M*9&&H[0+=*
M8##4[N7;,F;S\<*M:5%DH#COJM-JUB)PQ&+0RD)X:_5[&;&N.-TADG;F$(Z*
M@9%PFME85^[-",=.N9"%8R^22GV#2C$3YOL+VXQIGWD]K6%J;DOM8'$#
*MYB,IW\.0]0),*3N\)0(QHBU;<@T36U0 8%C1*D%(GND0"PMYNUC2 SX[04EJ*
M4LJ&YE:=UYD@?63UMK+$9A&.2-9!E[\3>=IY9XQL3L$+V"*4-06WS"#KR%Z*
MT=;QY';"$.H*[!,E$$YG?D>02LSS53U$6;1,ZK&%^-V,<^%W3K%.P9W;\G<*
MR:12ITHJ54FE!Y=4:KC]=M\9=,^:^R/WK.-T&F>VW6J===WAR.FT^Z-!0^1"
*MXEC#>'Q\=H+%L\=98*C0>/@R7]H0.+G,]/IP\/'4.CXF@^JRZ{AC'ORTD],W*
M1Q^MX_>O3CZ^.S@]/GFQ;3$)PQ[X@?U^@^!@&)'S;PT[F.!9LO9][H9_%3XS2(-
^^@,4$"()SE3$!HX8[PWHICMQB#5<3E7,CXO_V,"+$_)HU4JI M[8%[#O#F(%PRAP-*
-3=ECD&B5-:JA+JN\<%F2'DU879,V:_(M'"32-,K![,P; MTH9J+N?:M'O#]F @0-
XU!F>=D0TJI#=JGC7L86,T=)NM7L=>%G\'F.=^!5P' M3E3I1-_!#60?
[L.2&RD33_\5IE8\(>)P@(]&;4V8)1:17W1;\%^6%RY+(X? MKFN:R&+*
(CLT5]"K^*0&F_C;!45>A3K(6N'8/H]@ZM#H4?GBA)BAD[EJ0Q7P6 M0U2Y-5_:Y\%-
;>R;7;$YI1Y(:)'?37=AJ[,5TBA9'9?RHN00[#C@ M]!UV[=*W;W$K/K4+?
M,MW]:!ZAFO4T/3]:0@YXEQR=30/<,#IN-=+4C2K!P*
M=GI1&"YS%48\@5KNW_!K,2"#^[8!ESB4_%%0AOYJ):R-RZ"FSTO'KHA_0 * M:W)'$.*
(ZP;KZD^;:F[/.YN;-L)!,V&F9R:$\R"6/$6) F1OO<]KCI M&.0I6#
[<96$8"OI"Z>Z$0\)4[HU&[B]\![,"E,O.W:7S!+U%#9&..X.OIAL*
*MQEB!*X_MF6R9V"D"CX[9!IOSTU7Z+G\I+-/@-3DYA2\=*>\N#=22UF^")UI0 M0#U7?*
*T0==S5.3A 8\%.@DM\F>6)H[[0Y:+9T1LE@'R5"<\YZEDRI:0-0))Y**
M#-3T@RZWOS(_<,&UTGB]Q+X3[E:#!&4;;W='V_*8:&YD>[[JK_/GW$,W)M&W
*M(L6BY!Z*CGBAP5&FR-[;L6M_MU[IX1 0SR7<1.+\@TFZ0*[P%)GTD[U(SLHN M+'I*
CD(='ELA-%]R(U>LR7 5\>G@1"#&JM71 S^&,V$E&$E8-@J[EG&=:Y<# MF9=Y,W0_-
*R!#;ZAJ8Z+3B"5XT\BF^)7KCT'K7L2&+,5L2-;VZA8 M3,*YNC#''J\%M8D-F\&->8 MVY;*
1&-,EIHF 9<4N&"04.E!/0B>+3^XK[J1?D"CSQ=(U5R,VJHUKG;Z3:> MV-A)43?*
O6H;2A&=3>M.I<#TRJ'04D("A7KY$BD!D]LP*2]M%:(1#,@4"Y2? MA8SB^12$L!ZE\?*
KT/[I=)&%G#_T>C@D[6#F;B6'YK+=RB;SO0;/QQ'GZI/WT MR<'3S!LD#(Q105O-:
6G0.0U1=VL_BX1E-'L_4K3$WK50!2T &%2)M/_+3*
MACP\9O&!.YSC[E8Y[BK'_7!RW/=CBJ$R^G1)7%)+1(T6'=1'801*TC6FDIH*
*MP#.:5^HFUGBR+(V+JRXB+!^F6)P<;T$26983'>JRJ%CY/*XA\RI?XR:K96]"*
MCBB[GO[,N\EY6/@1;H)-H92], [#"LM:C-E7:W27!0E_8Y]IB-.H9+]/MN*
*M,/TR@PNS\8PTT62DIORMMP/P6L/$.)1>B/)WV%"4MDTL0VIDM*YVHPQ+59MD*
*MBZ,I. P$9C6-I"!VR:HM.68#[$*QGF7O#!]ZV7J5AX=S+?1 J#PC&VNDL!;6*
MB@8NNV/2F0+P>(E<_C5-1>ZN8.N),W%&:&4F V&ARC#+0(:VYSB<+PLDR9W
,%=$PX?PUA@6!+#Z_^U=ZW.;2!+_?G\%I:N]2O8L MPDM/)ZER+&?CC>/8EG.]=U^H
0:+!($,+;^^YN>&230TP_) C)5NXY>0+]F MIOLW/=V?*
*9DC9VCWNK.WSDB\K(_%T9ERJGES29&9:I,!O[C%(= +T.P[U(4([,'PH$,"*0* ME4?*
*SE#6,9U%@5=?TEN&8'9W\,9#1-I'==DQ'P8[3-MJ*UEG,HM#,;P$Q6D !*
MB"CZL,T5NB<4+=_7 76:#Z](G\BRX%$6:!U%!GDWY^-K$R119YHMLUTB_ER MV-
K:LQZ;<@QY;<0I-WD>ISSMYU#' TH:KSHO-,[R$:?
*<[0<+*O.N@#2&9KQRLJ>P685EMQFHCV0UE24TELX==!'MZWT9AT,>!%T8SGO>Z\.J*
*M)B3@0F)LY'2W4[T]0DF*I^$TG8YKNHZNF$1?EMENJRU31PVW8V 5$>=\L6R/*
M^<4+/<@M]#$*7.3'N"8%:$B8P[;3A75-5:R&>A1%1U#O&#L? M?713H[H]1U%D?E
&MGNK?/FH(-NX/[]Z^T>@C8Z($;U]DZ-X3PR0&68S#Y]O M;K\WOK0F_SD9QD?
FI35H_7?TY:[V/BP&#UD&KJ-AD,S3__%V-+DU>NCGR5_] MSN?.Q6T<_:'2?GIU?

UM[C>1;V MZ47]HL=;FV+K3VS]56?K+T757%W5R7]F2\.J:;2<#G'M&Z[9-%IVTS%:[::[
*M>#2S:9[<#\A(3_;K+38?X9*D!%-ULBS/=.2R)K\TH7(4XV[Z(DL=&#HWKDB-*
*]0]>@ZKKT*YL\|1*#3X; 8[LM&J-(.5UV!3;AB59K#R&B3.<*M1 M:0XKK*VK)5U$+Y)*
(O#"M^)Q[QB#>,!V$P]JHIM(6S32%V$N"XG>U5NTA;.@Z'?
*\4$XW3^4&B<9I9T00"2M?O9*46[_<"9!ZL^:]0MDKX9MRZQJ2RH1R5R(|)5RPQI-*
C|)ODO@XY:4I'5^[QO:XZJCQ(ALL29A|)T<;TFF.0OYL> MJJ6'0[P
**@+Z2SJ:S)\/X%V[C%T]'AK'T46"G!<_WKOXTEZ%TU1-*
'DA>@7&2$L;BK<3/4<2+:>=0$$?_G(MJ&L+&V36GT7NPQ#84,.:>$=A1+*
(>%.BIY#QMGQ@(>,7 M\&Y+0&F113KOMY;922V>SZUKLOI[Q2,?
1F#>ZL5%#^R/B;:EOZ)O?E8WGJ M>:IZ0Z'N*3_%GOMY^J..TA0(L$" BZX)@0 711,"*
2Z)@0"+!#@BB# FJP] MT9,NIKG\@A"P5C (N'P^"EB"#N:>!#&=N_/UR=2:IGMZ*
*MCQE9Z?/D7\H\!.19$$T(R+,HFA"09U$T(2!/ 7E6_($S[-__*E*H0<^L M\W:-*
*[L,@'$ZDDVD[M[X]P$,T=3*K*WH!T@F0K@(R%B"= .G*(5(!TNW:53H^*
*M.JNXNUUTD&Z)0W6,?'OLLUW8,R_X84'[M^>Y5_OF6(!FY=:$,V*H@D!FA5%*
*M$P(T$Z!9=4"SWLG'*H4.10?->MCU F^;+EX9]" 0-(&@54#& D$3"%HY1"H0*
*MM%W[36=''RKN>Y<003M#%O8%=E;$,?-+A*L".RND)@1V5A1-".Q,8&?5PMZY*
M2AP_O=BS/-]+)FD?:C"PMJ;HA]/%:6$V(ZAG[9T@6Y6G0!]Y4+AD 2J>Z X M=\(3#G["*
(5?L&B17R:I#X>G/IP7L*OAM4VH0.1B!TZ<\IYFL40)YT[81UY 'IQT-456&SEJ)?A?*
U=@+0MGOTO7 BR4[5\B.?&!A:%?B MCJ/ BP?$SXQ#'_L3J$6';#L<$C;(&
[CRA5$BD>NA1S;Q1NN7
*MN3XD*VO>!0X\$C*5X;'TGMP.JX$:^AYC&V)U1(L7L80>$JDB*!\CW)0_(DQR,A]3M*
MMD-"6H3 E[,%(",B'9=VHDUIC?"-%T/CV&1Y1Y<9W?H"W8_F M]6Z
@55IB!PH.T,DB>^{R}WX@QU"MT1^@4/W $A#D>/CF(H92+_! 8E>_R7
*M('B?/'0,P0V).>*Q/> X&92S,XI\J44;TU3_L_LL3/YMVZ'?IAU$U[]V:X&K"JE1J=*
MB&]PW8HP^E&GUM!%_AV:Q"GNT9'UM"]P=]K^5Z>B5V2]\9N4>0WB6)#E$-W7
M,Q+C\W[=QV[2Y9>EGT64J/3#,:IO=T(PS&NGQCNGKLO50Q9=;J.*C?!-,A;*
MSIBA$D]B1ZJ:LT!]IIBWB!<@_>?UU^-EQ4;IZ[7E0Z]IK$\&W3'YEAA"O%"Y
*M<[.M4M'6B1AGU'+1SC[,ZV1!U.Q+LK;;K^ 7TK\EC5[Y>DX)<]JM37<)' M*VZ?*
J@5)GO.N9C91LV%9.C85375, [4TTS,AHF-CF/IS;:!#;O&!,&NZ)/1*
M@I)QA&/^\:Z&XB/FH'7]J?NG?YP?77^[.NE/.U079,G/%I9E2]/MV(LP[3& M#UY:Y]:T
5E^G#%Q FB),X>Y!A%S",ACR,(9$X+)%^!=).!>D#75A943;D17
*M1/8#>N<(CV$5I3=$XV001H1[ARTTU(N;SGZLA3F9^7PTBG$W?9&5&4P6?**
*MD6"SH9:?FA9M>7'J3Z+TJ?QN*C."![C(C;;<[JP#PS.#+'-S@!-=/[Q+%[7T M??*
TN0J,NF\7OB 0VSI[3[Y%%_+AQ@@]A(EUD,;M /M3]-V1M[1YKB5G3FW[*
M74;>'K/7L=$V=S9K;=IA(H,95L-W-:VVV0I5^07VQ#8QL79!. YO^/&E:S+#
*MH1$>$U;B ^DTL.7IEA]3UWXB@LX1NGA?U07D*KZ9$PM"N=DPER:)'(5"6A*
*M+Q3R+Z$9?9ATGV)#W'_A\:8J$\<-D!;/D=(P;M^,O8G?2&=>C*0KS[8]%#E>*
*MJ2U.S%,O3KFPGE(2_D+6DT^@&'C87>PN>$#S5ST(;RE8W"/1JIV$T5LK>O/^*
MU9JVA^%M96$\'U86P4<*&$B>Z>\A%8CW.Y2N-U_AH- ZH7D8:6V-C%'O3CE*
*MPG)*1_C^W.V%1H5S;C5C9O8K\,"/;#LYTD*N=WU_&>P,:.S43N?*
8/$S])SE^16SK1LK=";DGT$R]-__M'U!+ P04 " "N/6U9Z+["&8X) #00 & &-G='@M,C R-
 # Y,S!X M97@S,60Q+FAT;>U;;7/;J!;^*ZQW]C:9L2V_)-O6=C.3.NZL9](D-W7V[GY$
*M$K*X04(+R([WU]]S0+)EQVW2;5YZ4W?:I((#'.!Y> X(#7YJ-$9I3-. A>2W*
MR<=3$LH@3UAJ2 8-9 ZYR8F$YEE-"4?F5)<"/)>\7#*"&FWFK\VVYW#9JO1 M.!I*
7<.BD$Q[I-WVX&^GU3D@K;>]PVZOVR(7'\G>U62X;\U/SH>3/R]&KMV+ MJ_>GXR&I-
3SO/]VAYYU,3ES&0;/5)A-%4\T-ERD5GC;1!QX0DK-FJ$):T<#3(&?
*C(9'@X092H*8*LW,N]K5Y$/C#5@8 M;@0[&GCE;V?KRW!Q-*
CYC&BS$.Q=+:%JRM.&D1ET)#-].E!]H;-36/.0Q/W MV]W6+_V,AB%/IPW!*
(@,IS<[;59KBTWB5%WG>HH):OB,8>V5>@/!J.KYTL3]*
*MS2:VE+WJL)3Y@F9VQ.+F5"TU=UEP*_-5,|>M6WUIK_S:!J*
MZ#@*6O$S/G9;+_M&W9C&E3P*;2&J7TW)+UB-/RU5N>NH"]%")FCFYC[W) N*
M5$0&G@]CESV%GP$@F:G2T78G,Z2U^G>7U\/1Y63\83P\GHS/S\CY!W)Q.3X;
MCB^.3\GHC]'P:C+^?03)8#&ZM)WZ4F4#7QW=;71Q=?GIZOAL0B;GY--H:-OM
MMCH/4SET8/+;B'PZOGQ_?#;ZU#C_XW3T)SD>3K!KG5;1S--,S']S;7BT^,+,
MC.ODE&M+GD0<*I"7B&NH+1GRI0J;>U5HUL!&BX-*
*CR66R:L&LZP[8"*PG_;%5@+^O.8&]; %E@OE7-% M(-*
:+$VP/AB9V+8JBQ6ZL67@P1NL=LVAU=35CMK-@8>) M#A
;@_'_VZTQB>F,$<5FG,U!J$S,-?DKIPJ6";&]$PJ_)%/DB5@+XU_DUD

M1(9RFMIEEDQB!E/,LT(8G]9IX;T$)R!)@6. K:!!@%7$%2"&829&CP!J!. 71 3G>./5?
DY4ZRH M!#N0< V1#\Z4"T,5TQD+K(-8;P:NR1"Z"=B&0?$7U6'8$>^9$-K]P8C'2,13
M@#:R9 7E.K .S"%;5?)Y&H&N4"LE/ U$'D*=0)<*;NM -8Y:E ':D:A(8-AS M+9E8D$!O-
UD#ZU&U=$B%V])/ $=NR8X'KQ,EDW6((E!5/MU7Q<*N)_E ,911P>+5C'A"IF:0$P
MYX@W@"]A&K"=8SF:): %(B>W"/'C6?J>(GU$Q2I"ET= M?*
="7>S<4K34404/8STT2@P6&N+TG(>;AP8Z8&PC>H_LODIDG3(,Y8-3&;'<3
MJ([A9$!S??\B&-?Y#,A0M.0B19DKJ "$:,:UE3>P8JFM!P\"5L)8%5=W' ;L
*M*D+%%4/JA?!B)@>1!%^T%#RTYY8Z}S4/.54<.\!=0&OE/L6:,\%10V';EDG5L$JE'"A;S5B*
*U!9J$\"Y]&5G?L MO_T=@[[W%Z1:)[R]K]^8R\'_&0Z0HU3*UP*8:Z(V[1>0MGOT5'*
*)6<^IS MP**8NEFF>06@S73RF[3A@DW18>R7&7 9&WC[2 :ED'[+YSRE((*
MHP40&G)8ABL%FL">VI$65A2>@5+O:/M)FU',RIRJTR(:19%L/'C,T"C
MWK!6T;+]U!:]{A]3V=9"@5!);7;.?HR-Y_WX#ZQ %U:,]P61W>?WQ"_W'#;*
*MA8>YD0!_^K;R'=&>AVCARR3:B%8;DPU%>"A/I8)>=*FY!>7Q%6ZP_[*.;AOUY@\#>Q1*
[N\&AW>/2@ M_3H6L/&" ASXA:>4>-X9< :$&+1Y2'.G-%K#"*
[=1LR&EW8+:5].EB|SOHIF MQ7F+.R/>HF$TA(:+27LLY0L-IY0!'@%V*^["%=#>*OS!*
8).FP[4X0.6U_[M[+7W>G.P],+@M1(@434*
>S,JAK0Q;Y!+WA5=S$>3V=2S!@&>BF=%AC% M/ Q9"C7@(+2Z_6J_[.501^6B9L?
H1B"%H)EFO?(_5<\1 873>-43AQ(FJ73!
MWB2EN9%E@KM&:E/6;INV5CPM;#"ECZLUM>-.8S9G?=CE_G4 MUU+DAO5QKC9[_-
*C VH*E2LG[|==*RY^?GG!7LU |W5G-P'/. $'G>;!;@8>*
M;0:L/NQ6J$>=GM:W,034#")&4)1.[6ZVO&FV#W;3\1AF/-+' &MC<)A M:H^5_E:!#?
&TM_&]QO88__M!Y5]DA_0=TK\%Z<\+YF',641&-RS(,6 BY^Y=R [4+P34&V!PCYC5XP:
< M#_H_).H'?'U\J@-2.]J[<%>[J+A-C/V!QS]W@.E"\2>?XG^P78B76VJ?!M=3 M)?,TQ -
**J7JEQE8^/E_/*)S:=+)4Y;7/WM>.*]?3EE_49W3*&FX31R/#5(_. M)*
\+M+Q^VSQH+Z,!E]:RKS3&5X,S%D,BYH=&WM7/]SVC@6_U=T M[.QM,H,!0](O0#-
#"9G-3IOD4CIW^Z-LRU@78WDE&<+]]?>>)(,A-$G;;)9F MZ:2 I2?I27H??3Z2#?U_>-
*XH2V@6LHC\.O[X@40B+*8LTR24C&I(G7.=D+'(M31A!'BMQJO&G[[N-*
'RO),^U#5TA436);[?A+]VJWU$6F^[MQYUNIT6N/I*#S^/AH3$_O1R.?
[\:V7:O/K__<#XD-:_9_'=GV&R>CD]MQE&C MY9.QI)GBFHN,ILWFZ)&:HG6>;?*
9G,_GC7FG(>2D.;YN)GJ:'C53(11K1#JJ MG?0Q!5X9C4[Z4Z8I"1,J%=/O:I_'9]X;L-
!]J4RHG//.TR$CN>Y!R29D;]C<>G,>Z:3KMUH_]W(:13R;>"F+-:0TVF]7*
M:9)/DE6BL)WK2I92S6<,:Z_4&Z:,RFX@=-+;;&);R;PL%XM,>S&=\G31_67,
*MITR1"S8GUV)*LU_J-@7>%9,_J5GK!7_'X.JH8,ISYB7,.MGPW_;T^Q6>S3E*
*M$V@-4WMV2+IN-(*U5N>V8"#2"#)'MPD/N"8=O]$F_68 8Y<_AY\A1#*3I:-^ M.]>DM?*
K_D-?#T?7X_.Q\.!B?7UZ0RS-R=7U^,3R_&GP@9^<7_@(GR[/P&)T
M;3IU7V7]0)X\:'3U^?K3Y\'%F(POR:?1T+3;:;6?IG+HP/C7$?DTN'X_N!A]
M\B[_\V"T.QD,Q]BU=LLU\SP3\]]":1XO[IF9\SKY3209.17@29V$3&(!HA.J
MN\1XN1VRE=B$)W8W[+HFV#6%D/K.,E)#5$A8[M3CFS-VZ =%3-_*Z9GN'DA#1U?*
AD7H0N]><(U\W!\63<3X<]"&OTQ,U-$V>O:2+@QP[D5W^O0&[O6B"_I\I(,C)=
*MD!OP/F4@WNHVGET41P(:S@2H/JB \HS0;$&*3,N"@:<@Z8PDA/"F9 I7DM.4*
*MQ#2$)$G$%(A="VMWQR!C(5.*R@6:3.D-(XB!99T*TB)P!II,T6ML PU"+D&'*
M@ADH4P6>0"P0F(0P(:K EU7Y.9/,58(=F'(%8@F'VRI7R53.0N,@UIN#:R" M;L),PZ*
*$B^HP['X(@#8^6$ R$C,,PAQ1,LJI.N /C"';%G)YUF,]1E]X5F8 M%A'4";"IQ&\=(,>1FW**
(>@0L AFV:TM$.C"HC:8!])'AK#I:%"D8 P%8,4T
MIXP_(54)B5,Q5R5&5PQ&"9:O\'+>@5]JG3FCK=[M+T(M!WM&MK&:Z&)XLI_*
*MW5,.3VX;@?0@XIC#I0G:Q#&A"F<1ZX2-$>S*5 CTB->1UR% MJ5*
%E$/2E"*U.,FE"%D$R8H< "PB!CBSL3^Z#1.:31@9 !]=%RE8^!WJ^<<' M[-
4]8\C>V4O.>Y=,XM/K)\@:55@:V&$OCRZH7BMH1@:PGYN@ADL4/IV]P'H M?
N_U+1@^/MI-#!_0PQT#\2E3T!L(9R/W'L9:'95H2 OU^"(H"0,&N'$M69$I M"@D5 '?-
N#,"%8L,_7@T<.*2ZM\;_? (A.9:[5'=!5\42+ED3DE M546@>,2IY-*
@!;K6P40@9UE0HU=FW5)&S!K^%(J!0QKX&@OE%&>_2"G2/G3+*
M.+'2N5#"JN:JV(=/ 4-#8&8H#W&]9^(7@>)@MU'\:#Z[_^;',^&C,0WKP(Q'
M"%6J1&:"G"J .6XX$;]41B66 -VH'2=UNSN+(8V!E$V45AS;2R837
MXM9U"]D#HA61JJ'(<2>< K AA^6X8J),,LM>&%EX3F0^QZ^ M+P.^X:*
[!=S2C:6&8"F.;Q3'L'?D,HE)MV0,NA?8CF-=>;M\6&K1"06!-93>? M
I50M=38R'P&\BPRDL",AZ/K!4GY#4O= ML?&??*
V]AV@/\Q=S0'7\,@ZHS,W(J%P@ZBN"0KZL@G3%50BSKQ#==S:O2]S=H#\-&?T
M!G6IW86:7DKY:L0Z8YN[,GT%MJC$114;,EZ7T2OV[M"$8 @!$?=

MBF,%RE@54P@W&!73&:2Y"..]DT3\6"0>X\$98PZ1IZ 6U/(J ;]^#@^Y^=
*MNR=^M\W/>F0?KTW[(9]G*Y$\..@:9W%Z')^*
*MXJ.I.'(P)Z4+YLE76FA1)MC'7DW*VM.QK560.AM,J:"M1DS OZO91SH-XDH_M7?*
*L.;:N@WL2**#%Q[#?>O/JY.J8;\5^1%97*,1SP#G@YC.6UAW#K!K!(WWAS*
M&+,'G^==YM- B;30K%>2?;7'/W L6>7E7M=7FB]/2N-U>S\GNS4G1^W&D;^? ME&>
*<%,,E=Y8V_\] MF2 _M> P%\;Y<.$LYB<+4^*
+NTMF7W([T/^I89\GZ^/ACF[Y1I\#?'H^,H^=@98 M6$";PP,5D^F.9 <]IO\9*
,IY2&I5>?//K_?L(-(EEOQ@(8W$PF=C/!$5,AN M2<25;^>O9SBG-ITLJ7OM=P'6SD?
7TY8_.9#3"?/L5H_&FLDNG0D>N>!Y_;8J M&6Q:R]Q]L#]E8'X;X>3_4$L#!!0 (
X];5DL0>SY) 8 .DF 8 M8V=T>"TR,#
*(T,#DS,'AE>#,R9#$N:'1M[5IM<]HX$/XK>W2N36;P*R&7&,H, M(62:F33D@C-*
W_2AL@74UEBN+$.[7WTJV 9/DF0(8!7;ZO5\^CQ"K=_
M,8Q^IDH"%\\#]>0,B#V90F$@)!B43KG,D(?)ZF)(&/5 @6QW B6#BA (YM
M'IJ.VS1MP^BTL:]>T8@G'CB.A2_7=@_/O::#<\]AJN/L'?C]_9U]=-!S_]T
MU<_'O;HYN3CO0PTYE"UM:6+Q1Y\Z8 MLU!&GF/;O[92$H8LF1@Q'4NTF.
[QRB;8)%H9>3XY3]"82'9+5>]K_08Q)<(; M<1FU-H=XJ&5:MAOS1!IC,F7QPGOGLRG-
*X)+.X9I/2?*NGEOP,Z."C=^U=.V,*
M_4T]!^<7LX0:$Z_KG@TMDQ/7PIGOI@S_89J>=HWSQ;\RAV3-AV.\I[W.;TVC:V^Q[
M=PC=T\&5WS]=C_968Z02WV/[$ 9GX'_HP[!['?=]|_^-P9\7_4_0[?FJQ+5M*
*M]T=.YZ]9)MEXL=PKW'L[Q7D" 4\2&JA=*Q<7&5'X,B," Q$O0-"4"PE\##T^ M2?*
3F!GY$!4GI3+(@]\-Y$IBPIU]]?7/DNG:KQZ>H3@M]Y;3V47W@C(LIRI/Q
M.XRYV!@AQ6GQ$&@2HE(-:2KI=$1%'M&&7<^_-VJ \E@S.)2!54W0QK,!']% M(2-*
)"/T[U),$M1!]F+(L4][B2]4,40D!':IU%2X M0:_T?(@8D81FQN
*NI@OH!CKT"C=UU4Q5&=%,&Z<+^)SP.89C0K$P(M(#C2M) M1C%6XR*DXGW-*
*KJ'7<5P(W?(Z2TE07&,+@?]A"<=>HA8:3W>Y_]G@?NX/!HHTI)/]5AK=PS*C0=H*
M@MZH;BL.K8A6Z^PY^VU+67/^;D3C]\73)T0+<*1SU38^9E5PH]-%\ N//&MUR*
M"=>#5HU[LQIW=7G+,KQSCYE<>!$+0YKH5./(M1NM]:GH-"QG:-%S3E0CX'%,
*MTHQZY9=U9]7'"%GZJIHM*Y Z8+.V@\O@_PDN]-['(MI!L,64L:*WUS[&|<\WD9Q_+:*
*M4#N)-*T_:,QQZ]F8HNR\DHX_%,TI9:K,TIOP"8JMGK?T1.GL$7[_^^$2\7 MX-\.-*
*HMP8LNP4'#;#J[-7B^-="Z<&^;MT1V"8J/'A*68G#*697'ESBOJ:._L!IU$$=*
M^&T9HI^>Q\G"^Q80%NE1L?).>@>X.[,0WMCZ[X4G9676QHGH=L)LRS>>)X+,D
M5.?I7'BE=JX]E50M)S:=+)4V\KS4)73]:IM^:A52B;4R$\=R%A2X9%;SL("*
M+;\=FP"TR,#(T,#DS,'AE>#,R9#(N:'1M[5IM<]HX$/XK>W2N36;P M&R2YQ-
#,4$*FZ;1)+CASUX_"EK&NPG)E$<+]^EO)-A@N;7II+B5W9 C@M5X>
MK9YG5Q+N_F19@S0A:4@C>!M\>_^1"<3FBH()24*K3.F$@A$EI$4/E I&>?P*
M1K)H3 $\USZPO=:^[5K6<1?;ZI>51.J#YSGX:KFM/7"/_/VVWSJ"RP^P?WF_5D?&I;C_-
;N.\Y)<%+Z[[4SMF?U/=P?)REU$IH =/VCCJ% WRO;>]G"MSE/W;Y\H5WX':Z3O88
MG;MW]:[HK;((9V,]\P""BTT&[1T6DW]M#^V^#<-!7Z,O
M;%Y[W]UD[+TA]$XN+H/!2=W;&\V1%?\>N0=P<0K!VP$,>U=O>N>#H77Q^_O!
*M1^CU WVGY;I/2OD_IKEB\7P1*UI_BQ1G*80B36FHHU:17%1"X?.42'0$GX.D MF9 *1*
*Q],4Y-<(,@H9)D=*I8F#?A+ UMV-&U7KXX;+7<3E],,#O-S977V<7L M Z="3C*
]6;]"+.1:#QD.2T1 TP@SU9!FBDY&5!8>;;O-XHO.6TT@.<2,5UE0 M-
*S.DX50B*G0922,8W&(^23$7(H8)RW.-%E^Z9(29$! XQ:'4T5Z9 59@<3A-*
M>">2%XSDT3$["I-
*)I#2*5V9A.RJ5!/D(J,.+8D9$3EZX;;P(%Q7N;!Q76>D;"Z+MLK:EBAX)QD.?6K M+YT'T[?*
*UY;QF87958F(D6!N(OC3X+4[F8]K\F-W2Z"[*UY)R ;Q2LY+X'U6#*
*M*HJU*P>IJ'[SNW1YH^D2$E[B,A!Q")U9PA2UM'^ICU.(0NK40)3S4(+=\7;7*
*M,:T6Z.I.'P5N<:D;0E1R0GBG'NU*4^,8I0^%8B">&B8T3?*
*=334:$8@2G1])E7FBA3JOT5 MKG__:N(K'+UK#E;9N[_*7GUYPW)*
[O;A/1KG@4T4[U5@/MRG(=([NUAG%4NI\GTU;'W1B0?V MWN'6C5*
(YHN#CF\4WT,F8]M[WO;&?BW9L"DHVV0V)H\@B6>[MY>V"3I'#G6>J*'TYP0^?#.*
<8U?4)7KL) M^EARPQA]_SC>S/V'D+#%!.[M3.;3>38AL>;+;1 M=H7HNI-
-8_F6X5N&;_AZXGX2]Q-&8SA=G(->Q#$+J=PR>LOH9\KH+EO=(IK?
M%IA"K'^:>-2,F1ZAE1?DEX?^??"4$Q3A6 K#>QV';:^/JX.^(LMY)-/Z .V*
MN$&M@ZP2[\K#6RM'Y*NVQ7-A&1E3 MJSA\(+&BTB7XYLO>6";^PN>;7L>)Y,_,*
V_%?4$L! A0#% @ MKCUM6;>Q.+#4#0 &X@ !$ (! &-G='@M,C R-# Y M,S N>'-D4$L!
A0#% @ KCUM675I 4-."P BI< !4 M (! PX &-G='@M,C R-# Y,S!?8V%L+GAM;%!+ 0(4
*Q0 (*X];5GL M*2KK;2$ ("TR,#(T,#DS,%]L86(N>&UL4$L! A0#% @ KCUM68J4*

*M8AOC-0 -@P$!4 (!*XX &-G='@M,C R-# Y,S!?<')E M+GAM;%!+ 0(4 Q0 (*X];5F)7_V-F=(! ,OE% 5 " M 4'$!C9W1X+3(P,C0P.3,P>#$P<2YH=&U02P$"% ,4 " "N/6U9Z+[" M&8X) #00 & @ $-EP(8V=T>"TR,#(T,#DS,'AE>#,Q M9#$N:'1M4$L! A0#% @ KCUM6;@B?1R7"0 \4$!@ M (!T: " &-G='@M,C R-# Y,S!X97@S,60R+FAT;5!+ 0(4 Q0 (*X] M;5DL0>SY) 8 .DF 8 " 9ZJ @!C9W1X+3(P,C0P.3,P M>&5X,S)D,2YH=&U02P$"% ,4 " "N/6U9+'9[+5<& "6)P & M @ 'XL (8V=T>"TR,#(T,#DS,'AE>#,R9# (N:'1M4$L%!@ * - H I@((6W @ $! end XML 62 cgtx-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2024-07-01 2024-09-30 0001455365 cgtx:AtMarketOfferingMember 2024-07-01 2024-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2024-01-01 2024-03-31 0001455365 cgtx:AtMarketOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:EquityLineFinancingMember 2023-07-01 2023-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2023-07-01 2023-09-30 0001455365 cgtx:EquityLineFinancingMember 2023-07-01 2023-09-30 0001455365 cgtx:AtMarketOfferingMember 2023-07-01 2023-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2023-04-01 2023-06-30 0001455365 cgtx:AtMarketOfferingMember 2023-04-01 2023-06-30 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:EquityLineFinancingMember 2023-01-01 2023-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2023-01-01 2023-03-31 0001455365 cgtx:EquityLineFinancingMember 2023-01-01 2023-03-31 0001455365 cgtx:AtMarketOfferingMember 2023-01-01 2023-03-31 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2024-07-01 2024-09-30 0001455365 us-gaap:CommonStockMember cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:CommonStockMember cgtx:EquityLineFinancingMember 2023-07-01 2023-09-30 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2023-07-01 2023-09-30 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2023-04-01 2023-06-30 0001455365 us-gaap:CommonStockMember cgtx:EquityLineFinancingMember 2023-01-01 2023-03-31 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2023-01-01 2023-03-31 0001455365 us-gaap:RetainedEarningsMember 2024-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001455365 us-gaap:RetainedEarningsMember 2024-06-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001455365 2024-06-30 0001455365 us-gaap:RetainedEarningsMember 2024-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001455365 2024-03-31 0001455365 us-gaap:RetainedEarningsMember 2023-12-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001455365 us-gaap:RetainedEarningsMember 2023-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001455365 us-gaap:RetainedEarningsMember 2023-06-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001455365 2023-06-30 0001455365 us-gaap:RetainedEarningsMember 2023-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001455365 2023-03-31 0001455365 us-gaap:RetainedEarningsMember 2022-12-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001455365 us-gaap:OtherCurrentLiabilitiesMember*

cgtx:InsurancePremiumFinancingAgreementMember 2024-09-30 0001455365 us-gaap:OtherCurrentLiabilitiesMember cgtx:InsurancePremiumFinancingAgreementMember 2023-12-31 0001455365 us-gaap:CommonStockMember 2024-09-30 0001455365 us-gaap:CommonStockMember 2024-06-30 0001455365 us-gaap:CommonStockMember 2024-03-31 0001455365 us-gaap:CommonStockMember 2023-12-31 0001455365 us-gaap:CommonStockMember 2023-09-30 0001455365 us-gaap:CommonStockMember 2023-06-30 0001455365 us-gaap:CommonStockMember 2023-03-31 0001455365 us-gaap:CommonStockMember 2022-12-31 0001455365 us-gaap:OverAllotmentOptionMember 2024-03-10 0001455365 cgtx:FollowOnPublicOfferingMember 2024-03-10 0001455365 cgtx:EquityIncentivePlan2021Member 2024-01-01 2024-09-30 0001455365 cgtx:EquityIncentivePlan2021Member 2024-01-01 2024-01-01 0001455365 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-07-01 2024-09-30 0001455365 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0001455365 cgtx:EmployeeStockPurchasePlanMember 2024-09-30 0001455365 cgtx:AmendedAndRestatedEquityIncentivePlan2017Member 2017-09-15 0001455365 cgtx:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001455365 srt:MinimumMember 2024-01-01 2024-09-30 0001455365 srt:MaximumMember 2024-01-01 2024-09-30 0001455365 srt:MinimumMember 2023-01-01 2023-09-30 0001455365 srt:MaximumMember 2023-01-01 2023-09-30 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001455365 srt:MinimumMember cgtx:RestrictedStockUnitsTimeBasedVestingMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0001455365 srt:MaximumMember cgtx:RestrictedStockUnitsTimeBasedVestingMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0001455365 cgtx:RestrictedStockUnitsTimeBasedVestingMember cgtx:NonEmployeeDirectorMember 2024-01-01 2024-09-30 0001455365 cgtx:RestrictedStockUnitsPerformanceBasedVestingMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-14 0001455365 cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember cgtx:AtMarketOfferingMember 2024-01-01 2024-09-30 0001455365 cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-09-30 0001455365 cgtx:EquityLineFinancingMember 2023-01-01 2023-09-30 0001455365 cgtx:AtMarketOfferingMember 2023-01-01 2023-09-30 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001455365 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001455365 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001455365 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001455365 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001455365 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001455365 2023-01-01 2023-12-31 0001455365 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001455365 cgtx:PerformanceBasedStockOptionsMember 2024-09-30 0001455365 cgtx:PerformanceBasedStockOptionsMember 2024-01-01 2024-09-30 0001455365 cgtx:InsurancePremiumFinancingAgreementMember 2023-11-01 2024-09-30 0001455365 cgtx:InsurancePremiumFinancingAgreementMember 2023-10-31 0001455365 2022-12-31 0001455365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001455365 us-gaap:MoneyMarketFundsMember 2024-09-30 0001455365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001455365 us-gaap:MoneyMarketFundsMember 2023-12-31 0001455365 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001455365 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001455365 us-

gaap:StockOptionMember 2024-01-01 2024-09-30 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001455365 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001455365 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001455365 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001455365 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001455365 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001455365 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001455365 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001455365 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001455365 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001455365 cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001455365 2023-04-01 2023-06-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001455365 2023-01-01 2023-03-31 0001455365 2024-11-08 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-14 2024-03-28 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-28 2024-03-28 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-14 2024-03-14 0001455365 us-gaap:OverAllotmentOptionMember 2024-03-10 2024-03-10 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001455365 2024-04-01 2024-06-30 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001455365 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001455365 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001455365 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001455365 cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember cgtx:AtMarketOfferingMember 2024-09-30 0001455365 cgtx:EquityIncentivePlan2021Member 2024-09-30 0001455365 cgtx:RestrictedStockUnitsPerformanceBasedVestingMember 2024-01-01 2024-09-30 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001455365 cgtx:LincolnParkCapitalFundLlcMember cgtx:EquityLineFinancingMember 2024-01-01 2024-09-30 0001455365 cgtx:AtMarketOfferingMember 2024-01-01 2024-09-30 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001455365 2024-01-01 2024-03-31 0001455365 cgtx:FollowOnPublicOfferingMember 2024-03-10 2024-03-10 0001455365 cgtx:LincolnParkCapitalFundLlcMember cgtx:EquityLineFinancingMember 2023-03-10 2023-03-10 0001455365 cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember cgtx:AtMarketOfferingMember 2023-01-03 2023-01-03 0001455365 cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember cgtx:AtMarketOfferingMember 2022-12-23 2022-12-23 0001455365 cgtx:AtMarketOfferingMember 2022-12-23 0001455365 2024-07-01 2024-09-30 0001455365 2023-07-01 2023-09-30 0001455365 2023-01-01 2023-09-30 0001455365 2024-01-01 2024-09-30 0001455365 2023-09-30 0001455365 cgtx:EquityIncentivePlan2021Member 2024-01-01 0001455365 2024-09-30 0001455365 2023-12-31 iso4217:USD shares cgtx:tranche iso4217:USD shares pure cgtx:segment 0001455365 --12-31 2024 Q3 0 0 0 0 32165478 40806092 P36M P36M P3Y false 10-Q true 2024-09-30 false 001-40886 Cognition Therapeutics, Inc. DE 13-4365359 2500 Westchester Ave. Purchase NY 10577 412 481-2210 Common Stock, par value $0.001 per share CGTX NASDAQ Yes Yes Non-accelerated Filer true true false false 41547995 22011000 29922000 3369000 1281000 1450000 3019000

26830000 34222000 207000 284000 542000 657000 27579000 35163000 1895000 3695000 9505000 4055000 1117000 1701000 188000 174000 544000 12705000 10169000 392000 520000 13097000 10689000 0.001 0.001 10000000 10000000 0 0 0.001 0.001 250000000 250000000 40806092 32165478 41000 32000 181759000 165826000 -167318000 -141189000 -195000 14482000 24474000 27579000 35163000 11392000 11669000 33522000 25596000 3071000 3076000 9721000 9939000 14463000 14745000 43243000 35535000 -14463000 -14745000 -43243000 -35535000 4293000 7684000 16516000 18035000 236000 314000 813000 -129000 -3000 -2000 -20000 -18000 195000 4526000 7996000 17114000 17888000 -9937000 -6749000 -26129000 -17647000 195000 3000 -9937000 -6749000 -25934000 -17644000 -0.25 -0.22 -0.69 -0.59 -0.25 -0.22 -0.69 -0.59 40418065 30365506 38080658 29696296 40418065 30365506 38080658 29696296 32165478 32000 165826000 -141189000 -195000 24474000 1329000 7557142 8000 11888000 11896000 191273 381000 381000 71973 -106000 -106000 1171000 1171000 195000 195000 -9151000 -9151000 39985866 40000 179160000 -150340000 28860000 53052 -22000 -22000 73350 65000 65000 1147000 1147000 -7041000 -7041000 40112268 40000 180350000 -157381000 23009000 673131 1000 496000 497000 20000 17000 17000 693 896000 896000 -9937000 -9937000 40806092 41000 181759000 -167318000 14482000 28991548 29000 155820000 -115401000 -199000 40249000 95823 197000 197000 189856 318000 318000 1187000 1187000 4000 4000 -6172000 -6172000 29277227 29000 157522000 -121573000 -195000 35783000 1009355 1000 2304000 2305000 1025000 1025000 -1000 -1000 -4726000 -4726000 30286582 30000 160851000 -126299000 -196000 34386000 5500 8000 8000 125000 210000 210000 1071000 1071000 -6749000 -6749000 30417082 30000 162140000 -133048000 -196000 28926000 -26129000 -17647000 80000 69000 3214000 3283000 115000 117000 195000 318000 2088000 -2034000 -1569000 -962000 3650000 1837000 -584000 -1426000 -114000 -109000 -20092000 -10562000 3000 117000 -3000 -117000 11896000 878000 2509000 82000 205000 128000 544000 632000 12184000 2082000 4000 -7911000 -8593000 29922000 41562000 22011000 32969000 1. Description of Business and Financial Condition Cognition Therapeutics, Inc. (the “Company”) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (“CNS”) and retina. The Company’s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates. In January 2024, the Company ceased operations at Cognition Therapeutics PTY LTD, a wholly owned subsidiary (the “Subsidiary”) and completed its liquidation of the Subsidiary (the “Liquidation”). In accordance with the Liquidation, the Company removed the AOCI balance associated with the currency translation adjustments and recorded a loss on liquidation of the Subsidiary in accumulated deficit. On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the “Shelf”) with the Securities and Exchange Commission (“SEC”) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously

entered into a sales agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (the “Sales Agents”) providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in “at-the-market” offerings under the Shelf (the “ATM”). During the nine months ended September 30, 2024, the Company sold 864,404 shares of its common stock pursuant to the ATM for gross proceeds of approximately $905. Please refer to Note 7 for further details. On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) for an equity line financing (the “Purchase Agreement”). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Company’s sole discretion, over a 36-month period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Park’s commitment to purchase shares of common stock under the Purchase Agreement. During the nine months ended September 30, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of September 30, 2024, $34,795 was available to draw pursuant to the Purchase Agreement. Please refer to Note 7 for further details. On March 14, 2024, the Company closed a follow-on public offering of 6,571,428 shares of the Company’s common stock at a public offering price of $1.75 per share (“March 2024 Offering”). As part of the March 2024 Offering, the underwriters exercised their option to purchase 985,714 shares of the Company’s common stock on March 28, 2024, at a public offering price of $1.75 per share. The gross proceeds from the March 2024 Offering were $13,225 and the net proceeds were approximately $11,896, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company. Liquidity and Going Concern The Company’s Consolidated Financial Statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $26,129 for the nine months ended September 30, 2024 and $25,788 for the year ended December 31, 2023. As of September 30, 2024, the Company had cash and cash equivalents of $22,011 compared to $<span

style="background:#ffffff;">29,922 of cash and cash equivalents as of December 31, 2023. The Company has incurred losses and negative cash flows from operations and had an accumulated deficit of $167,318 as of September 30, 2024. The Company expects to continue to incur losses for the foreseeable future. As of November 13, 2024, the date of issuance of these Consolidated Financial Statements, the Company believes that its cash and cash equivalents as of September 30, 2024 is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Company's ability to continue as a going concern. To execute its business plans, the Company will need substantial funding to support its continuing operations and pursue its growth strategy. Until such time that the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or abandon its product development programs, which could have a material adverse effect on its business prospects. 200000000 40000000 864404 905000 35000000 189856 34795000 6571428 1.75 985714 1.75 13225000 11896000 -26129000 -25788000 22011000 29922000 -167318000 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements as of September 30, 2024, and for the three and nine months ended September 30, 2024 and 2023, have been prepared in accordance with the rules and regulations of the SEC and generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company's management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company's financial position as of September 30, 2024, the statements of operations and comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results for the year ending December 31, 2024, or for any future period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K, filed with the SEC on March 26, 2024. Use of Estimates The preparation of

consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Receivables Grant Receivables Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health (“NIH”) and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. Grant Income The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the three and nine months ended September 30, 2024, the Company generated grant income of $4,293 and $16,516, respectively, as compared to $7,684 and $18,035 for the three and nine months ended September 30, 2023, respectively, primarily from reimbursements from the National Institute of Aging (the “NIA”), a division of the NIH for aging research. The current and non-current portion of deferred grant income as of September 30, 2024 was $1,117 and $0, respectively, as compared to the current and non-current portion of deferred grant income as of December 31, 2023 of $1,701 and $0, respectively. The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (“CROs”), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company’s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated

improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of September 30, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. Research and Development Costs The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy ("GA") secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to its research and development activities, including allocated facility-related expenses and external costs of outside vendors, including CROs, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses. Equity-based Compensation Following the provisions of ASC 718, Compensation — Stock Compensation, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company recognizes compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. The grant date fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur. Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to a lack of sufficient public market data for the Company's common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Prior to

the IPO, due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm's-length sales of the Company's capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company's financial position and historical financial performance, the status of technological developments within the Company's research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors determines the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. Concentration of Credit Risk The Company's financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds. Fair Value of Financial Instruments The Company applies ASC 820, Fair Value Measurement ("ASC 820"), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company's principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions based on market data and the entity's judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying value of the Company's cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: <table style="border-collapse:collapse;font-family:'Times New

Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</td></tr></table> Net Loss Per Share Basic net loss per share is computed by dividing the net loss per share by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Segments The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company’s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for

the purpose of allocating resources. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recent Accounting Pronouncements Not Yet Adopted In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements ("ASU 2023-06"), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures ("ASU 2023-09"). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity's effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity's unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures. Income Taxes In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate, apply that rate in providing for income taxes on a current year-to-date (interim period) basis, and include the tax impact for discrete items within the interim period. The Company maintains a full valuation allowance against all deferred tax assets as of September 30, 2024 and December 31, 2023, as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions. Basis of Presentation The accompanying consolidated financial statements as of September 30, 2024, and for the three and nine months ended September 30, 2024 and 2023, have been prepared in accordance with the rules and regulations of the SEC and generally accepted

accounting principles in the United States of America ("U.S. GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company's management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company's financial position as of September 30, 2024, the statements of operations and comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results for the year ending December 31, 2024, or for any future period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K, filed with the SEC on March 26, 2024. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Receivables Grant Receivables Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Health ("NIH") and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables. 0 Grant Income The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the three and nine months ended September 30, 2024, the Company generated grant income of $4,293 and $16,516, respectively, as compared to $7,684 and $18,035 for the three and nine months ended September 30, 2023, respectively, primarily from reimbursements from the

National Institute of Aging (the "NIA"), a division of the NIH for aging research. The current and non-current portion of deferred grant income as of September 30, 2024 was $1,117 and $0, respectively, as compared to the current and non-current portion of deferred grant income as of December 31, 2023 of $1,701 and $0, respectively. The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations ("CROs"), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH's supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company's performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of September 30, 2024, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. 4293000 16516000 7684000 18035000 1117000 0 1701000 0 Research and Development Costs The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy ("GA") secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to its research and development activities, including allocated facility-related expenses and external costs of outside vendors, including CROs, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses. Equity-based Compensation Following the provisions of ASC 718, Compensation — Stock Compensation, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company recognizes compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. The grant date fair value of stock options is estimated on the date of grant using the Black-

Scholes option pricing model. Forfeitures are recognized in the period in which they occur. Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to a lack of sufficient public market data for the Company's common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Prior to the IPO, due to the absence of an active market for the Company's common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, the Company has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm's-length sales of the Company's capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred stockholders and the prospects of a liquidity event. Among other factors are the Company's financial position and historical financial performance, the status of technological developments within the Company's research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company's competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Subsequent to the IPO, the board of directors determines the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. 0 Concentration of Credit Risk The Company's financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds. Fair Value of Financial Instruments The Company applies ASC 820, Fair Value Measurement ("ASC 820"), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the

price that would be received for an asset or paid to transfer a liability in the Company's principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions based on market data and the entity's judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying value of the Company's cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3 —

Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</td></tr></table> Net Loss Per Share Basic net loss per share is computed by dividing the net loss per share by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. Segments The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company's chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. 1 Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recent Accounting Pronouncements Not Yet Adopted In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements ("ASU 2023-06"), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures ("ASU 2023-09"). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity's effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity's unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1,

2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.   Income Taxes In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate, apply that rate in providing for income taxes on a current year-to-date (interim period) basis, and include the tax impact for discrete items within the interim period. The Company maintains a full valuation allowance against all deferred tax assets as of September 30, 2024 and December 31, 2023, as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions. 0 0 3. Financial Instruments and Fair Value Measurements Financial assets and liabilities measured at fair value are summarized below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Quoted Priced in </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Active Markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Observable Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">(Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">21,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,766 </td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">21,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,766 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Quoted Priced in </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Active Markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Observable Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> 29,391 </td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,391 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Quoted Priced in </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Active Markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Observable Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,766 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">21,766</p></td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,766 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,766 </td></tr></table> - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:59.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:14.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Quoted Priced in </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"> Active Markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"> Observable Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.5%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-

align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,391 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29,391</p></td></tr><tr><td style="vertical-align:bottom;width:38.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,391 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —

* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,391 </td></tr></table> 21766000 21766000 21766000 21766000 29391000 29391000 29391000 29391000 4. Accrued Expenses Accrued expense consists of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New*

***Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;background:#cceeff;margin:0pt;padding:0pt;"> Employee compensation, benefits, and related accruals </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> ***

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;background:#cceeff;margin:0pt;padding:0pt;"> 1,165 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> Research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> 7,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"> 2,520 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;background:#cceeff;margin:0pt;padding:0pt;"> Professional fees and other accruals </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 230 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 370 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> x </td></tr></table> x x <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;background:#cceeff;margin:0pt;padding:0pt;"> Employee compensation, benefits, and related accruals </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;background:#cceeff;margin:0pt;padding:0pt;"> 1,165 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> Research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"> 7,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,520 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:60.95%;background:#cceeff;margin:0pt;padding:0pt;"> Professional fees and other accruals </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 230 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 370 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:60.95%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr></table> 1480000 1165000 7795000 2520000 230000 370000 9505000 4055000 5. Other Current Liabilities In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through September 2024. As of September 30, 2024 and December 31, 2023, the outstanding principal of the loan was $0 and $544, respectively, and is included in other current liabilities on the consolidated balance sheet. 721000 0.0865 62000 0 544000 6. Commitments and Contingencies Operating Leases Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of September 30, 2024 were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> Operating lease assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 542 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">657</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 542 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 657 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"> Current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 174 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"> Non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities, non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 392 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 520 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"> Total operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 694 </td></tr></table> - Operating lease costs for the three and nine months ended September 30, 2024 was $55 and $164, respectively, as compared to operating lease costs for the three and nine months ended September 30, 2023 of $53 and $161, respectively. - The maturities of the operating lease liabilities and minimum lease payments as of September 30, 2024 were as follows: - <table style="border-collapse:collapse;font-

*size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> For the Years Ended December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Operating Leases </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (remaining) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> 56 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"> *

226 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> $ 158 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"> $ 91 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> $ 92 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 39 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> Total undiscounted lease payments </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 662</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (82)</p></td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580 </td></tr></table> The following table summarizes the lease term and discount rate as of September 30, 2024 and December 31, 2023, respectively: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> 3.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.1 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average discount rate </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> 8.1% </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"> 8.1% </td></tr></table> Operating cash flows used for operating leases for the nine months ended September 30, 2024 and 2023 was $168 and $154, respectively. Litigation and Contingencies From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability but instead discloses the nature and the amount of the claim and an estimate of the loss or range of loss, if such an estimate can reasonably be made. As of September 30, 2024 and December 31, 2023, there was no litigation or contingency with at least a reasonable possibility of a material loss. Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of September 30, 2024 were as follows: <table style="border-collapse:collapse;font-

size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;">Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> Operating lease assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 657 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"> Total operating lease assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 657 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"> Current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"> 188 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 694 </td></tr></table> The following table summarizes the lease term and discount rate as of September 30, 2024 and December 31, 2023, respectively: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> 3.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"> 4.1 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average discount rate </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.85%;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> 8.1% </td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"> 8.1% </td></tr></table> 542000 657000 542000 657000 188000 174000 392000 520000 580000 694000 55000 164000 53000 161000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> For the Years Ended December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Operating Leases </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (remaining) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> 56 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> 2025 </td><td

*style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"> 226 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> 158 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"> 91 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> 92 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> Total undiscounted lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"> 662 </td></tr><tr><td style="vertical-align:bottom;width:80.61%;margin:0pt;padding:0pt;"> Less: Imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (82) </td></tr><tr><td style="vertical-align:bottom;width:80.61%;background:#cceeff;margin:0pt;padding:0pt;"> Present value of operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580 </td></tr></table> 56000 226000 158000 91000 92000 39000 662000 82000 580000 P3Y6M P4Y1M6D 0.081 0.081 168000 154000 7. Stockholders' Equity Common and Preferred Stock The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of*

$0.001 per share. Common stockholders are entitled to dividends if and when declared by the Company's board of directors subject to the rights of the preferred stockholders. As of September 30, 2024, no dividends on common stock had been declared by the Company. ATM On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate (the "Shelf"). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in ATM offerings under the Shelf. The Company sold 864,404 shares of common stock pursuant to the ATM during the nine months ended September 30, 2024 for gross proceeds of approximately $905. As of September 30, 2024, there was $33,809 remaining of common stock available for sale under the ATM. Lincoln Park Purchase Agreement On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Company's sole discretion, over a 36-month period commencing on March 10, 2023. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Park's commitment to purchase shares of common stock under the Purchase Agreement (the "Commitment Shares"). The Company recorded $318 to other expense, net in connection with the issuance of the Commitment Shares. During the nine months ended September 30, 2024, the Company did not sell any shares of common stock to Lincoln Park. As of September 30, 2024, $34,795 was available to draw pursuant to the Purchase Agreement. March 2024 Offering In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of 7,557,142 shares of its common stock, which included the exercise of the underwriters' option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwriters' option to purchase 985,714 additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $11,896, after deducting $1,329 of underwriting discounts and commissions and other offering related expenses payable by the Company. 250000000 0.001 10000000 0.001 0 200000000 40000000 864404 905000 33809000 35000000 189856 318000 34795000 7557142

985714 1.75 985714 11896000 1329000 8. Equity-based Compensation 2021 Equity Incentive Plan On October 7, 2021, the date upon which the Company's Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company's 2021 Equity Incentive Plan (the "2021 Plan") became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the "2017 Plan"). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units ("RSUs"), and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers. As of September 30, 2024, the aggregate number of shares of common stock of the Company that may be issued under the 2021 Plan is 2,547,943. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2024 pursuant to an evergreen provision therein by 643,309 shares, representing 2% of total common shares outstanding at December 31, 2023. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company's shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company's board of directors or the compensation committee. No more than 7,543,185 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the "2007 Plan" and collectively with the 2017 Plan, the "Prior Plans") that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares. 2017 Equity Incentive Plan On September 15, 2017, the Company's board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The board of directors, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan. The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company's Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan provides for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised shall

subsequently be available for reissuance under the 2021 Plan. Employee Stock Purchase Plan The Company's board of directors approved the Employee Stock Purchase Plan (the "ESPP") prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company's common stock at a discounted purchase price. As of September 30, 2024, subject to adjustment as provided in the ESPP, a total of 209,532 shares of common stock are authorized and reserved for issuance under the ESPP. Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above. Stock Options The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.84%;background:#cceeff;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 91.78% – 92.29% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 91.53% – 92.68% </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-

***space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 4.23% – 4.45% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 3.46% – 4.26% </td></tr><tr><td style="vertical-align:bottom;width:61.84%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 0% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 0% </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 6.10 – 6.20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 6.18 – 6.36 </td></tr></table> Expected Term — The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method. Risk-Free Interest Rate — The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards’ expected term. ***

* Expected Volatility — Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time. Dividend Yield — The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future. Fair Value of Common Stock — Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors had determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors determined the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. Activity for options was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-*

align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Weighted-Average </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> Aggregate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> Intrinsic Value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Contractual Life </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in 000's) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In Years) </td></tr><tr><td style="vertical-

align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"> Balance, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,213,405 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"> 1,579 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"> 6.5 </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 247,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"> 1.97 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> (93,350) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"> 0.88 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> Options

forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> (4,225) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.66 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> Balance, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,362,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6.1 </td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> 3,599,654 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.5 </td></tr></table> - The weighted-average grant date fair value of stock options granted was $0 and $1.56 during the three and nine months ended September 30, 2024, respectively. The weighted-average grant date fair value of stock options granted was $1.25 and $1.59 during the three and nine months ended September 30, 2023, respectively. There were 0 and 247,500 stock options granted at an aggregate fair value of $0 and $385 for the three and nine months ended September 30, 2024, respectively. There were 19,500 and 595,769 stock options granted at an aggregate fair value of $24 and $950 for the three and nine months ended September 30, 2023, respectively. During the three and nine months ended September 30, 2024, there were 20,000 and 93,350 stock options exercised, with an aggregate grant date fair value of $12 and $58, respectively. During the three and nine months ended September 30, 2023, there were no stock options exercised. The intrinsic value of stock options exercised during the three and nine months ended September 30, 2024 was $29 and $121, respectively. Restricted Stock Units The fair values of RSUs are based on the fair market value of the Company’s common stock on the date of grant. Each RSU represents a contingent right to receive one share of the Company’s common stock upon vesting. RSUs with time base vesting conditions for employees vest annually over <span style="font-family:'Times New

Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three or four years on each anniversary of the Grant Date and RSUs for non-employee directors vest on the one-year anniversary of the Grant Date. RSUs with performance conditions for employees vest on the one-year anniversary of the performance achievement date. During the three and nine months ended September 30, 2024, the Company granted 35,100 and 873,800 RSU awards containing performance and time based vesting conditions to employees, respectively. During the three months ended September 30, 2024, one of the two performance target tranches for performance-based RSU awards was achieved. As of September 30, 2024, the Company determined that the achievement of the second tranche's performance target was probable and therefore recognized expense during the three and nine months ended September 30, 2024 related to the outstanding performance condition. The following table summarizes the Company's RSU activity for the nine months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> <span style="font-

family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"> Weighted-Average </td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Grant Date Fair Value </td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"> 522,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2.07 </td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-

space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"> 873,800 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.97</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(183,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2.17 </td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,125) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.25 </td></tr><tr><td style="vertical-

align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,204,348 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.98 </td></tr></table> Equity-based Compensation Expense The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.29%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"> 176 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"> 489 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 605 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 895 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,410 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,794 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:39.29%;background:#cceeff;margin:0pt;padding:0pt;"> Total equity-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,071 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,283 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> As of September 30, 2024, total future compensation expense related to unvested awards yet to be recognized by the Company was $3,121, which is expected to be recognized over a weighted-average remaining vesting period of approximately 1.89 years. Total unrecognized compensation expense related to unvested performance-based awards was $628, which is expected to be recognized over a weighted-average remaining vesting period of approximately 1.06 years. 2547943 643309 0.02 0.05 7543185 4334131 4334131 209532 1000000 0.01 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.84%;background:#cceeff;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 91.78% – 92.29% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 91.53% – 92.68% </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.23% – 4.45% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 3.46% – 4.26% </td></tr><tr><td style="vertical-align:bottom;width:61.84%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 0% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"> 0% </td></tr><tr><td style="vertical-align:bottom;width:61.84%;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 6.10 – 6.20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.13%;margin:0pt;padding:0pt;"> 6.18 – 6.36 </td></tr></table> 0.9178 0.9229 0.9153 0.9268 0.0423 0.0445 0.0346 0.0426 0 0 P6Y1M6D P6Y2M12D P6Y2M4D P6Y4M9D 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Weighted-Average </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> Aggregate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> Intrinsic Value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> Contractual Life </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in 000's) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In Years) </td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"> Balance, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,213,405 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"> 1,579 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"> 6.5 </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (93,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"> 0.88 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"> Options forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> (4,225) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"> 2.49 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"> Options expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,250) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-

bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,362,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.66 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6.1 </td></tr><tr><td style="vertical-align:bottom;width:43.59%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,599,654 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.5 </td></tr></table> 4213405 4.73 1579000 P6Y6M 247500 1.97 93350 0.88 4225 2.49 1250 2.66 4362080 4.66 P6Y1M6D 3599654 5.09 P5Y6M 0 1.56 1.25 1.59 0 247500 0 385000 19500 595769 24000 950000 20000 93350 12000 58000 29000 121000 1 P4Y P1Y P1Y 35100 873800 1 2 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"> Weighted-Average </td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> Grant Date Fair Value </td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"> 522,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">873,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"> 1.97 </td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"> (183,482) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.17</p></td></tr><tr><td style="vertical-align:bottom;width:43.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,125)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.25 </td></tr><tr><td style="vertical-align:bottom;width:43.52%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,204,348 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.98 </td></tr></table> 522155 2.07 873800 1.97 183482 2.17 8125 2.25 1204348 1.98 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-

align:bottom;width:39.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.29%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"> 176 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"> 489 </td><td style="vertical-

align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:39.29%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 605 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 895 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,410 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,794 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:39.29%;background:#cceeff;margin:0pt;padding:0pt;"> Total equity-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-

bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,071 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,283 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr></table> 291000 176000 804000 489000 605000 895000 2410000 2794000 896000 1071000 3214000 3283000 3121000 P1Y10M20D 628000 P1Y21D 9. Net Loss per Share The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"> Options issued and outstanding </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"> 4,362,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"> 4,184,594 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.21%;margin:0pt;padding:0pt;"> Restricted stock units issued and outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,204,348 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 522,594 </td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,566,428 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,707,188 </td></tr></table> - - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"> Options issued and outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"> 4,362,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"> 4,184,594 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.21%;margin:0pt;padding:0pt;"> Restricted stock units issued and outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,204,348 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 522,594 </td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,566,428 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,707,188 </td></tr></table> - 4362080 4184594 1204348 522594 5566428 4707188 false false false false "